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Paul Harrison is an artist with a background and 
prevailing interest in print, printmaking and publishing. 
His practice inherently combines the use of 
traditional print methods and materials with new and 
developing technologies. He is currently a researcher 
at the University of Dundee, Visual Research Centre, 
where he co-ordinates and facilitates activity in fine 
print publishing. 
  
His interests include the investigation of image 
processing and development currently taking place in 
and around the biosciences, and in particular the 
area of gene research. His work is generally of a 
collaborative nature and he is presently engaged in 
projects with scientists at the University of Dundee 
Biocentre, the Human Genetics Unit, MRC, 
Edinburgh and Cold Spring Harbor Laboratory 
(CSHL) New York. He is also artist in residence at 
the Human Genome Organisation (HUGO) and 
visiting fellow/artist in residence at the Centre for 
Economic and Social Aspects of Genomics 
(CESAGen) at the University of Cardiff. His most 
recent work includes a project funded by the 
Wellcome Trust, titled ‘Designs for Life’. 
  
An exhibition of work from the Designs for Life Project will be 
held at the Le Corum Conference Centre for the duration of 
HGM2010 where Paul will also be available for discussion. He 
will be conducting a series of informal interviews regarding 
personal experiences and views on the relationships between 
art and science and he would be delighted to hear from you if 
you would be interested in participating in such a discussion.  
Paul can be contacted on site or at; p.l.harrison@dundee.ac.uk 
 
The ‘Designs for Life’ project can be viewed in further detail at: 
www.designsforlifeproject.co.uk 
A number of other projects can be viewed at: 
www.paulliamharrison.co.uk or: www.vrc.dundee.ac.uk 
  
Cover Image: 
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The Human Genome Organisation (HUGO) is an international organisation of scientists involved in various aspects of 
human genetics. HUGO was conceived in 1988 at the first meeting on Genome Mapping and Sequencing at Cold Spring 
Harbor, New York. From an initial group of 42 scientists from 17 countries, HUGO has increased its membership to over 
1,200 members, from 69 countries in a period of only two decades. Over the years, HUGO has played an essential role 
behind the scenes for the human genome project. With its mission to promote international collaborative efforts to study 
the human genome and the myriad issues raised by our increasing knowledge of the genome, HUGO has had noteworthy 
successes in some of the less glamorous, but nonetheless vital, aspects of the human genome project. 
 
As a truly international organisation, and currently in its 22nd year, HUGO refocused its efforts towards the medical 
implications of genomic knowledge. Looking forward, HUGO is working to enhance the genomic capabilities of the 
emerging and developing countries of the world. The excitement and interest in genomic sciences in Asia, the Middle East, 





x to investigate the nature, structure, function and interaction of the genes, genomic elements and genomes of 
humans and relevant pathogenic and model organisms; 
x to characterise the nature, distribution and evolution of genetic variation in humans and other relevant organisms; 
x to study the relationship between genetic variation and the environment in the origins and characteristics of 
human populations and the causes, diagnoses, treatments and prevention of disease; 
x to foster the interaction, coordination, and dissemination of information and technology between investigators and 
the global society in genomics, proteomics, bioinformatics, systems biology, and the clinical sciences by 
promoting quality education, comprehensive communication, and accurate, comprehensive, and accessible 
knowledge resources for genes, genomes and disease; 
x to sponsor factually-grounded dialogues on the social, legal, and ethical issues related to genetic and genomic 
information and championing the regionally-appropriate, ethical utilisation of this information for the good of the 
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A Warm Welcome to Montpellier! 
 
We are delighted to organise, on behalf of the Human Genome Organisation (HUGO), the next HGM meeting in 
Montpellier in May 2010. 
Through an extraordinary international effort, scientists have sequenced the genome of plants, animals, microorganisms 
and humans. Comparative genomics opens new windows into the evolutionary mechanisms underlying genetic variation, 
adaptation and speciation. New sequencing and array technologies have revealed an unanticipated level of genomic 
structural variation, which has led to the discovery of DNA signatures for a growing number of diseases, while genome-
wide association studies have begun identifying variants predisposing to common multifactorial diseases. Impressive 
progress has already been made in deciphering genetic, epigenetic and environmental contributions to disease risk. 
We are living through an unprecedented era of progress in bioinformatics and biotechnology, and the "genomics 
revolution" is transforming health research. The new tools it provides will generate an entirely different type of health care, 
one that is predictive, preventive, participative and personalised ("P4 medicine"). We will see new ways of diagnosing 
diseases and new ways of thinking about disease prevention and health promotion. In terms of genomics-based medicine, 
knowing who we are will allow better targeting of cures. 
We aim to bring together senior and junior investigators, postdoctoral and postgraduate researchers and the most famous 
world experts in genomics and in genetics to share basic and translational research as well as educational and social 
issues. In addition, updates on research will be highlighted for epigenetic, non-coding RNAs, pharmacogenetics, and 
therapy for genetic disorders. HGM2010 also aims to promote communication between participants to address some of 
the most pressing educational, ethical, legal and social questions raised by recent advances in genetic and genomic 
research. 
The University of Montpellier is one of the oldest in the world, founded in 1160, and the Mediterranean climates as well as 
the reputation of hospitality and open-mindedness of the region are attractive to students (85,000 among a global 
population of 500,000). Montpellier, the "scientific city", is famous for research activity (5,000 researchers), particularly in 
life sciences, agronomics and chemistry. It is also the 5th largest University Hospital in France and number one for 
Medical Conferences.  
The Congress Centre (the Corum) is ideally situated in the attractive, pedestrianised town centre. Montpellier, capital of 
the Languedoc-Roussillon region, is a very pleasant place. Wander through its mediaeval streets lined with shops, bars 
and restaurants, visit one of the richest fine arts collections in Europe. The beaches of the Mediterranean are only 10 km 
away; you have the beautiful and famous Camargue and the stunning Millau bridge nearby and the region includes five of 
the most prestigious UNESCO world heritage sites.  
 
 
Mireille Claustres  
Chair, HGM2010  







HGM2010 President’s Welcome 
 
I wish to welcome all delegates of the HGM 2010 meeting to Montpellier.  The focus of this conference is on the next 
generation of genomic technologies and their impact on how we conceptualize medicine and how we conduct medical 
research. The precision and the comprehensiveness of the technologies permit discovery at orders of magnitude greater 
than few years ago, and we are now grappling with findings of high complexity. Thus, we move towards computational 
modeling and systems approaches in the analysis of genomic information. Montpellier is an intellectual center for the 
sciences and mathematics in France and in Europe and is the most appropriate venue to celebrate the impact of these 
advances.   
 
The pace of change in genomic medicine has been breathtaking, and HUGO is also changing, reflecting both the nature 
of genomics sciences, and the interests of our membership.  We are more global with greater representation from 
countries who are new entrants in genomic research, and we are more diverse in what we call our intellectual 
domain. Both the national origins of our key speakers and the representation of the delegates are indications of this 
change.  In addition, we will host the Chen Awards for  Distinguished Academic Achievement in Human Genetic and 
Genomic Research and Chen New Investigator Award .  These awards were started by Professor Yuan-Tsong (Y-T) 
Chen and Mrs Alice Der-Shan Chen of Taiwan to recognize an Asian geneticist who has contributed to the development 
of biomedical sciences in the region. The two awardees are Dr. Yusuke Nakamura from the University of Tokyo for his 
pioneering work on human variation, and Dr. Huck Hui Ng from the Genome Institute of Singapore for his groundbreaking 
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HGM 2010 has received financial support from the following organisations.  We would like to extend our utmost appreciation 
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Montpellier is the 8th largest city in France and is the capital of the Languedoc-Roussillon region and the Hérault department, located in the scenic South 
of France. During the 19th century the city developed into an industrial centre. In the 1960s, its population grew dramatically after French settlers from 
Algeria were resettled in the city following Algeria's independence from France. In the 1980s and 1990s, the city underwent a number of major 
redevelopment projects, including the building of Le Corum (the HGM2010 venue) and especially the development of the Antigone District. Montpellier 
also hosts one of the oldest universities, the University of Montpellier which was founded in 1160. As a “scientific city” Montpellier is famous for its 




Area: approximately 22 square miles / 57 square kilometers 
Population: approximately 250,000 
Language: French 
Time Zone: GMT / UTC +1 
Country dialing code: +33 
Telephone area code: 04 
Average daily Montpellier January temperature: 12 C / 54 F 
Average daily Montpellier July temperature: 29 C / 84 F 
 
Did You Know? 
The city is situated on hilly ground 10 kilometres (6 mi) inland from the Mediterranean coast on the River Lez. The name of the city, which was originally 
Monspessulanus, is said to be derived from mont pelé (the naked hill, because the vegetation was poor), or le mont de la colline (the mount of the hill) 
Montpellier is located 52 kilometres (32 mi) from Nîmes, 168 kilometres (104 mi) from Marseille, 248 kilometres (154 mi) from Toulouse, and 
750 kilometres (466 mi) from the capital of France, Paris. 
Montpellier's highest point is the Place du Peyrou, at an altitude of 57 m (187.01 ft). The city is built on two hills, Montpellier and Montpelliéret; thus 
some of its streets vary greatly in altitude. Some of the streets are also very old and narrow, giving an intimate feel. 
Main sights 
x The main focus point of the city is the Place de la Comédie. 
x The Musée Fabre 
x The Jardin des plantes de Montpellier – the oldest botanical garden in France, founded in 1593 
x La Serre Amazonienne, an Amazonian greenhouse 
x The fourteenth century Saint Pierre Cathedral 
x The Porte du Peyrou, a triumphal arch 
x The Saint Clément Aqueduct 
x The Antigone District and other housing projects were designed by the architect Ricardo Bofill from Catalonia, Spain 
x A number of châteaux, “ follies”, built by wealthy merchants surround the city 
The Festival de Radio France et Montpellier is a summer festival of opera and music held in Montpellier. The music festival concentrates on classical 
music and jazz with about 150 events, including opera, concerts, films, and talks. Most of these events are free and are held in the historic courtyards of 
the city or the modern concert halls of Le Corum. 
Your discovery of Montpellier wouldn’t be complete without sampling the fine local cuisine. Your taste buds will help you appreciate the city from another 
angle. 
Vibrant and active, Montpellier is a city that is simply alive and waiting to be discovered. 
 
Source: http://en.wikipedia.org/wiki/Montpellier 





HUGO Information Desk  
 
The HUGO Information Desk is located at the entrance of the Exhibition area (Level 0 of Le Corum). Visit us for information about 
HUGO and its activities, initiatives (HUGO-WHO White Paper Services; HUGO-OECD Analytical Paper; HUGO Blog etc.), forthcoming 
meetings, and membership, as well as general information and services about HGM2010. 
The HUGO Gene Nomenclature Committee (HGNC, www.genenames.org) will also be contactable at the HUGO Information Desk. 
Please drop by if you have any enquires about gene nomenclature. 
 
……………………………………………………………………………………………………………………… 
HGM2010 Secretariat  
 
Located in the Tiberiade Room (Level 0 of Le Corum), you can find free internet access and friendly volunteers who will assist you with 
on-site registration, payment and general enquiries. Speakers are welcomed to preview your presentations in the Tiberiade Room at 




Registration will take place on: 
 
Tuesday 18 May  9.00 AM – 5.00 PM 
Wednesday 19 May 8.30 AM – 5.00 PM 
 
The conference bag containing the HGM2010 Programme/Abstract book and other essential information can be collected at the on-site 
registration counters - located in the Berlioz Foyer (Level 0 of Le Corum).  From Thursday 20 May onwards, all registrant related 
matters should be directed to the HGM2010 Secretariat (Tiberiade Room – Level 0 of Le Corum) 






Badges will be issued upon registration and must be worn at all times during HGM2010. Friendly Hosts/Hostesses will be manning 
each entry point to the scientific sessions and ANYONE WITHOUT A BADGE WILL BE REFUSED ENTRY . Replacement badges will 
incur a charge of €10 each. Your badge allows you to attend the Welcome Cocktail reception on Tuesday 18 May and the conference 
dinner on Thursday 20 May. 
Badges are colour coded as follows: 
Blue  –  Speakers and Session Chairs 
Red  –  Participants 
Green  –  Exhibitors 
White  –  Single Day Pass Entrants 
Black  –  Staff and Volunteers 





Please drop by the HUGO Information Desk and speak to our friendly representative from Voyages Kuoni SA Destination Management 




Welcome Cocktail Reception 
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The Welcome Reception will be held in the Exhibition area (Berlioz Foyer – Le Corum of Level 0) in conjunction with the Inauguration of 
the Exhibition and poster presentations on Tuesday, 18 May. All HGM2010 registrants are welcome, so please come and view the 




Complimentary tea, coffee, and biscuits will be provided in the morning and afternoon tea breaks in the Exhibition Area (Berlioz Foyer – 
Le Corum, Level 0). Delegates can purchase a range of reasonably priced drinks and snacks from the Brassarie (Le Corum, Level 1). 
Admittance to the Welcome Cocktail Reception (Tuesday 18 May) and Conference Dinner (Thursday 20 May) is inclusive in your 
registration fee. Extra Cocktail and Conference Dinner Tickets for non-registrants can be purchased from the HGM2010 Secretariat 





All posters must be put up on the poster boards by 4pm on Tuesday, 18 May. Each presenter is required to present their poster at the 
session specified by their poster number in the Poster Abstract listing in this book.  Presenters not at their poster during the specified 
session will be ineligible for the Poster Prizes.   
Poster Session I (W) -  Wednesday 19 May  11.35 AM – 1.05 PM 
Poster Session II (T)  -  Thursday 20 May  11.25 AM – 12.55 PM 
Poster Session III (F)  -  Friday 21 May   12.25 PM – 1.55 PM 
 
……………………………………………………………………………………………………………………… 
Springer Poster Competition 
 
HUGO is delighted that Springer, a major publisher of books and journals in the field of genomic medicine -  including The HUGO 
Journal, the Official Journal of the Human Genome Organisation, will be sponsoring a poster competition at HGM2010. The competition 
will be judged by members of the HUGO Council and the HGM2010 International Scientific Committee.  
 
1st prize: €500 plus one year’s free subscription to three Springer Journals 
2nd prize: €300 plus one year’s free subscription to two Springer Journals 
3rd prize: €100 plus one year’s free subscription to The HUGO Journal 
……………………………………………………………………………………………………………………… 
HUGO Gene Nomenclature Committee Nomenclature Poster Prize 
 
The HUGO Gene Nomenclature Committee (HGNC) will again be awarding prizes to the authors of the two posters which contain the 
HIGHEST NUMBER of approved gene symbols. This will be judged by members of the HGNC team with a score of +1 for use of a 
correct symbol and -3 for an incorrect one. Each prize is a one year subscription to one Springer Journal of your choice and to The 
HUGO Journal; the HGNC would like to thank Springer for their sponsorship of this competition.  
 
……………………………………………………………………………………………………………………… 
Chen Award 2010 
 
HUGO wishes to thank Professor Yuan-Tsong Chen and Alice Der-Shan Chen of the Chens’ Foundation for the honour of once more 
administering the Chen Award (2010). Please join us to celebrate the achievements and talents in Genomic Sciences in the Asia Pacific 
region at the Chen Award lectures (18 May and 20 May). 
 
Distinguished Academic Achievement in Human Genetic and Genomic Research 2010  
 
Professor Yusuke Nakamura (Japan) 
 
Chen Young Investigator Award 2010  
 
Dr. Ng Huck Hui (Singapore) 
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PROGRAMME SUMMARY ______________________________________________ 
18 MAY 2010 
TIME PROGRAMME Venue 
9.00 AM - 12.00 PM HUGO-OECD Discussion (by invitation only)  Louisville Room 
12.00 PM - 1.00 PM Lunch Break   
1.00 PM - 2.00 PM Press Conference  Barcelone Room 
2.00 PM - 2.05 PM Opening Address by Edison T Liu (HUGO) Salle Pasteur 
2.05 PM - 2.10 PM Welcome Address by Mireille Claustres (INSERM) Salle Pasteur 
2.05 PM - 2.10 PM Address by Dominique Daegelen (INSERM) Salle Pasteur 
2.15 PM - 4.15 PM Plenary: Synthethic and Systems Genomics  Salle Pasteur 
4.15 PM - 4.35 PM Tea Break Berlioz Foyer 
4.35 PM - 6.35 PM  Plenary: Epigenetics in Development and Human Disease  Salle Pasteur 
6.35 PM - 8.05 PM Welcome Cocktail Reception / Poster Session Inauguration / Exhibition Inauguration  Berlioz Foyer 
19 MAY 2010 
TIME PROGRAMME Venue 
8.30 AM - 10.55 AM Symposium: Biobanking  Salle Pasteur  
  Symposium: Microbial Genomics and Metagenomics Salle Einstein 
9.30 AM - 9.55 AM Tea Break Berlioz Foyer 
11.00 AM - 11.40 AM Featured talk  Salle Pasteur  
11.40 AM - 1.10 PM Poster Session 1 & Exhibition Berlioz Foyer 
  
 Lunch Seminars  Sully 1 & 2 
  
 HUGO Council Meeting  Louisville Room 
1.10 PM – 3.10 PM Workshop: Computational Biology, Computational Genomics Salle Pasteur  
  Workshop: Genetic and Genomic Databases Salle Einstein 
  Workshop: Genomics, Ethics, Law & Society Sully 1   
  Workshop: Genome Variation in Disease I Sully 2 
  Workshop: Genome Variation in Evolution Sully 3 
3.15 PM – 4.35 PM Plenary: An Expanding RNA World  Salle Pasteur 
4.35 PM - 4.50 PM Tea Break Berlioz Foyer 
4.50 PM - 6.10 PM Plenary: Gene Expression and Human Variation Salle Pasteur 




PROGRAMME SUMMARY ______________________________________________ 
20 MAY 2010 
TIME PROGRAMME Venue 
8.30 AM - 10.45 AM Plenary: Human Genome Variation in Evolution and Disease Salle Pasteur  
9.50 AM - 10.05 AM Tea Break Berlioz Foyer 
10.45 AM - 11.25 AM Featured talk  Salle Pasteur  
11.25 AM - 12.55 PM Poster Session 2 & Exhibition Berlioz Foyer 
  
 Lunch Seminars  
Sully 1 & 2 & Salle 
Pasteur 
12.55 PM - 2.55 PM Workshop: Cancer Genomics I Salle Pasteur  
  
 Workshop: Evolutionary Genomcis Salle Einstein 
  
 Workshop: Genetics of Health and Disorder Sully 1   
  
 Workshop: Genomics Medicine and Pharmacogenomics Sully 2 
  
 Workshop: Genetics and Genomics in Developing Countries Sully 3 
3.00 PM - 5.15 PM Symposium: Quantitative Genomics (GWAS, QTL, Expression Cassettes) Salle Pasteur 
  
 Symposium: Next Generation Sequencing - 1000 Genome Project and Beyond Salle Einstein 
4.25 PM - 5.10 PM Tea Break Berlioz Foyer 
5.20 PM - 6.00 PM Featured talk  Salle Pasteur 
6.30 PM - 7.00 PM Bus transfer to Conference Dinner venue   
7.00 PM - 9.00 PM Conference Dinner   
21 MAY 2010 
TIME PROGRAMME Venue 
8.30 AM – 10.25 AM Symposium: Pathways Networks and System Biology Salle Pasteur  
  
 Symposium: Nutrigenetics and Nutrigenomics Salle Einstein 
9.30 AM - 9.45 AM Tea Break Berlioz Foyer 
10.30 AM - 12.00 PM Workshop: Cancer Genomics II Salle Pasteur  
  
 Workshop: Genome Variation in Disease II Salle Einstein 
  
 Workshop: Epigenetics and microRNA-mediated gene regulation Sully 1   
  
 Workshop: Structural Variations and Chromosomal Aberrations Sully 2 
  
 Workshop: Functional Genomics Sully 3 
12.00 PM - 1.30 PM Poster Session 3 & Exhibition Berlioz Foyer 
  
 Lunch Seminars  Sully 1 & 2 
1.30 PM - 5.00 PM HUGO Forum - Sequencing Futures: Sequencing Technologies Now and the Future Salle Pasteur 
3.30 PM – 4.00 PM Tea Break Berlioz Foyer 
5.00 PM - 5.15 PM Closing Ceremony Salle Pasteur 
14 HUGO J (2010) 4:1–190
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VENUE FLOORPLAN (LE CORUM - MONTPELLIER, FRANCE)     
 
   Level 0 – Registration Area, Secretariat Room (Tiberaide Room), Salle Einsten and Salle Pasteur 
 
 
   Level 1 – Sully 1, Sully 2 and Sully 3 
HUGO J (2010) 4:1–190 15
123




FULL PROGRAMME           ______________________________________________ 
18 May 2010 
Time Programme 
9.00 AM - 12.00 PM HUGO-OECD Discussion (By invitation only) 
HGM 2010 Registration 
12.00 PM - 1.00 PM Lunch Break 
1.00 PM - 2.00 PM Press Conference 
2.00 PM - 2.05 PM Opening Address by Edison T Liu (HUGO) 
2.05 PM - 2.10 PM Welcome Address by Mireille Claustres (INSERM) 
2.10 PM - 2.15 PM Address by Dominique Daegelen (INSERM) 
2.15 PM - 4.15 PM 
Synthethic and Systems Genomics 
Chaired by Edison T Liu 
Venue: Salle Pasteur 
 
Drew Endy 
Work towards an 8-bit engineered genetic combinatorial counter 
Christina D Smolke  
Programming cellular behavior with RNA controllers 
Yusuke Nakamura (Chen Award Lecture)  
DNA variations in human and medical genetics: My 25-year experience 
4.15 PM - 4.35 PM Tea Break 
4.35 PM - 6.35 PM 
Epigenetics in Development and Human Disease 
Chaired by Veronica van Heyningen 
Venue: Salle Pasteur 
 
Robert Feil  
Epigenetic mechanisms in genomic imprinting 
Anne C Ferguson-Smith  
Genomic imprinting and the epigenetic control of mammalian development and human 
disease 
Stephen Baylin  
Evolution and implications of the cancer epigenome 
6.35 PM - 8.05 PM Welcome Cocktail Reception  together with Poster Session Inauguration and Exhibition Inauguration 
 




FULL PROGRAMME           ______________________________________________ 
19 May 2010 
Time Programme Time Programme 
8.30 AM - 10.55 AM Biobanking Chaired by Anthony Brookes / Richard Cotton 
Venue: Salle Pasteur 8.30 AM - 10.55 AM  
Microbial Genomics and Metagenomics 
Chaired by Todd Taylor / Martin Hibberd 
Venue: Salle Einstein 
 
Bartha Maria Knoppers  
The Public Population Project in Genomics : An 
"Ethical" Proof of Concept 
 
Martin Hibberd   
Dengue virus genomics, a window into evolution, 
virulence and transmission patterns 
David B Goldstein  
Rare and common variants in human disease 
Peer Bork   
Comparative (meta) genomics: Lessons from a 
tiny bacterium and a complex microbial 
community 
09.40 AM - 09.55 AM Tea Break 9.30 AM - 9.45 AM Tea Break 
 
David Cox   
Advancing biobanking through public-private 
collaboration  
Stanislav Dusko Ehrlich  
Characterization of the human "other" genome 
by the MetaHIT Consortium 
Jennifer Harris  
Biobank harmonization for health 
Edward Rubin  
Assembly of genes and genomes from bio-mass 
degrading cow rumen 
10.55 AM - 11.00 AM Room Change 
11.00 AM - 11.40 AM Charles N Rotimi (Featured Talk)  Genetic diversity and health: Opportunities and challenges presented by African genomes 
Venue: Salle Pasteur 
11.40 AM - 1.10 PM 
Lunch & Exhibition Life Technologies 
Venue: Sully 1 Affymetrix Venue: Sully 2 HUGO Council Meeting 
(by invitation only)  
Venue: Louisville 
Poster Session 1  
Venue: Berlioz Foyer 
 
 




Chaired by Doron 
Lancet / John de Vos 
Venue: Salle Pasteur 
Genetic and Genomic 
Databases 
Chaired by Yoshiyuki 
Sakaki / Marie-Paule 
LeFranc 
Venue: Salle Einstein 
Genomics , Ethics, 
Law & Society 
Chaired by Ruth 
Chadwick / 
Benjamin Capps 
Venue: Sully 1 
Genome Variation in 
Disease 1 
Chaired by Christian 
Jorgensen / Elspeth 
Bruford 
Venue: Sully 2 
Genome Variation in 
Evolution 
Chaired by Martin 
Hibberd / Agnes Rotig  
Venue: Sully 3 
 
3.10 PM - 3.15 PM Room Change 
3.15 PM - 4.35 PM An Expanding RNA World  Chaired by Julian Venables / Sumio Sugano 
Venue: Salle Pasteur 
 
Gil Ast  
Importance of alternative splicing in transcriptomic diversity and disease 
Yoshihide Hayashizaki  
Transcriptome analysis — A way to illuminate the genome network 
4.35 PM - 4.50 PM Tea Break 
4.50 PM - 6.10 PM Gene Expression and Human Variation  Chaired by Edison T Liu / Doron Lancet 
Venue: Salle Pasteur 
 
Michael Snyder  
Transcription binding variation in eucaryotes 
Howard McLeod  
Using the genome to guide therapy 
6.10 PM End of Day  
6.30 PM - 8.00 PM Free and Easy HUGO Ethics Committee Meeting (by invitation only) PASNP Phase II Planning Meeting (by invitation only) 
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FULL PROGRAMME           ______________________________________________ 
20 May 2010 
Time Programme Time Programme 
8.30 AM - 10.45 AM 
Human Genome Variation in Evolution and Disease 
Chaired by Stylianos E Antonarakis / Richard Cotton 
Venue: Salle Pasteur 
 
Mark McCarthy  
Type 2 diabetes: Susceptibility variants across the allele frequency spectrum 
Stephen W Scherer  
Clinical context of copy number and structural variation in the human genome 
9.50 AM - 10.05 AM Tea Break 
 Felix Jin Li  Identification of copy number variation hotspots in human populations 
10.45 AM - 11.25 AM 
Ng Huck Hui (Chen Award Lecture)  
Deciphering and reconstructing the embryonic stem cell transcriptional regulatory network 
Venue: Salle Pasteur 
11.25 AM - 12.55 PM 
Lunch & Exhibition Roche 
Venue: Sully 1 
Agilent 
Technologies 
Venue: Sully 2 
President's Luncheon 
(by invitation only) 
Poster Session 2 
Venue: Berlioz Foyer 
Larry Kedes -  Archon Genomics XPRIZE  (Featured Talk) 
Swifter, Lower, Stronger: the $10 Million Olympic Medal for Next Generation Sequencing 
Venue: Salle Pasteur 
 
12.55 PM - 2.55 PM 
Cancer Genomics I 
Chaired by Philippe 
Broet / Bernard Klein 
Venue: Salle Pasteur 
Evolutionary 
Genomics 
Chaired by Harris A 
Lewis / Christian 
Hamel 
Venue: Salle Einstein 











Chaired by Lance 
Miller / Marc Delpech 





Dhavendra Kumar / 
Michele Ramsay 
Venue: Sully 3 
 
2.55 PM - 3.00 PM Room Change 
3.00 PM - 5.15 PM 
Quantitative Genomics (GWAS, QTL, Expression 
cassettes) 
Chaired by Martin Vingron / Yoshihide 
Hayashizaki 
Venue: Salle Pasteur 
3.00 PM - 5.15 PM 
Next Generation Sequencing - 1000 Genome 
Project and Beyond 
Chaired by Ruan Yijun 
Venue: Salle Einstein 
 
Emmanouil Dermitzakis  
Cellular genetics and genomics 
 
Henry Yang Huanming  
Human Genomics - From HGP to 1000 
genomes and beyond 
Frank Johannes  
Complex trait dynamics following epigenomic 
perturbation 
Ruan Yijun  
Chromatin Interaction and Transcription 
Regulation 
Augustine Kong  
Some thoughts on genetics studies in the near 
future 
Gilean McVean  
The landscape of human genetic variation as 
viewed from the 1000 Genomes Project 
4.25 PM - 4.40 PM Tea Break 4.55 PM - 5.10 PM Tea Break 
 
Martin Vingron  
Transcription factor binding site analysis and 
histone modifications point at two classes of 
promoters 
  
5.15 PM - 5.20 PM Room Change 
5.20 PM - 6.00 PM 
Manel Esteller (Featured Talk)  
Cancer Epigenetics: From DNA methylation to microRNAs 
Venue: Salle Pasteur 
6.00 PM End of Day 
6.30 PM - 7.00 PM Transfer to Dinner Venue 
7.00 PM - 9. 00PM Conference Dinner 
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FULL PROGRAMME           ______________________________________________ 
21 May 2010 
Time Programme Time Programme 
8.30 AM - 10.25 AM 
Pathways Networks and System Biology  
Chaired by Gerardo Jimenez-Sanchez / Laurent 
Journot 
Venue: Salle Pasteur 
8.30 AM - 10.25 AM 
Nutrigenetics and Nutrigenomics 
Chaired by Jean-Louis Gueant / Samir K 
Brahmachari 
Venue: Salle Einstein 
 
Hiroki R Ueda  
Systems Biology of Mammalian Circadian Clocks 
 
Susan E Ozanne  
Mechanisms linking poor early nutrition and 
later risk of type 2 diabetes 
Eran Segal  
Transcriptional Lego: Predictable control of gene 
expression by manipulating promoter building 
blocks 
Harris A Lewin  
Nutrition: Will livestock Lead the way? 
9.30 AM - 9.45 AM Tea Break 
 
Luis Serrano  
Systems biology analysis of the EGF MAPK 
pathway: From structures to data integration 
 Jean-Christophe Glaszmann  Genomics for food improvement 
10.25 AM - 10.30 AM Room Change 
10.30 AM - 12.00 NN 
Cancer Genomics II  
Chaired by Wei Chia-
Lin / Albertina de 
Sario 
Venue: Salle Pasteur 
Genome Variation in 
Disease II  
Chaired by Y T Chen / 
Valere Cacheux-
Rataboul 





Chaired by Lim 
Bing / Jean-Marie 
Blanchard 




Chaired by Lawrence 
Stanton / Richard 
Redon 
Venue: Sully 2 
Functional Genomics  
Chaired by Samir K 
Brahmachari / Alain 
Bucheton 
Venue: Sully 3 
 
12.00 NN - 1.30 PM Lunch Illumina Venue: Sully 1 
Poster Session 3 
Venue: Berlioz Foyer 
 
 
1.30 PM - 5.00 PM 
HUGO Forum - Sequencing Futures: Sequencing Technologies Now and the Future -  
Chaired by Herve Thoreau / Wei Chia-Lin 
Venue: Salle Pasteur 
 
Radoje Drmanac  
The path to affordable human genome sequencing for large-scale studies of genetic diseases 
Nathaniel Pearson  
Deciphering the oracle's words: Analysis tools for human whole genomes and exomes 
Marcus Droege  
Re-sequencing of the human genome using the 454 Genome Sequencer systems FLX & Junior 
Patrice M Milos  
An unbiased, quantitative view of genome biology only possible with Helicos Single Molecule Sequencing 
Francisco M De La Vega  
The road to 99.999% accuracy single molecule sequencing 
Stephen Turner  
Applications of SMRT™ sequencing outside the performance envelope of first and second generation sequencing 
Mostafa Ronaghi  
Current and future outlook of genomic technologies 
*Tea Break (3.30 PM – 4.00 PM) 
5.00 PM - 5.15 PM Closing Ceremony (Springer Poster Awards, HGNC Nomenclature Awards and Announcement of future HGM) 
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Can you see the mutation earlier?
Can you analyze heterogeneous samples?
Can higher accuracy reduce the  
coverage required to detect SNPs? 
Can you reduce the cost and time of validation?
Can true paired-end protocols reduce the noise?
Next-generation sequencing just leaped to the next 
level in accuracy. The SOLiD™ 4 System leverages 
advanced informatics and optimized reagents to 
deliver the highest accuracy of any NGS system. 
With throughputs of 100 GB per run and workﬂow 
automation, the SOLiD™ 4 System accelerates your 
large-scale genomic analysis to an unprecedented 
pace. Plus, new paired-end library options enable 
detection of novel splice variation and fusion 
transcripts with less input DNA. Using the SOLiD™ 4 
System, your lab will have the ability to detect  
more variation and spend less time and money  
doing it. Take a look at the new SOLiD™ 4 System. 
See what’s never been seen before.
Can you see 
the cell with  
early signs  
of disease?
Introducing the new, more accurate, higher throughput SOLiD™ 4 System.
SOLiD™ 4
S Y S T E M  S E Q U E N C I N G
For Research Use Only. Not for use in diagnostic procedures. © 2010 Life Technologies Corporation. All rights reserved. Trademarks of Life Technologies Corporation 
and its afﬁliated companies. All other trademarks are the sole property of their respective owners. 
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PANEL OF INTERNATIONAL SPEAKERS__________________________________ 




President, The BioBricks Foundation 
Assistant Professor, Stanford Bioengineering  
 
Title: Work towards an 8-bit engineered genetic combinatorial counter 
Modest information storage systems implemented inside living cells would enable new approaches for researching and 
controlling biological processes such as development, cancer, and aging.  Our current capacity to engineer and operate 
genetically encoded information storage systems is quite limited.  Specific limitations include the lack of sufficient 
molecular components to build with, rules of composition supporting device and system integration, an understanding for 
how to implement reliable behavior given thermal noise at the molecular scale, and an understanding for how to engineer 
reliable systems that evolve.  I'll introduce applications of genetic information storage systems, review past and current 
accomplishments from the field, introduce our experimental work on composable set/reset latches built with serine 
recombinases, and our theoretical work on a framework supporting the engineering of higher-order information storage 
systems.  Given that an 8-bit counter likely requires the successful integration of at least 10-fold more components than 
any existing engineered genetic system, I'll also discuss the current state of, and needs regarding, foundational tools 
supporting genetic engineering. 
Biosketch 
Drew Endy grew up in Pennsylvania earning degrees in civil and environmental engineering at Lehigh.  Following a summer internship at AMTRAK, he 
earned a PhD in biochemical engineering at Dartmouth.  He then studied microbiology and genetics as a postdoc at UT Austin and UW Madison. He 
worked with Roger Brent and Sydney Brenner at the Molecular Sciences Institute in Berkeley.  Drew joined MIT as a Fellow in Biology and Biological 
Engineering in 2002, later joining the faculty in the newly created Department of Biological Engineering.  At MIT, Drew developed and taught 5 courses 
in helping to launch MIT's new undergraduate major in BE.  His lab published a systematic redesign ("refactoring") of a natural organism's genome, 
successfully implementing over 600 simultaneous genetic changes while maintaining organism viability, a comprehensive "datasheet" for an abstracted 
genetic device, methods and a reference standard for measuring gene expression inside living cells, and a contrarian observation that incredibly tiny and 
"molecularly noisy" bacteria appear to implement reliable behavior.  Drew has helped found a few companies, the iGEM competition, the synthetic 
biology (SB#.0) conference series, and the BioBricks Foundation, a non-profit that is working to create open technology platforms supporting the next 
generation of biotech.  His group at Stanford Bioengineering is working to implement scaleable genetic memory systems, for storing and controlling 




Christina D. Smolke 
Assistant Professor of Bioengineering 
Bioengineering Department 
Stanford University  
 
Title: Programming cellular behavior with RNA controllers 
Cellular behavior is encoded and controlled by complex genetic networks. Synthetic genetic devices that interface with 
native pathways can be used to change natural networks to implement new forms of control and behavior. Significant 
recent work on the engineering of synthetic gene networks has been limited by an inability to interface with native 
networks and components. To overcome these limitations, we have developed RNA control devices that process and 
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transmit molecular signals that are received by integrated sensor domains to targeted protein level outputs, linking 
computation and logic to gene expression and thus cellular behavior in mammalian cells. The modularity inherent in our 
device design supports the rational assembly of these RNA controllers from independent components exhibiting basic 
functions and the extension to more sophisticated information processing schemes, highlighting the potential of synthetic 
biology strategies to support the rapid engineering of cellular behavior. Coupled with technologies that enable the de novo 
generation of new RNA sensor components, RNA devices allow researchers to construct various user-programmed 
information processing operations in living systems. The application of these molecular devices to developing new 
disease treatment strategies such as targeted molecular and cellular therapeutics will be discussed. 
Biosketch 
Christina Smolke has been an Assistant Professor in the Department of Bioengineering at Stanford University since January 2009. Prior to that she was 
an Assistant Professor in the Division of Chemistry and Chemical Engineering at the California Institute of Technology. She graduated with a B.S. in 
Chemical Engineering and a minor in Biology from the University of Southern California in 1997. She conducted her graduate training as a National 
Science Foundation Fellow in the Chemical Engineering Department at the University of California at Berkeley and earned her Ph.D. in 2001. Christina 
conducted her postdoctoral training as a National Institutes of Health Fellow in Cell Biology at UC Berkeley and began her position at Caltech in 2003. 
She has pioneered a research program focused on developing foundational technologies for the design and construction of engineered ligand-
responsive RNA-based regulatory molecules, their integration into cellular computation and signal integration strategies, and their reliable 
implementation into diverse cellular engineering applications. These technologies are resulting in scaleable platforms for the construction of molecules 
that allow regulation of targeted gene expression levels in response to user-specified endogenous and exogenous molecular ligands. Christina’s 
innovative research program has been recognized with the receipt of a National Science Foundation CAREER Award, a Beckman Young Investigator 
Award, an Alfred P. Sloan Research Fellowship, World Technology Network Award in Biotechnology, and the listing of Christina as one of Technology 
Review’s Top 100 Young Innovators in the World. 
……………………………………………………………………………………………………………………… 
Chen Award Lecture (18 May 2010) 
 
Yusuke Nakamura 
Director and Professor 
The University of Tokyo  
 
Title: DNA variations in human and medical genetics: My 25-year experience 
DNA variations have contributed enormously to the fields of human and medical science in the last two-three decades, 
especially for identification of genes responsible or susceptible to various diseases, those involved in cancer and those 
associated with efficacy or adverse reactions of various drugs. The types of genetic variation used in these studies have 
changed in the past 25 years and can be classified into five major classes: RFLP (restriction fragment length 
polymorphism), VNTR (variable number of tandem repeat), STR (short tandem repeat or microsatellite), SNP (single-
nucleotide polymorphism) and CNV (copy-number variation). Genetic linkage analysis using these tools mapped and 
discovered genes responsible for hundreds of hereditary diseases. Furthermore, construction of the international SNP 
database and recent development of high-throughput SNP typing platforms enabled us to perform genome-wide 
association studies, which have identified genes (or genetic variations) susceptible to common diseases or those 
associated with drug responses. Genome-wide sequencing of individual DNAs is gaining immense scope. I would like to 
summarize the history of polymorphic DNA markers and their contribution to the genetic analysis of both rare hereditary 
diseases and common diseases, as well as recent advances in pharmacogenetics, including our contribution to these 
areas. 
Biosketch 
Prof. Nakamura has been contributing to genomic medicine and also cancer research fields for more than two decades. He was one of pioneers in 
developing and applying genetic polymorphic markers (VNTR and SNP) in the medical genomics field. DNA polymorphic markers developed and 
mapped by his groups have contributed to map and clone genes responsible to hereditary diseases, those susceptible to common diseases, those 
related to drug response, and those involved in cancer.  His groups in Cancer Institute, University of Tokyo, Osaka University and RIKEN SNP Research 
Center (present name is RIKEN Center for Genomic Medicine) in Japan have isolated dozens of genes of medical importance by genomics approach. In 




addition, RIKEN SNP Research Center led by him participated in the International HapMap Consortium and made the largest contribution in the Phase 1 
HapMap project published in Nature (2005).  His contribution in human genetics and cancer research fields can be measured by his publication of more 
than 1,000 articles, including 32 articles in American Journal of Human Genetics, 107 in Cancer Research,15 in Nature, 36 in Nature Genetics, and 11 in 
Science, that have been cited for more than 65,000 times in total. 
……………………………………………………………………………………………………………………… 
Plenary: Epigenetics in Development and Human Disease (18 May 2010) 
 
Robert Feil 
Senior Scientist, CNRS 
Group Leader, The Institute of Molecular Genetics 
 
Title: Epigenetic mechanisms in genomic imprinting 
In contrast to other groups of animals, in placental mammals the maternally and paternally inherited genomes are 
functionally non-equivalent.  This functional asymmetry between the parental genomes is a consequence of differential 
marking of the genomic DNA in the egg versus the sperm.  These DNA methylation ‘imprints’ on the parental genomes 
persist in the developing embryo, and convey the allelic expression of genes from either their maternal or their paternal 
copy.  Some hundred genes are controlled by this epigenetic phenomenon called ‘genomic imprinting’.  Many of these 
play important roles in foetal development and growth, particularly of the placenta, others influence 
behaviour.  Pathological perturbation of genomic imprinting gives rise to growth-related and behavioural diseases in 
humans. Environmental stress can readily perturb imprints as well, and this may have long-lasting phenotypic 
consequences. Different ART technologies, for instance, seem to increase the frequency of the foetal overgrowth 
syndrome Beckwith-Wiedemann Syndrome (BWS) and other imprinting-related disorders.  
I will discuss our current understanding of how DNA methylation imprints become established during spermatogenesis 
and oogenesis, and how they are maintained during development.  Imprints are targeted to specific regulatory sequences 
that control imprinted gene expression, the so-called ‘imprinting control regions’ (ICRs). After fertilisation, these imprints 
are maintained in all the somatic cells and tissues.  Perturbation of this maintenance process gives rise to altered DNA 
methylation at ICRs, and consequently, imprinting-related diseases. Our group is particularly interested in the organisation 
of chromatin at ICRs and to which extent histone modifications contribute to imprint establishment and maintenance. We 
also explore the importance of histone methylation in the tissue-specific regulation of imprinted gene expression. I will 
present several examples of how lysine methylation on histone H3 controls imprinted genes in the placenta, and in brain, 
and will describe the enzymatic machineries involved. 
Biosketch 
We are interested in the regulation of genomic imprinting in mammals, and in how this epigenetic mechanism influences embryonic and extra-embryonic 
development. Our projects aim at unravelling the role of chromatin modifications and DNA methylation, and investigate the pathological deregulation of 
imprinting in human diseases and as a consequence of in vitro manipulation. 
……………………………………………………………………………………………………………………… 
 
Anne C Ferguson-Smith 
Professor of Developmental Genetics  
Department of Physiology Development and Neuroscience 
University of Cambridge  
 
Title: Genomic imprinting and the epigenetic control of mammalian development and human disease 




Epigenetic modifications play key roles in chromosome architecture and integrity, chromatin structure and gene activity and repression. 
One of the key challenges in contemporary genome biology is to understand the relationship between the epigenome and the 
underlying DNA sequence with which it interacts.  Genomic imprinting is a normal epigenetic regulatory process causing genes to be 
expressed from only one of the two parental chromosome homologues according to their parental origin. Imprinted genes function 
prenatally and postnatally in a range of developmental pathways controlling normal organogenesis, growth and metabolism. 
Perturbations of genomic imprinting are responsible for several disorders exhibiting parental-origin effects in their patterns of 
inheritance. Abnormal imprinting has also been implicated in a wide range of different cancers.  More recently, genome-wide 
association studies that have considered the parent-of-origin of variants have identified novel associations between imprinted domains 
and complex diseases. 
The mouse is a useful model for the analysis of defective imprinting mechanisms and the phenotypic contributions of genes whose 
dosage is perturbed in imprinting disorders. Recent advances have included the identification of mutations in trans-acting factors in 
mouse and human that are required for the stable maintenance of epigenetic states at multiple imprinted domains, and whose further 
analysis is likely to provide novel insights into molecules that integrate genomic with epigenomic information.  In recent years, data 
have emerged identifying discordance of imprinting between mouse and man, polymorphic imprinting between different individuals and 
tissue and cell-specific imprinting within individuals. This suggests that epigenetic control modulating mono-allelic and biallelic 
expression at imprinted loci might be a dynamic process with the potential to act as a regulatory mechanism controlling gene dosage in 
different developmental contexts. This potential plasticity of epigenetic control at imprinted domains may contribute to their vulnerability, 
and help contribute to our understanding of the mechanisms and consequences of epimutation of the genome in a wider context.  
Biosketch 
The Ferguson-Smith team is interested in the molecular events governing mammalian development, and in understanding situations where normal 
developmental processes have been disturbed. In particular, their integrated programme of research is directed towards investigating the function, 
regulation and evolution of imprinted genes and also, in using genome imprinting as a model to understand the relationship between genomic 
organization and the epigenetic control of genome function.  Current research focuses on three main themes: (1) Stem cells and the epigenetic 
programme in vitro and in vivo, (2) Functional epigenomics including the roles of small and large non-coding RNAs, repetitive sequences and cis-acting 
regulatory features, (3) Developmental and physiological functions of imprinted genes in health and disease and the extent to which this is influenced by 
the environmental modulation of epigenetic states. Genomic imprinting is a remarkable normal process that causes some genes to be expressed from 
maternally inherited chromosomes and others from paternally inherited chromosomes. This means that the egg and sperm contribute unequal functions 
to the developing conceptus through the parental-origin specific expression of imprinted genes. In mouse and man, disorders can arise when the dosage 
of imprinted genes is altered through imbalances in the parental-origin of particular chromosomes, by mutations in the single active allele or by mutations 
affecting the epigenetic process controlling imprinting. The team is investigating the developmental consequences of altering the dosage of imprinted 
genes on the epigenetic regulation of prenatal growth and development. Currently they are particularly interested in exploring of the consequences 
altering the dosage of imprinted genes in postnatal processes - notably in the regulation of neurogenesis and metabolism. This functional analysis 
combined with comparative analysis in different mammalian species, is contributing to our understanding of the evolution of genomic imprinting. 
Genome function is regulated by epigenetic modifications that can affect a number of processes including chromosome architecture and integrity, 
chromatin structure and gene expression. During multiple stages in the lifetime of the organism these modifications, including DNA methylation and 
histone modifications, provide a dynamic, heritable and reversible method to affect genome function without changing the DNA sequence. Large and 
small non-coding RNAs are also involved. It is well-established that all these epigenetic modifications regulate the parental-origin specific expression of 
imprinted genes. Most imprinted genes identified to date are located in clusters of maternal and paternally expressed alleles controlled by both short and 
long range cis-acting epigenetic regulatory features. Imprinted domains are therefore an excellent in vivo model system to investigate the role of 
epigenetic modifications in genome function. Anne Ferguson-Smith obtained her PhD from Yale University. She commenced her studies on genomic 
imprinting during postdoctoral work first at The Babraham Institute and then at the Wellcome/CRC Institute of Cancer and Developmental Biology in 
Cambridge. She contributed to the identification of the first imprinted genes and determined the value of the mouse as a model for studying imprinted 
disorders in human. During this time, she also identified a role for DNA methylation in imprinting control. Anne subsequently obtained a faculty position 
at the University of Cambridge where her team identified and characterized a novel large imprinted domain (the Dlk1-Dio3 cluster) implicated in a wide 
range of disease processes and provided novel insights into our understanding of imprinting function, regulation and evolution. The team continues to 
pioneer the application of imprinting in a wider context as a model for understanding the epigenetic control of mammalian genome function.  She is 
currently Professor of Developmental Genetics in the Department of Physiology Development and Neuroscience at the University of Cambridge and an 




Professor of Oncology 
The Johns Hopkins University School of Medicine 
McKusick-Nathans Institute of Genetic Medicine 
 
Title: Evolution and implications of the cancer epigenome 
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We now increasingly realize from work over the past decade, especially, that cancer is a disease of epigenetic as well as genetic, 
abnormalities. Thus, changes in heritable gene expression patterns dictated by other than alterations in the primary base sequence of 
DNA, are more frequent than genetic changes in cancer, and critically important. For example, every individual patient’s tumor, for all 
cancer types studied to date, harbors hundreds of genes which are transcriptionally silenced by the abnormal addition of an epigenetic 
regulatory modification, DNA methylation, to the proximal promoter region. From such observations we may now talk about not only the 
cancer genome but the cancer epigenome and efforts are now expanding to jointly study both.  
  
One of the most important roles of epigenetic abnormalities in cancer may be a response to chronic cell stress that helps to underpin 
abnormal cell expansion and survival in the earliest phases of tumorigenesis. These events provide the cell population “substrate” for 
enhancing the likelihood that subsequent genetic and epigenetic events can foster subsequent progression events towards invasive 
disease and metastases. Concrete examples of this may be found in the pre-invasive promoter DNA methylation, and associated 
transcriptional silencing and loss of gene function, for genes controlling virtually every key signaling pathway fundamental for 
tumorigenesis including cell cycle and control of stem/progenitor cell regulation (p16, p15), the Wnt pathway (APC, SOX17), DNA 
repair (MLH1), cell adhesion and invasion (E-cadherin), and apoptosis (DAP-kinase). The keys to the molecular events which may 
drive the above abnormalities may be emerging from links between epigenetic control of gene expression in embryogenesis and the 
above abnormal expansion of progenitor cell populations. This may involve a molecular progression which abnormally locks in a 
normally “plastic” chromatin regulation of gene expression which maintains the state of embryonic stem (ES)/progenitor cells. In turn, 
this molecular progression may promote abnormal progenitor cell compartment survival and impede normal lineage commitment and 
maturation of involved cells and result in a primitive state of abnormally expanding cells in early cancer evolution.  
  
The translational implications of understanding the cancer epigenome are potentially profound.  For example, promising use of 
abnormal gene promoter DNA methylation as a biomarker system for cancer risk assessment, early cancer diagnosis, molecular 
staging of tumors, and monitoring of drug sensitivities is distinctly emerging. The possibility of”epigenetic therapy” for cancer is 
increasingly being pursued and particularly the concept of reversal of epigenetic gene silencing is being studied as a molecular target 
strategy for cancer therapeutics.  
Biosketch 
Scientific Summary: Our research has contributed heavily to the concept that epigenetically mediated loss of gene function is a major player in the 
progression of human cancer. This process, for which aberrant gene promoter hypermethylation is a signature and a component of aberrant loss of 
transcription for involved genes, is now known to be an alternative to coding region mutations for loss of function of over half the classic tumor 
suppressor genes and for a growing list of candidate tumor suppressor genes in virtually every type of human cancer. We are attempting to understand 
the abnormalities of chromatin and methylation assembly that may account for the appearance of these epigenetic abnormalities during tumor 
development and how they mediate the transcriptional repression. We are learning, in this regard, that an interaction between the DNA methylation, 
histone de-acetylase (HDAC), and histone methylating enzymes mediates the transcriptional silencing. We have also discovered that the enzymes that 
catalyze DNA methylation, the DNA methyltransferases (DNMT's), are more complex than previously thought and can both inhibit transcription, and 
interact with HDAC's, independent of mediating the methylation. In collaboration with the Vogelstein-Kinzler lab, we have identified that an interaction 
between DNMT's is required, in colon cancer cells, to maintain the abnormal promoter methylation and silencing of important tumor suppressor genes. 
All of these studies are giving us a much more complete picture of the machinery that mediates aberrant promoter methylation in cancer. They, also, are 
contributing to the translational goal of targeting reversal of abnormal gene silencing as a cancer prevention and/or therapy strategy. 
General Summary: The Baylin laboratory, in close collaboration with the Herman laboratory, seeks to uncover the molecular basis for a change in the 
DNA of cancer cells which causes impaired function of important regulatory genes which are necessary to prevent the formation of tumors. Many such 
losses of gene function in cancer are caused by gene mutations, which cause the cell to produce defective proteins from these genes. These genetic 
changes are permanent in the DNA and cannot be reversed. The change studied by the Baylin and Herman labs is an alternative way in which cancer 
cells inactivate genes by adding methyl groups to the start regions of genes and this is associated with a "silencing" of the gene. This process prevents 
the gene from making any protein and, over the past several years, is being recognized as a very frequent abnormality in all types of human cancer. 
Unlike DNA mutations, DNA methylation abnormalities are reversible by drugs in a laboratory setting and this reversal allows cancer cells to reactivate 
the silenced genes and produce normal protein. Understanding how the abnormal DNA methylation arises in cancer cells, and how this change leads to 
silencing of genes, is extremely important for enriching the possibility of reversing this process as a strategy to prevent and/or treat cancer. Clinical trials 
are already underway at Hopkins and other institutions with some of the drugs that can potentially accomplish these goals. The Baylin and Herman labs 
work closely with clinicians to monitor these trials and to improve the approaches for ultimate success. 
……………………………………………………………………………………………………………………… 
Symposium: Biobanking (19 May 2010) 
 
Bartha-Maria Knoppers  
Professor  
Director, Centre of Genomics and Policy, Faculty of Medicine  
Department of Human Genetics, McGill University, Canada  
Former Chairperson, HUGO Ethics Committee  




Title: The Public Population Project in Genomics : An “ Ethical” Proof of Concept 
It is not the number or size of biobanks that makes them a valuable asset for research, but rather their quality and 
interoperability. It was with these two goals in mind that the Public Project in Genomics (P3G) was launched in 2007. 
What are the results of this effort? Where is it going? More importantly, what were the challenges it faced and the lessons 
learned that can serve to guide the next generation of genomic research? 
Biosketch 
Dr. Knoppers (PhD., O.C.) is Director of the Centre of Genomics and Policy at the Department of Human Genetics, Faculty of Medicine, McGillUniversity. 
She is former Chair of the International Ethics Committee of the Human Genome Organization (1996-2004) and currently, Chair of the Ethics Working 
Party of the International Stem Cell Forum (U.K.). In 2003, she founded the international Public Population Project in Genomics (P3G) and became the 
Principal Investigator of CARTaGENE. CARTaGENE is a resource of samples and data on the genetic diversity of the population of Quebec 
……………………………………………………………………………………………………………………… 
 
David B Goldstein 
Director, Duke Institute for Genome Sciences and Policy 
Center for Human Genome Variation 
 
Title: Rare and common variants in human disease 
There are now several confirmed common variants that influence common diseases, responses to infection, and 
responses to drugs.  For most common diseases however all common variants identified explain only a few percent of the 
known heritability, and many of the signals emerging from genome wide association studies have yet to be tracked to 
single common variants, raising the possibility that in some cases the signals emerge from associated  sets of rare 
variants. Here I argue that progress in identifying the so called ‘missing heritability’ for many human traits will be facilitated 
using an extreme phenotype whole-genome sequencing paradigm.  I illustrate the basic structure and motivation for this 
approach using examples from our work on host determinants of control of HIV-1. 
Biosketch 
Dr. David Goldstein is Professor of Molecular Genetics & Microbiology, Department of Biology and Director of Duke Institute for Genome Science & 
Policy, Center for Human Genome Variation since June 2005. Dr. Goldstein received his PhD in Biological Sciences from Stanford University in 1994, 
and from 1999 to 2005 was Wolfson Professor of Genetics at University College London. In April 2007, he was appointed Honorary Professor, Institute 
of Neurology, University College London, UK. 
Dr. Goldstein is the author of over 100 scholarly publications in the areas of population and medical genetics.  His principal interests include human 
genetic diversity, the genetics of neurological disease, and pharmacogenetics.  As part of the Center for HIV-AIDS Vaccine Immunology (CHAVI), his 
laboratory also has a particular focus on the host genetics of HIV infection. He is the recipient of one of the first seven nationally awarded Royal Society / 
Wolfson research merit awards in the UK for his work in human population genetics.Dr. Goldstein was awarded the Triangle Business Journal Health 




Senior Vice President and Chief Scientific Officer 
Applied Quantitative Genotherapeutics 
Pfizer Inc. 




Title: Advancing biobanking through public-private collaboration 
In order to make drugs that matter, the pharmaceutical needs to engage the broader scientific and healthcare community 
in a more collaborative fashion than is presently the case. Historically, there has been poor alignment of molecular 
understanding with clinical need.  What is required to improve this alignment is long-term clinical epidemiological data 
associated with critical samples not presently available to industry.  While academia often looks to industry as simply a 
source of cash, private sector contributions of knowledge and data, added to public sector data and samples, could 
potentially be much more valuable than cash alone.  But how does one reconcile altruism, protection of stakeholders  and 
open collaboration, primary principles of public biobanking, with intellectual property and profit, which are often viewed as 
synonymous with industry involvement? One solution is collaboration at the “precompetitive stage”, such that all 
knowledge gained from an  industry-academic collaboration would be freely available to all in the public domain, with no 
intellectual property restrictions. Such public domain biological knowledge would then be the basis for development of 
novel therapies by either the public or the private sector.  Scientists in industry and academic could lead by example, 
setting up such pre-competitive collaborations and demonstrating to the world that they can work.  One example of such 
an approach is the “expert centre” concept now being developed as part of the Biobanking and Biomolecular Resources 
Research Infrastructure (BBMRI) in Europe.  
Biosketch 
David serves as Chief Scientific Officer for the Applied Quantitative Genotherapeutics Unit of Pfizer’s Biotherapeutics Research & Development. This 
new unit brings together human genetics, systems biology, and cell biology, combining internal capabilities with outside collaborations, to focus on 
increasing preclinical target validation with the aim of significantly improving clinical survival. David is a co-founder of Perlegen, and was most recently 
Chief Scientific Officer of the company since its formation in 2000. David was Professor of Genetics and Pediatrics at the Stanford University School of 
Medicine as well as the co-director of the Stanford Genome Center. He obtained his A.B. and M.S. degrees from Brown University in Rhode Island and 
his M.D. and Ph.D. degrees from the University of Washington, Seattle. He completed a Pediatric Residency at the Yale-New Haven Hospital in New 
Haven, Connecticut and was a Fellow in both genetics and pediatrics at the University of California, San Francisco. David is certified by the American 
Board of Pediatrics and the American Board of Medical Genetics. He was an active participant in the large scale mapping and sequencing efforts of the 
Human Genome Project while carrying out research involving the molecular basis of human genetic disease. David has been a member of several 
commissions and boards, including the National Bioethics Advisory Commission (NBAC) and the Health Sciences Policy Board of the Institute of 
Medicine. He has also served on a number of international committees, including the Council of the Human Genome Organization (HUGO). He has 
authored over 100 peer-reviewed scientific publications and has served on numerous editorial boards. Dr. Cox’s honors include election to the Institute 





Norwegian Institute of Public Health (NIPH) 
Oslo, Norway  
Title: Biobank harmonization for health 
Unravelling the causes of complex diseases and translating these efforts into public health and clinical practice are 
primary goals of biomedicine. It has become well recognized that conducting the high-throughput and interdisciplinary 
science underlying this agenda is heavily reliant on access to large-scale biobanks of wide geographic span which curate 
a rich array of data including genotypes, other biomarkers, clinical measures, environmental exposures, life-style and 
social factors plus biospecimens. The FP6 project entitled ‘Promoting Harmonisation of Epidemiological Biobanks in 
Europe’ (PHOEBE) (http://www.phoebe-eu.org) was designed to promote the harmonization of European population-
based biobanks to optimise their ability of biobanks to communicate with one another, share ideas, information and data, 
and collaborate effectively in a complex world where laws and ethical guidelines often differ between nations and over 
time.  To fulfil its mission PHOEBE worked closely with other international harmonization initiatives to help bring 
coherence to these issues and to forge a common way forward. This presentation will describe the challenges 
encountered and solutions proposed to help harness the full potential of biobanking in the generation and translation of 
research findings to improve health. 
Biosketch 




Dr. Jennifer R. Harris is a senior researcher in genetic epidemiology at the Norwegian Institute of Public Health (NIPH) in Oslo. She led the FP6 project 
Promoting Harmonization of Epidemiological Biobanks in Europe (PHOEBE), she is a scientific partner in FP7 project European Network of Genetic and 
Genomic Epidemiology (ENGAGE) and has been extensively involved in several other international biobanking initiatives such as P3G, BBMRI and 
GenomEUtwin. She is also a special expert at the National Institute on Aging, NIH, USA where she develops research directions integrating genetics 
and genomics with behavioural and social research.  She is the founder of the NIPH twin panel and program of research, which was established under 
her research interests to integrate developmental approaches with genetic research into complex phenotypes. Her current research uses the discordant 
twin design to study epigenetic and CNV influences on autoimmune disorders and she is also studying genetic and environmental influences on body 
composition. 
She obtained her PhD in Human Development and Genetics from the PennsylvaniaStateUniversity and was awarded a post-doctoral research fellowship 
at the Karolinska Institutet in Stockholm through the John D. and Catherine T. MacArthur Foundation. She has broad commitment to the wider scientific 
community and serves on several expert panels, boards, steering groups, scientific advisory committees and editorial boards. 
……………………………………………………………………………………………………………………… 
Symposium: Microbial Genomics and Metagenomics (19 May 2010) 
 
Martin Hibberd 
Senior Group Leader 
Assoc Director, Infectious Diseases 
Genome Institute of Singapore  
Title: Dengue virus genomics, a window into evolution, virulence and transmission patterns 
Dengue infection results in a wide clinical spectrum, ranging from asymptomatic, through fever to life threatening 
complications.  However, the mechanisms that lead to these outcomes remain largely unknown. To investigate if there are 
early processes that can perhaps direct the host response in a way that can lead to a specific disease, we have used 
whole genome expression profiling from the first few days to convalescence and correlated this with disease progression. 
We have also noted that these host-responses can be linked to clades of viruses and are now exploring their relationship 
to viral sequence. Recent developments in technology has enabled us to sequence these viruses deeply, to recognize 
minority genomes that may have an impact on disease outcome and may also potentially be used to follow viral evolution 
occurring in one single transmission. Little is known about the pattern and dynamics of dengue virus (DENV) 
transmissions within outbreak situations. By exploiting genomic data from an intensively studied, we are able to describe 
the molecular epidemiology of DENV at a uniquely fine-scaled temporal and spatial resolution. We also investigated host 
response differences between these strains and found that they exhibited a marked difference in inducing type I IFN 
response. Investigating further strains suggested that this difference is strain-dependent but not serotype-specific. Our 
report indicates the existence of a strain-specific virulence factor that may impact on disease severity. 
This genomics approach has identified new understandings of the causes of different outcomes; and the identified genes 
in humans and virus may be suitable targets for the development of much needed drugs and diagnostics against dengue. 
Biosketch 
Dr Martin Hibberd BSc(Hons) PhD; Senior Group Leader, Infectious Diseases at the Genome Institute of Singapore and has adjunct positions at the 
National University of Singapore and Imperial College (London, UK). Graduated with Honors from Brunel University in 1985 (West London, UK) and 
received his Doctorate, on the immune-genetics of the human T-cell antigen receptor, from King’s College, London. Has a broad scientific background 
spanning both microbial and human determinants of infectious and inflammatory diseases. Previous posts include WHO-funded Senior Microbiologist at 
the UK’s central Public Health Laboratories, and for seven years prior to his current appointment he was Lecturer and Senior Lecturer in Pediatric 
Infectious Diseases at the Imperial College School of Medicine, one of the very top-ranking British universities. Current research interests cover both 
pathogen and host aspects of infectious disease, understanding how microbial agents causes the observed disease (including pathogen identification 
and sequence characterization) and why specific individuals are susceptible to the disease (using host genetics on a genomic scale). Approaching 
infectious disease from these two directions also allows specific host pathogen responses to be investigated (utilizing RNA micro and low density arrays). 
This work aims to identify key host responses to specific pathogens that could be targeted by new therapies. 
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Senior group leader (bioinformatics) at the EMBL (Heidelberg) 
Joint coordinator of EMBL Structural and Computational Biology unit 
Visiting group leader at the MDC (Berlin-Buch)  
 
Title: Comparative (meta) genomics: Lessons from a tiny bacterium and a complex microbial community 
Environmental sequencing is uncovering genomic parts of various microbial communities, but our understanding of their 
functioning remains limited. I will briefly introduce the powers and pitfalls of metagenomics (Raes and Bork, 2008) and will 
zoom in on the human gut where recent technological advances (Qin et al., 2010) have led to a wealth of data and where 
first concepts arise on how the landscape of gut microbiomes around the globe might look like. As in the future, single cell 
sequencing will enable the study of the species in a community one by one and as one not only needs a broad overview, 
but also a detailed understanding of the roles of individual species, I will also introduce a pilot study of one of the smallest 
bacteria, Mycoplasma pneumoniae. Data on the transcriptome, metabolome and proteome have been consistently 
generated and integrated to reveal a wealth of information about the biology of a genome-reduced bacterium that was 
found to be remarkably complex (Kuehner et al, 2009, Yus et al., 2009, Guell et al., 2009). 
 
Raes J and Bork B, Nat Rev Microbiol. 2008 Sep;6(9):693-9 
Qin J et al., Nature. 2010 Mar 4;464(7285):59-65 
Kuehner S et al., Science. 2009 Nov 27;326(5957):1235-40 
Yus E et al., Science. 2009 Nov 27;326(5957):1263-8 
Guell M et al., Science. 2009 Nov 27;326(5957):1268-71 
Biosketch 
Peer Bork, PhD, is senior group leader and joint head of the Structural and Computational Biology unit at EMBL, a European research organization with 
headquarters in Heidelberg. He also holds an appointment at the Max-Delbrueck-Center for Molecular Medicine in Berlin. Dr Bork received his PhD in 
Biochemistry (1990) and his Habilitation in Theoretical Biophysics (1995). He works in various areas of computational biology and systems analysis with 
a focus on function prediction, comparative analysis and data integration. He has published more than 400 research articles in international, peer-
reviewed journals, among them more than 45 in Nature, Science and Cell. According to ISI (analyzing the last 10 years), Dr. Bork is currently the most 
cited European researcher in Molecular Biology and Genetics. He is on the editorial board of a number of journals including Science and PloS Biology, 
and functions as senior editor of the journal Molecular Systems Biology. Dr Bork co-founded four biotech companies, two of which went public. More 
than 25 of his former associates now hold professorships or other group leader positions in prominent institutions all over the world.  He received the 
"Nature award for creative mentoring" for his achievements in nurturing and stimulating young scientists. He was also the recipient of the prestigious 
"Royal Society and Academie des Science Microsoft award" for the advancement of science using computational methods. 
……………………………………………………………………………………………………………………… 
 
Stanislav Dusko Ehrlich 
Research Director  
Microbial Genetics Research Unit, Department of Microbiology and the 
Food Chain, INRA Centre of Jouy-en-Josas 
National Institute of Agronomic Research (INRA), France  
 
Title: Characterization of the human “other” genome by the MetaHIT Consortium 




Humans live in association with a large number of microorganisms, which affect our health and well-being. Most reside in 
the intestine, where their numbers exceed 10-fold the number of our cells. The intestinal micro-organisms are thought to 
have an important role in health and disease, but are still poorly characterized. To understand and exploit the impact of 
the gut microbes on human health and wellbeing it is necessary to decipher the content, diversity and functioning of the 
gut microbial community. 
 The European project on the metagenomics of the human intestinal tract, MetaHIT, (http://www.metahit.eu) has as a first 
objective creation of a catalog of the microbial genes from our intestinal tract, thus laying foundations for characterization 
of the gut microbial community. Next, it aims to explore associations between microbial genes and human phenotypes. 
For that, it develops, on the one hand, molecular tools for profiling of the intestinal microbial genes that are harbored by 
any individual and on the other a bio-informatics resource to organize and interpret heterogeneous information, including 
sequencing data and clinical metadata. Finally, MetaHIT develops approaches to detect and analyze functional 
interactions of microbes and the human host, focusing on the role of target genes in the microbial cell and the effect of 
gene products on the human host. 
 We have established an extensive catalog of the gut microbial genes, based on the Illumina metagenomic sequencing. 
The catalog contains 3.3 million nonredundant microbial genes, derived from 576.7 Gb sequence of the DNA prepared 
from faecal samples of 124 individuals of the European origin. The sequencing and the assembly was carried out BGI 
Shen Zhen, one of the MetaHIT partners. The gene set is more than 150 times larger than the human gene complement, 
contains an overwhelming majority of the prevalent microbial genes present in the cohort and likely includes a large 
proportion of the prevalent human intestinal microbial genes. The gene pool is largely shared among individuals of the 
cohort. Over 99% of the genes are bacterial, suggesting that the entire cohort harbors between 1000 and 1150 prevalent 
bacterial species and each individual at least 160 such species, which are also largely shared. We define and describe 
the minimal gut metagenome and the minimal gut bacterial genome in terms of functions encoded by the gene set.  
 Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2110). 
Biosketch 
Dr. S. Dusko Ehrlich received his Ph.D. from Université Paris VII in 1973 and was a research associate of Prof. Joshua Lederberg, Nobel prize winner, 
at Stanford University Medical school, from 1973 till 1977. He joined French National Institute for Medical Research (INSERM) as a Research Director in 
1977, founded and led a research group at the National Center for Scientific Research (CNRS) Institute Jacques Monod at the University  Paris VII until 
1986. He joined National Institute for Agricultural Research (INRA) in 1986, founded the Microbial Genetics Unit and directed it till 2008. He founded the 
Microbiology Department of INRA in 1991 and chaired it till 2002. He has authored over 300 research papers and holds an H-index of 58. He is a 
member of the European Molecular Biology Organisation, the Croatian Academy of Arts and Sciences and the French Academy of Agriculture and 
currently coordinates the European Commission FP7 project MetaHIT (Metagenomics of the Human Intestinal Tract). His research interests are mainly 




Director of the U.S. Department of Energy Joint Genome Institute (JGI) 
Director of the Genomics Division at Lawrence Berkeley National 
Laboratory (LBNL)  
Title: Assembly of genes and genomes from bio-mass degrading cow rumen 
The paucity of enzymes able to efficiently deconstruct plant material represents an important bottleneck in industrial scale 
production of cellulosic biofuels. The cow rumen harbors many uncultured microbes that have evolved optimized 
molecular machineries for the efficient conversion of biomass into monomeric sugars. In this study we generated and 
analyzed 100 gb of metagenomic sequence from the microbial community adherent to switchgrass incubated in cow 
rumen to characterize the genes from and the genomes of organisms involved in its deconstruction. We identified more 
that 300 novel full length cellulolytic genes and demonstrated approximately a third of the 100 expressed and tested for 
cellulose degradation activity as positive. Near complete draft coverage of 2 novel microbial genomes was generated. Our 
deep metagenomic sequencing of biomass adherent microbes followed by computational and functional analyses has 




dramatically expanded the number and diversity of cellulolytic genes able to degrade biomass as well as revealed the 
draft genomes for several completely novel uncultured rumen microbes. 
Biosketch 
Internationally recognized geneticist Eddy Rubin has served since 2002 as Director of the U.S. Department of Energy Joint Genome Institute (JGI), and 
Director of the Genomics Division at Lawrence Berkeley National Laboratory in Berkeley, CA. As Director of the JGI, one of the world's largest 
sequencing centers, he oversaw the sequencing and analysis of 13% of the human genome (human chromosomes 5, 13 and 16), parts of the 
Neanderthal genome and the genomes of more than 200 animals, plants and microbes. Following the completion of the Human Genome Project, Dr. 
Rubin reoriented the JGI towards the application of genomics to studies related to bioenergy and climate change.  
With more than 200 peer-reviewed publications, over 30 of them in the leading journals Science and Nature, his research focuses on the development of 
computational and biological approaches for studying genomes. His early scientific work centered on the functional exploration of the human genome, 
harnessing sequence comparisons between species for the discovery of genes and non-coding sequences of pivotal evolutionary and biomedical 
importance.  More recently, he spearheaded the new science of metagenomics, deriving important insights from his investigations of microbial 
communities inhabiting environments ranging from gutless ocean-dwelling worms to cow rumen.  
In addition to his research and the training of more than 50 scientists who have passed through his laboratory, Dr. Rubin has been an influential leader in 
the field of genomics through his community activities. He sits on the editorial boards of several leading journals, including the Board of Reviewing 
Editors for the journal Science, has organized and chaired major genomics meetings and is a member of multiple scientific advisory boards. Through 
government advisory committee membership, Dr. Rubin has actively influenced the directions of genomic research at the U.S. Department of Energy 
and U.S. National Institutes of Health. 
……………………………………………………………………………………………………………………… 
Featured Talk (19 May 2010) 
 
Charles N. Rotimi 
Director, Center for Research on Genomics and Global Health (CRGGH)  
 
Title: Genetic diversity and health: Opportunities and challenges presented by African genomes 
Africa is the common birthplace of all human populations. As a result, modern humans have lived longer on the Africa 
continent than in any other geographical regions of the world. This long evolutionary history has led to several important 
cultural and genetic characteristics of the African people. For example, greater genetic variation is seen in present-day 
Africa populations, resulting in more haplotypes, lower levels of linkage disequilibrium (LD), more divergent patterns of LD 
and more complex patterns of population substructure. Africa has the highest linguistic diversity in the world with an 
estimated 2,000 languages; notably, Nigeria as a nation has over 500 listed languages. Also, due to vast cultural practices 
and uneven economic developments, African populations display considerable phenotypic variation. Given these 
important observations and the critical role of Africa in human evolutionary history, it is surprising that there has not been 
a global effort to systematically sample African populations for a comprehensive documentation of the scope and extent of 
genetic variation on the continent. In fact, an argument can be made that Africa has been, for most part, left out of the 
genomic revolution to date. A stark demonstration of this point is the fact that, despite the well documented success 
stories of genome-wide association studies (GWAS) in identifying susceptibility variants for several human diseases 
(www.genome.gov/gwastudies), it is remarkable that only one GWAS, the MalariaGen Project, has been published in a 
large collection of African individuals to date. This observation is particularly troubling given that Africa is faced with the 
heaviest global burden of disease, the least equipped health care system and perhaps, the least technologically 
developed to take advantage of the growing health and economic success stories of the genomic revolution. 
The inclusion of three African populations in the international HapMap and several more African populations in the 1000 
genome project and the recent whole genome sequencing of a Yoruba and Southern African individuals are beginning to 
address this inequity in genomic research. This presentation will explore our current understanding of the scope of genetic 
diversity in Africa and its implication for health and human history. A case will be made that, by not fully engaging African 
populations in genomic research, scientists are likely to compromise the novel insights that could be gleaned from 




studying the different genetic architecture of Africa people. For example, reduced LD in African populations is likely to 
provide a better chance of identifying causal variants for human diseases and the long evolutionary history of the African 
people is also likely to advance our understanding of human adaptive history. 
Biosketch 
Charles Rotimi, PhD, a genetic epidemiologist and a biochemist, is a senior investigator in the Inherited Disease Branch of the NHGRI intramural 
program. He is the Director of the Center for Research on Genomics and Global Health (CRGGH). The mission of this new trans-NIH center is to 
advance research into the role of culture, lifestyle, genetics and genomics in disease etiology and health disparities. Dr. Rotimi develops genetic 
epidemiology models and conducts population genetics research that explores the patterns and determinants of common complex diseases in human 
populations with particular emphasis on populations of the African Diaspora. As a senior investigator and director of the CRGGH, Dr. Rotimi leads a 
team of researchers across multiple disciplines (Medicine, genetics/genomics, epidemiology, statistics and informatics) to understand the complex 
interactions between inherited characteristics and environmental factors in disease susceptibility, variable drug response and health disparities. For 
example, his team conducted the first GWAS of an African American cohort that identified several genetic variants including PMS1, SLC24A4, YWHA7, 
IPO7, and CACANA1H underlying susceptibility to Hypertension and blood pressure control.  His lab also conducted the first and only genome-wide 
linkage study of Type 2 Diabetes in West Africans (the AADM Study). Dr. Rotimi’s lab continues to contribute to the global understanding of human 
genetic variation and its implication for differential disease distribution, variable drug response and human migration history. He is the current president 
of the African Society of Human Genetics (www.afshg.org). 
……………………………………………………………………………………………………………………… 
Plenary: An Expanding RNA World (19 May 2010) 
 
Gil Ast 
Professor of Molecular Biology and Bioinformatics 
Department of Human Molecular Genetics and Biochemistry 
Tel Aviv University Medical School 
Title: Importance of alternative splicing in transcriptomic diversity and disease 
Alternative splicing is a major mechanism for generation of transcriptomic and proteomic diversity, especially in humans. 
Mutations that affect splicing are correlated with many human diseases and cancer. However, despite decades of 
research we still do not understand how short exonic sequences recognized within the vast intronic oceans in which they 
are embedded are selected by the splicing machinery. For many years, studies aiming to shed light on this process were 
focused at the level of RNA. However, we increasingly understand that splicing is not an isolated process; rather it occurs 
and regulated co-transcriptionally. Studies by our group and others show that DNA structure in terms of nucleosome 
positioning and specific histone modifications may also play a role in splicing. We will first discuss evidence regarding the 
coupling between transcription and splicing and between chromatin structure and splicing. Finally, we will show how GC 
content led to the appearance of two types of exon/intron structures – termed exon and intron definition – which the 
splicing machinery handles differently. Splicing-disrupting mutations in these two systems have different outcome on the 
exon selection process. Overall, we will show how the genomic environment surrounding mutations affect the exon 
selection process. 
Biosketch 
Our group has made seminal contributions to our understanding of the acquisition of complexity in the expression of genomic information through 
alternative mRNA splicing, and the involvement of this process in genetic disorders and cancer. The broad focus of our laboratory is on regulation of 
splicing of pre-mRNA and the importance of alternative splicing in the generating transcriptomic diversity unique to our species. We study mechanisms 
of alternative splicing regulation using a combination of computational and experimental methods. We also study the potential link between DNA 
packaging by histones and epigenetic modifications and how these effect processing of pre-mRNA. 
……………………………………………………………………………………………………………………… 







Omics Science Center  
RIKEN Genomic Sciences Center  
Title: Transcriptome analysis — A way to illuminate the genome network 
The first step on the road to knowledge was taken in 1995 when we first glimpsed the RNA complexity. We realized the 
need of new technologies to construct the full-length cDNA library (Cap trapper method, normalization, subtraction, new 
cDNA vector and thermoprotection technology of reverse transcriptase using trehalose), and high throughput sequencing 
(Riken integrated sequence analysis system; RISA) was essential to reach the goal of large-scale data collection. In order 
to process the data we started to collect people, and the International FANTOM consortium was founded in 2000. The 
combination of talented people and data have given us millions of full-length cDNA sequences, CAGE tags and ditags, 
collected in the de facto world standard database (5 visits/second) 
The efforts of the FANTOM consortium have revealed non-coding RNA (ncRNA) as the major product of the genome 
(53%), and that the actual number of genes is diminished through the history of life science due to gene fusion, but 
increased by the number of ncRNA. We also learned that 72% of all genes have sense/antisense transcripts. 
All the discoveries we have made regarding RNA have given us a new view of the central dogma, collapsing the old DNA 
to protein concept. The double stranded RNA (dsRNA) for RNAi cannot only be created by virus and miRNA and S/AS is 
a new source of dsRNA. RNA is flexible and regulates gene expression through RNAi and other mechanisms. Now we 
have found a group of transcription factors that act like a switch between RNAi and regular gene expression by interacting 
with the RNAi machinery directly. Altogether these new findings dissolve the central dogma into a new picture with new 
interaction cascade and the unexpected complexity of combined omics.  
Biosketch 
Yoshihide Hayashizaki received his M.D. and Ph.D. from Osaka University Medical School in 1982 and 1986, respectively.In 1992, he joined RIKEN, 
and was appointed Project Director for the RIKEN Genome Project in 1995. Since then he has been taken a transversal data-driven approach to analyze 
transcriptomes by developing unique technologies including a series of full-length cDNA technologies. With this approach, he has established large 
amount of full-length cDNA clone bank. This activity was followed by organization of FANTOM (Functional Annotation of Mammalian), an international 
consortium, originally to annotate a large number of cDNA and subsequently expanded to transcriptome and network analysis. FANTOM activities 
revealed that more than 63% of the genome — not just the ~1.5% fraction that are protein-coding exons — is transcribed as RNA. In 2008, he appointed 
to the Director of the Omics Science Center. The center was established to link a variety of omics subdisciplines to molecular networks and pathways in 
order to advance our understanding of biological phenomena as systems at the molecular level. 
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Plenary: Gene Expression & Human Variation (19 May 2010) 
 
Michael Snyder 
Professor and Chair of Genetics 
Director, Stanford Center for Genomics and Personalized Medicine  
 
Title: Transcription binding variation in eukaryotes 
Variation in transcriptional regulation is thought to be a major cause of phenotypic diversity. Although widespread 
differences in gene expression among individuals of a species have been observed, few studies have examined the 
variability of transcription factor (TF) binding, and thus the extent and underlying genetic basis of TF binding diversity is 
HUGO J (2010) 4:1–190 35
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largely unknown. We mapped differences in transcription binding among individuals and elucidated the genetic basis of 
such variation on a genome-wide scale for both yeast and humans.  For humans we mapped the binding sites of RNA 
Polymerase II (PolII) and a key regulator of immune responses, NFțB (p65), in ten lymphoblastoid cell lines and found 
that 25% and 7.5% of the respective binding regions differed between individuals. Binding differences were frequently 
associated with SNPs and genomic structural variants (SVs) and were often correlated with differences in gene 
expression, suggesting functional consequences of binding variation.  
  
To further understand the genetic basis of transcription factor binding variation, we mapped the binding sites of Ste12 in 
pheromone-treated cells of 43 segregants of a cross between two highly diverged yeast strains and their parental lines. 
We found that the majority of TF binding variation is cis-linked and that many variations are associated with 
polymorphisms residing in the binding motifs of Ste12 as well as those of several proposed Ste12 cofactors. We also 
identified trans factors that modulate Ste12 binding to specific promoters. Ste12 binding strongly correlates with gene 
expression indicating that binding variation is functional. Overall these different studies identified genetic regulators of 




Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine.  Dr. 
Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University.  He is a leader in 
the field of functional genomics and proteomics.  His laboratory study was the first to perform a large-scale functional genomics project in any organism, 
and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis 
of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip for 




Director, UNC Institute for Pharmacogenomics and Individualized 
Therapy  
 
Title: Using the genome to guide therapy 
The field of pharmacogenomics has seen some exciting advances in the recent past. The Human Genome Project and 
International HapMap projects have uncovered a wealth of information for researchers. This has lead to the discovery of 
clinically predictive germline genotypes (e.g. UGT1A1*28-irinotecan, TYMS TSER-fluoropyrimidines, CYP2D6-tamoxifen, 
CYP2C19-clopidogrel), germline haplotypes (e.g. VKORC1 Haplotype A-warfarin) and somatic mutations (e.g. epidermal 
growth factor receptor-gefitinib/erlotinib, KRas-cetuximab/panitumumab). The introduction of FDA approved 
pharmacogenetic tests (UGT1A1*28, CYP2C9/VKORC1, CYP2D6/CYP2C19) and the initiation of genotype-guided 
clinical trials have provided the first steps towards the integration of pharmacogenomics into clinical practice. It is also 
clear that there are many non-scientific barriers to clinical application. These include integration of new tests into health 
systems, changing old habits to allow application of new data, and the reality that the cost of both testing and the 
therapeutic options are a key driver in health care. As the scientific evidence matures, A team research approach must be 
more aggressively applied in order to overcome the many obstacles to delivering more careful selection of drug therapy. 
Biosketch 
Dr Howard McLeod is Fred N. Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, 
University of North Carolina, Chapel Hill.  Dr McLeod holds appointments in the Schools of Pharmacy and Medicine and the Lineberger Cancer 
Center.  Dr McLeod is also the Principal Investigator for CREATE, a member of the NIH funded Pharmacogenetics Research Network and is a member 
of the FDA committee on Clinical Pharmacology.  He also directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing 
countries use genetic information to improve National Drug Formulary decisions.  Howard has published over 350 peer reviewed papers on 
pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance 
individualized medicine. 





Plenary: Human Genome Variation in Evolution and Disease (20 May 2010) 
 
Mark McCarthy 
Robert Turner Professor of Diabetes 
Oxford Centre for Diabetes, Endocrinology and Metabolism 
 
Title: Type 2 diabetes: Susceptibility variants across the allele frequency spectrum 
Ongoing efforts to define additional common variants influencing traits of biomedical importance are motivated by the 
biological insights that follow the identification of robust causal relationships between genome sequence variation in a 
given location and the phenotype of interest. Once the “low hanging fruit” have been picked, further success is 
increasingly dependent on improvements in power that flow from combined analysis of multiple GWA and replication data 
sets. A growing number of global consortia have emerged to manage such efforts. 
For type 2 diabetes (T2D), the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium has 
concentrated current efforts on T2D signals in European-descent populations. In recent months, the efforts of the 
consortium have contributed to expansion of the number of confirmed T2D common variant signals to almost 40. The 
newly-identified loci include several that appear to influence insulin action (though most are associated with deficits in 
beta-cell function), several that map to imprinted loci and have been shown to have parent-of-origin effects, and the first 
located on the sex-chromosomes. One of the striking features of these data is the frequency with which the same regions 
harbour independent signals influencing other, non-diabetes-related, traits: this speaks to tissue-specific subtleties in 
regulatory control around the genes concerned.  
The principal challenges going forwards are: (a) to move from these association signals to understanding of biological 
mechanisms through identification of the causal variants driving these effects and the genes and pathways through which 
they operate; (b) to obtain a more complete enumeration of alleles contributing to genetic risk of T2D through extending 
the spectrum of variants evaluated; and (c) to translate these discoveries into advances in clinical management of 
diabetes. The growing capacity of high-throughput sequencing technologies is likely to have a transformative effect on all 
three, and I will describe some of the approaches we are taking to address these challenges.  
Biosketch 
Mark McCarthy is Robert Turner Professor of Diabetes at Oxford University, based at the Oxford Centre for Diabetes, Endocrinology and Metabolism 
(OCDEM) and at the Wellcome Trust Centre for Human Genetics. His work on the genetics and genomic basis of type 2 diabetes seeks to define the 
relationship between genetic variation, environment, intermediate phenotypes, and clinical disease, in the belief that such information will translate into a 
significant impact on clinical care for people with diabetes, through more rational and effective deployment of available preventative and therapeutic 
modalities.  
He obtained his medical degree at the University of Cambridge and postgraduate clinical training in general medicine, diabetes and endocrinology at the 
London Hospital. Following research training with – amongst others – Newton Morton and Eric Lander, he took up an appointment as Senior Lecturer 
(subsequently Professor in Genomic Medicine) at Imperial College in 1995, moving to Oxford as the Robert Turner Professor of Diabetes in 2002. In the 
past decade, his group has become established as one of the leading international teams working on the genetics of T2D, with expertise extending from 
physiological characterisation through to high-throughput genomic analysis and related issues in computational biology. Prof McCarthy currently leads 
the T2D component of the Wellcome Trust Case Control Consortium, and has been intimately involved in many of the recent discoveries generated by 
the application of genome wide association approaches to diabetes, obesity and related traits. His group is increasingly involved in efforts to understand 
how such information can be translated into advances in clinical management, and in extending these studies beyond the European context. He has a 
strong commitment to the wider research community, having served as a member and chair of the Diabetes UK Research Committee, and on Wellcome 
and MRC panels. He serves on the Editorial Board of Diabetes, Diabetologia, PLoS Medicine, Human Molecular Genetics and several other journals.  
……………………………………………………………………………………………………………………… 




Stephen W Scherer 
Director, McLaughlin Centre and the Toronto Centre for Applied 
Genomics 
Professor, Hospital for Sick Children and University of Toronto 
Title: Clinical context of copy number and structural variation in the human genome 
During the past ¿ve-years, copy number variation (CNV) and structural variation (SV) have emerged as highly prevalent 
forms of genomic variation, bridging the interval between long-recognised microscopic chromosomal alterations and 
single-nucleotide changes. These genomic differences among humans reÀect the dynamic nature of genomes, and 
account for both natural variations among us and variations that predispose to conditions of medical consequence. I will 
discuss CNV-SV in their historical and medical contexts, focusing on how these variations can be recognised, 
documented, characterised and interpreted. I will also discuss how they can cause disease or inÀuence adaptation to an 
environment. Our recent work on autism spectrum and related neuropsychiatric disorders will also be described to 
illustrate salient characteristics and residual enigmas of this complex form of genetic variation. 
Biosketch 
Dr. Scherer holds the GlaxoSmithKline-CIHR Endowed Chair in Genetics and Genomics at The Hospital for Sick Children and University of Toronto. He 
has made numerous contributions to medical genetics including mapping sequencing and disease gene studies of human chromosome 7. He 
collaborated with the J. Craig Venter Institute to generate the first genome sequence of an individual ushering in an era of genomic medicine. In 2004, 
his team co-discovered global gene copy number variation (CNV) and has since shown that CNV is the most abundant type of variation of human DNA. 
His group has also discovered CNV to contribute to the etiology of autism and the Database of Genomic Variants he founded facilitates hundreds of 
thousands of diagnoses each year.  He sits on the Scientific Advisory Board of Combimatrix Diagnostics and Autism Speaks, and he is on the Board of 
Trustees of Genome Canada and the Human Genome Organization (HUGO). Dr. Scherer has won numerous honors including the 2004 Steacie Prize, 
an International Howard Hughes Medical Institute Scholarship, and the 2008 Premier Summit Award for Medical Research. 
……………………………………………………………………………………………………………………… 
 
Felix Jin Li 
Professor and Vice President of Fudan University 
Professor at the National Human Genome Center in Shanghai 
Co-Director of CAS-MPG Partner Institute for Computational Biology at 
Chinese Academy of Sciences  
Title: Identification of copy number variation hotspots in human populations 
Copy number variants (CNVs) in the human genome contribute to both Mendelian and complex traits as well as genomic 
plasticity in evolution. Much progress was made to unravel the CNV formation mechanisms; however, the evaluation of 
CNV mutation rate at genome level poses an insurmountable practical challenge. We showed that an approximate 
estimation of CNV mutation rate could be achieved using the phylogeny information of flanking SNPs. This allows a 
genome-wide comparison of mutation rates between CNVs for identifying mutational hotspots using HapMap genotyping 
data. The mutation rates for the majority of 4,330 CNVs investigated in this study are at the order of 10-5 per generation, 
consistent with experimental observations at individual loci. Notably, the mutation rates of 132 (3.0%) CNVs are at the 
order of 10-3 per generation, therefore, identified as hotspots. Further analyses revealed that genome architecture has a 
potential role in inciting mutational hotspots in the human genome. 
Biosketch 
Li Jin is a Chinese geneticist who led the research that concluded that all East Asians, including the Chinese, originated from Africa, adding support to 
the recent single-origin hypothesis of which he is considered a leading proponent. His team analyzed the Y chromosomes of males around China and 
compared this group with those of Southeast Asians and Africans. Results of the analysis suggested that Southeast Asia was the first destination of the 
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migration from Africa to Asia which began approximately 60,000 years ago; from there, migrants moved into Southern China, then crossing the Yangtze 
River to Northern China. The 1998 study, which used genetic markers called microsatellites to compare Chinese populations, did not support an 
independent origin of Homo sapiens in China. The findings contradict the hypothesis that Peking Man (Homo erectus) was the ancestor of the Chinese 
people.  
Jin is a professor and Dean of School of Life Sciences of Fudan University, as well as a professor at the National Human Genome Center in Shanghai. 
Jin is the principal investigator of East Asian populations for the Genographic Project which collects DNA samples to map historical human migration 
patterns around the world. His research interests are in human and medical genetics, population genetics, genomics & bioinformatics, anthropology. 
……………………………………………………………………………………………………………………… 
Chen Award Lecture (20 May 2010) 
 
Ng Huck Hui 
Senior Group Leader, Genome Institute of Singapore  
Associate Professor (Adjunct), National University of Singapore and 
Nanyang Technological University  
Title: Deciphering and reconstructing the embryonic stem cell transcriptional regulatory network 
Embryonic stem (ES) cells are characterized by their ability to self-renew and remain pluripotent. Transcription factors 
have critical roles in the maintenance of ES cells through specifying an ES-cell-specific gene expression program. 
Deciphering the transcriptional regulatory network that describes the specific interactions of these transcription factors 
with the genomic template is crucial for understanding the design and key components of this network. To gain insights 
into the transcriptional regulatory networks in ES cells, we use chromatin immunoprecipitation coupled to ultra-high-
throughput DNA sequencing (ChIP-seq) to map the locations of sequence specific transcription factors. These factors are 
known to play different roles in ES cell biology. Our study provides new insights into the integration of these regulators to 
the ES cell-specific transcription circuitries. Collectively, the mapping of transcription factor binding sites identifies new 
features of the transcriptional regulatory networks that define ES cell identity. Using this knowledge, we investigate nodes 
in the network which when activated, will jump-start the ES cell-specific expression program in somatic cells. 
Biosketch 
Huck-Hui NG is currently a Senior Group Leader of the Genome Institute of Singapore (GIS) and an Associate Professor (Adjunct) with the National 
University of Singapore and the Nanyang Technological University. 
Huck-Hui NG graduated from the National University of Singapore and obtained his PhD from the University of Edinburgh. He spent the next few years 
working at the Harvard Medical School as a Damon Runyon-Walter Winchell research fellow.  
His lab is studying gene regulation in stem cells. Specifically, his group is using genome wide approaches to dissect the transcriptional regulatory 
networks in embryonic stem cells and to identify key nodes in this network. More recently, his lab has begun to investigate the reprogramming code 
behind the induction of pluripotency in somatic cells. His research work has earned him several prestigious national accolades including the Singapore 
Youth Award 2005 and the National Science Award 2007. 
……………………………………………………………………………………………………………………… 
Symposium: Quantitative Genomics (GWAS, QTL, Expression Cassettes) (20 May 2010) 
 
Emmanouil Dermitzakis 
Department of Genetic Medicine and Development 
University of Geneva Medical School 
 




Title: Cellular genetics and genomics 
Gene expression is an important phenotype that informs about genetic and environmental effects on cellular state. The 
elucidation of the genetics of gene expression (also know as eQTLs) is highly informative of the impact of genetic variants 
in the cell and the subsequent consequences in the organism. In this talk I will discuss recent advances in three key areas 
of the analysis of gene expression in human populations: (i) analysis of gene expression in multiple populations and 
tissues and the degree of overlap off genetic effects among populations and tissues; (ii) interrogation of gene expression 
in population samples using next generation sequencing (RNAseq) and the impact of the increased resolution on 
understanding the fine structure of genetic effects; (iii) integration of eQTLs with GWAS signals to understand the causal 
regulatory effects on complex traits. Perspectives on cellular phenotypic variation and the elucidation of their genetic 
effects will also be discussed. 
Biosketch 
Emmanouil Dermitzakis is currently a Louis-Jeantet Professor of Genetics in the Department of Genetic Medicine and Development of the University of 
Geneva Medical School. He obtained his B.Sc. in 1995 and M.Sc. in 1997 in Biology from the University of Crete (Greece) and his PhD in 2001 from the 
PennsylvaniaStateUniversity in the US, studying the evolutionary biology and population genetics of regulatory DNA in mammals and Drosophila. His 
post-doctoral work was at the University of Geneva Medical School, focusing on comparative genome analysis and the functional characterization of 
conserved non-genic elements. He previously was an Investigator and Senior Investigator at the Wellcome Trust Sanger Institute since April 2004. His 
current research focuses on the genetic basis of regulatory variation and gene expression variation in the human genome (see also 
http://www.sanger.ac.uk/humgen/genevar), the processes that govern non-coding DNA evolution. He has authored and co-authored more than 50 
papers in peer-reviewed journals with more that 20 of them in journals such as Nature, Science and Nature Genetics. His papers have attracted more 
than 4000 citations and his H-factor is 27. He has been invited to give talks and keynote lectures in the most prestigious genetics meeting in the world 
and is the organizer of multiple training courses including the Wellcome Trust HapMap course and co-organizer of the Wellcome Trust School of Human 
Genomics with Leena Peltonen. He has served as an analysis co-chair in the pilot phase of the ENCODE (ENCyclopedia Of Dna Elements) consortium 
and member of the analysis group of the Mouse Genome Sequencing Consortium and the International HapMap project. He now has a leading analysis 
role in the extension of the HapMap (aka HapMap3 project) and is a member of the analysis group of the 1000 genomes project. He currently serves in 




Faculty of Mathematics and Natural Sciences 
Department:Bioinformatics  
Gron Institute Biomolecular Sciences & Biotechnology  
Groningen Bioinformatics Centre 
University of Groningen  
Title: Complex trait dynamics following epigenomic perturbation 
Understanding the role of epigenetic variation in complex trait inheritance is one of the major challenges at the horizon of 
quantitative genetics. To address this challenge experimentally two groups have recently constructed so-called Epigenetic 
Recombinant Inbred Lines (EpiRILs). These populations were derived from two parents with identical DNA sequences but 
drastically divergent methylation profiles as a result of differential epigenomic perturbation. This system therefore provides 
a unique opportunity to study patterns of epigenetic inheritance against an isogenic background. Estimates suggest that 
epigenetic variation in these populations can account for up to 30% of the variation observed in complex traits, even eight 
generations later. 
However, many of the segregating epialleles display intriguing time-dependent characteristics. These non-Mendelian 
properties hint at a dynamic rather than a static epigenetic architecture.  Here we incorporate these phenomena into a 
quantitative genetics framework. We explicitly model the time-dependent behavior of epigenetic variation over generation 
time, and trace its phenotypic consequences at the level of the population.  Theoretical arguments show that the 
simultaneous action of allele-specific expression, recombination and epiallelic stability are key parameters in this system. 
Our results have direct implications for the dissection of complex traits in humans. 
Biosketch 
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The basic motivation of my research is to understand the heritable basis of complex traits in experimental populations through statistical genetic and 
bioinformatic approaches. Here are some topics that I am currently interested in: 
- QTL mapping methods with a particular focus on the characterization of time-dependent effects 
- Conceptual and methodological approaches to the epigenetic analysis of complex traits 
- Methodological issues in mapping chromatin differences between organisms or tissue types using ChIP-chip or ChIP-seq 





Vice President of Statistics 
DeCOde, Iceland  
 
Title: Some thoughts on genetics studies in the near future 
With the cost of full genome sequencing coming down rapidly, it is expected to have a profound impact on how human 
genetics studies are performed in the next few years, particularly in the area of disease variants identification. However 
there is much information in the existing SNP data that remains to be exploited. Realizing their full potential would not only 
allow us to do more now, but, most importantly, would put us in the best position to take advantage of the sequencing 
data when they arrive. 
Biosketch 
Augustine Kong has served as Vice President of Statistics at Decode genetics since 2001. Dr. Kong received his Ph.D. in statistics from Harvard 




Director, Max Planck Institute for Molecular Genetics, Germany 
Head of Computational Molecular Biology Department  
 
Title: Transcription factor binding site analysis and histone modifications point at two classes of promoters 
This talk will summarize our work on prediction of transcription factor binding site prediction and identification of common 
binding sites among co-expressed genes. Our analyses demonstrates that promoters with high and low contents in CpG 
dinucleotides, respectively, show distinctly different features. This division is also visible in an analysis of the relationship 
between histone modifications and gene expression levels. 
Biosketch 
Martin Vingron is a mathematician by education who has done his PhD in computational biology at EMBL in 1991. At the time and for a number of years 
of postdoctoral training his research has focused on the analysis of protein sequences, sequence analysis, sequence comparison, and molecular 
evolution. Methods of discrete optimisation were used for the design of comparison algorithms and probability theory was applied to answer questions of 
significance of computational results. Later, as a department head at the German Cancer Research Center, his focus shifted towards the processing and 
mathematical analysis of DNA microarrays. Accordingly, the methods largely drew on statistical data analysis techniques. During the last years his 
research interest lies in utilizing gene expression data as well as evolutionary data for the elucidation of gene regulatory mechanisms. He also acts as a 
chair of the *RECOMB* <http://recomb.org/> (Research in Computational Molecular Biology) steering committee. 





Symposium: Next Generation Sequencing – 1000 Genome Project and Beyond (20 May 2010) 
 
Henry Yang Huanming  
President & Professor 
Beijing Genomics Insitute (BGI)-Shenzhen, China 
 
Title: Human Genomics - From HGP to 1000 genomes and beyond 
The impacts of the International Human Genome Project (HGP) on life sciences and medicine have been acknowledged by 
most of us since its completion in 2003. The International HapMap Project, with its goals to provide powerful tools to link 
the differences in our genome and differences in our health, has generated millions of SNPs which have made GWAS 
(Genome-Wide Association Studies) a successful strategy for identification of genomic variations related to human 
common diseases. 
  
The International 1000 Genomes Project was proposed by BGI in China, Sanger Institute in UK, and the 3G centers in USA 
in 2006, and later joined by groups in Germany and 3 major sequencer-producers.  The project is designed to identify 
SNPs with lower MAF (Minor Allele Frequency) than those by HapMap, and other genomic variations such as CNVs (Copy 
Number Variations), by sequencing hundreds of samples from the 3 major populations. Since its initiation in 2008, this 
project has generated much more sequence data than the total amount of data ever existing.  The project has just 
extended to its Phase II by sequencing much more samples from more selected populations to much higher depth. All the 
data, both preliminary and processed, will be freely available to the scientific community in the world. 
  
Meanwhile, genomes of a dozen of individuals have been completely sequenced to various depth.  The concept of human 
pan-genomes has been proposed based on the non-or-all of genomics regions existing in various populations. The human 
metagenomes projects have generated more than 3 millions of microbial ORFs, approximately 150 times that of the 
estimated number of human genes.  The coverage and assemble of the human ancient genome have demonstrated the 
power of improving sequencing and innovative bioinformatics tools for the next-generation sequencing 
technology.  Perhaps it could be concluded that now we have really entered the genomics era. 
Biosketch 
Dr. Yang received his Ph.D. from University of Copenhagen, Denmark, in 1988, and his postdoc training in France and USA afterwards.  He returned to 
China in 1994 and co-founded BGI (formerly Beijing Genomics Institute) in 1999. 
As the co-founders of BGI, he and his collaborators have made a significant contribution to the HGP and HapMap projects, as well as to sequencing and 
analysing genomes of rice, chicken, silkworm, giant panda, cucumber, and many microorganisms. BGI published the first Asian’s genome, human pan-
genome, human ancient genome, and human gut metagenoms by means of new-generation sequencing technoloty and innovative bioinformatic tools 
recently. BGI now has becomes one of the major genomics centers in the world. 
Dr. Yang has received many awards and honors, including Research Leader of the Year by Scientific American in 2002 and Award in Biology by the 
Third World Academy of Sciences㧔TWAS㧕in 2006. He was elected as a foreign member of EMBO in 2006, and an Academician of Chinese Academy 
of Sciences in 2007, and a fellow of TWAS in 2008. 
……………………………………………………………………………………………………………………… 






Senior Group Leader 
Assoc Director, Genomic Technologies  
 
Title: Chromatin Interaction and Transcription Regulation 
Genomes are known to be organized in 3D structures in vivo through interactions with protein factors for nuclear process 
such as transcription, and DNA elements separated by long genomic distances are known to functionally interact. This 
view has been further emphasized by recent observations that many transcription factors bind remotely to gene promoters. 
However, it is still largely unknown to us how and to what extent chromatin interactions are involved in transcription 
regulations on a whole genome scale.  To study these questions, we have developed the Chromatin Interaction Analysis 
using Paired-End-Tag sequencing (ChIA-PET) strategy for de novo detection of genome-wide chromatin interactions, and 
demonstrated this approach through the comprehensive mapping of chromatin interactions involved in transcription 
regulations mediated by estrogen receptor Į (ERĮ) in a human genome (Nature 2009 462: 58-64). In order to map all 
chromatin interactions involved in all transcription regulation networks in the human genome, we have applied the ChIA-
PET strategy to active transcriptional marks such as RNA polymerase II (RNAPII) and trimethylation of lysine 4 on histone 
H3 (H3K4me3) as analysis targets in a number of human cells. Our results have shown that both RNAPII and H3K4me3 
are excellent targets for ChIA-PET experiments to detect long-range chromatin interactions between gene promoters and 
distal regulatory elements, as well as to identify co-localization of remote genes (intra-chromosome and inter-chromosome) 
in close proximity of nuclear space. Through comprehensive mapping of chromatin interactions and transcriptional 
activities, we have revealed that a large proportion of actively transcribed genes are involved in extensive chromatin 
interaction looping structures. The most abundant gene-centric chromatin interactions are appeared to be within local 
range of megabase genomic span, and nearby genes such as gene family members are organized to share common 
transcription factories. In addition, we have identified many hot spots of interaction hubs, in which clusters of genes 
crossing large megabase distance and different chromosomes are co-localized in close proximity. Collectively, our data 
suggests that long-range chromatin interaction is a primary mechanism for transcription regulation in human genomes. 
Further analyses of the chromatin interaction and transcription maps will provide deep insights to advance our 
understanding of transcription regulatory networks and the human genome biology. 
Biosketch 
My primary interest is to elucidate the structures and dynamics of all functional DNA elements in complex genomes through transcriptome 
characterizations and genome interrogation. To facilitate such understanding we have developed Paired-End-Tag (PET) sequencing and mapping 
methodologies. We are applying these sequencing-based technologies to address complex biological questions such as how cancer cells progress and 
how stem cells maintain their unique properties. Another major interest of mine is to discover previously uncharacterized microbial genes and genomes 




Professor of Statistical Genetics 
Department of Statistics 
Oxford University  
Title: The landscape of human genetic variation as viewed from the 1000 Genomes Project 
The 1000 Genomes Project pilot generated over 5Tbp sequence in three separate pilot experiments. These assess the 
effectiveness of low coverage sequencing (approximately 4x) to find shared variants, a high coverage trio design, and 
targeted sequencing of 1000 genes in 700 samples.  These data provide a comprehensive and detailed view of the 




landscape of common variation of all types, from SNPs to small indels to structural variation, although much work remains 
in integrating all sources of information. 
  
I will review what we have learned about the landscape of naturally-occurring variation from the project to date and what 
the full project expects to achieve.  I will focus on characterising the nature and scale of variation across the genome, the 
distribution of mutations of likely functional consequence, differences between populations and the implications for our 
understanding of natural selection.  I will also discuss some of the different approaches that are being used to interrogate 
the data, from mapping approaches to de novo assembly. 
Biosketch 
Research interests: 
Population genetics, Coalescent modelling, Statistical genetics, Pathogen evolution and variation 
My research covers several areas in evolutionary biology and population genetics, combining both theoretical work and empirical analyses. Of particular 
interest is the analysis of recombination from population genetic data, the relationship between linkage disequilibrium and properties of the underlying 
genealogy, and methods for inferring genealogical history from DNA sequence data.  I am a co-chair of the Analysis Group in the 1000 Genomes Project 
and am involved in genome-sequencing projects that aim to answer question in medical genetics, the epidemiology of infectious disease and 
evolutionary biology. 
……………………………………………………………………………………………………………………… 
Featured Talk (20 May 2010) 
 
Manel Esteller 
Director, Cancer Epigenetics and Biology Program (PEBC) 
Leader of the Cancer Epigenetics Group 
Title: Cancer Epigenetics: From DNA methylation to microRNAs 
An altered pattern of epigenetic modifications is central to many common human diseases, including cancer. Many 
studies have explored the mosaic patterns of DNA methylation and histone modifications in cancer cells on a gene-by-
gene basis, among them the seminal finding of transcriptional silencing of tumor suppressor genes by CpG island 
promoter hypermethylation. Epigenetic gene inactivation in transformed cells involves many "belts of silencing". We are in 
the process of completing the molecular dissection of the entire epigenetic machinery involved in methylation-associated 
silencing, such as DNA methyltransferases, methyl-CpG binding domain proteins, histone deacetylases, histone 
methyltransferases, histone demethylases and Polycomb proteins. The first indications are also starting to emerge about 
how the combination of cellular selection and targeted pathways leads to abnormal DNA methylation. In addition to 
classical tumor-suppressor and DNA repair genes, epigenetic gene silencing includes genes involved in premature aging 
and microRNAs with growth inhibitory functions. Recent technological advances are now enabling cancer epigenetics to 
be studied genome-wide. It is time to "upgrade" cancer epigenetics research and put together an ambitious plan to tackle 
the many unanswered questions in this field using genomics approaches to unravel the epigenome. 
Biosketch 
Manel Esteller (Sant Boi de Llobregat, Barcelona, Catalonia, Spain, 1968) graduated in Medicine with Honours from the Universidad de Barcelona in 
1992, where he also obtained his Ph.D. degree specialising in molecular genetics of endometrial carcinoma, in 1996. He was an Invited Researcher at 
the School of Biological and Medical Sciences at the University of St. Andrews, (Scotland, UK) during which time his research interests focused on the 
molecular genetics of inherited breast cancer. From 1997 to 2001, Esteller was a Postdoctoral Fellow and a Research Associate at the Johns Hopkins 
University and School of Medicine, (Baltimore, USA) where he studied DNA methylation and human cancer. His work was decisive in establishing 
promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours.  
From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory, where his principal area of research 
were the alterations in DNA methylation, histone modifications and chromatin in human cancer. Since October 2008, Dr Esteller is the Director of the 




Cancer Epigenetics and Biology Program of the Bellvitge Institute for Biomedical Research (IDIBELL) in Barcelona and leader of the Cancer Epigenetics 
Group. His current research is devoted to the establishment of the epigenome maps of normal and transformed cells, the study of the interactions 
between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy. 
Author of more than two hundred-twenty original peer-reviewed manuscripts in biomedical sciences, he is also a Member of numerous international 
scientific societies, Editorial Boards and reviewer for many journals and funding agencies. Dr Esteller is also Associate Editor for Cancer Research, The 
Lancet Oncology and Carcinogenesis, Editor-in-Chief of Epigenetics and Advisor of the Human Epigenome Project, Associate Member of the 
Epigenome Network of Excellence and President of the Epigenetics Society. His numerous awards include: Best Young Cancer Researcher Award 
bestowed by the European School of Medical Oncology (1999), First Prize in Basic Research at the Johns Hopkins University and Medical Institution 
(1999), Best Young Investigator Award from the European Association for Cancer Research (2000), Young Investigator Award from the American 
Association for Cancer Research-AFLAC (2001), Carcinogenesis Award (2005), Beckman-Coulter Award (2006), Francisco Cobos Biomedical Research 
Award (2006), Fondazione Piemontese per la Ricerca sul Cancro (FPRC) Award (2006), Swiss Bridge Award (2006). National Research Award in 
Oncology "Maria Julia Castillo" (2007), "Dr Josep Trueta" Award by the Academy of Medical Sciences of Catalonia (2007), Innovation Award from the 
Commonwealth of Massachussets (2007), Human Frontier Science Program Award (2007) "Dr. Jacint Vilardell" Foundation Award (2008), DEbiopharm-
EPFL Award (2009), Dr. Josef Steiner Cancer Research Award (2009), Lilly Foundation Preclinical Biomedical Research Award (2009), Fundación 
Esteve Award (2009), Fundación AECC Award for Children Cancer Research (2009), Carmen y Severo Ochoa Foundation, Molecular Biology Research 
Award(2009).  
 
Dr Manel Esteller is the Director of the Cancer Epigenetics and Biology Program of the Bellvitge Institute for Biomedical Research (IDIBELL), Leader of 
the Cancer Epigenetics Group, Professor of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor. 
 
……………………………………………………………………………………………………………………… 
Symposium: Pathways Networks and System Biology (21 May 2010). 
 
Hiroki R. Ueda  
Project Leader, Laboratory for Systems Biology 
Manager, Functional Genomics Unit 
RIKEN Center for Developmental Biology, Riken, Kobe 
Title: Systems Biology of Mammalian Circadian Clocks 
Mammalian circadian clock system is a complex and dynamic system consisting of complicatedly integrated regulatory 
loops and displaying the various dynamic behaviors including i) endogenous oscillation with about 24-hour period, ii) 
entrainment to the external environmental changes (temperature and light cycle), and iii) temperature compensation over 
the wide range of temperature. 
  
The logic of biological networks such as circadian clocks is difficult to elucidate without (1) comprehensive identification of 
network structure1-3,6, (2) prediction and validation based on quantitative measurement and perturbation of network 
behavior4,7, and (3) design and implementation of artificial networks of identified structure and observed dynamics6.  In 
this symposium, I will report on the current progress of the analysis and synthesis of mammalian circadian clocks. I will 
also introduce some current attempts towards understanding sptio-temporal gene expression in the adult mouse brain.  
  
References 
1. Ueda, H.R. et al, Nature 418, 534-539 (2002).  
2. Ueda, H.R. et al, Nat. Genet. 37, 187-92 (2005). 
3. Sato T. K. et al, Nat Genet. 38, 312-9 (2006). 
4. Ukai H. et al, Nat Cell Biol.  9, 1327-34 (2007). 
5. Ukai-Tadenuma M. et al, Nat Cell Biol.  10, 1154-63 (2008). 
6. Minami Y. et al PNAS 106, 9890-5 (2009). 
7. Isojima Y. et al, PNAS 106, 15744-49 (2009). 
Biosketch 
Dr. Hiroki R. Ueda was born in Fukuoka, Japan, in 1975. He graduated from the Faculty of Medicine, the University of Tokyo, in 2000, and obtained his 
Ph.D in 2004 from the same university. While an undergraduate student, he worked as a research assistant on a biological simulation system project at 




Sony Computer Science Laboratories. While a graduate student, he next went on to work as a researcher from 2000 and then group leader from 2002 at 
Yamanouchi Pharmaceutical Co. 
He was appointed as a team leader of laboratory for systems biology at RIKEN Center for Developmental Biology (CDB) from April, 2003 and promoted 
to be a project leader at CDB from September, 2009. He was also appointed as a manager of Functional Genomics Unit at the CDB from October, 2004. 
He also became a visiting professor in Tohoku University in April, 2005-March, 2006, Tokushima University from April, 2005 and National Institute of 
Genetics from April, 2010, and an invited professor of biology in Osaka University from April, 2006, and an invited professor of mathematics in Kyoto 
University from April, 2009. 
He identified system-level network structure of mammalian circadian clocks. For this discovery, He received Tokyo Techno Forum 21, Gold Medal 
(Tokyo Techno Forum 21, 2005), Young Investigator Awards (MEXT, 2006) and IBM Science Award (IBM, 2009).  He recently solved the fundamental 
problem in chronobiology on the underling mechanism of singularity behavior of circadian clock that had been unsolved for more than 30 years. For this 
discovery, he received a Young Investigator Promotion Awards (Japanese Society for Chronobiology, 2007). He also recently discovered temperature-
insensitive reaction in mammalian circadian clock, which will lead to a long-standing problem, "temperature-compensation" of circadian clock.   He 
invented diagnostic method of body time and rhythm disorders, which opens up the new possibility of chronotherapy. For this invention, he received 
Japan Innovator Awards (Nikkei Business Publications Inc. 2004).  His current research interests include system-level understanding of biological time, 
space and information, and systems-based medicine on human disease.  His current research interests include system-level understanding of biological 





Department of Computer Science And Applied Mathematics 
Weizmann Institute of Science, Israel  
 
Title: Transcriptional Lego: Predictable control of gene expression by manipulating promoter building blocks 
The ability to control the timing and levels at which genes are expressed is key to most biological processes. Although we 
know the sequence preferences of key players in this process, we are still far from understanding how these elements 
combine within regulatory sequences to encode the transcriptional outcome. Based on our theoretical analyses, we 
devised hypotheses regarding the effect that different nucleosome disfavoring sequences that vary in length, composition, 
and distance from transcription factor binding sites, will have on the transcriptional outcome. To systematically test these 
hypotheses, we designed and synthesized ~80 promoter sequences, and fused each promoter to a fluorescent reporter, 
resulting in the largest library of designed promoter variants to date. Our results show that by manipulating either or both 
transcription factor binding sites and nucleosome disfavoring sequences in the vicinity of the site, we can tune expression 
levels in a predictable manner. Importantly, sequence changes that only alter nucleosome disfavoring sequences result in 
effects on expression comparable in magnitude to those that result from changes to transcription factor binding sites. In 
fact, compared to binding site changes, alterations of nucleosome disfavoring sequences likely yield more gradual 
changes in expression levels, and thus offer means to fine-tune gene expression with high resolution. These results have 
intriguing implications for evolution of gene expression, suggesting that sequence changes that alter the DNA-encoded 
nucleosome organization may provide an efficient genetic mechanism by which genomes may evolve and fine-tune gene 
expression. Overall, our results bring us a step closer towards understanding the role of various promoter elements and 
their combined effects on transcription, and suggest that directed design of promoter sequences that yield pre-specified 
expression patterns may be within reach. 
Biosketch 
My research interests are in Computational Biology , and more specifically in developing quantitative models for all levels of gene regulation, including 
transcription, chromatin, and translation.  
……………………………………………………………………………………………………………………… 
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Susan E Ozanne  
Principal Research Associate 
British Heart Foundation Senior Fellow  
Department of Clinical Biochemistry  
University of Cambridge Metabolic Research Laboratories  
Title: Mechanisms linking poor early nutrition and later risk of type 2 diabetes 
A large number of epidemiological studies have revealed that there is a relationship between poor early growth and the 
development of cardiovascular disease, insulin resistance and type 2 diabetes in later life. The mechanistic basis of these 
relationships is not known. However, compelling evidence has emerged over the last fifteen years to suggest that early 
environmental factors and in particular early nutrition play an important role in mediating these relationships. Studies of 
individuals who were in utero during a period of famine, the Dutch Hunger Winter, have shown a direct relationship 
between maternal nutrition and glucose tolerance in the offspring in adult life. Further support for the importance of the 
fetal environment has come from studies of monozygotic twins who were discordant for type 2 diabetes. These revealed 
that the diabetic twins had significantly lower birth weights than their non-diabetic co-twins. A number of animal models 
have been developed to investigate the mechanisms by which the early environment determines future susceptibility to 
disease. These include models of maternal calorie restriction, intrauterine ligation and maternal dexamethasone treatment. 
The most extensively studied is the maternal low protein model where rats are fed a low (8 %) protein diet during 
pregnancy and lactation. The offspring have a low birth weight and undergo an age-dependent loss of glucose tolerance. 
This is associated with both pancreatic ß cell dysfunction and insulin resistance. The ß-cell dysfunction is accompanied by 
reduced expression of the transcription factor HNF4a. In vitro analysis has revealed that the insulin resistance is 
associated with changes in expression of key insulin-signalling proteins (including protein kinase C zeta and the p110ß 
catalytic subunit of PI 3-kinase) in muscle and adipocytes. Strikigly similar changes in insulin signalling protein expression 
are observed in muscle and adipose tissue biopsies from young men with a low birth weight. These differences in protein 
expression occur prior to the development of insulin resistance and type 2 diabetes, thus may be molecular markers of 
early growth restriction and thus disease risk. If extended to a clinically accessible tissue in humans this would make 
targeted intervention strategies a realistic possibility. The molecular mechanisms by which a phenomenon that occurs in 
utero has a phenotypic consequence many years later are only just starting to emerge and are thought to involve 
epigenetic modifications. 
Biosketch 
Early Programming of Appetite, Type 2 Diabetes, Breast Cancer and Ageing: The major focus of our research is to understand the mechanistic 
basis of the relationships between poor early growth and subsequent increased risk of type 2 diabetes, obesity, breast cancer and premature death. 
There are a large number of epidemiological studies suggesting that such relationships exist, however the molecular mechanisms mediating such 
phenomena are not understood.  
Poor Early Growth and Diabetes: We carry out global and candidate expression studies at both the protein and RNA level using both rodent models 
and human tissues. Our aim is to identify the mechanisms by which poor early growth is linked to increased risk of type 2 diabetes and insulin resistance. 
In particular we are investigating the role played by the early environment.  
Human studies: Tissue samples from low birth weight and control humans are used to establish insulin-signaling defects that may provide early 
indications of metabolic disease. Our insulin signaling protein expression studies in muscle and adipose tissue have already shown early defects in adult 
subjects who had a low birth weight. Ongoing studies in placenta will relate the expression of insulin signaling molecules to the nutritional status of both 
mother and baby. 
Animal models: We are studying a rodent model of early nutritional growth restriction to identify molecular markers for prediction of risk of type 2 
diabetes in later life. Nutritionally early growth restricted rats have been shown to develop impaired glucose tolerance in old age. At the molecular level, 
studies have shown defects in the pancreas, muscle, liver and adipose tissue of growth restricted rats. We are now extending these studies to determine 
the molecular mechanisms underlying these changes such as the role of epigenetic alterations. 
Programming of Appetite: We have shown that appetite can be programmed by maternal nutrition during lactation and that the down regulation of 
appetite secondary to poor maternal nutrition is so powerful that it prevents diet-induced obesity in mice. We are currently involved in establishing the 
mechanisms underlying the early programming. 




Animal Models: To determine the basis of appetite programming we have set up a model for poor fetal nutrition and then catch up growth in rats and 
mice using cross fostering techniques and altered maternal diet. In these animals, samples are taken at various time points and the expression of 
molecules, such as leptin and other adipocytokines, known to be involved with appetite regulation is examined. We are also determining the effect of the 
model on the neurodevelopment of appetite circuits using in situ hybridisation and tracing techniques. 
Poor Early Growth and Breast Cancer: Epidemiological studies suggest that both low and high extremes of birthweight are associated with increased 
breast cancer risk. Some of the factors thought to mediate this risk are obesity and type-2 diabetes. It is also thought that an increased estrogen 
exposure mediates this risk in the high birth weight group. In animal studies, excessive in-utero estrogens have been shown to induce a higher 
mammary tumour risk and incidence. Our low-protein model is characterised by age-dependent loss of glucose tolerance, insulin resistance and type-2 
diabetes. We have recently shown that maternal plasma estradiol levels are also 35% higher than controls in the last week of gestation. In the offspring, 
we have observed a period of retarded mammary development followed by rapid catch-up growth mainly of undifferentiated stem cells i.e structures 
such as terminal end buds and luminal epithelial cells. We are therefore investigating the hypothesis that fetal growth restriction followed by rapid catch-
up growth increase an offspring's susceptibility to breast cancer in later life. 
Oxidative Stress, Senescence and Ageing: For the past decade we have studied the long-term consequences of poor early growth using our rodent 
models and one of our most striking observations has been that life span can be increased or decreased by restricting their growth either during suckling 
or during fetal life respectively. These differences in lifespan are associated with differences in kidney telomere length. We have hypothesized that the 
rate of early growth may affect degrees of oxidative damage which in turn affect organ function leading to altered longevity. To test this we first 
investigated the effects of oxidative stress on regulation of stress response proteins, DNA replication and induction of cellular senescence using human 
fibroblasts. In parallel with the in vitro cell system we are actively examining the telomere length and expression of stress response proteins such as p53, 
p21 and DNA damage checkpoint proteins such as gama-H2AX and 53BP1 as well as senescence marker, SA-beta-gal in organs of our model animals 
in order to understand the molecular mechanisms underlying the ageing process. 
……………………………………………………………………………………………………………………… 
 
Harris A Lewin 
Professor of Immunogenetics 
Gutgsell Endowed Chair  
Department of Animal Sciences 
Director, Institute for Genomic Biology  
University Illinois, USA  
Title: Nutrition: Will livestock Lead the way? 
The sequencing, annotation and functional characterization of the genomes of cattle and pigs have been rapidly 
translated into new products and services for the livestock industry.  The animal breeding industry adopted marker-
assisted breeding in the late 1990s and is now implementing genomic selection for complex traits, such as milk production 
and carcass composition.  In addition, the mapping and positional cloning of genes responsible for a large number of 
monogenic and polygenic traits has resulted in the creation of new models for human diseases and has informed our 
understanding of the genetics of complex traits.  One of the most important areas of interface between human and 
livestock genomics is in the area of nutrition.  In human and animal health, there is a dynamic interplay between host 
genotype and diet.  However, for many diseases, the specific genes, pathways and networks that are influenced by diet 
are not well understood. In cattle and other livestock species it has been common practice for the past 50 years to 
develop special diet formulations based on breed and/or environmental conditions.  Recently, we have discovered what 
may be the first example of a diet-regulated QTL (DGAT1) in dairy cattle that influences the development of metabolic 
disorders associated with the onset of lactation. Our data suggest that controlling energy intake during the prepartal 
period in DGAT1 genotyped animals can be used to optimize milk production performance while minimizing the incidence 
of postpartal metabolic disorders, such as fatty liver disease and ketosis.  For human diseases, understanding of diet-
genotype interactions may be critical to promoting wellness in individuals genetically predisposed to diabetes, obesity, 
heart disease, gastrointestinal and immunological disorders and cancer.  By implementing dietary restrictions in 
genetically-defined individuals, it may be possible to reduce the incidence and severity of such diseases.  Thus, 
“personalized nutrition” could take on a significant role as a first line of defense against the “diseases of affluence” 
currently plaguing Western and developing nations. Research using non-inbred cattle and pigs as models may contribute 
critical knowledge that will pave the way toward the implementation of genetics-driven nutritional management of human 
diseases. 
Biosketch 
Professor Lewin's current research interests are in the area of mammalian comparative and functional genomics. His research has resulted in the 
development of high-density comparative maps for the cattle, human and other mammalian genomes, and novel software for in silico gene mapping 




using the human genome as a template. In addition, his group produced the first large-scale cDNA microarray and oligoarray for functional genomics of 





Department of Biological Systems  
CIRAD 
Title: Genomics for food improvement 
Genome analysis in crop species is progressing dramatically. Even crops referred to as ‘orphan’ until recently have their 
genome being sequenced. New sequencing techniques make it possible to undertake massive re-sequencing among 
representative crop genetic resources in order to access and exploit genetic diversity. The Centres of the Consultative 
Group on International Agricultural Research (CGIAR) together host more than 600,000 accessions of some twenty food 
crop species  (cereals, pulses, roots and tubers, banana and plantain) including traditional varieties developed through 
many generations of selection by farmers, as well as wild species, breeding lines and improved varieties.  Besides 
breeding activities aimed at productivity increase for global food security, international programmes are aimed at 
improving tolerance to abiotic stresses as well as nutritional content, principally for Zinc, Iron and B-carotene. Integrated 
projects for exploiting the just-available or soon-to-come genome sequence are also developing for diverse crops such as 
grapevine, tomato, cocoa or coffee, with their respective specific foci on product quality. Examples selected among the 
above initiatives will be briefly described. 
Biosketch 
Jean-Christophe Glaszmann is Director of the new Department of Biological Systems created in CIRAD (Centre de coopération internationale en 
recherche agronomique pour le développement), Montpellier, France, in January 2007. Agronomist and PhD in genetics, Jean-Christophe is an expert in 
genetic resources, comparative genomics and plant breeding. Employed by CIRAD since 1979, he worked in the Philippines in IRRI (International Rice 
Research Institute) for 6 years, and moved back to Montpellier in 1987. Jean-Christophe has been on the Board of Directors of Genoplante, and Director 
of the CIRAD/INRA/Supagro joint research unit “Polymorphisms of interest in agriculture”. He is currently leader of the subprogramme “Genetic Diversity 




Head, Department Structural & Computational Biology, EMBL 
(Germany) 
ICREA Professor and Group Leader 
Center for Genomic Regulation, Barcelona (Spain)  
Title: Systems biology analysis of the EGF MAPK pathway: From structures to data integration 
Signal transduction in living systems is essential to be able to interact and respond to the changes in the 
environment.  The number of players and the different interactions they made result in very complex networks (specially in 
eukaryotes) which cannot be understood in a quantitative manner without the help of computer modeling and 
simulations.  In order to model adequately protein interaction networks we need to incorporate time, space and structural 
information and move away from a node-edge flat network.  Here we have used structural information, quantified all 
proteins in three different cell lines and localize them in a dynamic fashion to be able to produce a realistic model of the 
EGF-MAPK pathway that considers around 160 proteins.  On top of  it we have mapped human SNPs associated to 
disease on the structural map and analyzed them in terms of their effect on stability, activity and interaction with other 
proteins.  





In our group we are aiming at a quantitative understanding of biological systems to an extent that one is able to predict systemic features and with the 
hope to rational design and modify their behaviour.  This applies to any system comprising biological components that is more than the mere sum of its 
components, or, in other words, the addition of the individual components results in systemic properties that could not be predicted by considering the 
components individually.  By achieving this objective we are aiming at new global understanding and treatment of human diseases in which the target 
will not be a single molecule but a network.  For this purpose in our group we develop on one hand new software and theoretical approximations to 
understand complex systems and on the other we do experiments to validate our predictions. 
……………………………………………………………………………………………………………………… 




Scientific Director and Senor Advisor, X PRIZE Foundation 
Visiting Professor, Geffen School of Medicine, University of California 
Los Angeles 
Weston Visiting Professor, Weizmann Institute for Science  
  
Title: Swifter, Lower, Stronger: the $10 Million Olympic Medal for Next Generation Sequencing 
Dr. Laurence Kedes (BS, 1961; MD, 1962; BA (Hon), 2009) is the William M. Keck Emeritus Professor of Biochemistry & 
Molecular Biology and of Medicine at the University of Southern California, Keck School of Medicine. He was the founding 
Director of the Institute for Genetic Medicine (IGM). Prior to joining USC, he had a 20-year career on the Stanford faculty 
of medicine where he pioneered molecular genetics and eukaryotic gene expression, while also serving as a clinical 
hematologist. 
 
Dr. Kedes’s research interests have used molecular biology and molecular genetic technologies to study the 
differentiation of organisms and cells.  He has made numerous contributions to understanding the role of gene expression 
in generating cellular phenotypes.  He led the effort to successfully clone the first animal cell genes coding for a protein 
and to provide the first DNA sequence for animal protein genes.  His interests in DNA sequences led him to formulate the 
need for bioinformatics methods to deal with such information and to collaborate in production of one of the first sets of 
computer programs (MOLGEN) to handle DNA sequence and other molecular genetic information.  These efforts led to 
the creation by Dr. Kedes and others of BioNet, the first national computer network (pre-internet) funded by the NIH to 
archive and make available for all scientists DNA sequence information.  The operation was the direct forerunner of 
GenBank, the international repository of all genetic sequences and helped form the foundation for the field of genomic 
bioinformatics.  
  
In 2005, Dr. Kedes became the Scientific Director and Senior Advisor of the non-profit X PRIZE Foundation and helped 
lead the effort to create the $10 million Archon Genomics X PRIZE (http://genomics.xprize.org/). The purpose of the 
Archon Genomics X PRIZE competition is to develop radically new technology that will dramatically reduce the time and 
cost of sequencing genomes, and accelerate a new era of predictive and personalized medicine. The X PRIZE 
Foundation aims to enable the development of low-cost diagnostic sequencing of human genomes. 
Biosketch 
Dr. Laurence Kedes (BS, 1961; MD, 1962; BA (Hon), 2009), is the William M. Keck Emeritus Professor of Biochemistry & Molecular Biology and of 
Medicine at the University of Southern California Keck School of Medicine. He was the founding Director of the Institute for Genetic Medicine (IGM). 
Prior to joining USC, he had a 20-year career on the Stanford faculty of medicine where he pioneered molecular genetics and eukaryotic gene 
expression while also serving as a clinical hematologist. 
 
Dr. Kedes’s research interests have used molecular biology and molecular genetic technologies to study the differentiation of organisms and cells. He 
has made numerous contributions to understanding the role of gene expression in generating cellular phenotypes. He led the effort to successfully clone 
the first animal cell genes coding for a protein and to provide the first DNA sequence for animal protein genes. His interests in DNA sequences led him 
to formulate the need for bioinformatics methods to deal with such information and to collaborate in production of one of the first sets of computer 
programs (MOLGEN) to handle DNA sequence and other molecular genetic information. These efforts led to the creation by Dr. Kedes and others of 
BioNet, the first national computer network (pre-internet) funded by the NIH to archive and make available for all scientists DNA sequence 
information.  The operation was the direct forerunner of GenBank, the international repository of all genetic sequences and helped form the foundation 
for the field of genomic bioinformatics.  





In 2005 he became the Scientific Director and Senior Advisor of the non-profit X-Prize Foundation and helped lead the effort to create the $10 million 
Archon Genomic X-Prize for rapid, inexpensive genome sequencing. 
 
……………………………………………………………………………………………………………………… 
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Radoje Drmanac 
Chief Scientific Officer and Co-founder 
Complete Genomics, Inc.  
 
Title: The path to affordable human genome sequencing for large-scale studies of genetic diseases 
Complete Genomics has developed a novel, highly accurate, high-throughput, inexpensive genome sequencing 
technology based on submicron DNA nanoball™ arrays (prepared by clonal DNA amplification in solution) and unchained 
base reading using combinatorial probe-anchor ligation (cPAL™) chemistry.  These advances reduce both reagent 
consumption and imaging time and enable Complete Genomics to offer a sequencing service at its own commercial-scale 
genome center at a significantly lower cost than current methods for large-scale sequencing projects. The service 
includes reporting a list of sequence variants discovered using 120Gb of mapped reads per genome.  We will present 
some recent results and plans to produce further high quality human genome sequences at a medically-relevant cost and 
scale.  
Biosketch 
Dr. Radoje (Rade) Drmanac, chief scientific officer and co-founder of Complete Genomics since 2006, is one of the leading research scientists and 
inventors in the field of DNA sequencing-by-hybridization (SBH) and genomic microarrays. In 1994, he co-founded Hyseq (later Nuvelo) where, as chief 
scientific officer, he led the effort to discover and patent thousands of genes which formed the basis of Nuvelo’s drug development pipeline. Prior to 
Hyseq, Rade was a group leader at Argonne National Labs from 1991 to 1994 as part of the Department of Energy’s Human Genome Project. He 
completed his postdoctoral studies in 1990 in Hans Lehrach’s group at the Imperial Cancer Research Fund in London. He earned his Ph.D. in molecular 





Bioinformatics Scientist, Knome Inc  
 
Title: Deciphering the oracle's words: Analysis tools for human whole genomes and exomes 
As sequencing costs plummet, and a tide of data rises, the thorough analysis of individual human genomes is emerging 
as a key bottleneck in the path to biological discovery.  Making sense of such data requires comprehensive, well curated 
reference and phenotype data; robust parsing and interchange of 'moving target' file formats; reliable and efficient query 
matching; smart approaches to summary and comparative sequence analysis; innovative data visualization methods; and 
sound algorithms for predicting the functional significance of novel alleles, in order to pick leading candidates for empirical 
validation.  By developing integrated toolkits to meet these challenges, small companies focused on genome analysis can 
usefully complement major sequencing platform providers, and serve as important  partners to academic researchers in 
their quest to glean insights from ever finer data on human genetic variation. 




Nathaniel Pearson is a geneticist at Knome, Inc., a human genome sequence analysis firm based in Cambridge, MA (USA), where he and his 
colleagues build and collaboratively deploy new analytic tools, in order to help biomedical researchers generate useful knowledge from the rising tide of 
human whole-genome and exome sequence data.  Through laboratory, computational, and field work, he has sought to cast light on how our genomes 
offer ever deeper insights into human health, and reflect key aspects of our evolutionary history.  Fascinated by human genetic variation since working 
as a young student in the laboratory of Luca Cavalli-Sforza (Stanford), he traveled with Spencer Wells (now at Cornell) to collect DNA samples from 
people throughout central and southwest Asia, to resolve ancestral demography and migration in those regions.  In doctoral work with Bruce Lahn and 
Marty Kreitman (Univ. of Chicago), he surveyed and interpreted patterns of sequence variation on the great ape sex chromosomes, spotlighting the roles 
of mutation, recombination, and natural selection in driving long-term X-Y divergence.  Later, in post-doctoral work on mammalian sensory genes with 
Jianzhi Zhang (Univ. of Michigan), he first delved into the emerging world of high-throughput sequencing, grasping its power to address important open 




Global Marketing Director  
Genome Sequencing 
Roche Applied Science 
Title: Re-sequencing of the human genome using the 454 Genome Sequencer systems FLX & Junior 
The Genome Sequencer FLX Systems (GS FLX and GS Junior), powered by 454 Sequencing, are based on a next-
generation DNA sequencing technology featuring a unique mix of long reads, exceptional data accuracy and shortest run 
time. It has been proven to be the most versatile of all currently available next-generation sequencing technologies, 
supporting more than 700 high profile studies in over 7 applications categories. 454 technology users have pursued 
innovative research in de novo sequencing, re-sequencing of whole genomes and target DNA regions, metagenomics, 
and RNA analysis. 454 Sequencing is a powerful tool for human genetics research, including re-sequencing the complete 
human exome or detection of low frequency somatic mutations linked to cancer. 
This presentation will provide a short overview about the 454 Sequencing technology, and will focus on applications 
possible to address with the Genome Sequencer systems, with special emphasis on human re-sequencing (data 
presentation). It will also provide information on the newest product developments, including the 2010 launch of kits 
allowing to generate read lengths of >700 - 1000 or the first next generation benchtop instrument, the GS Junior. 
Biosketch 
1990 - 1995: Study of molecular biology at the University of Bielefeld 
1995 - 1999: PhD study at the University of Bielefeld: Sequencing and bioinformatic analysis of antibiotic resistance plasmids 
2000 - 2002: International Product Manager for genome sequencing and bioinformatics, MWG Biotech AG, Germany 
2002 - 2004: Business Unit Director, sequencing department, MWG Biotech AG, Germany 
2004 - 2005: Head of Marketing and Sales, MWG Biotech AG, Germany 
2005 - Today: Global Marketing Director Genome Sequencing, Roche Applied Science 
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Patrice M Milos 
Senior Vice President and Chief Scientific Officer 
Helicos BioSciences Corporation  
 
Title: An unbiased, quantitative view of genome biology only possible with Helicos Single Molecule Sequencing 
Helicos Single Molecule Sequencing provides a unique view of genome biology through direct sequencing of cellular 
nucleic acid in an unbiased manner providing both quantitation and sequence information.  The simple sample 
preparation involves no ligation or PCR amplification, allowing direct sequencing of DNA or RNA molecules. With this 
simplicity comes the opportunity to measure genome biology in ways not previously possible.  We will discuss the 
diversity of applications possible on the HeliScope Genetic Analysis system and more importantly discuss why issues of 
amplification and sequence bias matter in your everyday research efforts. Further we will demonstrate applications unique 
to the Helicos single molecule sequencing technology providing clear differentiation from current amplification based 
technologies including the direct sequencing of RNA, the unique ability to sequence ancient and degraded nucleic acids 
and absolute quantitation of miRNAs, DNA and RNA molecules. 
Biosketch 
Dr. Milos joined Helicos in June 2007. Her expertise and extensive knowledge in the life sciences advances the company's efforts to develop innovative 
and breakthrough technology. She previously served as Executive Director at Pfizer Global Research and Development, where she was responsible for 
leadership, strategic alignment and execution of the scientific disciplines of pharmacogenomics, proteomics, metabonomics and RNA profiling across the 
Pfizer portfolio from early discovery into the marketplace. She joined Pfizer in 1993 and held numerous research positions of increasing responsibility 
focusing on Cardiovascular and Metabolic Disease, Pharmacogenomics, DNA Sequencing, Biomarkers and Molecular Sciences. 
Dr. Milos serves on the National Advisory Council for Human Genome Research and was pivotal in the establishment and oversight of key Pfizer 
strategic investments in the genomics area, most notably, the Genetic Association Information Network. She also sits on several editorial boards for 
journals and has published and presented extensively in the genomics area. Dr. Milos conducted post-doctoral fellowships at Brown University and 
Harvard University. She earned her MS and PhD degrees at Rensselear Polytechnic Institute in Troy, NY and received her BA from The College of Saint 
Rose in Albany, NY. 
……………………………………………………………………………………………………………………… 
 
Francisco M. De La Vega 
Principal Research Fellow, 
Computational Genomics Research,  
Genetics Systems R&D, 
Life Technologies  
Title: The road to 99.999% accuracy single molecule sequencing 
Life Technologies continues to improve the SOLiD™ System, a massively parallel second-generation sequencing system 
based on oligonucleotide probe ligation and clonally amplified DNA fragments attached to beads. The use of beads have 
provided increasing sequencing throughputs reaching 100 Gb/run today, and soon approaching 300 Gb/run by increasing 
packing and reducing bead dimension coupled to signal to noise improvements. Recent chemistry enhancements allow 
longer read lengths, providing 25-125 bp reads from either paired-end or mate-pair libraries with insert sizes ranging from 
~100bp to ~20 kb.  This ever-increasing throughput has reduced the cost of sequencing a human genome to US$6,000 
today, to US$3,000 by the end of 2010, and continues to come down. A cornerstone of the SOLiD technology is its error 
detection and correction ability. Currently in SOLiD 4, error detection and reference-assisted correction codes provides an 
average 99.95% read accuracy, the highest in second-generation sequencing. We are working in new error corrections 
codes for SOLiD that can provide up to 99.999% read accuracy without the need of reference sequence, which would be 
essential in applications such as cancer somatic mutation detection, sequencing pooled or complex samples, and low 
pass GWAS by sequencing, among others. In addition, Life Technologies is actively developing a novel third generation 
HUGO J (2010) 4:1–190 53
123

single-molecule sequencing platform based on real-time monitoring of FRET on the surface of a quantum-dot (Qdot™) 
monocrystal. This technology provides a portable nanometer-sized sequencing engine that enables continuous long read 
lengths using active-sequencer exchange and tunable high accuracy using recursive sequencing. The ability to rapidly 
and inexpensively produce very long reads can enable new applications that rely on understanding the long-range 
structure of nucleic acids (e.g. haplotyping) and, in combination with highly accurate “short-read” SOLiD data, would 
provide flexible and comprehensive genome analysis solutions. 
Biosketch 
Francisco M. De La Vega is Principal Research Fellow in Computational Genetics at Life Technologies in Foster City, California. He earned his Doctor of 
Science degree in Genetics and Molecular Biology at CINVESTAV (Mexico City), where he later was appointed assistant professor and headed the 
Department of Genetics Bioinformatics Unit. He joined Applied Biosystems in 1997 to lead the development of bioinformatics probe design pipelines for 
gene expression microarray and real time PCR genomic assays products for gene expression and genotyping, and later created the SNPbrowser™ 
Software, a tool to select SNPs and assays for genetic association studies. Francisco led the design and analysis of a pioneering project that genotyped 
over 200,000 SNPs in four human populations to develop validated genotyping assays and survey the patterns of genetic variation along the genome. In 
collaboration with the University of Kiel, participated in the discovery of a gene of Crohn disease by a novel approach, for which he was co-recipient of 
the 2008 Bio-IT World Best Practices Award in Basic Research. More recently, he managed the development of bioinformatics analysis tools for the 
SOLiD™ System, a second-generation massively parallel sequencing platform, and currently is working on the applications of high-throughput 
sequencing technologies in human genetics, cancer research, and genomic medicine. Francisco represents Life Technologies at the 1000 Genomes 




Founder & Chief Technology Officer 
Pacific Biosciences  
 
Title: Applications of SMRT™ sequencing outside the performance envelope of first and second generation 
sequencing 
Despite their nearly universal use in DNA sequencing for several decades, DNA polymerases possess performance 
characteristics far beyond what first and second generation sequencing technologies have achieved.  Through the use of 
phospholinked nucleotides, which can be incorporated with near-native kinetics by DNA polymerases, and zero-mode 
waveguides, which allow single-molecule detection at the high nucleotide concentrations required by native DNA 
replication, the natural power of these enzymes has been harnessed by Pacific Biosciences for single-molecule, real-time 
(SMRT™) DNA sequencing, which exhibits long read lengths, high speed and thus fast time to results. The high 
processivity of certain phage polymerases is translated into long readlength and applied to the shotgun whole genome 
assembly of a hydrogen-producing bacterium, Rhodopseudomonas palustris (R. pal). To demonstrate the effectiveness of 
long reads and strobed reads in resolving complex genome structure, we employed a hybrid assembly strategy using 
Pacific Biosciences’ long reads and strobe reads in conjunction with reads from the Illumina sequencing platform.  The 
resulting assembly produced significantly fewer contigs and longer contig lengths than the starting Illumina assembly, with 
no misassembles when compared to the finished genome sequence.  We show the role these assemblies play in the 
network analysis of hydrogen production by R. pal.  Because of the kinetic information that accompanies the primary 
sequence extracted with every read, it is possible to detect the presence of modified nucleobases in DNA strands.  In 
addition to allowing direct detection of epigenetic marks such as methylcytosine, it also provides a means of performing 
hypothesis-free investigation of structural modifications to DNA bases at the whole-genome level. The fast time to result is 
ideal for analysis of viral genomes in the context of outbreaks of infectious disease.  To demonstrate the agility of the 
system we apply SMRT sequencing to raw samples taken from influenza patients to analyze the strains present at the 
single molecule level. 
Biosketch 
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and secured its Series A funding in 2004.  He was awarded a Ph.D. in Physics by Cornell 
University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures.  His work 




contributed to the establishment of the Nanotechnology Center at Cornell.  He was a member of the project team at Cornell which developed the 
technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the 
technology to the scientific community.  Dr. Turner's undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of 
Science in Applied Mathematics, Electrical Engineering and Physics.  He is the author of over 30 scientific papers in fields ranging from nanofluidics, 
genetics, cell attachment to chemically- and topographically- modified surfaces, x-ray lithography and process modeling.  He is listed as the inventor on 
nine U.S. patents and more than 20 published patent applications.  Dr. Turner was recipient of the MIT Technology Review "TR100" Award in 2003 and 
the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008.  He is a sitting member of the National Institutes of Health grant 





Senior Vice President & Chief Technology Officer 
Illumina Inc  
 
Title: Current and future outlook of genomic technologies 
Recent advancements in genomic technologies are changing the scientific horizon, dramatically accelerating biomedical 
research.  For wide implementation of these technologies, their accuracy, throughput, cost, and workflow need to be 
addressed. In the past seven years, the cost of full human genome sequencing has been reduced by 4-5 orders of 
magnitude, and reduction will continue by another 10-fold in the next couple of years. At that cost level, major biomarker 
discoveries will fuel adoption of the latest genomic technologies for medicine, agriculture, consumer products, and 
forensics. In this talk, we will discuss Illumina’s efforts and provide our perspectives on the future of genomics. 
Biosketch 
Mostafa Ronaghi, Ph.D., joined Illumina in August 2008 and is responsible for leading internal research programs and evaluating new technologies for 
the Company. 
Mostafa is an experienced entrepreneur and was involved in the start-up of four life sciences companies. In 2007, Mostafa co-founded Avantome, a 
privately-held sequencing company. Before this, he co-founded NextBio, a search engine for life science data. In 2001, Mostafa co-founded ParAllele 
Bioscience, which was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization of highly multiplexed 
technology for genetic testing. In 1997, he co-founded Pyrosequencing AB, which was renamed to Biotage in 2003, and led the company to a successful 
initial public offering in June 2000 on the Stockholm Stock Exchange. Mostafa was a principal investigator at Stanford University from 2002–2008 and 
focused on the development of novel tools for molecular diagnostic applications. He serves on the board of directors of Microchip Biotechnologies, 
NextBio, and Aurora Biofuels. 
 Mostafa earned his Ph.D. from the Royal Institute of Technology in Sweden. Mostafa holds more than 20 pending and issued patents and has written 
more than 50 peer-reviewed publications in journals and books. 
……………………………………………………………………………………………………………………… 
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Exhibitor Showcase    __________________________________________________ 
Booth 2, 4, 6 
ILLUMINA UNITED KINGDOM 
Chesterford Research Park 
Little Chesterford 
Nr Saffron Walden 
Essex 
CB10 1XL, UK 
Contact Person: Colette King 
Direct: +44(0)1799 534 172 




At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies 
possible that were not even imaginable just a few years ago. With such rapid advances in technology taking place, it is mission critical to have solutions 
that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. Our offering includes leading-edge solutions 
for:  
•           DNA sequencing 
•           SNP genotyping  
•           Copy number variation  
•           DNA methylation   
•           Gene expression  




Booth 3, 5 
 
BGI (Beijing Genomics Institute at Shenzhen) 
Bei Shan Industrial Zone,  
Yantian District, Shenzhen  
518083, China 
Contact Person: Wang Wei Wei 




Carrying out lots of projects, BGI has established its own technical platforms based on large-scale genome sequencing, efficient bioinformatics analyses, 
and innovative genetic health-care initiatives. These distinguished achievements have made a great contribution to the development of genomics in the 
world, and have established BGI as a world-class research institution. 
 
Booth 7 
DNA Vision S.A 
Avenue George Lemaitre 25 - B-6041  
Charleroi – Belgium 
Contact Person: Elise Debel 
Direct: (+32) 071347884 
Tel: (+32) 071347880 
Fax: (+32) 071347879 
EliseDebel@dnavision.be 
www.dnavision.be/  
DNAVision, specialized in molecular biology, provides a wide range of genetic services and products to the pharmaceutical, food, and biotechnology 
industries.Our scientists use theoretical knowledge and practical know-how to discover and develop genetic markers meeting biological and medical 
needs. DNAVision is a research and development company with expertise in molecular biology, specifically in genetic analysis. Using state-of-the-art 











6190 Corte Del Cedro, Carlsbad, 
CA 92011-1515 
USA 





GenVault is the global leader in providing biosample workflow, transport, and storage solutions for genomic medicine, discovery, and identification. The 
company’s dryͲstate platform enables the extraction, preservation, recovery, and distribution of DNA and RNA at ambient temperature. With GenTegra, 
GenPlates, and the Dynamic Archive, GenVault is innovating best practices for sample management and preservation. Learn more at 
www.genvault.com. 
 
Booth 9, 11 
AGILENT TECHNOLOGIES 
1 rue Galvani 
91745 Massy cédex 
France  
Tel:  (+33)478778442 
redia_traore@non.agilent.com 
 www.agilent.com  
Agilent Technologies is a leading supplier of life science research systems that enable scientists to study complex biological processes and disease 
mechanisms. Engineered for sensitivity, reproducibility and workflow productivity, Agilent's solutions include instrumentation, software, consumables and 
services for genomics, proteomics and metabolomics applications.   
Agilent’s genomics portfolio features:  
x Stratagene molecular biology reagents  
x 60-mer Oligo catalog and custom microarrays for array-based Comparative Genomic Hybridization (aCGH),  GeneExpression, miRNA, 
methylation and ChIP-on-Chip  analysis 
x SureSelect Target Enrichment products for next-generation sequencing 
x a microarray scanner 
x a Quantitative PCR platform 
x the 2100 Bioanalyzer, leading microfluidic platform for DNA, RNA and protein quality control  
x Liquid handling platforms 
x Genespring software for microarray and qPCR data analysis 
 
From sample preparation to data analysis, Agilent provide complete solutions optimizing workflow productivity and performance through automation. 







4906 CR  OOSTERHOUT 
THE NETHERLANDS 
Tel: +31 162 408 333 




Luminex Corporation develops manufactures and markets proprietary biological testing technologies with applications throughout the diagnostics and life 
sciences industries. The Company’s xMAP® multiplex solutions include an open architecture, multi-analyte technology platform that delivers fast, 
accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, 
including the genomics and proteomics markets. The Company’s xMAP technology is sold worldwide and is already is use in leading clinical laboratories 










LGC Genomics (AGOWA) 
TGS Haus 8 
Ostendstr. 25 D-12459 
Berlin Germany 
Contact Person: Franziska Hanke 
Tel: (+49) 03053042204 
Fax: (+49) 03053042201 
hanke@agowa.com  
http://www.agowa.de/  
LGC Genomics (www.lgcgenomics.com) is the Berlin-based division of LGC with specific expertise in the delivery of a wide range of genomic services 
and products to a variety of customers. These include pharmaceutical and biotechnical companies, private and public research organisations and 
medical institutions. 
LGC Genomics delivers Next Generation Sequencing services, DNA sequencing, genomics services, nucleic acid extraction services and DNA 
extraction products. 
LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards.  
 
Booth 13, 14. 15 
The Centre for Arab Genomic Studies (CAGS) 
Centre for Arab Genomic Studies 
P.O. Box 22252, Dubai 
United Arab Emirates 





Since its establishment in 2003 by H.H. Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai and UAE Minister of Finance, with an aim to 
alleviate human suffering from genetic diseases in the Arab World, the Centre For Arab Genomic Studies  has dedicated itself to the mission of 
improving human health by characterizing and preventing genetic disorders in Arab countries based on the recent advances in human genetics. 
 One of the major projects undertaken by CAGS is the Catalogue of Transmission Genetics in Arabs (CTGA) database, which is a continuously updated, 
open-access compendium of bibliographic material and observations on human gene variants and inherited, or heritable, genetic diseases in Arabs 
(www.cags.org.ae).  Data collections on genetic disorders have so far been completed for the UAE, Bahrain, Oman and Qatar, work is ongoing for other 
Arab countries.  Currently, the database hosts entries for nearly 940 genetic disorders and 370 related genes. 
 CAGS regularly comes out with many open access publications, aimed at both the scientific community as well as the public. CAGS conducts the Pan 
Arab Human Genetics Conference (PAHGC) is a biennial event organized every alternate year. CAGS is active in conducting cutting edge research in 
the field of genetic disorders seen in the Arab World.  
 The support of H.H. Sheikh Hamdan Bin Rashid Al Maktoum has been instrumental in achieving most of the Centre’s objectives.  This support has been 
further reinforced with the establishment of a CAGS genetics award to honor individuals and institutions working in the field with an aim to encourage 
genetic research in the Arab World.   
 




D - 10587 Berlin 
Deutschland 
Contact Person: Claudia Moeller 
Tel:  (+49)6217591317  
claudia.moeller@roche.com 
http://www.roche.com/index.htm  
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Roche provides state-of-the-art instruments and reagents for research. Discover novel variants in complex genomes with unprecedented sensitivity and 
specificity using the new GS Junior Benchtop System – sequencing for everyone and everyday – and GS FLX. MagNA Pure 96s purify nucleic acids 
from 96 samples in <1 hour, LightCycler® 1536s revolutionize real-time qPCR, and NimbleGen arrays find your gene of interest. For cell analysis, RTCA 
DP Instruments measure cell invasion and migration in up to three 16-well CIM-Plates and Innovatis Instruments automate cell counting using validated 
processes. 
LIGHTCYCLER, GS FLX, GS JUNIOR, MAGNA PURE, XCELLIGENCE and INNOVATIS are trademarks of Roche. 
 
Booth 19 
DNA Genotec Inc 
2 Beaverbrook Road 
Kanata, Ontario, Canada 
K2K 1L1 
Contact Person: Danielle Hodgson 
Tel:  613 723 5757 
danielle.hodgson@dnaenotek.com 
http://www.dnagenotek.com/index.html  
DNA Genotek is focused on improving nucleic acid sample collection. The company’s Oragene® product line offers researchers a non-invasive, all-in-one 
system for the collection, stabilization, transportation and purification of high quality DNA or RNA from saliva.  Oragenes’ reliability and ease-of-use have 
resulted in rapid worldwide adoption by top-tier health institutions. 
 
Booth 20 
Caliper Life Sciences 
Central Parc 
1 Allée de l’Epervier 
93420 Villepinte 
Contact person: Abderazzak Bensaid 
Tel: +33 1 48 63 71 35 
Fax: +33 1 48 63 71 33 
Abderazzak.bensaid@caliperls.com 
www.caliperLS.com  
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and 
enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in 
vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art 
microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. 
 
Caliper has a broad expertise in automating the processes involved in the core areas of genomics research including:  extraction and purification, PCR 
reaction setup, automation of RT-PCR as well as the separation and direct detection of DNA and RNA. Caliper’s new LabChip XT has the ability to 
quickly, and with high resolution isolate nucleic acid fragments of specific size. The LabChip XT shares technology with Caliper’s current separation 
instruments, but in addition to analysis it can actually collect sample for processing.  The applications for this are numerous, including microRNA 
sequencing, transcriptome analysis, SNPs, and de novo sequencing 
 










Contact Person: Vicky Bannes 
Tel: 44 (0) 1628 552 556 
Fax: 44 (0) 1628 552 580 
vicky_barnes@affymetrix.com 
http://www.affymetrix.com/estore/  




Affymetrix is evolving into a provider of scalable, innovative genomic analysis tools and reagents for discovery, exploration, validation, and genetic 
testing. The acquisitions of Panomics and USB bring high-throughput, multi- to single-gene assays and premium-value molecular biology reagents to 
customers, enabling complete solutions for genome-wide and targeted studies and a range of products for cellular and protein analysis. 
Today, Affymetrix technologies enable researchers to better understand the role that genes play in disease, the effectiveness and safety of therapies, 
and many other biological factors that affect human well-being. Our mission is to revolutionize how the world benefits from genetic information. 
 






Contact Person: Brigit Jung 
Tel: +49 062214878913 
Fax: +49 0622148768913 
birgit.jung@springer.com / Nicola.Klupsch@springer.com  
http://www.springer.com  
Springer is a major publisher of books and journals in genomic medicine, including The HUGO Journal, the Official Journal of the Human Genome 
Organisation. Please stop by our booth to order books at a special conference discount and take a closer look at sample issues of journals. Staff will be 




One Kendall Square 
Ste. 7301 
Cambridge, MA 02139 
USA 
Contact person: Sharon 
Tel: 617 264 1857 
Fax: 617 264 1757 
sbleakney@helicosbio.com 
http://www.helicosbio.com/  
Helicos BioSciences (NASDAQ: HLCS) is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, 
and diagnostic markets. Helicos's proprietary True Single Molecule Sequencing (tSMS)™, technology allows direct measurement of billions of strands of 
DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and 
committed to providing scientists the tools to unlock the era of genomic medicine. The company is currently planning the introduction of its first product, 
the Helicos™ Genetic Analysis System.Based on Helicos's tSMS technology, the Helicos Genetic Analysis System enables ultra-highthroughput genetic 
analysis by directly sequencing single molecules of nucleic acids. The tSMS workflow is based on a simple, cost effective sample preparation process 




IMGT, Laboratoire d'ImmunoGénétique Moléculaire,  
LIGM Institut de Génétique Humaine, IGH, UPR CNRS 1142 
141 rue de la Cardonille 34396 MONTPELLIER Cedex 5, France 
Contact Person: Marie-Paule Lefranc 
Tel: +33 499619965 
Fax: +33 499619901 
Marie-Paule.Lefranc@igh.cnrs.fr 
http://imgt.cines.fr/   
IMGT®, the international ImMunoGeneTics information system® (http://www.imgt.org), created in 1989 by Professor Marie-Paule LEFRANC at 
Montpellier, France (Montpellier 2 University and CNRS), is the global reference in immunogenetics and immunoinformatics. Based on IMGT-
ONTOLOGY, IMGT® is a high-quality integrated knowledge resource specialized in the immunoglobulins (IG) or antibodies, T cell receptors (TR), major 
histocompatibility complex (MHC), of human and other vertebrate species, proteins of the immunoglobulin superfamily (IgSF) and MHC superfamily 
(MhcSF), and related proteins of the immune system (RPI) of any species. IMGT® comprises six databases (IMGT/LIGM-DB, IMGT/GENE-DB, 
IMGT/3Dstructure-DB, IMGT/mAb-DB, etc.), fifteen interactive on-line tools for sequences, genome and three-dimensional (3D) structure analysis, and 
more than 10 000 web pages of synthesis and knowledge. IMGT® is extensively used by scientists in medical research (autoimmune diseases, 
infectious diseases, AIDS, leukemias, lymphomas, myelomas and other cancers), veterinary research, biotechnology related to antibody engineering and 




humanization (phage displays, combinatorial libraries, chimeric, humanized and human antibodies), diagnostics (clonalities, detection and follow-up of 
residual diseases) and therapeutical approaches (graft, immunotherapy, vaccinology). IMGT® is available at http://www.imgt.org, freely for the academic 








1 Main Street, Suite 530 
Cambridge, MA 02142 
USA 
Contact Person: Ari Kiirikki 
Tel: 978 7714876 
Fax: 617 250 8610 
akiirikki@knome.com 
http://www.knome.com/service/knomediscovery.html  
Saving you from making significant platform commitments, Knome provides rapid and economical access to the latest cutting-edge sequencing 
platforms, robust analytical capabilities and experienced bioinformatic professionals. Whether your need is sequencing one or one hundred samples, 





2333 BZ Leiden 
The Netherlands 
Contact Person: Linsay Chung 
Tel: +31 715681000 
Fax: +31 715681010 
l.Chung@bioke.com 
http://www.bioke.com/  
BIOKÉ is a key provider of products and services in life sciences. Many experts in academic institutions, hospitals and research companies as well as 
pharmaceutical and biotechnology companies are using our products to speed up their research and diagnostics. It is our aim to accelerate your 
progress in R&D and diagnostics by sharing knowledge.  
We provide innovative products and services in the field of genomics, proteomics and molecular diagnostics. In these field we collaborate with experts 
from the University of Leiden, and other universities or research institutions. The mission of BIOKÉ is defined by four keywords: acceleration, co-
operation, innovation and knowledge. 
 
Booth 28 
Fluidigm Europe B.V. 
Parnassustoren, Locatellikade 1 
1076 AZ Amsterdam 
The Netherlands 
Contact person: Eve Marquis 
Tel : +31 20 578 88 53  




Bridging the gap between discovery and clinically useful biomarkers requires next-generation technology—tools that deliver radically new efficiencies for 
the analysis of nucleic acids. The BioMark™ line of life-science products from Fluidigm is meeting this challenge through unique microfluidic chips 
known as Dynamic and Digital Arrays. Using the recognized gold standard in PCR, these innovative products utilize TaqMan® or similar assays to 
deliver significant advancements in throughput and time to data while reducing reagent costs and the tyranny of pipetting.  In addition, Fluidigm’s 
exclusive Digital Arrays enable exquisite quantification of template libraries and detection of rare mutations as described in recent breakthrough 
publications. Discover the New 48.48 AccessArray™ for target enrichment and sample multiplexing.  
 
Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science 
research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. 
These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfluidic device 




(IFC). Fluidigm’s systems, consisting of instrumentation, software and single-use chips, increase throughput, decrease costs and enhance sensitivity 




GATC Biotech SARL 
Parc scientifique et technologique de Luminy  
Bat CCIMP Case 922  
13288 Marseille cedex 09, 
 France 
Contact Person: Marita Strohm 
Tel: +33 04918284 
Fax: +33 0442011200 
m.strohm@gatc-biotech.com 
http://www.gatc-biotech.com/   
GATC Biotech is Europe’s leading service provider of DNA sequencing and bioinformatics for industry and academic research. 
For nearly two decades we have been continuously developing new and comprehensive solutions for DNA sequencing and bioinformatics sequence 
evaluation – for individual DNA samples through to complete genome projects. 
All our solutions are precisely matched to the specific requirements of the customer. We can do this because we use all leading sequencing 
technologies on the market, such as Applied Biosystems ABI 3730xlTM  for Sanger sequencing and Illumina’s Genome Analyzer IITM  and Roche 
Diagnostics GS FLXTM for Next Generation sequencing. 
With a total of eleven sequencing instruments – four for Next Generation sequencing - GATC has the largest commercially available sequencing 
capacity in Europe with two terabases per year. 
We serve over 10,000 customers in 40 countries around the globe and have subsidiary companies in Great Britain, France and Sweden – the fact that 
GATC Biotech is one of the top companies in this sector is not only down to technical or scientific reasons, however: 
 
Booth 30 
Malaysian Genomics Resource Center(MGRC)  
27-9, Level 9, Signature Office, 
Mid-Valley City,Kuala Lumpur 
59200, Malaysia 
Contact Person: Mazlina Binti Mat Ali 
Tel: +6 03 2283 3401 
Fax: +6 03 2282 8102 
mazlina@mgrc.com.my 
www. mgrc.com.my 
We aspire to be the leading provider of bioinformatics services, offering high-end and rapid turnaround services that are valued by our customers. We 
hope that our services will expedite scientific breakthroughs and IP generation in the medical, agricultural and industrial sectors, and that these 
discoveries benefit mankind. We aim to stay ahead in this exciting field by continuously expanding, updating, and improving our services, resources and 
expertise. 
 We want to help create awareness of the enormous potential bioinformatics holds, and to help strengthen the understanding of its underlying principles 
and applications among Malaysians. Through this, we are committed to promoting Malaysia as a leader on the global bioinformatics and genomics stage. 
Booth 31 
Eurofines MWG GmbH 
Anzingerstr. 7a, Ebersberg  
85560, Germany 
Tel:  +49 80928289959 
Fax:  +49 809221084 
npichler@eurofinsdna.com 
http://www.eurofinsdna.com  
Eurofins MWG Operon, founded in 1990 and member of the Eurofins Group, is an international provider of genomic services established around the 
core business lines DNA sequencing, oligonucleotides, siRNA and gene synthesis. The company's main mission is focussed on customer convenience 
and high quality services in industrial scale for the life science industries and academic research institutions around the world. 
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Booth 32, 33, 34 
Life Technologies 
25 Avenue de La Baltique BP 96  
91943, Courtaboeuf Villebon sur Yvette,  
France 
Tel: +33 0 169598539 
Fax: +33 0 169598500 
corinne.malphettes@lifetech.com 
www.lifetechnologies.com/home.html  
Applied Biosystems is now a part of Life Technologies Corporation (NASDAQ:LIFE), a global biotechnology tools company dedicated to improving the 
human condition. Applied Biosystems systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries 
and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance 
personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life 
Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and 
possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the 
combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: 
www.lifetechnologies.com. 










IMGT®, the international ImMunoGeneTics information system® 
http://www.imgt.org, is a high-quality integrated knowledge resource 
specialized in the immunoglobulins (IG), T cell receptors (TR), major 
histocompatibility complex (MHC), immunoglobulin superfamily (IgSF), 
major histocompatibility complex superfamily (MhcSF) and related 
proteins of the immune system (RPI) of human and other vertebrate 
species, created in 1989 by Marie-Paule Lefranc (Université Montpellier 2, 
CNRS). 
 
IMGT® consists of 
x 6 databases (sequences, genes, structures, monoclonal antibodies) 
x 15 interactive online tools 
x 10 000 pages of web resources. 
 
The IMGT Home page http://www.imgt.org (Montpellier, France) provides 











INTERNATIONAL PANEL OF CHAIRS       __________________________________ 
 
Stylianos E Antonarakis 
Professor and Chairman 
University of Geneva Medical School 
Department of Genetic Medicine and Development 
Stylianos Antonarakis is the Director of the Division of Medical Genetics at the University of Geneva in Switzerland. Before moving to Geneva he was a 
professor at Johns Hopkins University in the USA. His lab participates in many projects involving the genetics of monogenic and polygenic disorders as 
well as the annotation of the human genome and particularly of human chromosome 21. He is on the editorial board of many high profile journals such 
as Genome Research and Genomics and has recently served as president of the European Society for Human Genetics. He has published more than 
470 papers in peer-reviewed journals since 1982. 
 
Samir K Brahmachari  
Secretary to Govt. of India, 
Department of Scientific and Industrial Research and Director General, CSIR  
Prof. Samir K.  Brahmachari pioneered functional genomics initiative in India and led the Indian Genome Variation Consortium project as the Director, 
Institute of Genomics and Integrative Biology, CSIR. His core expertise is in structural and computational biology. Since November 2007, he has 
assumed the office of the Director General of Council of Scientific and Industrial Research (CSIR), which is the largest publicly-funded organization 
involved in scientific and industrial research, with 37 constitutional laboratories across India. He is a member of the HUGO Council and the Advisory 
Board of the X Prize in Genomics. As a member of the expert group on Human Rights and Biotechnology Commission of United Nations, he has 
addressed issues of unethical exploitation of genetic resources of the Third World and has championed the concept of rights of patients in benefit 
sharing in the development of genomic medicine. He has successfully led the Indian team in the Pan Asia SNP Project. He is the recipient of a large 
number of National and International awards and elected member of all four National Academies of Sciences and Engineering in India. In 2009, the 
Week magazine has identified him as one of the twenty-five most valuable Indians. Currently he is leading the Open Source Drug Discovery (OSDD) 




Principal Investigator, French National Center for Scientific Research (CNRS) 
Director, Intitute of Molecular Genetics of Montpellier 
Director, Montpellier Institute of Biology  
Dr Blanchard (PhD) is Director of the Institute of Molecular Genetics in Montpellier (IGMM, www.igmm.cnrs.fr) and of the Montpellier Institute of Biology 
(IFR122), a cluster of laboratories belonging to the department of Biology and health of Montpellier University. He is Vice-President of the Cancéropôle 




Group Leader, Genome Institute of Singapore 
Director of the JE 2492 University Team (University Paris-Sud)  
 
Our team develops new statistical models and methods devoted to genomic-oriented data analyses and transfers the results of this methodological 
research to bioclinical research. Three topics are investigated by the team that relate to class comparison, class prediction and class discovery. In 
particular, the team focuses on clinical cancer research and investigates the prognostic interest of combining markers from genome, transcriptome, and 
proteome for predicting clinical outcome. More precisely, we recently proposed an integrative genomic signature for refining the assessment of 




Bioinformatics and Genomics  
Department of Genetics 
University of Leicester 
Professor Brookes is an internationally recognized leader in genomics and bioinformatics, having made significant contributions to method development, 
disease and population genetics, DNA variation analysis, and database systems for organizing gene-disease information. His publications include over 
130 peer-reviewed articles and reviews, and he has filed 6 patent applications on cloning, genotyping, and DNA analysis. Professor Brookes began his 
research career in the UK by achieving a first class degree in Medicine and Medical Biochemistry at Manchester University, and then a molecular 
genetics PhD at the Imperial Cancer Research Fund and the University of London. He subsequently established a research group in the MRC Human 
Genetics Unit in Edinburgh, where his team was involved in identifying the Presenilin-1 gene that causes Alzheimers Disease. He then moved to 
Sweden, first to Uppsala University where he received Docenture in Genetics, and then to the Karolinska Institute where he was awarded both 
Docentureand a Professorship in Genome Research. Professor Brookes now holds a Chair in Bioinformatics and Genomics at the University of 
Leicester in the UK, and an Adjunct Professorship in the KarolinskaInstitute in Sweden. In these positions he coordinates the European FP7-
GEN2PHEN informatics project, and runs the HGVbaseG2P genetic association database. He serves on the HUGO Council and acts as Editor & Chair 




of Publications Committee for the HUGO Journal, and he is also a member of both the Public Population Project in Genomics (P3G) and the Open 
Researcher & Contributor ID (ORCID) Technical Working Group. Additionally, he is a Co-Founder and Board Member of the Human Genome Variation 
Society, and works as communicating Editor for Human Mutation. Other significant achievements include launching and running the international 





European Bioinformatics Institute (EMBL-EBI) 
HUGO Gene Nomenclature Committee (HGNC) 
Professor Brookes is an internationally recognized leader in genomics and bioinformatics, having made significant contributions to method development, 
disease and population genetics, DNA variation analysis, and database systems for organizing gene-disease information. His publications include over 
130 peer-reviewed articles and reviews, and he has filed 6 patent applications on cloning, genotyping, and DNA analysis. Professor Brookes began his 
research career in the UK by achieving a first class degree in Medicine and Medical Biochemistry at Manchester University, and then a molecular 
genetics PhD at the Imperial Cancer Research Fund and the University of London. He subsequently established a research group in the MRC Human 
Genetics Unit in Edinburgh, where his team was involved in identifying the Presenilin-1 gene that causes Alzheimers Disease. He then moved to 
Sweden, first to Uppsala University where he received Docenture in Genetics, and then to the Karolinska Institute where he was awarded both 
Docentureand a Professorship in Genome Research. Professor Brookes now holds a Chair in Bioinformatics and Genomics at the University of 
Leicester in the UK, and an Adjunct Professorship in the KarolinskaInstitute in Sweden. In these positions he coordinates the European FP7-
GEN2PHEN informatics project, and runs the HGVbaseG2P genetic association database. He serves on the HUGO Council and acts as Editor & Chair 
of Publications Committee for the HUGO Journal, and he is also a member of both the Public Population Project in Genomics (P3G) and the Open 
Researcher & Contributor ID (ORCID) Technical Working Group. Additionally, he is a Co-Founder and Board Member of the Human Genome Variation 
Society, and works as communicating Editor for Human Mutation. Other significant achievements include launching and running the international 




INSTITUTE of HUMAN GENETICS 




Dr Valere CACHEUX, PharmD, PhD 
Principal Investigator 
Genome Institute of Singapore 
Our team has for objectives to identify and characterize the genomic architecture of chromosomal rearrangements in genomes. In cancer genomes 
these rearrangements can lead to fusion genes and could be used as markers in tumor screening. Then, chromosomal anomalies associated with 
congenital disorders can aid the identification of new genetic syndromes. Using known technologies such as FISH and microarrays in combination with 
DNA-PET technology, we can also precisely identify all the breakpoints of chromosomal anomalies and understand the genomic organization of such 
rearrangements. With the precise description of the breakpoints, a second focus is to understand why these rearrangements occur in cancer genomes 
and in associated diseases rearrangements. 
 
Benjamin Capps 
Assistant Professor in Biomedical Ethics 
Director of Graduate Studies, Centre for Biomedical Ethics  
 
Benjamin joined the Centre for Biomedical Ethics in 2008. He was previously a Research Associate at the Centre for Ethics in Medicine, University of 
Bristol, UK. He read for a Doctorate in Medical Ethics (awarded in 2004) and completed a two-year Postdoctoral Fellowship at the University of Bristol 
(2004-6), both funded by the Wellcome Trust’s Biomedical Ethics Programme. He has coordinated a number of projects, including an ethics review for 
the UK’s Department of Trade and Industry Foresight project: ‘Brain Science, Addiction and Drugs’ (2004-5); a commissioned report on “‘Public Interest’ 
and ‘Public Good’ as Applied to UK Biobank Access Decision-Making” for the UK Biobank’s Ethics and Governance Council (2007-8); and an 
international multi-centre project on ‘New Developments in Neuroscience and Genetics’ (2007-8). This latter project was funded by the European 
Monitoring Centre for Drugs and Drug Addiction, an agency of the European Union. Benjamin is an Honorary Associate at the ESRC Centre for 
Economic and Social Aspects of Genomics (Cesagen); and has been a Visiting Fellow at the Centre for Biomedical Ethics, at the National University of 
Singapore (2007 & 2008), University of Brisbane (2008), and the Hastings Centre, New York (2005). His primary research interests are in stem cell 
science and ethics; 'neuroethics', drugs (mis)use and addiction research. His research also focuses on the development of jurisprudential and political 











Ruth Chadwick is Director of the ESRC (Economic and Social Sciences Research Council) Centre for Economic and Social Aspects of Genomics 
(Cesagen), Cardiff University, UK. She also holds a Link Chair between Cardiff Law School and the School of English, Communication and Philosophy 
(ENCAP). She has co-ordinated a number of projects funded by the European Commission, including the EUROSCREEN projects (1994-6; 1996-9) and 
co-edits the journal Bioethics and the online journal Genomics, Society and Policy. She is Chair of the Human Genome Organisation Ethics Committee 
and has served as a member of several policy-making and advisory bodies, including the Panel of Eminent Ethical Experts of the Food and Agriculture 
Organisation of the United Nations (FAO), and the UK Advisory Committee on Novel Foods and Processes (ACNFP). She was editor-in-chief of the 
award winning Encyclopedia of Applied Ethics (1998), of which a second edition is now being prepared. She is an Academician of the Academy of Social 
Sciences and a Fellow of the Hastings Center, New York; of the Royal Society of Arts; and of the Royal Society of Medicine. In 2005 she was the winner 




Director and Distinguished Research Fellow 
Institute of Biomedical Sciences 
Academia Sinica 
 
Professor Yuan-Tsong (Y-T) Chen was originally from Taiwan and have been committed to biomedical research for over 30 years. He recognises the 
tremendous impact that genetics and genomics have had on the improvement of health and treatment of diseases and has established the Chen Award, 
with HUGO, to celebrate research accomplishments in Human Genetics and Genomics in Asia Pacific and around the world. Professor Chen received 
his MD degree from National Taiwan University (Taipei) and a PhD from Columbia University (USA). He is currently a Distinguished Research Fellow 
and Director of the Institute of Biomedical Sciences, Academia Sinica, Taiwan, and Professor of Pediatrics and Genetics at Duke University Medical 
Center (USA). Professor Chen is a physician/scientist, recognised for his work on human genetic disorders. His translational research leads to the 
development of now standard therapies for two devastating inherited metabolic diseases: a simple and effective cornstarch therapy for severe 
hypoglycemia in glycogen storage diseases and an enzyme replacement therapy, the first ever treatment, for a debilitating, progressive and often fatal 
myopathy called Pompe disease. Professor Chen has also identified the genetic basis of and developed DNA-based diagnosis for several major 
heritable diseases, and more recently, his team in Taiwan has uncovered genes/SNPs associated with drug-induced Stevens-Johnson syndrome and 
warfarin sensitivity. His latest pharmacogenomic studies of adverse drug reactions paved the way for personalised medicine by preventing drug toxicity 
with a gene test. Professor Chen is an elected member of Academia Sinica and of the Academy Sciences for the Developing World. 
 
Richard Cotton 
Director, Genomic Disorders Research Centre  
President, Human Genome Variation Society 
Co-Editor, Human Mutation; Convenor, Human Variome Project 
Richard Cotton AM BAgSc., Ph.D, D.Sc. (Melbourne) initiated the Mutation Research Centre, now renamed the Genomic Disorders Research Centre, in 
January, 1996 (www.genomic.unimelb.edu.au). He has always been interested in the biochemical genetics of human disease and has recently focussed 
on mutation. Amongst his more notable scientific achievements are the conception, planning and execution of the fundamental experiment, which 
proved that when two immunoglobulin producing cells were fused, the immunoglobulin of both parental cells were produced in the hybrid. This laid the 
experimental and theoretical foundation for the widely used monoclonal antibody technique. He also conceived the widely used tetrohydrobiopterin (BH4) 
load test to identify the serious variants of PKU, but BH4 is currently being trialed in heart disease. He is particularly interested in improving mutation 
detection technologies to make them cheaper and simpler, so that they can be more widely applied, and holds several patents in the area. A recent 
development has been a method to detect DNA damaging compounds. He has written two books entitled "Mutation Detection", initiated in 1991 the 
journal entitled "Human Mutation", and in 1991 initiated bi-yearly international workshops on Mutation Detection and in 1998 bi-yearly HUGO Mutation 
Detection Courses. In 1996 he has also started a worldwide initiative (The HUGO Mutation Detection Database Initiative, recently formed into the 
Human Genome Variation Society (HGVS) website: www.hgvs.org.) to capture and distribute lists of mutations. In June 2005, he was admitted as a 
Member of the Order of Australia for service to science through genetic research, particularly through the development of technologies to detect gene 
mutations that underlie birth defects or cause disease and through efforts to document findings. In June 2006, he convened a Meeting, co-sponsored by 
WHO, which initiated the Human Variome Project (www.humanvariomeproject.org). This project aims to collect worldwide genetic variation and its 
associated phenotype affecting human health. He convened a HVP planning meeting in Spain in May 2008 
(www.humanvariomeproject.org/meetings/HVP2008/). The third HVP meeting will be held at the UNESCO headquarters in Paris in May 10-14, 2010 
(www.humanvariomeproject.org/meetings/paris/). He is the author of over 300 scientific papers and 3 patents. 
 
Albertina De Sario 
Group Leader, INSERM  
 
Albertina De Sario, PhD, CNRS Scientist, is group leader since 2003. Her group studied epigenetic modifications in human heterochromatic regions: the 
group defined a molecular border between heterochromatin and euchromatin in human chromosome 21 and identified an epigenetic tumor marker 
based upon DNA hypomethylation in heterochromatic genes. This new marker was validated for colon cancer diagnosis. Currently, the general aim of 
the group is to study the role played by epigenetics in the etiology of rare inherited diseases. A first project focuses on the epigenetic regulation of CFTR 
responsible for cystic fibrosis. A second ongoing project investigates epigenetic changes (DNA methylation and histone modifications) and aberrant 
transcription of heterochromatic genes in ICF (Immunodeficiency, Centromeric instability, Facial Dysmorphy) syndrome.  
 
John De Vos 
Cellular Therapy Processing Facility Director, 
Assistant Professor, Faculty of Medicine, Department of Hematology, 
University Hospital of Montpellier  




Dr. De Vos (M.D., PhD.) is the Cellular Therapy Processing Facility Director of the Universtity Hospital of Montpellier. He is the former manager of the 
Regional High Density Microarray Core Facility (2003-2010). The focus of his research in the INSERM UNIT U847 is to model the networks controlling 
pluripotency in human embryonic or reprogrammed stem cells. He has founded the expression atlas AMAZONIA! that provides an access to the 
expression profile of all human genes in normal or malignant, pluripotent and somatic human cell types. 
 
Marc Delpech 
Paris Descartes Medical School (Paris Descartes University)  
 
Marc DELPECH, MD, PhD, 58 years old, professor of Biochemistry and Molecular Biology, Paris Descartes Medical School (Paris Descartes University), 
head of the Cochin hospital Biochemistry and Molecular Genetics laboratory, head of a team of the Department  : « Genetics, Development and 
Molecular Pathology » of Cochin Institute U1016 INSERM. The main topics of this research team are molecular Genetics of auto-inflammatory 
syndromes and amyloidosis.He isPresident of the AFSSaPS (French Drug Agency) “National Committee for Medical in vitro Diagnosis”. Member of 
several Scientific Committee (University Paris Descartes, “Deafest cystic fibrosis”, “Hemophiliacs French Association”, French Blood Transfusion, 
French Biomedicine Agency,...). Member of the French Academy of Medicine. 
 
Jean-Louis Guéant 
Inserm U954, Medical Faculty of Nancy 
Chief Department of Biochemistry-Molecular Biology-Nutrition-Metabolism, 
University Hospital Center of Nancy, France  
 
Dr Guéant, MD, DSc, AGAF, is the scientific deputy dean and the director of Inserm U954 « Nutrition-Genetics and Environmental Exposure » at the 
Medical Faculty of Nancy, Nancy-University, France. He is deputy president of the Inserm scientific committee of Cardiovascular-Nutrition-Metabolism 
and president of the French Universitary Association of Medical Biochemistry and Molecular Biology. His field of interest is the one-carbon metabolism in 
nutrigenetics and nutrigenomics. He coordinates the program « Nutrivigene » of the French national agency for research. The Inserm Research Unit 954 
aims to evaluate short and long term effects of deficiency in methyl donors/precursors in relation with perinatology, fetal programming, inherited 
metabolic rare diseases and aging. Its field of interest is focused on the links between the one-carbon metabolism and epigenetic mechanisms involved 
in cellular stress, inflammation, genotoxicity and immunomodulation, in brain, heart, and digestive organs. The project is designed with a transversal 
approach, using relevant cellular and animal models and validating the experimental pathomechanisms in population studies. A national reference 




Director, Institute for Neurosciences of Montpellier, 
Genetics and therapy of retinal and optic nerve blindness, Montpellier, France  
Genetics of sensory diseases, University hospital, Montpellier  
Dr. Hamel (MD, PhD) is Director of the Institute of Neurosciences of Montpellier (Inserm research laboratory) and head of the Department of Genetics of 
Sensory Diseases at the University Hospital, Montpellier, France. Dr Hamel’s team is involved in gene discovery for retinal dystrophies and optic 





Omics Science Center  
RIKEN Genomic Sciences Center  
Yoshihide Hayashizaki received his M.D. and Ph.D. from Osaka University Medical School in 1982 and 1986, respectively.In 1992, he joined RIKEN, 
and was appointed Project Director for the RIKEN Genome Project in 1995. Since then he has been taken a transversal data-driven approach to analyze 
transcriptomes by developing unique technologies including a series of full-length cDNA technologies. With this approach, he has established large 
amount of full-length cDNA clone bank. This activity was followed by organization of FANTOM (Functional Annotation of Mammalian), an international 
consortium, originally to annotate a large number of cDNA and subsequently expanded to transcriptome and network analysis. FANTOM activities 
revealed that more than 63% of the genome — not just the ~1.5% fraction that are protein-coding exons — is transcribed as RNA. In 2008, he appointed 
to the Director of the Omics Science Center. The center was established to link a variety of omics subdisciplines to molecular networks and pathways in 
order to advance our understanding of biological phenomena as systems at the molecular level. 
 
Martin Hibberd 
Senior Group Leader 
Assoc Director, Infectious Diseases 
Genome Institute of Singapore  
Dr Martin Hibberd BSc(Hons) PhD; Senior Group Leader, Infectious Diseases at the Genome Institute of Singapore and has adjunct positions at the 
National University of Singapore and Imperial College (London, UK). Graduated with Honors from Brunel University in 1985 (West London, UK) and 
received his Doctorate, on the immune-genetics of the human T-cell antigen receptor, from King’s College, London. Has a broad scientific background 
spanning both microbial and human determinants of infectious and inflammatory diseases. Previous posts include WHO-funded Senior Microbiologist at 




the UK’s central Public Health Laboratories, and for seven years prior to his current appointment he was Lecturer and Senior Lecturer in Pediatric 
Infectious Diseases at the Imperial College School of Medicine, one of the very top-ranking British universities. Current research interests cover both 
pathogen and host aspects of infectious disease, understanding how microbial agents causes the observed disease (including pathogen identification 
and sequence characterization) and why specific individuals are susceptible to the disease (using host genetics on a genomic scale). Approaching 
infectious disease from these two directions also allows specific host pathogen responses to be investigated (utilizing RNA micro and low density arrays). 
This work aims to identify key host responses to specific pathogens that could be targeted by new therapies. 
 
Gerardo Jimenez-Sanchez 
Chief Scientific Officer, BioFields 
Chair, Working Party in Biotechnology, Organisation for Economic Co-operation and 
Development (OECD) 
 
Dr. Gerardo Jimenez-Sanchez was born in Mexico City. He is a M.D. with a Ph.D. in Human Genetics and Molecular Biology from Johns Hopkins and 
training his business administration from the IPADE Business School. He is a certified Pediatrician and a member of the National Academy of Medicine, 
the American Society of Human Genetics, the American Society of Gene Therapy, the Society for Inherited Metabolic Disease, the European Society of 
Inborn Errors of Metabolism. He is founder Director of the National Institute of Genomic Medicine in Mexico and Chairman of the Working Party on 
Biotechnology at the Organization for Economic Cooperation and Development (OECD). He is the leading investigator in the Mexican Genomic Diversity 
Project and the Mexican Medical Re-sequencing Initiative. Dr. Jimenez-Sanchez is Professor of Genomic Medicine at the National Autonomous 
University of Mexico, Member of the National Academy of Medicine. He serves as Council member of the Human Genome Organisation, as well as on 
the Board the Public Population Projects in Genomics (P3G). He is founder President of the Mexican Society of Genomic Medicine and Regional Editor 




Head of Medical and Development Genetics 





Research Director, Institute for Functional Genomics, Montpellier 
Director, MGX - Montpellier GenomiX, Montpellier  
 
Laurent Journot is currently Research Director at the Institute for Functional Genomics in Montpellier. He obtained his B.Sc. and “Aggrégation” from the 
Ecole Normale Supérieure de Cachan and his M.Sc. from Montpellier University. During his post-doctoral training at the ZMBH in Heidelberg, he cloned 
and characterized the G protein-coupled receptor for PACAP, a neuropeptide that displays anti-proliferative and anti-apoptotic activities. He previously 
was a Senior Investigator at the Centre for Pharmacology and Endocrinology in Montpellier, and focused on the signalling mechanisms elicited by 
PACAP to prevent neuronal apoptosis. His current research focus on the physiological roles of imprinted genes. Parental genomic imprinting is an 
epigenetic mechanism of regulation that restrains the expression of a small subset of mammalian genes to one parental allele. Journot's main 
contribution is the demonstration that, despite seemingly disparate functions, imprinted genes work in a single gene network that controls embryonic 
development and whose function at the cellular level remains to be identified. Journot is also the Director of MGX - Montpellier GenomiX, a technological 




Professor of Unversity-Hospital Practitioner 
Director of the Institute of Research in Biotherapy  
 
Bernard Klein is the head of the Institute of Research of Biotherapy that groups 100 people working on normal and cancer stem cells with the aim to 
develop drugs (cell drugs) involved in the field of regenerative medicine. Bernard Klein has founded the Cell and Gene therapy Unit at the University 
Hospital of Montpellier, coordinates 150 hour courses for teaching the regenerative medicine field and is an active member of national agencies for 
agreement of cell therapy clinical trials. 
 
Dhavendra Kumar 
Consultant, Clinical Genetics at the University Hospital of Wales 
Hon. Senior Research Fellow, Institute of Medical Genetics, Cardiff University, 
Cardiff, Wales, UK 
Lead Clinical Geneticist, Clinical Cardiovascular Genetics  
Dr. Dhavendra Kumar is Consultant in Clinical Genetics at the University Hospital of Wales and Hon. Senior Research Fellow in the Institute of Medical 
Genetics, Cardiff University, Cardiff, Wales, United Kingdom. He is the lead Clinical Geneticist for Clinical Cardiovascular Genetics. After qualifying in 
Medicine from the King George’s Medical College, University of Lucknow, India, he completed postgraduate training in Pediatrics with an MD. Since 
1980 he has pursued a career in Medical Genetics in the UK. In 1990 he became a Diplomate of the American Board of Medical Genetics. He is a 
Fellow of the American College of Medical Genetics (FACMG) and as well as Royal Colleges of Physicians (FRCP-London and FRCP-Ireland) and 
Paediatrics and Child Health (FRCPCH-UK). He has published three books (Genetic disorders of the Indian Subcontinent-Springer/Kluwer, Genomics 
and Clinical Medicine- Oxford University Press and Principles and Practice of Clinical Cardiovascular Genetics-Oxford University Press) and has several 
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publications in pediatrics and clinical genetics. He established and developed a new biomedical journal (Genomic Medicine-Springer) that led to setting 
up the official journal of the Human Genome Organization (‘The HUGO Journal’). He serves on the editorial board of the HUGO Journal as Editor in 
Chief. He is currently a member of the publications committee of HUGO. Dr. Kumar’s current clinical and research interests include clinical 
cardiovascular genetics, applications of genomics in medicine and human health and promoting genetics and genomics for improving the health in 
emerging economies of the developing world. He is currently actively involved in promoting medical genetics and genomics in developing countries 




Ralph & Lois Silver Chair of Human Genomics 
Department of Molecular Genetics 
Head, Crown Human Genome Center 
Weizmann Institute of Science 
Prof. Doron Lancet is a genome and bioinformatics researcher at the Weizmann Institute of Science. He headed there the Department of Membrane 
Research and Biophysics, and is currently Professor at the department of Molecular Genetics, where he studies the genetics and genome organization 
of the olfactory receptor gene superfamily. Since 1992 Lancet has been active in the Israeli and international genome scenes, and is currently Director of 
Israel's National Knowledge Center for Genomics, and of the Crown Human Genome Center at the Weizmann Institute. In this realm, his research has 
included the discovery of genes for monogenic diseases, as well as high throughput SNP scoring for elucidating polygenic diseases and 
pharmacogenetics. In the realms of bioinformatics, Lancet and group have developed GeneCards, a widely-used web-based human gene compendium. 
Lancet is a member of the European Molecular Biology Organization (EMBO) since 1996 and of HUGO since 1994. He has won international prizes in 




Professor University Montpellier 2, Institute of Human Genetics CNRS-UPR1142 
Founder and Director of IMGT®, the international ImMunoGeneTics information 
system® 
Marie-Paule Lefranc is Professor Classe Exceptionnelle at the University Montpellier 2, Senior Member of the University Institute of France. She is 
Founder and Director of IMGT®, the international ImMunoGeneTics information system®, http://www.imgt.org, that she created in 1989, at Montpellier, 
France. She is Head of the Laboratoire d’ImmunoGénétique Moléculaire, created with Prof. Gérard Lefranc and located, since 1998, at the Institute of 
Human Genetics (CNRS-UPR1142). She has authored over 300 scientific publications in international journals on the molecular immunogenetics of 
immunoglobulins, T cell receptors, antibody engineering, and on human genetics and immunoinformatics. Three of her major contributions are: firstly, 
the finding of large chromosomal deletions which encompass several immunoglobulin genes and account for the simultaneous absence of IgG1, IgG2, 
IgG4 and IgA1 isotypes in healthy individuals, allowing the overall ordering of the human immunoglobulin constant genes; secondly, the full 
characterization of the human T cell receptor gamma locus, for which she received the ROSEN prize of Cancerology in 1988; thirdly, the definition of the 
IMGT Scientific chart rules and IMGT-ONTOLOGY concepts, which are the foundations of IMGT® which has become the global reference in 
immunogenetics and immunoinformatics. 
 
Harris A Lewin 
Professor of Immunogenetics 
Gutgsell Endowed Chair  
Department of Animal Sciences 
Director, Institute for Genomic Biology  
University Illinois, USA  
 
Professor Lewin's current research interests are in the area of mammalian comparative and functional genomics. His research has resulted in the 
development of high-density comparative maps for the cattle, human and other mammalian genomes, and novel software for in silico gene mapping 
using the human genome as a template. In addition, his group produced the first large-scale cDNA microarray and oligoarray for functional genomics of 
ruminants, which have been applied to a systems level analysis of embryonic development and diet-genotype interactions. 
 
Bing Lim 
Senior Group Leader, Genome Institute of Singapore 
Associate Professor of Medicine, Harvard Medical School 
Associate Physician, Beth Israel Hospital, Harvard Medical School 
Research Focus: ES cell as an engine for Pluripotency, Tissue Regeneration and Epigenomic alteration;  ES cells hold great promises for cell 
therapeutics; The focus of our team is to elucidate 3 fundamental paradigm underlying the basis for the practical exploitation of ES cells, combining a 
gene discovery effort with gene functionalization studies. 
 




Edison T Liu 
Executive Director, Genome Institute of Singapore (Biomedical Sciences Institutes) 
Professor of Medicine, National University of Singapore 
President, Human Genome Organisation 
Dr. Edison Liu received his residency training in internal medicine at WashingtonUniversity, St. Louis, and clinical cancer fellowships at 
StanfordUniversity (Oncology), and at the University of California at San Francisco (Hematology). He then pursued post-doctoral studies as a Damon-
Runyan Cancer Research Fellow at the University of California at San Francisco in the laboratory of Dr. J. Michael Bishop. In 1987, he joined the faculty 
of Medicine at the University of North Carolina at Chapel Hill where he was director of UNC's Specialized Program of Research Excellence (SPORE) in 
Breast Cancer. In 1996, he joined the NCI as the Director of the Division of Clinical Sciences. In 2001, Dr. Liu assumed the position of Executive Director, 
Genome Institute of Singapore. His current scientific research investigates the dynamics of gene regulation on a genome scale that can explain 
biological states in cancer. Dr. Liu has contributed over 245 articles, reviews, and book chapters to the scientific literature. Dr. Liu also is the Executive 
Director of the Singapore Tissue Network, the national tissue repository in Singapore. Dr. Liu’s awards include the Leukemia Society Scholar (1991-
1996), the Brinker International Award for basic science research in Breast Cancer (1996), the Rosenthal Award from the American Association for 
Cancer Research (2000), the President’s Public Service Medal for his work in helping Singapore resolve the SARS crisis, and a Doctor of Medicine 




Department of Cancer Biology 
Wake Forest University School of Medicine  
My research is focused on the discovery and characterization of mechanistic and clinically useful aspects of carcinogenesis from a systems biology 
perspective. Using genomics technologies such as DNA microarrays, my laboratory investigates the transcriptional dynamics and genomic architectures 
of primary tumors and cell lines at various stages of the oncogenic process and in different clinical contexts. Integrative analysis of genome-wide 
expression patterns, copy number alterations, and clinicopathologic features allows us to uncover transcriptional programs of mechanistic and 
prognostic relevance. This strategy has led to the identification and validation of gene expression signatures in liver, breast, ovarian and lung cancers 
that 1) reflect the activity of specific growth-regulating pathways, 2) define known and novel tumor subtypes, and 3) predict clinical outcomes such as 
disease recurrence and therapeutic response. Examples include prognostic signatures in breast cancer that reflect the operational configuration of the 
TP53 pathway (Miller et al, PNAS, 2005) and delineate new prognostic tumor subtypes based on “genetic grade” (Ivshina et al, Cancer Res, 2006). More 
recently, we have discovered a copy number-related transcriptional signature of disease recurrence in stage I non-small cell lung carcinoma (NSCLC) 
that outperforms all conventional prognostic factors, and identifies a substantial subgroup of patients that may benefit from adjuvant chemotherapy 
(Broët, et al, Cancer Res,2009).  We have also pioneered novel data mining strategies that integrate multiple forms of clinico-genomic information 
(expression, copy number, patient survival) and are capable of pinpointing known and novel candidate oncogenes. Using this approach, we have 
recently identified and validated a novel breast cancer oncogene at chromosome 8p11 that promotes transformation, anchorage-independent growth, 
invasion through matrigel, and tumor formation in mouse xenograft models with an ability to interact with and activate H-Ras. Other candidate genes 




Head, Molecular Genetics Laboratory, National Health Laboratory Service and 
University of the Witwatersrand 
Chair, Wits Bioinformatics Steering Group  
Professor Michèle Ramsay (PhD) is head of the Molecular Genetics Laboratory in the Division of Human Genetics at the National Health Laboratory 
Service and University of the Witwatersrand. She is Chair of the Wits Bioinformatics Steering Group, joint champion of a cross-faculty Research Thrust, 
“Molecular Biosciences: Health for Africa” and joint editor and author of a textbook, “Molecular Medicine for Clinicians” (Wits University Press). In 
addition she is the Interim Director of the Sydney Brenner Institute for Molecular Bioscience (Wits University) which focuses on a molecular 
understanding of non-communicable diseases in African populations. Her research interests include the genetic basis and molecular epidemiology of 
single gene disorders in South African populations and the role of genetic and epigenetic variation in the molecular aetiology of foetal alcohol spectrum 






Richard Redon has been appointed Senior Researcher by the Inserm in March 2009. As laureate of the Inserm/CNRS young investigator program 2009, 
he leads a new research group working on the genetics of sudden cardiac death at the ‘institut du thorax’ in Nantes, France. He obtained his PhD at the 
University of Strasbourg and was awarded the Young Investigator Award of the European Society of Human Genetics in 2002. He completed his 
postdoctoral fellowship in 2006 at the Sanger Institute (UK) then focused on Copy Number Variation (CNV) discovery with high-density array 
CGH. Redon has led several breakthroughs in the field of genomics including establishing the first detailed map of copy number variations in humans. 






Research Director at INSERM (Institut National de la Santé et de la Recherche 
Médicale), France  
 
Dr. Rötig (PhD) is the head of the group working on mitochondrial diseases in Necker Hospital (Paris). This group has initially settled and integrated 
platform of clinic, biochemistry and molecular analysis to investigate patients with OXPHOS disease. The scientific field of this group is the identification 
of genes involved in mitochondrial disorders and the investigation of their pathophysiology. They have described the first non-neuromuscular 




Senior Group Leader 
Assoc Director, Genomic Technologies  
 
My primary interest is to elucidate the structures and dynamics of all functional DNA elements in complex genomes through transcriptome 
characterizations and genome interrogation. To facilitate such understanding we have developed Paired-End-Tag (PET) sequencing and mapping 
methodologies. We are applying these sequencing-based technologies to address complex biological questions such as how cancer cells progress and 
how stem cells maintain their unique properties. Another major interest of mine is to discover previously uncharacterized microbial genes and genomes 
that are relevant to human health. 
 
Yoshiyuki Sakaki 
President, Toyohashi Institute of Technology 
Emeritus Professor, University of Tokyo 
Special Consultant of RIKEN  
Dr. Yoshiyuki Sakaki is the President of Toyohashi Institute of Technology since April 2008. He is also Emeritus Professor of the University of Tokyo and 
Special Consultant of RIKEN. He has been the Director of RIKEN Genomic Sciences Center from 2004 to 2008(March) and also the President of HUGO 
(Human Genome Organization) from 2002 to 2005.  He has represented Japan in the international Human Genome Project, and the RIKEN team led by 
him made significant contributions to the completion of the human genome sequence, particularly playing a major role in completing the sequence of 
chromosome 21 and 11.  Currently he is the chief coordinator of Genome Network Project, a Japanese nation-wide project towards the comprehensive 
study on the transcriptional regulatory networks of the human genome.  He was awarded to "Chevalier" from France Government 2001, in recognition of 
his contribution to the scientific cooperation between France and Japan, the Award of Japanese Society of Human Genetics (2001),and Medal of Purple 
Ribbon from Japanese Government (2003). 
 
Stephen W Scherer 
Director, McLaughlin Centre and the Toronto Centre for Applied Genomics 
Professor, Hospital for Sick Children and University of Toronto 
 
Dr. Scherer holds the GlaxoSmithKline-CIHR Endowed Chair in Genetics and Genomics at The Hospital for Sick Children and University of Toronto. He 
has made numerous contributions to medical genetics including mapping sequencing and disease gene studies of human chromosome 7. He collaborated 
with the J. Craig Venter Institute to generate the first genome sequence of an individual ushering in an era of genomic medicine. In 2004, his team co-
discovered global gene copy number variation (CNV) and has since shown that CNV is the most abundant type of variation of human DNA. His group has 
also discovered CNV to contribute to the etiology of autism and the Database of Genomic Variants he founded facilitates hundreds of thousands of 
diagnoses each year.  He sits on the Scientific Advisory Board of Combimatrix Diagnostics and Autism Speaks, and he is on the Board of Trustees of 
Genome Canada and the Human Genome Organization (HUGO). Dr. Scherer has won numerous honors including the 2004 Steacie Prize, an International 
Howard Hughes Medical Institute Scholarship, and the 2008 Premier Summit Award for Medical Research. 
 
Lawrence Stanton 
Senior Group Leader 
Deputy Director, Research Affair 
Genome Institute of Singapore  
Research Focus: Transcriptional control of embryonic stem cells; Human embryonic stem (ES) cells provide a unique avenue to study genes that are 
involved in the earliest stages of differentiation during embryo development. My lab is primarily focused on identification of genes and regulatory 
pathways that control embryonic stem cell growth and differentiation. We have generated a comprehensive map of the transcriptome from ES cells using 
genome-wide expression technologies. We have focused particular attention on a set of transcription factors that are uniquely expressed in ES cells and 
likely play an important role in determining the differentiation status of the ES cells. Functional genomic approaches are being applied to dissect the 
transcriptional networks that are governed by these known and novel transcription factors, for example REST, Zic3, and Zfp206. The influence these and 
other transcription factors have on ES cells is then monitored by transcriptional profiling and functional assessment of differentiation capability. Direct 
targets for key transcription factors are being identified by chromatin precipitation (ChIP) experiments. We are also looking at the epigenetic changes 
that are mediated by the binding of these transcription factors. The activity of many of these genes is being exploited to drive lineage-specific 
differentiation of human ES cells and lead to better understanding of the molecular events that underlie early embryonic development and cellular 
differentiation. Our long-term goal is to derive cell types in vitro that will provide therapeutic utility for certain degenerative diseases in man. 





Professor, Department of Medical Genome Sciences, Graduate School of Frontier 
Sciences, The University of Tokyo  
 
Dr. Sugano (MD, PhD) is a Professor at the Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo. 
The main emphasis of his research is to identify and collect genes of human en masse in the form of full-length cDNAs.  He initiated the FLJ project of 
collecting and determining the entire sequences of human full-length cDNAs in 1999. He is now using second generation sequencers to characterize 
transcriptome landscape. He was a Council Member of the Human Genome Organisation (2002-2008) and was Chair of Human Genome Organisation 




Team Leader  
MetaSystems Research Team 
RIKEN Advanced Science Institute  
Todd Taylor is Team Leader of the MetaSystems Research Team in the Computational Systems Biology Research Group at RIKEN Advanced Science 
Institute, Yokohama, Japan. His team's main area of research is the analysis of and development of tools for metagenomic sequence data derived from 
various human health- and environmental-related microbial communities. He has been a research scientist at RIKEN since 1998, and received his Ph.D. 
in Molecular and Medical Genetics from Oregon Health Sciences University, Portland, Oregon. During graduate school he conducted linkage analysis 
studies for various disorders and was responsible for the initial identification and mapping of the locus for Hallervorden-Spatz syndrome, a rare 
autosomal recessive disorder. As an active member of the International Human Genome Sequencing Consortium, Todd served as coordinator for 
chromosomes 11, 18p, and 21. He also helped to coordinate the finishing of chimpanzee chromosomes 22 and Y. Todd has been a HUGO member 
since 1999 and has served on the HUGO council since 2006. 
 
Herve Thoreau 
Production Leader, Sequencing 
Genome Institute of Singapore  
 
Hervé began to work at Genome Institute of Singapore in 2001. He is the Production Leader for Genome Technology and Biology group. The GT&B 
group is applying cutting edge innovative genomic technologies and next generation sequencing platform to study genome variation and transcription 
regulation in complex biological systems. Prior to joining Genome Institute of Singapore, Hervé worked for 4 years in the French Biotechnology 
Company, GENSET S.A., as team leader of the Mapping Production group. Hervé holds a B.Sc. in Industrial Bio-experimentation from E.S.T.B.A, Paris. 
Concurrently he is also pursuing graduate studies in Biological Engineering at the Université de Technologie de Compiègne (UTC), conferring the 
diplôme d’ingénieur. 
 
Veronica Van Heyningen 
Section Head 
MRC Human Genetics Unit 
Honorary Professor University of Edinburgh, FRS, FRSE, FMedSci  
First degree in genetics (Cambridge); DPhil on early gene mapping studies using somatic cell hybrids, with Walter Bodmer (Oxford); Beit Memorial 
Fellow, MRC Mammalian Genome Unit, Edinburgh; eventually rose through the ranks at MRC Human Genetics Unit, Edinburgh from postdoctoral fellow 
to group leader and Section Head. Honorary Professor University of Edinburgh, FRS, FRSE, FMedSci. Howard Hughes International Research Scholar 
1993-1998. Member of UK Human Genetics Commission 2000-2005. EMBO member 2003.  Fellow of the Royal Society 2007. Human geneticist (non-
clinical) working on developmental eye anomalies such as aniridia and anophthalmia/microphthalmia. Interested in what detailed analysis of the human 
phenotypes in individuals with known mutations can tell us about the biological role of the genes involved. Ultimately most human developmental genes 
need to be explored in model systems and we are currently studying the roles of PAX6 and SOX2 in humans, the mouse and zebrafish. A major area of 
endeavour since the early 1990s is to understand the mechanisms of long-range regulation of gene expression. Transcription factors like PAX6 and 
SOX2 show complex spatiotemporal and quantitative control of expression, requiring a large number of strongly sequence-conserved cis-regulatory 
elements, found upstream, downstream and within the gene. Such regulatory regions can stretch more than a megabase either side of the gene. We are 
aiming to understand the spatial and functional organisation of these interacting elements (which often function as enhancers in reporter transgenic 
assays), additively recapitulating the sum of the total gene expression pattern. Expression-associated patterns of open chromatin suggest dynamic 
genomic organisation.  Another emerging interest is in the mechanisms underlying disease with non-Mendelian segregation patterns. We are exploring 
how environmental factors effect phenotype modification. 
 
Julian Venables 
Lead Scientist at the CNRS Institute of Molecular Genetics at Montpellier (IGMM)  
 
Dr Venables gained his PhD from Leicester UniversityU.K. and this was followed by post-doctoral experience at the MRC Human Genetics Unit in 
Edinburgh (January 1999- June 2001) and then the Institute of Human Genetics in Newcastle. From February 2007 he coordinated a group of 




bioinformaticians in a project to characterize the transcriptome of breast and ovarian cancers in Sherbrooke, Québec. Since February 2010 he is lead 




Director, Max Planck Institute for Molecular Genetics, Germany 
Head of Computational Molecular Biology Department  
 
Martin Vingron is a mathematician by education who has done his PhD in computational biology at EMBL in 1991. At the time and for a number of years of 
postdoctoral training his research has focused on the analysis of protein sequences, sequence analysis, sequence comparison, and molecular evolution. 
Methods of discrete optimisation were used for the design of comparison algorithms and probability theory was applied to answer questions of significance 
of computational results. Later, as a department head at the German Cancer Research Center, his focus shifted towards the processing and mathematical 
analysis of DNA microarrays. Accordingly, the methods largely drew on statistical data analysis techniques. During the last years his research interest lies 
in utilizing gene expression data as well as evolutionary data for the elucidation of gene regulatory mechanisms. He also acts as a chair of the *RECOMB* 
<http://recomb.org/> (Research in Computational Molecular Biology) steering committee. 
 
Wei Chia-Lin 
Senior Group Leader, Genome Technology & Biology 
Group Leader, Clone Production & Management Genome Institute of Singapore 
The primary focus of my research is to develop and apply sequencing based genomic technologies for genome and epigenome function elements 
interrogation pertinent to lineage specification and development.  Using various second generation sequencing platforms, my research focuses on 
integrating the technology development effort to construct global, high resolution and unbiased functional networks constituted by the key genetic 
modulators in stem cell genomes and their dynamics throughput developmental process.  Furthermore, we are also interest to characterize how these 
modulators can directly impact on gene expressions.  Such knowledge will provide fundamental understanding in various nuclear processes including 
transcription, add new insight on the unique gene expression patterns crucial for cell fate determination and open the possibility of manipulating such 
structures to achieve cell type specific differentiation. 
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Poster No: P002-W 
GENCODE: A reference gene set for the human genome  
 
J. Rajan1, J. Mudge1, B. Aken1, M. Diekhans7, R. Harte7, F. Kokocinski1, M. Lin3, M. Tress2 , M. Van Baren4, J. Gilbert1, M. 
Brent4, M. Gerstein6, R. Guigo5, M. Kellis3, A. Reymond8, S. Searle1, T. Hubbard1, J. Harrow1 
1Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK, 2Spanish National Cancer Research Centre (CNIO), Madrid, 
Spain, 3MIT Computer Science and AI Laboratory, Broad Institute, Cambridge, MA, USA, 4Lab. for Comp. Genomics and 
Dept. of CS, Washington Univ, St. Louis, Missouri, USA , 5Centre for Genomic Regulation, Barcelona. Catalonia. Spain, 
6Department of Molecular Biophys. and Biochem. Yale University New Haven, CT USA, 7Center for Biomolecular Science 
and Engineering, UCSC, CA, USA. 8Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland 
The HAVANA group at the Wellcome Trust Sanger Institute aim to complete the manual annotation and experimental 
transcript validation of the human genome by 2011. This work is being carried out as part of the GENCODE consortium, a 
subgroup of the ENCODE (the Encyclopedia Of DNA Elements) project. Currently over 50% of the genome has been 
manually annotated by HAVANA, with Ensembl gene objects used in the areas not yet described to create the merged 
GENCODE genebuild. This annotation contains protein-coding, non-coding and pseudogene loci and is supported by 
mRNA, EST or protein evidence and is especially important in the accurate description of splice variation and duplicated 
gene clusters. Our annotation process also identifies sites in the reference genome where improvements are required, 
including both sequencing errors in CDS as well as genuine polymorphisms. We work with the Genome Reference 
Consortium (GRC) to ensure such regions are properly represented. 
In addition, Havana are an integral part of the consensus CDS (CCDS) project, whereby protein translations for human 
and mouse genes are agreed upon by HAVANA, Ensembl, UCSC and RefSeq. All CCDSs are contained within the 
GENCODE reference set which is now shown as the default Ensembl human gene build since Ensembl build 56. Next 
generation generation technologies are beginning to impact on annotation and we will describe how the 1000 genomes 
project and RNAseq transcriptome data will be integrated into the reference gene set. Also, we will highlight how 
proteomics data can be integrated and improve existing annotation. 
 
 
Poster No: P019-W 
Reconstitution of meta-regulation networks by MIR@NT@N using transcriptomics analyses reveals that several 
miRNAs are antagonistically regulated by retinoic acid and estrogen in breast cancer cells.  
Charles-Henri Lecellier5, Antony Le Béchec1,*, Anne Saumet2,*, Elodie Portales-Casamar3, Guillaume Vetter1, Pierre-J 
Zindy4, Michèle Moes1, Charles Theillet2, Wyeth W. Wasserman3, Evelyne Friederich1 
1Cytoskeleton and Cell Plasticity lab, Life Sciences Research Unit-FSCT, University of Luxembourg, L-1511 Luxembourg. 
2Institut de Recherche en Cancérologie de Montpellier INSERM U896, Université Montpellier1, CRLC Val d’Aurelle Paul 
Lamarque, Montpellier, F-34298, France. 3Centre for Molecular Medicine and Therapeutics, Child and Family Research 
Institute, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada. 4Structure and 
Function of the Cell Nucleus, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal 
(Québec), Canada 5Institut de Génétique Moléculaire de Montpellier UMR 5535 CNRS, 1919 route de Mende, F-34293 
Montpellier cedex 5, France Université Montpellier 2, Place Eugène Bataillon, F-34095 Montpellier cedex 5 Université 
Montpellier 1, 5 Bd Henry IV, F-34967 Montpellier cedex 2, France. 
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Identifying meta-regulation networks whose perturbations are causal to the development of cancers is one of the major 
challenges to understand cell biology and treat cancer cells. We conceived a new computational framework, named 
MIR@NT@N, which reconstructs such networks of transcription factors and microRNAs. It builds on the JASPAR/PAZAR 
databases for transcription factor binding profiles with further information derived from miRBase and microRNA.org (for 
miRNA target predictions). Graph-based algorithms identify specific sub-networks, emphasizing feedback and feed-
forward loops. We used this method to analyze independent transcriptomics data of breast cancer cells. We thereby 
revealed that several miRNAs are antagonistically regulated by retinoic acid and estrogen. Moreover, our analyses 
characterized additional oncogene and tumour suppressor miRNAs implicated in breast tumorigenesis and unveil some 
miRNA-based molecular mechanisms of cancer chemotherapies targeting transcription factors. MIR@NT@N is a user-
friendly web resource freely available at http://maia.genouest.org/demo/ 
 
 
Poster No: P034-W 
Digital Gene Expression Pipeline : from mapping to visualization  
1Anthony Boureux, 2,3Nicolas Philippe, 2Laurent Bréhélin, 4Jorma Tarhio, 3Thérèse Commes and 2Éric Rivals 
1CRBM UMR5237, Université de Montpellier II - CNRS, 1919 route de Mende, 34095 Montpellier, France, 2Laboratoire 
d'Informatique, de Robotique et de Microélectronique, Université de Montpellier II, UMR 5506 CNRS, 161 rue Ada, 34392 
Montpellier, France, 3Groupe d'études des transcriptomes, Université de Montpellier II, Institut de Génétique Humaine, 
UPR1142-CNRS, 141, rue de la cardonille, 34095 Montpellier, France and 4Helsinki University of Technology, PO Box 
5400, FI-02015 HUT, Finland 
Massive parallel high-throughput sequencing is now widely used to analyze the transcriptome or interactome at 
unprecedented depth on a genome-wide scale. However, exploration of these massive data remains a challenge. These 
techniques yield short sequence reads that are then mapped on a genome sequence to predict putatively transcribed or 
protein-interacting regions. Factors such as background distribution, sequence errors, and read length can impact on the 
prediction capacity of sequence census experiments. Here we suggest a computational approach to measure these 
factors and analyze their influence on both Digital gene expression (DGE) and chromatin immunoprecipitation-sequencing 
(Chip-seq) assays. This investigation provides new clues on both methodological and biological issues. For instance, by 
analysing Chip-seq read sets, we estimate that 4.6% of reads are affected by SNPs. We show that, although the 
nucleotide error probability is low, it significantly increases with the position in the sequence. Choosing a read length 
above 19 bp practically eliminates the risk of finding irrelevant positions, while above 20 bp the number of uniquely 
mapped reads decreases. With our procedure, we obtain 0.6% false positives among genomic locations. Hence, even 
rare signatures should identify biologically relevant regions, if they are mapped on the genome. 
Therefore, we propose a new pipeline to analyze SAGE, DGE and RNA-Seq data. First, sequences are mapped to the 
genome using the best length (usually between 19 and 20 bp), and sorted in located (none, once or multiple times) or 
erroneous sequences. Second, located sequences can be visualize on genomic browser as Ensembl 
(http://www.ensembl.org) or UCSC Genome Browser (http://genome.ucsc.edu) with their occurrences among others 
genomic tracks. 
 
Poster No: P049-W 
Identifying and Prioritizing Human Disease Genes using FunSimMat  
Mario Albrecht1, Andreas Schlicker1, Hagen Blankenburg1, Sarah Diehl1 and Thomas Lengauer1 
1Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Campus E1.4, 
66123 Saarbrücken, Germany. 
Large-scale experiments such as genome-wide association studies (GWAS) and RNA interference (RNAi) screens 
associate candidate genes with complex disease processes. Since the number of discovered candidates is frequently 
quite large, computational methods are applied for identifying and prioritizing the most relevant candidates for further 
validation experiments. Here, we present our extended FunSimMat web service that offers various functional similarity 
measures for ranking candidate genes and proteins based on the Gene Ontology. We show that our novel approach 
achieves excellent results in discovering important disease genes from human GWAS and RNAi screens. FunSimMat is 
easy-to-use and publicly available free of charge at http://www.funsimmat.de 
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Poster No: P064-W 
Comparing human trophoectoderm with embryonic stem cells: a molecular analysis of the first developmental 
bifurcation 
Bai Qiang1, Said Assou1,2 Marilyne Dijon-Grinand1, Tanguy Le Carrour2, Samir Hamamah1,2,3,4, John De Vos1,2,3,5  
1INSERM, U847, Montpellier, F-34000 France ; 2CHU Montpellier, Institute for Research in Biotherapy, Hôpital Saint-Eloi, 
Montpellier, F-34000 France ; 3Université MONTPELLIER1, UFR de médecine, Montpellier, F-34000 France ; 4CHU 
Montpellier, Département de Médecine et Biologie de la Reproduction, Hôpital Arnaud de Villeneuve, Montpellier, 
F-34000; 5CHU Montpellier, Unité de Thérapie Cellulaire et Génique, Hôpital Saint-Eloi, Montpellier, F-34000 France 
 
Introduction:  
The first week of human development is characterized by the differentiation of the early embryo into the inner cell mass 
(ICM) and the trophectoderm (TE). Whereas the ICM, maintained in vitro as human embryonic stem cells (hESC) has 
been analyzed by innumerable studies, the human TE at blastocyst stage is by contrast still mostly unelucidated. TE is of 
prime importance since it latter develops into placenta that will provide the nutrient support for further embryonic 
development. It plays also a major role in the shaping of the blastocyst stage. The aim of the present study was to 
compare the TE and the hESC transcriptome and define the first steps of differentiation taking place during the human 
embryonic development. 
  
Materials and Methods:  
Five TE samples were obtained from fresh embryos issued during an in vitro fertilization (IVF) program. At blastocyst 
stage (day 5), the TE was mechanically seperated. The human embryos were donated to research after informed consent 
from the couples. This embryo research program directed at deriving new hESC lines has received an IRB agreement. 
Each TE was individually analyzed by whole genome U133P Affymetrix (Santa Clara, CA) oligonucleotides microarrays. A 
double in vitro transcription amplification step according to the manufacturer’s instructions was used. Gene enrichment is 
analyzed with Gene Set Enrichment Analysis (GSEA, Broad Institute, Cambridge) and statistical analysis was carried out 
with Significance Analysis of Microarray (SAM, Stanford, CA). 
 
Results:  
Using SAM with a false discovery rate of 0.2774% and a fold change of at least 5, we delineated a TE signature 
comprising 7521 probeset (PS) overexpressed in TE cells and a hESC signature comprising 1083 overexpressed in hESC. 
We observed that some pluripotency genes such as OCT4/POU5F1 and NANOG were found in the hESC signature, 
whereas LIN28, a gene known to repress the let-7 miRNA and to be preferentially expressed in both hESC and oocytes, 
was also highly expressed in TE cells. The TE signature comprised the transcription factors (TF) GCM1, GATA3, IRX4 
and PPARG, suggesting that these TF may have critical roles in TE differentiation. TE cells also displayed a remarkable 
expression of cell surface molecules such as CD55 and CD53, which could be used to recognize TE cells during in vitro 
differentiation of hESC into TE cells. A GSEA comparison between the TE samples and 10 hESC samples revealed in TE 
cells a strong enrichment of gene involved in protein synthesis activity, such as ribosome genes (GO:0005840), structural 
constituent of ribosome (GO:0003735) and translation (GO:0006412). Finally, specific expression of DNMT genes and 
cancer/testis antigen genes suggests a unique epigenetic pattern in TE. 
 
Conclusions: 
This whole genome expression analysis of TE and its comparison with hESC should improve the understanding of a 
critical step of the human blastocyst development and the creation of the ICM, i.e. pluripotency. In addition, as TE may 
play a deleterious role in hESC derivation, the screening of TE specific cell-to-cell signaling could highlight specific 
pathways to block in order to improve the ICM in vitro development. 
 
Poster No: P081-W 
Integrative analysis of transcription factor binding and chromatin modifications data obtained by ChIP-seq in 
human genome: example of estrogen receptor (ERĮ) binding sites 
1Yuriy L. Orlov, 1Mikael Huss, 1Roy Joseph, 1Edwin Cheung, 1Neil D. Clarke, 1Huck-Hui Ng, 1Edison T. Liu 
1Genome Institute of Singapore, Genome #02-01, 60 Biopolis Street, Singapore 138672 
HUGO J (2010) 4:1–190 79
123

Advances in high throughput sequencing technology have enabled the identification of transcription factor (TF) binding 
sites in genome scale. Such genome wide TF binding maps in human include Oct4, Sox2 and Nanog in stem cells and 
cancer related transcription factors estrogen receptor (ERĮ), FOXA1. Key problem of gene expression regulation analysis 
is detection of functional binding sites responsible for gene activation. TF binds to only a small fraction of sequence motifs 
or eligible binding sites in the genome. Moreover, this limited number of occupied sites might be significantly different 
between different cell types. We studied the model of ERĮ binding in human genome. Previous genome-wide positional 
analysis showed that a large proportion of in silico predicted ERĮ binding sites is not occupied in vivo in the MCF-7 human 
breast cancer cell line. We discuss here interplay between TF binding and chromatin landscape revealed by ChIP-
sequencing together with statistical issues. First, the distribution of binding sites across gene is uneven and focused on 
proximal gene regions. Our analysis has revealed thousands of binding sites in the genome located at gene distal regions 
for ER binding sites and key developmental regulators. Second, DNA accessibility (nucleosome depletion) facilitates TF 
binding as maybe measured by different techniques. Epigenetic modifications play important role in regulation of gene 
expression adding additional complexity to transcription network functioning. We have studied associations between 
different histone modification using published (GEO NCBI) and in-house data for activation histone marks H3K4me3, 
H3K4me1, H3K9ac and repressive histone marks H3K27me3 and H3K9me3 together with RNA Pol II sites. We found 
strong associations between chromatin activation marks and TF binding sites and present it qualitatively. To meet issues 
of statistical analysis of genome ChIP-sequencing maps we developed computer program to filter out noise signals and 
find significant association between binding affinity and number of sequence tags. Better computer prediction of TF 
binding for ERĮ could be achieved using genome wide chromatin modification data. Our data provide new insights onto 
dynamical activation of TF binding in human genome by analysis of the changes in chromatin landscape. 
 
2. Genetic and Genomic Databases  
(19 May 2010, 1.05 PM - 3.05 PM, Salle Einstein) -  Chaired by Yoshiyuki Sakaki and Marie-Paule LeFranc 
 
Poster No: P005-W 
THE HUMAN VARIOME PROJECT – PILOT PROJECTS AND PROGRESS  
Cotton R.G.H. and collaborators 
Convenor, Human Variome Project; Head, Genomic Disorders Research Centre, Howard Florey Institute; Department of 
Medicine, the University of Melbourne, Melbourne, Australia 
The Human Variome Project (2007) (www.humanvariomeproject.org) was initiated in June 2006 (Ring, Kwok et al. 2006) 
drawing attention to the importance of collection of variation and its phenotype and to develop programs to put this into 
effect. 
 
The project builds on work and concepts of the HGVS over many years (www.hgvs.org) to focus on all variation 
associated with disease. The project will include those discovering mutations, their effects and then collect the data 
making it instantly available for those who need it to inform clinical decisions and research. 
The HVP and InSiGHT (www.insight-group.org) has developed a major pilot study to develop procedures and systems to 
allow effortless flow of de-identified data from the patient/clinic/diagnostic laboratory via curated locus or gene specific 
databases to central databases/genome browsers such as NCBI, UCSC and EBI. The system will be easily adaptable to 
other genes and to multiple laboratories, states and countries worldwide. 
A country specific collection pilot is underway in Australia and an International Confederation of these countries has been 
initiated with Korea and China in the application process. 
Other pilot studies developed include specific ethical studies related to mutation collection, loading of LSDB content to 
dbSNP, funding of curation of LSDBs, a system of Microattribution/reward for mutation submission. A high level meeting 
in Spain (Kaput, Cotton et al. 2009) developed plans to implement the recommendations of the HVP Melbourne meeting 
(Cotton, Appelbe et al. 2007). The HVP was features recently in relation to Neurogenetic databases in Science (Cotton, 
Auerbach et al. 2008) and HVP Neurogenetic Database Initiative is being formed after an HVP Neurogenetics forum in 
Hawaii October 2009. 




Poster No: P022-W  
Exploring hematological malignancies transcriptome using a comprehensive gene expression profiling resource, 
Amazonia! Hematology.  
1-3Sylvie Tondeur, 1,2Tanguy Le Carrour, 1,2Said Assou, 2Véronique Pantesco, 1,2Bernard Klein, 3Jean-François Schved, 
1,2John De Vos 
1CHU Montpellier, Institute for Research in Biotherapy, Hôpital Saint-Eloi, Montpellier, F 34000 France ; 2INSERM, U847, 
Montpellier, F 34000 France ; 3CHU Montpellier, Laboratoire d’Hématologie, Hôpital Saint-Eloi, Montpellier, F-34000 
France. 
Microarray technology can monitor the expression of the whole genome of a cell or a tissue type in one experiment. This 
tool represents a major technical breakthrough and has known a rapid development in the last years. Its application 
provided real advances in numerous domains such as in cancerology and has notably contributed to a better 
understanding of the physiopathology and the evolution of hematological malignancies. Gene expression data accumulate 
in public repositories such as Gene Expression Omnibus (GEO) or Array Express, in individual web pages or as various 
supplemental data in the literature. Because of the huge quantity of data generated and the know-how needed for 
analyses, these published data cannot be routinely accessed. 
We have developed the web based tool Amazonia! (http://www.amazonia.transcriptome.eu/), for an easy and free access 
to a large selection of public transcriptomes. A thematic atlas, Amazonia! Hematology, provides the possibility to query 
and to visualize the expression of a given gene in representative and selected human transcriptome datasets in the field 
of haematological malignancies. This atlas provides expression bar plots for single genes, across samples selected from 
a wide range of normal and malignant cells and tissues. When produced by the same platform type, datasets were 
renormalized and combined in order to generate series of several hundreds samples. More than 2,000 samples types are 
annotated, colored and ordered for 9 hematological malignancies and for normal haematopoiesis. 
To illustrate the powerfulness of this simple tool, we show how Amazonia! Hematology reveals the specific expression of 
the T-cell leukemia, homeobox 3 gene TLX3 (HOX11L2) in a subset of T-ALL, or of the Wilm’s Tumor gene WT1 in a 
subset of AML. 
Amazonia! Hematology advantageously complements large public repositories by providing a simple way to query a 
compilation of selected human transcriptome data. 
 
Poster No: P037-W 
SNDs (Single Nucleotide Differences) Pollute dbSNP  
Juergen Reichardt1,5, Lucia Musumeci1,6*, Jonathan W Arthur2,3*, Florence SG Cheung1, Ashraful Hoque4 and Scott 
Lippman4  
1Plunkett Chair of Molecular Biology (Medicine) Bosch Institute The University of Sydney Medical Foundation Building 
(K25) 92–94 Parramatta Road Camperdown, NSW 2006, Australia 2 Discipline of Medicine, Sydney Medical School, The 
University of Sydney, Camperdown, NSW 2006, Australia 3 Sydney Bioinformatics, The University of Sydney, 
Camperdown, NSW 2006 Australia 4  The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA 
5Presenter  
The creation of single-nucleotide polymorphism (SNP) databases (such as NCBI dbSNP) has facilitated scientific 
research in many fields. SNP discovery and detection has improved to the extent that there are over 17 million human 
reference (rs) SNPs reported to date (Build 129 of dbSNP). SNP databases are unfortunately not always complete and/or 
accurate. In fact, half of the reported SNPs are still only candidate SNPs and are not validated in a population.  
We describe the identification of “bogus” (bs) SNPs in humans, that may contaminate the dbSNP database. These 
bsSNPs, reported as real SNPs in the database, do not exist as such, but are merely artifacts due to the presence of a 
paralogue (highly similar duplicated) sequence in the genome. Using sequencing we showed how bsSNPs could originate 
in two paralogous genes and evaluated samples from a population of 100 individuals for the presence/absence of SNPs. 
Moreover using bioinformatics, we predicted as many as 8.32% of the biallelic, coding SNPs in the dbSNP database to be 
bogus.  
 
Our identification of bsSNPs in the database will allow researchers to not only select truly informative SNPs for 
association studies, but also aid in determining accurate SNP genotypes and haplotypes. 




Poster No: P052-W 
First genetically characterized mouse model for age-related cataracts is a mutation in the beta-A2-crystallin 
encoding gene  
Jochen Graw1, Oliver Puk1, Nafees Ahmad1, Sibylle Wagner2, Martin Hrabé de Angelis2, Helmholtz Center Munich – 
German Research Center for Environmental Health,  
1Institute of Developmental Genetics and 2Institute of Experimental Genetics D-85764 Neuherberg; Germany.  
Age-related cataracts are the major cause of blindness worldwide and have been associated with falls and increased 
mortality, possibly because of associated systemic conditions. Major risk factors for cataracts are diabetes and UV light. 
However, the suggested contribution of genetics to the etiology of age-related cataracts is largely unknown. 
In a large-scale high-throughput ENU mutagenesis screen we analyzed the offspring of paternally treated C57BL/6J mice 
for malformation of the eye by non-invasive in-vivo techniques including slit-lamp biomicroscopy, funduscopy and eye size 
measurement by laser interference biometry. In total, we screened 1700 F1 mice; the most efficient screen was the laser 
interference biometry at the age of 11 weeks. This test detected 77 variations; 13 mutants could be confirmed so far. One 
of them was characterized by a clear, but significantly smaller lens without any changes for cornea thickness, anterior 
chamber depth or aqueous humour size. At the age of 11 weeks, the mean lens axis length is 2.1 mm (+ 0.01 mm) for 
wild type mice and 1.9 mm (+ 0.03 mm) for heterozygotes. The smaller size of the clear lens was more pronounced in the 
homozygous mutants (1.7 mm + 0.03 mm), which were fully fertile and viable. The mutation was mapped to chromosome 
1 between the markers D1Mit251 and D1Mit253. Using a positional candidate approach, the ȕA2-crystallin encoding gene 
Cryba2 was sequenced; a TĺC exchange at cDNA position 139 leads to an S47P amino acid exchange. 
Histologically, the eye of newborn homozygous mutants showed small vacuoles at the anterior pole of the lens. At the age 
of three weeks, some clefts appeared at the anterior cortical region; the other main tissues of the eye, cornea and retina, 
appeared without major changes. Later, at the age of 25 weeks, the lenses of the heterozygous mutants develop a 
subcapsular cortical cataract, but the lenses of homozygous mutants are completely opaque. 
These findings demonstrate the first mutation in the Cryba2 gene in any organism so far. The Cryba2 gene is very closed 
to the gamma-crystallin gene cluster; mutations in the gamma-crystallin genes have been shown to cause congenital 
dominant cataracts in mouse and man. Surprisingly, no congenital cataract mutation could be attributed up to now to this 
gene. If the data on our new Cryba2 allele in the mouse are extrapolated to the situation in human cataract patients, 
CRYBA2 should be considered as a strong candidate gene for human age-related cataracts, and the slightly smaller size 
of the lens might be understood as an early biomarker for age-related cataracts. Moreover, data from the Allen Brain Atlas 
(http://mouse.brain-map.org) demonstrate that Cryba2 is expressed also in the hippocampus. Therefore, mutations in the 
human CRYBA2 gene are expected also to modify the function of the hippocampus (mainly long-term memory and spatial 
navigation), and ophthalmologists have to consider additional neurological deficits in these patients. 
 
Poster No: P067-W 
A technology platform for isolation and expression profiling of rare cell populations from developing mouse 
embryos 
Sook Peng YAP, Sumantra CHATTERJEE, Wenqing Jean LEE, Hsiao Yun CHAN, Petra KRAUS, Thomas LUFKIN 
Stem Cell and Developmental Biology, Genome Institute of Singapore, 60 Biopolis Street, #02-01 Genome, Singapore 
138672 
Global whole embryo gene expression profiling during mouse embryogenesis has largely been completed. These studies 
generated data following major fluxes in gene expression but failed to look at specific cell populations. Cells in low 
abundance are masked by the larger pool of cells found in the developing animal. In order to investigate the molecular 
mechanisms directing different specialized lineages of cells in vivo, we need to isolate them accurately from other 
embryonic cells for expression profiling studies. 
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To achieve that, we set out to establish a technology platform that would allow enrichment for the cells of interest by 
merging the technologies available from the genomics field with classical molecular genetic approaches using mouse as a 
model.  
A developmental gene with a known expression pattern was engineered endogenously with the enhanced green 
fluorescent protein (EGFP) by homologous recombination in mouse embryonic stem cells (mESC). The modified mESC 
were microinjected to generate a transgenic line of mice. The expected EGFP expression pattern was observed in 
heterozygous embryos at midgestation, and the cell populations expressing the gene of interest were efficiently isolated 
by Fluorescent Activated Cell Sorting (FACS) to greater than 90% purity. RNA was extracted from the sorted cells and 
subsequent expression profiling studies done using Illumina Mouse WG-6 Microarrays. 
From our work, we have determined the smallest number of cells required for us to obtain the minimum RNA necessary 
for reproducible gene expression profiling on the Illumina microarray platform. By comparing the expression profiles of 
EGFP+ and EGFP- cells, we identified a list of genes, including novel and known genes, which are highly expressed in 
the specific cell lineage isolated. 
In summary, a robust strategy to isolate low abundance cell population to high purity for the analysis of spatio-temporal 
changes in the transcriptome of any specific developing tissue or organ in vivo has been established. 
 
Poster No: P084-W 
From HGM10 (1989) to HGM 2010: IG and TR gene concept and IMGT/GENE-DB 
1Véronique Giudicelli  and 1Marie-Paule Lefranc  
1IMGT®, the international ImMunoGeneTics information system®, Laboratoire d’ImmunoGénétique Moléculaire LIGM, 
Université Montpellier 2, Institut de Génétique Humaine IGH, UPR CNRS 1142, 141 rue de la Cardonille, 34396 
Montpellier cedex 5, France 
In 1989, at HGM10 in New Haven (USA), the T cell receptor gamma genes were, for the first time, entered in the newly 
created Genome DataBase (GDB). This was a first major step as it acknowledged the concept of gene for the antigen 
receptors, the immunoglobulins (IG) and T cell receptors (TR), despite their unique particularities. Indeed, IG and TR 
chains are coded by genes belonging to four types, variable (V), diversity (D), joining (J) and constant (C), which show an 
unusual molecular organization due to the necessity of DNA rearrangements for the IG and TR chain synthesis, in B and 
T cells, respectively. These rearrangements contribute to the huge diversity and fine specificity of the variable domains of 
the IG and TR that bind specifically to the antigens, in the adaptive immune response. The potential expressed repertoire 
is estimated to 2x10 to the twelfth different IG and TR per individual. Owing to these particularities, IMGT®, the 
international ImMunoGeneTics information system® (http://www.imgt.org), was created in 1989 by Marie-Paule Lefranc at 
LIGM, Montpellier, France. IMGT® is a high-quality integrated knowledge resource specialized in the IG, TR, major 
histocompatibility complex (MHC), immunoglobulin superfamily (IgSF), MHC superfamily (MhcSF) and related proteins of 
the immune system (RPI) of human and other vertebrate species. IMGT/GENE-DB (Nucl. Acids Res., 33, D256-D261, 
2005), the IMGT® genome database, was developed to standardize and classify the IG and TR gene data and to manage 
the related knowledge. The official nomenclature of human IG and TR genes and alleles, based on IMGT-ONTOLOGY, 
the first ontology for immunogenetics, was approved in 1999 by the HUGO Nomenclature Committee (HGNC) and 
acknowledged by the WHO-IUIS. Rules for the identification of gene and allele functionality were defined, with each IG 
and TR gene and allele being represented by an IMGT reference sequence. Another breakthrough is the IMGT unique 
numbering and its graphical representation, the IMGT Collier de Perles, which allow the standardization per domain type. 
In March 2010, IMGT/GENE-DB includes the 674 human IG and TR genes (1245 alleles). Five hundred ninety-six genes 
(1139 alleles) are organized in 7 loci on 4 chromosomes, spanning a total of 6 megabases: IGH (14q32.33), IGK (2p11.2), 
IGL (22q11.2), TRA (14q11.2), TRD (14q11.2), TRB (7q34) and TRG (7p14) (The Immunoglobulin FactsBook, 2001; The 
T cell receptor FactsBook, 2001). Seventy-eight orphons (106 alleles) are found outside the main loci. IMGT® gene data 
are provided on Ensembl Genome Browser (EBI) via a DAS server. IMGT/GENE-DB gene entries are cross-referenced 
by HGNC database, Genatlas, Entrez Gene (NCBI) and Vega (Wellcome Trust Sanger Institute). IMGT/GENE-DB 
reference sequences are crucial for the assignment of new alleles of IG and TR from different haplotypes (1,000 genomes 
project), for gene expression studies in normal and pathologic situations (cDNA high-throughput sequencing) and for 
biotechnology related to antibody engineering and antibody humanization. 
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Antagonism of the Testis-Specific Enhancer of SOX9- an ‘anti-testis’ effect of DAX1 
1,2Vincent R. Harley, 1,2Louisa M. Ludbrook, 1Pascal Bernard, 3Ryohei Sekido, 4Dagmar Wilhelm,  1Stefan Bagheri-Fam, 
3Robin Lovell-Badge 
1Prince Henry’s Institute of Medical Research, Melbourne, Australia, 2Dept. of Biochemistry & Molecular Biology, Monash 
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The role of the orphan nuclear hormone receptor Dosage Sensitive Sex Reversal-Adrenal Hypoplasia Congenita on X 
chromosome, gene 1 (DAX1) during gonad formation is contentious. Here we investigated an ‘anti-testis’ effect of DAX1 
when it is present at high doses. In humans, duplications of the DAX1 gene at locus Xp21 cause Disorders of Sex 
Development (DSD), whereby XY individuals develop an ambiguous or female sex phenotype. Exactly how DAX1 
duplication causes the failure of typical testicular development is unclear. We hypothesized that, when present in excess, 
DAX1 must repress the action of early testis-specific genes. 
Using a mouse line transgenic for Dax1 with gonad-specific expression, we investigated the expression of the critical 
testis-specific gene, SOX9. Immunostaining of Dax Tg gonads revealed reduced Sox9 protein levels in gonads with high 
Dax1 dose. The low Sox9 protein levels may reflect a reduced transcriptional activity of the Testis-Specific Enhancer of 
Sox9 (TES), (which drives Sox9 transcription in the developing XY gonad). Indeed, TES activity was repressed in vivo and 
in vitro by higher doses of Dax1. Moreover, in a heterozygous knockout mouse model for Sox9 (50% dose of Sox9 gene); 
the introduction of extra copies of Dax1 causes the most severe disruption to testicular development as shown by 
immunohistochemical analysis. In these mice, ovotestes expressing a female gonadal somatic cell marker at both poles 
are formed in developing XY embryos. 
These data support the hypothesis that Dax1 functions in an ‘anti-testis’ manner by affecting Sox9 expression, when 
present at higher than typical doses. Using in vitro reporter activation assays and EMSA we provided additional evidence 
to suggest that the Sox9 transcriptional repression by Dax1 is mediated through a disruption of the ability of the nuclear 
hormone receptor Steroidogenic Factor-1 to bind to and activate the TES. 
With this work we have identified a potential mechanism for disruption of the male-specific sex determination pathway 
caused by DAX1 duplication and leading to DSD in XY individuals. 
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H-InvDB: a comprehensive annotation resource for human transcriptome 
1Chisato Yamasaki, 1Jun-ichi Takeda, 1Takuya Habara, 2,3Makoto Ogawa, 4Makoto Shimada, 2,5Kentarou Mamiya, 1Akiko 
Noda, 1Ryuichi Sakate, 2Katsuhiko Murakami, 1Tadashi Imanishi and 1,6Takashi Gojobori 
1Biomedicinal Information Research Center, National Institute of Advanced Industrial Science and Technology, 2Japan 
Biological Informatics Consortium, 3DYNACOM Co., Ltd., 4Fujita Health University 5Hitachi Software Engineering Co., Ltd., 
6National Institute of Genetics WaterfrontBio-ITResearchBuilding, 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan. 
H-Invitational Database (H-InvDB: http://www.h-invitational.jp/) is a comprehensive annotation resource for human 
transcriptome. By extensive analyses of all human transcripts, we provide curated annotations of human genes, 
transcripts and proteins that include gene structures, alternative splicing isoforms, non-coding functional RNAs, protein 
functions, functional domains, sub-cellular localizations, metabolic pathways, protein 3D structure, genetic polymorphisms, 
relation with diseases, gene expression profiling, molecular evolutionary features, protein-protein interactions (PPIs) and 
gene families/groups. The latest release of H-InvDB (release 7.0) provides annotation for 296,912 human transcripts in 
46,499 human gene clusters based on human full-length cDNAs, mRNAs and the reference human genome sequences 
(NCBI b37.1). H-InvDB consists of three main views, the Transcript view, the Locus view and the Protein view, and six 
sub-databases; G-integra, H-ANGEL, DiseaseInfo Viewer, Evola, PPI view and Gene Family/Group view. We also provide 
data mining tools such as “Navigation search”, an extended search system that enables complicated searches by 




combining 16 different search options (http://www.h-invitational.jp/hinv/c-search/hinvNaviTop.jsp) and “H-InvDB 
Enrichment Analysis Tool (HEAT)”, a data mining tool for automatically identifying features specific to a given human gene 
set (http://hinv.jp/HEAT/ ). 
We also develop VarySysDB (http://h-invitational.jp/varygene/), a database of annotated genetic polymorphisms on 
human genes based on gene models of H-InvDB and public polymorphism databases. VarySysDB provides information of 
human genetic polymorphism and effects derived from a polymorphism on human transcriptome. We analyzed single 
nucleotide polymorphisms and deletion-insertion polymorphisms from dbSNP, copy number variations from Database of 
Genomic Variants, short tandem repeats and single amino acid repeats from H-InvDB. We also annotated the 
polymorphisms altering functional domains (InterPro) and protein 3D-structures (GTOP). VarySysDB consists of two kinds 
of viewers, GBrowse and Sequence View, to facilitate understanding of the positional relationship among polymorphisms, 
genome, transcripts, loci and functional domains, providing useful information on polymorphisms affecting gene 
expression and phenotypes. 
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HUGO Statement on Next Generation Genomic Sequencing 
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Since HUGO released its Statement on Human Genomic Databases in 2002, developments in next generation 
sequencing technologies have significantly advanced the possibilities of developing individualized medical treatments and 
diagnostics along with other biotechnologies that may be used for industrial, military and clinical purposes. With increasing 
numbers of genome-wide association studies (GWAS), the realisation of these possibilities in the near future is likely to re-
invigorate public discussion of the social, political and ethical issues that surround genomics. Many of these issues are 
familiar; however, some will present new challenges. The Centre for Biomedical Ethics at the National University of 
Singapore is aiming to assist HUGO’s Ethics Committee in generating an in-depth analysis of the issues that are both 
already under discussion as well as those likely to emerge in response to further developments in GWAS. It is proposed 
that this analysis will contribute to the formulation of a white paper, tentatively entitled “The Impact of Next Generation 
Genomic Sequencing on Society, Policy and Law”, and a supporting policy statement on whole genome sequencing.  
 
Preparations have commenced on the drafting of these documents, which I aim to discuss at the HUGO’s 14th Human 
Genome Meeting in 2010. To stimulate ongoing discussions in this area, I will address five key issues. The first relates to 
procedural consent and the right of participants to withdraw from GWAS. The second relates to the new challenges 
GWAS presents in maintaining confidentiality and protecting the privacy of research participants, their families and the 
communities they belong to. Third, is the so-called democratisation of DNA and issues arising with the disclosure of 
GWAS results, not only to research participants, but third parties such as genetically related others and commercial 
genetics companies. Forth, I shall speak about the governance of GWAS and concepts such as benefit sharing, solidarity, 
equity and genetic heritage. Finally, I will conclude with some remarks on the deeper cultural impacts of GWAS, 
particularly with respect to genetic determinism and public understandings of statistical risk and uncertainty.  
 
Attending the HGM 2010 will be tremendously helpful in my research as it will provide me with the opportunity to network 
with leading scientists in genomics and participate in the presentations and workshops on whole generation sequencing. 
Attendance will also present opportunities for me to make anecdotal observations about current considerations of the 
ethical/social issues from the point of view of the scientists working in GWAS, which will help me to undertake the most 
up-to-date analysis of current concerns in the area. This will benefit my research, and that of others studying the ethical 
issues surrounding genomics, by not only helping to ensure that my scholarly contributions accurately reflect the state of 
the art in GWAS, but will open up the work of HUGO to wider audiences interested in genomics research. As a result, 




HUGO is set to benefit as the outcomes of my discussions will contribute substantially to the development of the white 
paper and policy statement on whole genome sequencing. This, in turn, will benefit HUGO in the generation of a public 
policy position that is defensible on the grounds that it is theoretically-derived and is supported by the extant empirical 
literature in ethics. I will also contribute a blog on the outcomes of my attendance to HUGO Matters, which will hopefully 
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Disclosing Genetic Information to Genetic Relatives Without Consent - the Australian Experience 
Prof R.J.A. Trent 
The National Health and Medical Research Council (NHMRC) of Australia, GPO Box 1421, Canberra ACT 2601, Australia. 
(Presented by Prof R.J.A. Trent, Chair of the NHMRC Human Genetics Advisory Committee) 
The NHMRC is Australia's peak body for supporting health and medical research; for developing health advice for the 
Australian community, health professionals and governments; and for providing advice on ethical behaviour in health care 
and in the conduct of health and medical research (www.nhmrc.gov.au). 
In 2003 following a joint inquiry by the Australian Law Reform Commission and the NHMRC's Australian Health Ethics 
Committee a report was issued titled “Essentially Yours - the protection of human genetic information in Australia” - 
www.austlii.edu.au/au/other/alrc/publications/reports/96/. One of the recommendations of this report was to change the 
Commonwealth Privacy Act 1988 to allow disclosure of genetic information to genetic relatives without the consent of the 
patient provided there was reasonable belief that this was necessary to lessen or prevent a serious threat to the life, 
health or safety of their genetic relatives. Previously this was possible if the threat was both serious and imminent but with 
DNA predictive testing, the requirement for imminent became a limitation. In this context, it is assumed that for most 
circumstances a patient would agree to provide this information to family members but, in the unusual case that the 
patient refused, it was now possible for health practitioners to do this without breaching the Privacy Act. In December 
2009, the Office of the Privacy Commissioner and the NHMRC released guidelines that were obligatory before medical 
practitioners could make use of the amended legislation - www.nhmrc.gov.au/publications/synopses/e96syn.htm. 
The guidelines were prepared by an NHMRC working group comprising expertise in medicine, clinical genetics, ethics and 
a consumer representative. The guidelines took nearly two years to prepare with a number of consultation steps involving 
the community and health professionals. Two of the NHMRC’s principal committees provided input including the Human 
Genetics Advisory Committee and the Australian Health Ethics Committee. 
It is important to note that the changed legislation included specific inclusions and exclusions such as: (1) it is not 
mandatory for health practitioners to disclose genetic information to genetic relatives, (2) disclosure without consent to 
non-genetic relatives e.g. spouses or partners is not allowed, (3) a serious threat to an unborn child is not covered, (4) 
changes impact on privacy legislation but not the health practitioner’s duty of confidentiality. (5) In the context of the 
Australian health system, the changes are to the Commonwealth Privacy Act hence only relate to private patients. To 
cover public patients, it will be necessary for the different States and Territories to mirror these changes in their own 
Privacy Acts.  
 
It will be important to monitor how often this provision in the privacy legislation is used, and whether there are problems in 
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of Health, Maryland, USA 
Ethics issues on research on stored human tissue samples are important in biomedical research. We carried out a survey 
among biomedical research scientists and policy makers (mainly ethics review committee members) to determine their 
attitudes concerning controversies surrounding such research. 55 (45.8%) responded. 26 (47.2%) were males. 19 (34.5%) 
were scientists and 35 (63.6%) were policy makers. 40 (72.7%) favoured giving sample donors the option to provide 
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advance consent to unspecified future research on their samples, under the condition that future research be approved by 
an ethics committee. 31 (56.4%) favoured using consent forms that offer a greater variety of consent options for future 
research than binary yes or no options. Many supported regulations that require that scientists in a sample collections' 
country of origin be given authorship opportunities and control over research performed on sample collections that are 
removed from their country of origin with response rates varying from 33 (60.0%) to 50 (90.9%) to the different questions 
probing these issues. 51 (92.7%) favored involving ethics committees from samples' country of origin in the research 
approval process when samples have been transported out of their country of origin. 19 (34.5%) felt that when there is a 
time lag between collection and use of samples the standards at the time of use of samples should be applied for their 
use. Characterizing attitudes regarding the consent process for collecting stored samples and collaborative research on 
stored samples such as we have attempted to do in this study may inform policy recommendations. 
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Admixture mapping is a whole genome association strategy that takes advantage of population history - or genetic 
ancestry - to map genes for complex disease. Admixture mapping is beginning to generate important scientific insights. 
However, because it uses racial/ethnic groupings to examine differential disease risk, there is heightened potential for 
ethical and social consequences. Here we examine one of the first admixture studies, a scan for Multiple Sclerosis (MS) 
risk factors in an African American population. We explore perceptions of admixture mapping, its ethical and social 
implications, and potential risks and benefits. Our data primarily draws on in-depth, one-on-one interviews with leading 
population-geneticists, bioethicists, and African Americans with MS. Unsurprisingly, our analysis underlined fears about 
exacerbating racial/ethnic sensitivities as a key concern of admixture mapping. However, a belief in the ongoing scientific 
value of ancestry and population-based studies, and even the opportunity they may offer for social progress was also 
highlighted. Thus, such studies may represent a transition point between simplistic notions of race/ethnicity, and more 
empirically-based understandings of human genomic diversity. Most of the geneticists we spoke to cited social and/or 
scientific imperatives to move beyond the use of race in genetic research, and clinical practice. To enact this wish, and to 
make best use of emerging genetic information, our analysis underlined the need for concerted efforts to promote deeper 
public awareness of population history, and genetics. These undertakings should be co-cultivated by all stakeholders - 
including social and basic scientists, media, policy-makers, clinicians, and the public themselves. 
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Understanding the contribution of rare and common genetic genetic variants, environmental exposure, and gene-by-
environment interactions to disease susceptibility will likely require multi- and trans-ethnic genome-wide studies that 
compare completely sequenced genomes of many individuals with and without a particular disease. Of particular 
importance to this endeavor will be accounting for the role of population stratification at fine scales both in terms of 
genomic and geographic location. Here, we present results from sequencing, assembly, and genomic analysis of of two 
diploid genomes from Phase 3 HapMap sequenced to ~20X coverage using LifeTech SoLiD technology. The two donor 
individuals are of Mexican-American and African-American ancestry and represent the first "admixed" genomes to be 
completely sequenced to high coverage. We demonstrate that genomic sequencing may provide finer resolution of 
"admixture breakpoints" by using allele frequency estimates based on Phase 1 of the 1000 Genomes Project. 
Furthermore, we compare the distribution of functional and putatively neutral genetic variation among 8 sequenced 
genomes and find that difference in demographic history may account for modest, but statistically significant, differences 
in distributions of synonymous vs. benign, possibly damaging, and probably damaging non-synonymous coding variants. 
We also use the comparative personal genomic data sets as well as 1000 Genomes Project data to quantify the extent to 
which one would expect variants to be private, rare within a given population, or common and segregating among 
populations. 
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The beta-defensin gene cluster (DEFB) at chromosome 8p23.1 is one of the most copy number (CN) variable regions of 
the human genome. Whereas individual DEFB CNs have been suggested as independent genetic risk factors for 
psoriasis, the role of multisite sequence variations (MSV) is less well understood and so far has been reported for prostate 
cancer. Studying the correlation of CN and sequence variations with the expression of defensins, a very high density of 
variations (~1 MSV/41bp) was found within the promoter region of DEFB4. 
PCR, cloning and Sanger sequencing allows simultaneous assessment of MSVs and CNs, but is labour and cost 
intensive as well as prone to methodological bias introduced by bacterial cloning. Here, we report amplicon sequencing of 
pooled individual PCR products by the 454 technology allowing in-depth determination of MSV haplotypes and estimation 
of DEFB CNs in parallel. 
Six PCR products spread over ~87 kb of DEFB and harbouring 24 known MSVs were amplified from DNA samples of 
lymphoblastoid cell lines, pooled and sequenced on a Roche 454 GS FLX sequencer. We inferred 22 haplotypes ranging 
between 2 and 7 per amplicon. Two additional sequence variations were detected. Minimal CNs were estimated from the 
ratio of haplotype calls (HC) and compared to absolute CNs determined by alternative methods. The 454 haplotyping 
results were compared to those by cloning/Sanger sequencing. Intrinsic problems related to chimera formation during 
PCR and differences between haplotyping by 454 and cloning/Sanger sequencing are discussed. 
Deep amplicon sequencing using the 454 technology yield thousands of HCs per amplicon for an affordable price and 
may represent an effective method for parallel haplotyping and CN estimation in small to medium-sized cohorts. The 
presented method represents a valuable approach to facilitate further studies of highly CN variable loci such as the beta-
defensin locus, especially by identifying haplotypes in regions interfering with the expression of genes located therein. 
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Metabolic syndrome (MetS) is defined as a group of metabolic risk factors, including dyslipidemia, central obesity, insulin 
resistance, and hypertension. The prevalence of this common age-dependent disorder has greatly increased during the 
past decades. Biological mechanisms and genetic loci underlying MetS are largely unknown. The overlap between MetS, 
coronary heart disease (CHD), and Type 2 diabetes suggests that the same genetic determinants may contribute to their 
complex pathophysiology. 
 
We analyzed copy number variation (CNV) in the genome, with two distinct strategies to assess the contribution of 
common and rare CNVs as risk factors for MetS. Probe signal intensity data from Illumina human610-quad beadchip, 
which is enriched for CNV-targeted probes, was analyzed for 1,100 MetS cases and their matched controls. The search 
for common CNVs utilized a recent high-density genomic map of known CNVs from a study of individuals of European 
and African ancestry: We analyzed CNV-tagging SNPs from this reference set in our MetS cases and controls. In parallel 
to our analysis of common CNVs, we searched for rare CNV associations, concentrating on those overlapping with genes 
or covering large genomic regions, with the hypothesis that these structural variants may have large effects on individual 
phenotypes. 
 
In our MetS case-control analysis, two of the CNV tag-SNPs indicated loci harboring possible copy number variant 
association with metabolic syndrome as whole, but this was not replicated in a meta-analysis of three large population 
cohorts. We also analyzed the CNV tag-SNPs and the distinct component traits of MetS, and identified several interesting 
susceptibility loci especially for high-density lipoprotein (HDL) levels. Some of these loci, such as ABCA1, have been 
implicated in previous studies, and several more, such as WWOX, with relevant biological function in lipid metabolism, 
were observed. Our analysis of rare CNVs identified a novel gene region, implicated in insulin resistance and energy 
metabolism, where a few of our study subjects, who are located at the far ends of the population distribution of relevant 
phenotypes, carry large CNVs. These results provide ground for replication studies in large population cohorts and 
hopefully eventually elucidate the genetic background of MetS, CHD, and their risk factors. 
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Aneuploidy and DNA replication stress cooperatively destabilize somatic genome and may lead to 
neurodegeneration in Alzheimer’s disease brain 
 
Yuri B Yurov, Svetlana G Vorsanova and Ivan Y Iourov 
Mental Health Research Center, Russia Federation 
There are two commonly accepted models for cell death in the Alzheimer’s disease (AD) brain based on (i) cell cycle 
failure and (ii) chromosome missegregation. We propose that aforementioned models may be transformed into a unified 
one featuring genetic/genomic instability linked to neurodegeneration and is based on intriguing relationship between 
somatic genome instability and neuronal cell death. According to this unified theory, genetically damaged, abnormal and 
aneuploid neurons accumulated during neurogenesis in the developing and adult brain have to demonstrate abortive cell 
cycle re-entry and DNA replication stress. Here we analysed such remarkable biomarkers of genomic instability as mosaic 
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aneuploidy, which is an indicator of large-scale genomic alterations due to mitotic chromosome non-disjunction, and 
abortive DNA replication as an indicator of abnormal neurogenesis and DNA replication stress. Different regions of the AD 
post-mortem brain were monitored by molecular neurocytogenetic approaches (interphase MFISH and MCB FISH, FISH-
based DNA replication assays). Aneuploidy was observed in 2-15% of neural cells and replicating DNA signals 
(singlet/duplet) were present in 0.4-3.7% of neural cells of hippocampus and prefrontal cortex of the AD brain. The 
frequency of abnormal neural cells (aneuploid and abnormally replicated) affecting different chromosomes was higher in 
the brain area affected by neurodegeneration (hippocampus, prefrontal cortex) than in less-affected area (cerebellum). 
These data indicate that molecular cytogenetics allows analyzing genomic landscapes at single-cell level and at molecular 
resolutions in the postmortem brain and may provide for missing information about genome variation/instability and 
neuronal dysfunction/death in the AD brain. Authors were supported by Philip Morris USA, Inc. 
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Alzheimer’s disease (AD), the most frequent cause of neurodegenerative dementia, is a genetically complex disorder for 
which until shortly only one major genetic risk factor was known, i.e. the apolipoprotein E gene. Recent GWA studies in 
over 25000 individuals identified several interesting novel candidate genes that reached genome-wide significance levels. 
One of these genes is the complement receptor 1 gene (CR1), encoding a large transmembrane receptor that is crucial in 
immunity by regulation of the complement cascade. Here we report an initial follow-up of the GWA finding in a Flemish-
Belgian group of 1060 patients and 890 control individuals. We investigated the effect of simple (SNPs) as well as 
complex (structural) variations in the CR1 locus on the genetic risk of AD. Genetic association analysis of 30 tagSNPs 
spanning the CR1 locus confirmed the association observed in the GWA studies, with signals located at the 5’ end (3 
SNPs) and the 3’ end (4 SNPs) of the CR1 gene. Two SNPs known to be associated with the number of CR1 molecules 
present on erythrocytes were not associated with AD. In addition, different isoforms of CR1 protein are known to be 
expressed that differ from each other in the number of complement factor (C3b and C4b) binding sites. These different 
isoforms are the result of structural variation at the genomic level. The CR1 locus encompasses a number of copies of a 
low copy repeat (LCR). Using Multiplex Amplicon Quantification (MAQ) we assessed the copy number polymorphisms 
(CNP) that arises from this LCR in AD patients and control individuals and preliminary data showed that increased copy 
number is associated with an increased risk for AD. Taken together, our study confirms and extends the association of 
CR1 variants with AD. Moreover we showed structural polymphisms to be involved in AD risk, with longer isoforms i.e. 
isoforms with more complement factor binding sites, conferring a higher risk for AD. 
 
Poster No: P070-W 
Genome-wide association study using microsatellites identifies a new psoriasis susceptibility locus on 
chromosome 6 
1Hidetoshi Inoko, 1Akira Oka , 1Hideki Hayashi, 1Akira Ozawa and 2Stepahn Beck  
1Department of Molecular Life Science, Division of Basic Medical Science and Molecular MedicineTokai University School 
of Medicine, 143 Shimokasuya, IseharaᇬKanagawa-Prefᇬ 259-1193 Japan  2UCL Cancer Institute, Paul O'Gorman 
Builing, University College London, 72 Huntley Street, London  WC1E 6BT UK 
Psoriasis is a common skin disorder characterized by inflammatory cell infiltration and hyperproliferation of epidermal cells. 
To identify novel psoriasis susceptibility loci, we conducted a genome-wide association study (GWAS) of 25,946 
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microsatellites in 1377 cases and 1091 controls, representing four populations of Asian and European ancestry. We find a 
microsatellite D6SX on chromosome 6 to be significantly associated (P = 3.21E-10, OR = 2.3) with disease risk in the 
Asian (Japanese and Mongolian) but not European (French and Spanish) cohorts. A single SNP, D6SY around the 
microsatellite D6SX showed statistical association with the disease, suggesting that this D6SY is directly involved in the 
susceptibility to psoriasis. D6SY is located 1 kb upstream of the first codon of an ‘orphan’ G-protein coupled receptor 
(GPCR-Z). Using quantitative expression analysis of sorted peripheral blood mononuclear cells, we find this GPCR-Z 
gene expression to be up-regulated in fetal skin and naïve CD4+ T cells in individuals positive for GPCR-Z, implicating a T 
cell-mediated pathway involving GPCR-Z in susceptibility to psoriasis. Relatively young disease alleles as exemplified by 
D6SY (5% frequency in healthy Japanese population), which has recently happened to be generated on the frequent SNP 
haplotype in the history of human population and still remained low in allelic frequency, cannot be detected by 
conventional tag SNP or SNP haplotype association analysis. Therefore, microsatellite-based genome-wide association 
study provides a complementary tool for genetic dissection of common and rare diseases. 
 
5. Genome Variation in Evolution 
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Genetic Interactions Reveal a Novel B-Cell Signaling Pathway in Systemic Lupus Erythematosus 
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Witte11, José Luis Callejas12, John B Harley4, Patrick Gaffney4, Javier Martin3*, Joel M. Guthridge5, and Marta E. Alarcón-
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BACKGROUND:  
Epistasis or genetic interaction might explain larger genetic effects on the susceptibility to diseases than single-gene 
associations and help define functional pathways with potential therapeutic targets. 
AIM:  
To identify genes that modify the susceptibility to SLE through their interaction with the B-cell scaffold protein with ankyrin 
repeats gene (BANK1).  
METHODS:  
We searched for genetic interactions in the Affymetrix 100k genome-wide scan performed in 256 cases and 515 controls 
from Sweden. A subsequent replication study included two independent multicenter cohorts of European-Americans 
(n=676 cases and 850 controls) and Europeans (n=1265 SLE cases and 1506 controls). We developed a genotypic 
interaction test based on contingency tables for all possible genotype combinations between pairs of SNPs with r2 <.80 
and calculated a Pearson S score of interaction association and its chi-squared P value. Each interacting combination 
was tested against the hypothesis of independence to derive an epistasis score (Se) and a P value (Pe) was obtained 
through permutation.  




BANK1 showed genetic interactions with 29 genes, including the B-cell tyrosine kinase (BLK) and the inositol 1,4,5-
triphosphate receptor 2 (ITPR2). One fifth of SLE patients (21%) vs. 8 % of controls were homozygous for the risk alleles 
of polymorphisms in these three genes with a significant epistatic effect (Pe < 0.0002). The interactions BANK1xITPR2 
and BANK1xBLK were replicated in two independent European-American (P = 2.1 x 10-6) and European sets (P = 4.11 x 
10-9). The data was verified using multifactor dimensionality reduction (MDR). Moreover, BLK co-immunoprecipitated and 
co-localized with BANK1 in co-transfected HEK-293T. Exogenous expression of BANK1 in human Daudi B cells curbed 
BLK from reaching the plasma membrane with the subsequent accumulation in cytoplasmic compartments. Expression of 
BANK1 and BLK but not ITPR2 was modulated by IFNĮ. 
CONCLUSIONS. 
BANK1, BLK and ITPR2 are genetically and functionally interacting partners and through their protein-protein interactions 
might result in a novel B-cell signaling pathway regulated by type I interferons. This pathway may affect B-cell responses 
to self-antigens in human lupus. 
 
Poster No: P028-W 
 
Recombination-based genomics: A new method to exploring genetic variation through inference of 
recombination events  
 
J. Bertranpetit 
Institut de Biologia Evolutiva (UPF-CSIC), Spain 
 
Recombination is a main force shaping genome diversity. It is often overlooked that it contains phylogenetic information: a 
recombination event creates a junction between two parental sequences that is transmitted to the subsequent generations 
much as a mutation is. In this paper, we present an algorithm, implemented in the IRiS program, to detect past 
recombination events in extant sequences, with specificity of parental and recombinant sequences. The algorithm detects 
recombination events from tree incompatibilities found along the sequence. We have validated and calibrated the 
algorithm for the human genome given human demographic history and the human recombination model by means of 
coalescent simulations implementing a standard model of human demography. Among the possible parameters that can 
be used to run IRiS, we chose the set that optimized simultaneously the false positive rate, sensitivity and accuracy in 
placing the recombination event in the sequence. 
 
We discovered that this method saturates when the sequence set to which it is applied contains a large number of 
recombinations. Younger recombination events (such as those happening in the last 500 generations of the coalescent 
simulation, or created instantly from extant, actual sequences) are detected by IRiS with greater sensitivity, which could 
provide markers of close relationships between populations or even between individuals. Regions for which sperm typing 
has been used to recognize recombinants give a very good concordance. 
 
We also applied IRiS to haplotypes for 18 X-chromosome regions in HapMap Phase 3 populations. The regions were 
selected to be free of genes, segmental duplications, and copy number variants. Recombination events detected for each 
individual can be recoded as binary allelic states and combined into recotypes, which can be analyzed as haplotypes are. 
Principal component analysis and multidimensional scaling based on recotypes reproduced the relationships between the 
11 HapMap Phase III populations that can be expected from known human population history, further validating IRiS. 
 
Poster No: P043-W 
Why is sickle cell uncommon in the Mediterranean?  
Bridget S Penman1, Oliver G Pybus1, David J Weatherall2 and Sunetra Gupta1  
1University of Oxford, Zoology Department, South Parks Road, Oxford, United Kingdom, OX1 3PS 2Weatherall Institute of 
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Several human genetic disorders of haemoglobin have risen in frequency due to the protection they offer against death 
from malaria, sickle cell anaemia being a canonical example. We have used mathematical models to address the issue of 
why this highly protective mutant, present at high frequencies in sub-Saharan Africa, is uncommon in Mediterranean 
populations which instead harbour a diverse range of thalassaemic haemoglobin disorders. We demonstrate that these 
contrasting profiles of malaria-protective alleles can arise and be stably maintained by two well-documented phenomena: 
an alleviation of the clinical severity of Į and ȕ-thalassemia in compound thalassaemic genotypes, and a cancellation of 
malaria protection when Į-thalassemia and the sickle cell trait are co-inherited. The complex distribution of globin mutants 
across Africa and the Mediterranean can therefore be explained by their specific intracellular interactions.  
(Penman BS, Pybus OG, Weatherall DJ, Gupta S. 2009 Epistatic interactions between genetic disorders of hemoglobin 
can explain why the sickle cell gene in uncommon in the Mediterranean, PNAS 106: 21242-6) 
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Genomic study of the chromosome 9 locus linked with FTLD and ALS 
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Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are two severe neurodegenerative 
disorders. FTLD has a prevalence close to that of Alzheimer’s disease in the population below age 65 years whereas ALS 
is the most common motor neuron disorder. FTLD and ALS belong to an overlapping clinicopathological spectrum of 
disorders, that might have common genetic etiologies. Both diseases share presence of TDP-43 inclusions in affected 
neurons, which suggests that they share overlapping disease mechanisms. A positive family history is observed in up to 
50% of FTLD patients and in 5 to 10% of ALS patients indicating a significant genetic contribution to disease aetiology. 
Although recent findings have identified several genes, these do not fully explain the genetic aetiology indicating that other 
genes remain to be identified. One such unidentified gene resides at chromosome 9p13-p21, i.e. the ALSFTD2 locus that 
is causally linked in 13 families with FTD and ALS worldwide, suggesting that this gene is likely to explain the disease in a 
substantial fraction of patients. 
We identified an extended Belgian family with autosomal dominant FTLD-ALS, DR14. The index patient with clinical FTLD 
showed TDP-43 positive FTLD pathology. A genome-wide linkage study showed significant linkage to a region at 
chromosome 9, overlapping with the ALSFTD2 locus (multipoint LOD score = 3.38) and nearly significant linkage with a 
second locus at chromosome 14q31-32 (multipoint LOD score = 2.79), suggesting that a major modifier gene might reside 
in this region. We excluded mutations in all genes in the ALSFTD2 locus by standard genomic sequencing and/or 
transcript analyses. We also sequenced 340kb of the highest conserved elements in mammalians. In addition, we 
completely sequenced the 130kb linkage disequilibrium block in which association was found in a recently published ALS 
genome-wide association study, at the same genomic region. The absence of mutations in all these sequenced regions 
suggested that the underlying genetic defect resides outside these regions or is undetectable using standard mutation 
identification strategies. Therefore we performed other approaches. First, chromosome-specific copy number variation 
(CNV) analysis using array-CGH did not reveal segregating pathogenic CNVs. Second, we are currently performing 
macro-restriction mapping to obtain more information on the presence of more complex rearrangements including 
inversions. In addition, we have determined the complete genome sequence of selected patients of family DR14 and are 
currently analyzing these data. Identified genetic variants in the linked region will be analyzed in the complete family and 
in unrelated patients with FTLD and/or ALS. This strategy will allow for the detection of simple DNA variations and 
complex structural variations, maximizing the chance of identifying the ALSFTD2 genetic defect and a modifying gene at 
chromosome 14q. This (these) novel gene(s) will significantly contribute to the understanding of neurodegenerative 
disease mechanisms in FTLD, ALS and associated neurodegenerative disorders. 
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Copy number variations in Korean population and their evolutional and functional implications 
Yim SH1, Hu HJ1,2, Kim JH1,2, Jung SH1,2 and Chung YJ1,2 * 
1Integrated Research Center for Genome Polymorphism, 2Department of Microbiology, The Catholic University of Korea, 
School of Medicine, 505 Banpo-dong, Seocho-gu, Seoul, Korea.  
Recent discovery of the copy number variation (CNV) in normal individuals has been widening our understanding of 
genomic variation. However, most of the reported CNVs have been identified in Caucasians, which may not be directly 
applicable to people of different ethnicities. To profile CNV in East-Asian population, we screened CNVs in 3,578 healthy, 
unrelated Korean individuals using the Affymetrix Genome-Wide Human SNP array 5.0. We identified 144,207 CNVs 
using a pooled dataset of 100 randomly chosen, Korean females as a reference. The average number of CNVs per 
genome was 40.3, which is higher than that of CNVs previously reported using lower-resolution platforms. The median 
size of CNVs was 18.9 Kb (range 0.2 – 5,406 Kb). Copy number losses were 4.7 times more frequent than copy number 
gains. CNV regions (CNVRs) were defined by merging overlapping CNVs identified in two or more samples. In total, 4,003 
CNVRs were defined encompassing 241.9 Mb accounting for ~ 8 % of the human genome. A total of 2,077 CNVRs 
(51.9%) were potentially novel. Known CNVRs were larger and more frequent than novel CNVRs. Sixteen percent of the 
CNVRs were observed in  1% of study subjects and 24% overlapped with the OMIM genes. A total of 476 (11.9%) 
CNVRs were associated with segmental duplications. To our knowledge, this is the largest-scale profiling of CNV in East-
Asian population using high-resolution SNP arrays. CNVS/CNVRs identified in this study will be valuable resources for 
studying human genome diversity and its association with disease. 
 
Poster No.: P090-W 
Revealing origins of human populations embedded in their genomes. 
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of Mathematical Sciences, Tel Aviv University, Tel Aviv 69978, Israel 5Rappaport Faculty of Medicine and Research 
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The onset of the era of analyses of dense marker sets covering the whole genome has revolutionised the field of (human) 
population genetics. Driven largely by the needs of biomedical research the new data is helping to unveil our demographic 
past outlined by the study of mtDNA and Y-chromosome variation during the past ca. 20 years.  
Here we have analysed (Illumina 650K SNPs) over 500 new Eurasian samples together with the publicly available 
database (HGDP panel) and illustrate the power of full genome analyses by addressing two specific questions: i) the 
place of the genetic variation of the Jewish Diaspora in the genetic landscape of West Eurasia, and ii) genetic origins of 
the Munda speakers of India. We use principal component and structure-like analyses to reveal the structure in the 
genome wide SNP data. 
We have analysed 14 worldwide Jewish communities covering the vast geographic span of Jewish Diaspora together with 
68 non-Jewish populations, of which 25 have not been previously reported. The reference populations now represent all 
the Diaspora host populations as well as current Middle East and North African populations. We show that most Jewish 
samples form a relatively tight cluster which falls within the genetic variation of the contemporary Levantine populations. 
The patterns of ancestry components of the Ashkenazi and to a slightly lesser extent Sephardi and Moroccan Jews 
contain signal for some admixture with the European populations and are very similar to the pattern observed among the 
Cypriots. In contrast, the most distant Diaspora communities in India and Ethiopia cluster together with their host 
populations. 
Alternative models put the origins of Munda languages speakers either in South Asia (the Munda speakers sport 
exclusively autochthonous South Asian mtDNA variants) or to Southeast Asia where the other Austro Asiatic languages 
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are spread. Y-chromosome variation supports the latter model through sharing of hg O2a in both regions. We show that in 
addition to the dominant ancestry component shared between the Indian Dravidic and Munda speakers the latter retain 
(up to 30%) an ancestry component otherwise prevalent in East Asia. There is no widespread sign of South Asian 
ancestry component in Southeast Asia. This provides genomic support to the model by which Indian Austro-Asiatic 
populations derive from dispersal from Southeast/East Asia followed by an extensive admixture with local Indian 
populations. 
In conclusion we have shown effective use of whole genome genetic variation data in resolving thus far elusive problems 
in our demographic past. 
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microRNA expression profiling in Mexican breast tumors differentiates normal and tumor tissue and identifies 
novel microRNAs involved in breast cancer. 
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K1, Jimenez-Sanchez G1, Uribe-Figueroa L1, Romero-Cordoba S1 
1Laboratorio de Oncogenomica, Instituto Nacional de Medicina Genomica, Mexico, 2FundacionMexicana de Fomento 
Educativo para la Prevencion y Deteccion Oportuna del Cancer de Mama, Mexico. 
 
Breast cancer represents the first cause of cancer-related death in Mexican women, and the incidence of this tumor is 
increasing in the whole Latin American region, particularly in younger women. However, there is limited information about 
the genomic alterations involved in the development of breast tumors in Latin American patients. Genomic analysis of 
breast tumors has led to the development of new tools for a better classification and risk prediction. In particular 
microRNA expression signatures are capable to differentiate normal and breast cancer tissues and can define specific 
clinico-pathological phenotypes in breast tumors. However, to our knowledge, analysis of miRNA expression patterns has 
not been reported in tumors from a Latin American population. In order to determine the microRNA expression profile in 
breast cancer samples from Mexican patients, we analyzed the expression of 667 miRNAs in 25 tumors and 20 adjacent 
normal tissues using TaqMan low-density arrays. All samples contained more than 80% tumoral tissue and the RNA 
integrity number of the total RNA in all samples was higher than 6. The expression of specific microRNAs (miR-21 and 
miR-10b) was further validated in an independent set of 10 tumors. 122 miRNAs showed significant differential expression 
in breast tumors compared to the normal adjacent tissue. Importantly, the role of 60% of these miRNAs have not been 
previously reported in breast cancer. The miRNAs with the most significant (P0.01; Fold Change: 2) expression changes 
were: miR-204, miR-129-3p, miR-488, miR-452, miR-139-3p, miR-145, miR-495, miR-668, miR-136*, miR-380*, miR-206, 
miR-770-5p, miR-145* (down-regulated), and miR-184, miR-210, miR-492, miR-431, miR-96, miR-142-3p, miR-25*, miR-
149*, miR-190b, miR-592, miR-454* (up-regulated). Down-regulation of miR-10b and over-expression of miR-21 was 
confirmed with an independent TaqMan miRNA assay. Bioinformatic analysis of mRNA targets of the down-regulated 
miRNAs identified oncogenes like ERBB2, YY1 and several MAP kinases, while the over-expressed miRNAs regulate 
known tumor-suppressors like FOXA1 and SMAD4. Pathway analysis identified that some biological process which are 
important in breast carcinogenesis can be affected by the altered profile of miRNA expression, including signaling through 
MAP kinases and RAS, as well as biological processes like programmed cell death and ERBB2-ERBB3 signaling. Our 
data represents one of the firsts analyses of microRNA expression patterns in a Latin American population, identifying the 
altered expression of several microRNAs whose altered expression might have an important impact on cancer-related 
cellular pathways and whose role in breast cancer has not been previously described. 
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Copy number analysis by high-density DNA array revealed common and specific genetic changes in subtypes of 
colorectal cancer 
 
Chien-Hsing Lin, Shih-Ching Chang, Ya-Hui Chang, Wei-Shone Chen and Shih-Feng Tsai 
Division of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan 
Colorectal cancer (CRC) is one of the major leading causes of cancer deaths around the world, and is arisen from the 
accumulations of multiple somatic and germline mutations and environmental factors. CRC tumor is a heterogeneous 
disease, and ~15% CRC samples are characterized to carry genetic mutations and/or epigenetic modifications, causing 
mismatch repair deficiency (MMR) and resulting in microsatellite instability (MSI). The majority of CRC samples (85%) 
have functional MMR systems and microsatellite stabilities (MSS), but show numerical chromosomal abnormality based 
on previous karyotyping and structural changes as detected by comparative genomic hybridization. Currently, single-
nucleotide polymorphism (SNP) array can be used to detect subtle copy number (CN) alteration at the genome-wide scale. 
CN variations are known to contribute to the levels of gene expressions, and thus fine-scale CN profiling of CRC can 
improve the knowledge about CRC tumorgenesis. 
Due to the lack of high-resolution CN alteration analysis in different CRC subtypes, especially from Han Chinese 
population, 1173 CRC tumors were collected from the Taiwan population, and can be divided into 75 high-frequency MSI 
(MSI-H, 6.4%), 96 low-frequency MSI (8.2%) and 1002 MSS (85.4%) based on microsatellite instability assay. Affymetrix 
SNP 6.0 array, consisting of ~1.8 million probes, was used to detect genome-wide CN alterations of 16 MSI-H and 13 
MSS CRC samples and CN variations of 424 randomly-selected general controls from Taiwan. High-density array probes 
allow the detecting CNVs of 20kb in size. Nearly a quarter of CN alterations were smaller than 100kb, which might have 
been missed in previous studies due to low-resolution technologies. Some CN alterations were commonly found in all 
CRC samples, e.g., subtle CN gains in chr2p, chr14q and chr22p, compared to general controls. There were distinctive 
differences in the CN coverage between CRC MSS and MSI-H subtypes (300Mb v.s. 42Mb per genome, p-value=0.001). 
Chr7, 8q, 13 and 20 gains, and 8p and 18 losses were frequently found in MSS but not MSI-H. However, there were 
significant CNV variations among CRC MSS samples. Cancer-associated genes were found to show variable copy 
number in these CRC samples, e.g., EGFR gain and MALT1 loss, but the biological functions of the majority of these 
genes remain unknown. These CRC common and subtype-specific CN-altered genes should be seriously considered 
when investigating the mechanism of heterogeneous CRC tumorgenesis, and might be used as candidate markers in the 
drug therapy studies. 
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Genetic diagnosis of familial breast cancer using clonal sequencing 
GR Taylor1,2, JE Morgan1, IM Carr1, E Sheridan1, CE Chu2, B. Hayward1, N Camm2, HA Lindsay2, CJ Mattocks3, AF 
Markham1, DT Bonthron1 &  
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Leeds LS9 7TF, 2Department of Clinical Genetics, Leeds Teaching Hospitals Trust St James’s University Hospital, Leeds 
LS9 7TF, 3National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, SP2 8BJ. 
Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity and capacity of 
the Illumina GA II platform for the detection of TP53(OMIM *191170), BRCA1(OMIM *113705) and BRCA2 (OMIM 
*600185) mutations in established tumour cell lines and DNA from patients with germline mutations. A total of 656 coding 
variants were identified in 4 cell lines and 65 patient DNAs. All of the known pathogenic mutations (including point 
mutations and insertions/deletions of up to 16 nucleotides) were identified, using a combination of the Illumina data 
analysis pipeline with custom and commercial sequence alignment software. In our configuration, clonal sequencing 
outperforms current diagnostic methods, providing a reduction in analysis times and in reagent costs compared with 
conventional sequencing.  
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Genome-wide association study for colorectal cancer in German familial cases, and implication of MAPK 
signalling pathways in disease susceptibility 
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Rare high-penetrance germline mutations account for less than 5% of colorectal cancer (CRC) cases. Much of the 
remaining variation in genetic risk is supposed to be attributable to multiple common susceptibility loci. So far, ten 
common low risk variants have been identified through genome-wide association studies (GWAS). 
We performed a GWAS with 371 German familial CRC cases and 1263 healthy controls using the Affymetrix 6.0 Array. 
After application of quality control criteria, 610.664 SNPs were included in the analysis, and replication studies in four 
additional case-control sets (4915 cases and 5607 controls) were conducted.  
Known risk loci at 8q24.21 and 11q23 were confirmed, and a previously unreported association, rs12701937 (p = 1.1x10-
3; OR 1.14, 95% CI 1.05 to 1.23, dominant model in the combined cohort) was identified. The association was stronger in 
familial compared to unselected cases for this SNP (p = 2.0x10-4; OR 1.36, 95% CI 1.16 to 1.60, dominant model), as 
well as for two other unreported polymorphisms, rs6038071 and rs11014993 (p = 2.5x10-3, recessive model, and p = 
2.7x10-4, dominant model). Trying to increase the power to detect association between genes and disease, several 
bioinformatics tools were used to search for enrichment of pathways or Gene Ontology (GO) categories among the 
associated polymorphisms. Three different and independent software tools (ConsensusPathDB, ToppGene Suite, and the 
recently published approach ALIGATOR) successfully pointed to the over-representation of genes related to the mitogen-
activated protein kinase (MAPK) signalling pathways among the most strongly associated markers from the GWAS (allelic 
p <10-3). The risk of CRC increased significantly with an increasing number of risk alleles in these genes (ORper allele 
1.34, 95% CI 1.11 to 1.61), and for carriers of more than four risk alleles the risk of disease was increased ~3-fold 
compared to carriers of 4 risk alleles. 
Our study replicated two of the known risk loci for CRC and identified three risk polymorphism more specific for familial 
than for sporadic CRC cases. MAPK signalling pathway genes were enriched among the most significantly associated 
markers, showing a significant increase in CRC risk with increasing number of risk alleles. This and other similar 
approaches are clearly needed in order to reveal the large proportion of missing heritability of complex diseases such as 
CRC. 
Poster No: P065-T 
transcriptional and translational consequences of genomic re-arrangments in breast cancer  
Leena Ukil, Koichiro Inaki, Yuen Fern Ho, Kartiki Desai and Edison Liu 
Cancer Biology and Pharmacology 2, Genome Institute of Singapore 
In addition to oncogenic transformation, various cancers are often associated with a stochastic selection of chromosomal 
rearrangements. Some of these events result in the expression of fusion genes that are causal in tumor progression and 
recurrence. The expression and the function of such fusion genes have been extensively studied in hematopoietic 
cancers and soft tissue tumors with the prototype rearrangement being the t(9:22)(q34:q11) translocation in chronic 
myeloid leukaemia (CML) that generates the BCR-ABL1 fusion gene. Recent findings of fusion gene expression in 
prostate cancer and lung cancer suggest that such fusion transcripts can be found in solid tumors. By contrast, gene 
fusions in breast cancer have not been well studied. For the comprehensive identification of such fusion genes, we have 
used massively parallel and high-throughput paired-end sequencing technology (PET) to analyze the transcriptome and 
the genome in 3 breast cancer cell lines and 5 primary breast tumors and have recorded a high number of potential 
rearrangements. Herein we show the transcriptional consequences of these structural genomic rearrangements in 
generating fusion transcripts and further analyze their functionality using a polysomal assay. We find that single 
HUGO J (2010) 4:1–190 97
123

segmental tandem replication spanning several genes is a major source of two gene fusion transcripts. In addition, we find 
that almost 90% of the fusion transcripts associate with polysomes and are hence translated. 
 
Poster No: P082-T 
Cluster Analysis of Risk Factor Genetic Polymorphisms in Gallbladder Cancer 
Kshitij Srivastava, Anvesha Srivastava, Balraj Mittal 
Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India-226014 
Introduction: 
Being relatively rare worldwide, gallbladder cancer (GBC) shows highest incidence and mortality rates in Northern India. 
Apart from gallstones being the predominant risk factor, the precise etiology of GBC is poorly understood. Cancer being a 
complex and polygenic disease, multiple genetic variants may interact to cause the disease or act as risk factors. 
Identification of risk sets of factors contributing to the disease will aide in determining individuals at risk for the disease. In 
this study, we applied a pathway-based multigenic approach to examine the associations of a comprehensive panel of 
polymorphisms in DNA-repair, apoptotic and inflammatory pathway genes with GBC risk. 
Methods: 
In the present population-based case-control study with 230 patients newly diagnosed with GBC and 230 unaffected 
controls, we applied a multigenic approach to examine the associations with GBC risk of a comprehensive panel of 16 
selected polymorphisms in three pathways, DNA repair pathway [ERCC2 Asp312Asn (Ex10-16G>A; rs1799793) and 
Lys751Gln (Ex23+61A>C; rs13181); MSH2 (IVS1+9G>C; rs2303426) and (-118T>C; rs2303425); OGG1 Ser326Cys 
(Ex6-315C>G; rs1052133) and (IVS4-15C>G; rs2072668); XRCC1 Arg194Trp (Ex6-22C>T; rs1799782) and Arg399Gln 
(Ex10-4A>G; rs25487)], apoptotic pathway [CASP8 -652 6N ins/del (rs3834129), Asp302His (Ex13+51G>C; rs1045485) 
and (IVS12-19 G>A; rs3769818)] and inflammatory pathway [PTGS2 (-1195G>A; rs689466), (-765G>C; rs20417) and 
(Ex10+837T>C or +8473; rs5275); TLR2 –196 to –174del (TLR2 ǻ22); and TLR4 Thr399Ile (Ex4+936C>T; rs4986791)]. 
Genotyping for all the polymorphisms was done using the PCR-restriction fragment length polymorphism method. Odds 
ratio (OR) and 95% confidence interval (95% CI) were calculated in multivariate logistic regression analysis for the 
association of individual SNPs with gallbladder cancer. A fuzzy latent classification approach, grade-of-membership 
analysis (GoM), was taken to identify risk sets defined by the probabilities of being affected with GBC and for genotypes 
found at the examined genes. 
Results: 
Individually, only ERCC2 Asp312Asn, MSH2 IVS1+9G>C, OGG1 Ser326Cys and OGG1 IVS4-15C>G, XRCC1 
Arg399Gln, CASP8 -652 6N ins/del, PTGS2 -1195G>A, PTGS2 -765G>C and TLR2 –196 to –174del exhibited 
statistically significant main effects. However, we found a significant gene-dosage effect for increasing numbers of 
potential high-risk alleles in inflammatory pathway and all three pathways combined. For the inflammatory pathway, 
compared with the referent group (fewer than three adverse alleles), individuals with >2 variant alleles [odds ratio 
(OR)=1.93, 95% CI=1.26–2.96) had increasingly elevated risks of bladder cancer (Ptrend=0.007). Each additional 
adverse allele was associated with a 1.07-fold increase in risk (95% CI 1.03–1.12). For the combined analysis of DNA-
repair, apoptotic and inflammatory pathway SNPs, compared with the referent group (0-10 adverse alleles), the ORs for 
individuals with >10 adverse alleles was 2.42 (95% CI=1.56–3.77; Ptrend<0.001). GoM analysis revealed three high 
intrinsic risk sets (I, II and III), having a higher density of various genotypes compared to set IV, V and VI, at low intrinsic 
risk for GBC. 
Conclusion: 
This is the first comprehensive study to use a multigenic analysis for GBC, and the data confirm the importance of taking 
a multigenic pathway based approach to risk assessment. 
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Poster No: P006-T 
Combination of metabonomic, transcriptomic and genomic approaches unravels the link between various serum 
metabolites and an immune response pathway 
Johannes Kettunen2,3,#, Michael Inouye1,2,#, Pasi Soininen4,5, Kaisa Silander3, Samuli Ripatti3, Linda S. Kumpula5, Pekka 
Jousilahti6, Antti J. Kangas5, Satu Männistö6, Markku J. Savolainen5,7, Aarno Palotie2,3,8, Veikko Salomaa6, Markus 
Perola3, and Mika Ala-Korpela4,5,7, Leena Peltonen2,3,8 
1Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, 2Department 
of Human Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, 
3Institute of Molecular Medicine FIMM, University of Helsinki and Unit of Public Health Genomics, National Institute for 
Health and Welfare, Helsinki, Finland, 4NMR Metabonomics Laboratory, Laboratory of Chemistry, Department of 
Biosciences, University of Kuopio, Kuopio, Finland, 5Computational Medicine Research Group, Institute of Clinical 
Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland, 6Unit of Chronic Disease 
Epidemiology and Prevention, National Institute for Health and Welfare, Helsinki, Finland, 7Department of Internal 
Medicine and Biocenter Oulu, Clinical Research Center, University of Oulu, Oulu, Finland, 8The Broad Institute of MIT and 
Harvard, Cambridge, MA, USA, #These authors contributed equally 
In this study we have integrated the metabonomic, transcriptomic and genomic profiles of 518 individuals sampled from 
the capital region of Finland. In our previous work we identified a set of highly correlated genes associated with serum 
lipid levels, the Lipid-Leukocyte module (LL), by using co-expression network analysis. In this work we show that LL 
module displays significant correlation with over 80 metabolic measures quantified via 1H NMR spectroscopy of serum; 
these include omega 6 and 7 fatty acids (p = 8*10-6), apolipoprotein B (p = 1*10-9), isoleucine (p = 4*10-16), triglycerides 
(p = 2*10-24) and different lipoprotein subclasses, for example: very large VLDL particles, p = 1*10-24, small LDL, p = 
2*10-4 and medium HDL, p = 2*10-8. We use genetic variation to construct a directed network graph and infer causality. 
In addition, we show that the connectivity of the module is dependent on metabolite concentrations in serum, evidence 
that network modules are themselves dependent on the environment. This study is a roadmap for the systematic 
integration of metabonomic, transcriptomic and genomic data in human population samples. 
 
Poster No: P023-T 
Role of rare DNA sequence variants in early-onset myocardial infarction in French-Canadians 
1Ken Sin Lo, 1Mélissa Beaudoin, 2,3Manuel A. Rivas, 1,4,5Michael Phillips, 1,5Marie-Pierre Dubé, 1Nathalie Laplante, 
2,3Mark J. Daly,  1,5John D. Rioux, 1,5Jean-Claude Tardif, 1,5Guillaume Lettre 
1Montreal Heart Institute, Montréal, Canada, 2Massachusetts General Hospital, Boston, USA, 3Broad Institute, Cambridge, 
USA, 4Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, Montréal, Canada, 5Université de 
Montréal, Montréal, Canada 
 
 
Myocardial infarction (MI), commonly known as a heart attack, is the interruption of blood supply to part of the heart due to 
occlusion of a coronary. The major risk factors for MI have been identified and include older age, male gender, tobacco 
use, high triglyceride and LDL cholesterol levels, low HDL cholesterol levels, obesity, diabetes, high blood pressure and 
chronic stress. A positive family history of MI is also an important risk factor, as shown by heritability studies in twins and 
large pedigrees. Understanding the genetic etiology of MI would have major implications in terms of prevention, prediction 
and drug development. 
Several genome-wide association studies (GWAS) have identified loci that harbor common SNPs associated with MI risk. 
In many cases, the causal genes and alleles remain unknown. Because genotyping SNP arrays are specifically designed 
to capture common genetic variations, GWAS will not address whether rare genetic variants at the associated loci also 
contribute to disease risk. Here, we set to test this hypothesis by deep re-sequencing of 68 MI candidate genes (369 kb) 
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in French-Canadian early-onset MI patients and unaffected individuals. These candidate genes were identified from MI 
GWAS findings and linkage signals. 
To find rare mutations that influence MI risk, we used Agilent’s SureSelect solution-based capture technology combined 
with next-generation DNA re-sequencing on an Illumina Genome Analyzer II sequencer (short-insert paired-end 76 bp 
reads protocol). To minimize costs and maximize power, we re-sequenced 500 French-Canadians early-onset MI patients 
and 500 matched controls in pools of 50 DNA samples. Sequence reads will be aligned using BWA. DNA polymorphisms 
will be called using a Bayesian likelihood calculation implemented in the software Syzygy. To simplify downstream 
analyses and help pinpoint most susceptible loci associated with MI, we have developed a robust pipeline that annotates 
new DNA sequence variants, assesses their functional effect at the protein level, and performs statistical tests. Associated 
rare variants will be genotyped in an independent cohort of 2,000 early-onset French-Canadian MI cases and 2,000 
matched controls. 
 
Poster No: P038-T 
Identification of novel sequence variants using high-throughput re-sequencing of ulcerative colitis genes in 
French-Canadian patients 
1Mélissa Beaudoin, 1Ken Sin Lo, 1Philippe Goyette, 2,3Manuel Rivas, 1Caroline Lagacé, 1,5Andrew M.K. Brown, 1,5Michael 
S. Phillips, 4Alain Bitton, 2,3Mark J. Daly, 1,5Guillaume Lettre and 1,5John D. Rioux 
1Montreal heart Institute, Montreal, Canada 2Massachusetts General Hospital, Boston, USA  3Broad Institute, Cambridge, 
USA 4Royal Victoria Hospital, Montreal, Canada 5Université de Montréal, Montreal, Canada 
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that causes chronic inflammation of the gastrointestinal 
tract. The mucosal inflammation is continuous and restricted to the colon and rectum. UC can occur in people of any age, 
but it usually starts between the ages of 15 and 30, and less frequently between 50 and 70 years of age. It affects men 
and women equally and segregates within families. A higher incidence of UC is seen in Caucasians and people of Jewish 
descent. The precise incidence of UC is unknown; however, some studies indicate as many as 10 to 15 out of 100,000 
persons have the disease. The most common symptoms of UC are abdominal pain and bloody diarrhea. UC can be 
difficult to diagnose because its symptoms are similar to other intestinal disorders, such as Crohn’s disease, another type 
of IBD. UC is a complex polygenic disease, influenced by both environmental (e.g. smoking, urban environment) and 
genetic (e.g. DNA polymorphisms within the major histocompatibility region (MHC)) factors. About 5 percent of people 
with ulcerative colitis develop colon cancer. 
Genome-wide association studies have identified 20 loci associated with UC risk. In most cases, the causal genes and 
alleles are unknown. To identify causal polymorphisms and other rare DNA sequence variants, we re-sequenced the 
coding sequence of 55 candidate-genes from these 20 associated regions with the Illumina Genome Analyzer II DNA 
sequencer. We used a pooled DNA approach (4 groups of 50 UC French-Canadian cases and 3 groups of 50 French-
Canadian controls) and PCR for target enrichment.  
We re-sequenced 4.6 GB of DNA and obtained an average coverage of 30X per DNA sample. Quality-filtered sequence 
reads were aligned against the reference human genome using the Burrows-Wheeler Aligner (BWA) software (78% of the 
reads were on target). DNA polymorphisms were identified using a Bayesian likelihood calculation implemented in the 
Syzygy software. We identified 2,006 high quality DNA sequence variants, including 2 nonsense (2 novel), 233 missense 
(126 novel), and 6 splice site (6 novel) variants. Validation in the original re-sequenced samples, as well as replication in 
independent large UC cohorts will be presented. 
 
Poster No: P053-T 
Leveraging the 1000 Genomes Project for Next-Generation Microarrays 
Michael A. Eberle, Jennifer L. Stone, Karine Viaud, Luana Galver, Chan Tsan and Ken Kuhn 
Illumina, Inc., San Diego, CA, USA 
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High-throughput sequencing is expanding the catalogue of variation at an unprecedented rate, enabling a more 
comprehensive understanding of the underlying linkage disequilibrium (LD) patterns within and across populations. This 
information is required to optimally design the next generation of whole-genome genotyping (WGA) arrays that will allow 
the exploration of new hypotheses, including the role of intermediate and rare variation in disease. Until recently the 
primary source of information for developing WGA arrays was the International HapMap Project as it provided detailed 
information on frequencies and LD between almost four million SNPs in three distinct populations. Selecting an optimal 
subset of these SNPs allows the creation of arrays that interrogate over 90% of all common HapMap variants either 
directly or indirectly through LD with only 600-800k tagSNPs. These tools have proven successful in evaluating common 
variants for association in many diseases and traits, for which, before the genome-wide association era, little was 
understood. However, the catalog of SNPs available through HapMap represents only a small, and potentially biased, 
subset of the total variation in the human population. With the advent of high-throughput sequencing, the 1000 Genomes 
Project has greatly increased the spectrum of known variants and provides an excellent resource for content to develop 
the next generation of microarrays for “rich” genome-wide association studies (GWAS). These microarrays will interrogate 
the entire genome, including rarer content down to ~1% MAF. We have evaluated the whole-genome coverage provided 
by chips whose content was based on the HapMap data. Using the phased genotype data from the 1000 Genomes 
Project, we calculate that less than 70% of the common (>5%) variants and less than 60% of all variants seen at least 
twice are tagged by even the most comprehensive arrays currently available. Using a “greedy” approach to selecting tag 
SNPs, we show that ~2 million intelligently selected markers can effectively cover the SNPs from the 1000 Genomes 
Project in all three HapMap populations, excluding singletons. Additionally, because the 1000 Genomes Project is 
sequencing to ~4x depth, many of the available genotype calls have been imputed and/or are based on only a limited 
number of reads leading to potential false positives and genotype errors. We will also present the results of validation 
experiments using hundreds of thousands of SNPs to assess false positive rate and categorize potential errors in these 
imputed genotype calls. 
 
Poster No: P068-T 
Ensembl: Recent developments in human genome annotation 
1Amonida Zadissa, 1Bronwen Aken, 1Susan Fairley, 2Julio Fernandez Banet, 1Felix Kokocinski, 1Magali Ruffier, 1Amy 
Tang, 1Jan Vogel, 1Simon White, 1Jennifer Harrow, 1Steve Searle. 
1Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK 2European Bioinformatics Institute, Hinxton, Cambridge, UK. 
Ensembl produces automatic gene annotation for the human genome and other vertebrate species. Recent developments 
in our annotation strategy allow us to provide more complete annotation for the human genome to users: For the human 
genome we now merge our annotation with manual annotation from HAVANA to produce the GENCODE gene set. We 
have also developed a pipeline to build transcript models from RNAseq data. 
The GENCODE consortium aims to annotate all human protein-coding loci, non-coding loci and pseudogenes that are 
based on experimental. While HAVANA manual annotation produces high quality curated gene models, the process is 
time-consuming. Currently manual annotatin covers only 70% of the human genome and Ensembl automatic methods can 
provide annotation for the remaining 30%. Additionally, Ensembl's automatic annotation can be used to improve the 
existing manually annotated gene models using new experimental data released in the public domain. Therefore, to 
create an up-to-date GENCODE gene set, we have developed a pipeline to combine the the HAVANA and Ensembl gene 
sets to produce a merged gene set. 
In addition to the GENCODE project, we still import manually-curated immunoglobulin and T-cell receptor genes from 
IMGT and we guarantee that all CCDS models are present in our gene sets. 
RNAseq transcriptome data provides an opportunity to assess tissue-specific transcription and also to search for isoforms 
that are in new gene loci or that have not yet been annotated in existing gene loci. We have developed a pipeline to 
generate transcript models using only RNAseq data with encouraging results. Using 75bp paired-end reads, we are able 
to build multi-transcript gene models, some of which are in locations that currently do not have transcript annotations in 
Ensembl or HAVANA. Our transcript models have been entered into the RGASP project for external assessment. We 
hope to display the results from this pipeline on our website in the near future. 





Poster No: P085-T 
An atlas of combinatorial transcriptional regulation in mouse and man  
Timothy Ravasi1,2, Carlo Vittorio Cannistraci1, Shintaro Katayama3, Vladimir B. Bajic1,4, Kai Tan2, David A. Hume17, 
Harukazu Suzuki3, Yoshihide Hayashizaki3 and Trey Ideker2 
1Red Sea Integrative Systems Biology Laboratory, Division of Chemical & Life Sciences and Engineering, Computational 
Bioscience Research Center (CBRC), King Abdullah University for Science and Technology (KAUST), Jeddah, Kingdom 
of Saudi Arabia. 2 Departments of Medicine and Bioengineering, University of California, San Diego, 9500 Gilman Drive, 
La Jolla, CA 92093 USA. 3 RIKEN Omics Science Center, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho Tsurumi-ku 
Yokohama, Kanagawa, 230-0045 Japan. 4 South African National Bioinformatics Institute, University of the Western Cape, 
Private Bag X17, Bellville, 7535 South Africa 5 The Roslin Institute and Royal (Dick) School of Veterinary Studies, The 
University of Edinburgh, Roslin, EH259PS, UK. 
Combinatorial interactions among transcription factors are critical to directing tissue-specific gene expression. To build a 
global atlas of these combinations, we have screened for physical interactions among the majority of human and mouse 
DNA-binding transcription factors (TFs) and mapped the active promoters using CAGE coupled with next generation 
sequencing. The complete networks contain 762 human and 877 mouse interactions. Analysis of the networks reveals 
that highly connected TFs are broadly expressed across tissues, and that roughly half of the measured interactions are 
conserved between mouse and human. The data highlight the importance of TF combinations for determining cell fate, 
and they lead to the identification of a SMAD3/FLI1 complex expressed during development of immunity. The availability 
of large TF combinatorial networks in both human and mouse will provide many opportunities to study gene regulation, 
tissue differentiation, and mammalian evolution. 
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Sequence variants at CYP1A2 and AHR loci associates with coffee consumption.  
Patrick Sulem 1 , Daniel F. Gudbjartsson 1 , Frank Geller 2 , Inga Prokopenko 3,4 , Bjarke Feenstra 2 , Katja K.H. Aben 5,6 , 
Barbara Franke 7,8 , Martin den Heijer 6,9 , Peter Kovacs 10 , Michael Stumvoll 11,12 , Reedik Mägi 3,4 , Lisa R. Yanek 13 , 
Lewis C. Becker 13 , Heather A. Boyd 2 , Simon Stacey 1 , Gudmundur B. Walters 1 , Adalbjorg Jonsdottir 1 , Gudmar 
Thorleifsson 1 , Hilma Holm 1 , Sigurjon A. Gudjonsson 1 , Thorunn Rafnar 1 , Gyda Bj örnsdottir 1 , Diane M. Becker 12 , 
Mads Melbye 2 , Augustine Kong 1 , Anke Tönjes 11 , Thorgeir Thorgeirsson 1 , Unnur Thorsteinsdottir 1,14 , Lambertus A. 
Kiemeney 5,6,15 , Kari Stefansson 1,14  
1 deCODE genetics, Sturlugata 8, 101 Reykjavik, Iceland. 2 Department of Epidemiology Research, Statens Serum Institut, 
2300 Copenhagen S, Denmark. 3 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, 
OX3 7LJ, UK. 4 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK. 5 
Comprehensive Cancer Center IKO, 6501 BG Nijmegen, the Netherlands. Department of Genetics, 6 Department of 
Epidemiology, Biostatistics & HTA, 7 Department of Genetics, 8 Department of Psychiatry and 9 Department of 
Endocrinology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, the Netherlands. 10 Interdisciplinary 
Centre for Clinical Research, 11 Department of Medicine, and 12 LIFE Study Center, University of Leipzig, 04103 Leipzig, 
Germany. 13 The Johns Hopkins GeneSTAR Research Program, Division of General Internal Medicine, The Johns 
Hopkins Medical Institutions, Baltimore, MD21287, Maryland. 14 University of Iceland, Faculty of Medicine, 101 Reykjavik, 
Iceland. 15 Department of Urology, Radboud University Nijmegen Medical Centre.  
 Coffee is the most commonly used stimulant and the amount of coffee consumed has been shown to be heritable. There 
has been substantial debate on the effect of coffee consumption on health, e.g. whether it increases risk of hypertension 
and protects against Alzheimer’s disease. We performed a genome-wide association scan of 6,611 coffee drinkers of 
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European descent (From Iceland, The Netherlands , Germany and the US) followed by a replication in an additional set of 
4,050 individuals (from Iceland and Denmark) and identified two genome wide significant associations (P< 1.10-7). The 
first association is with a SNP located in a cluster of the dioxin response element between CYP1A1 and CYP1A2 , the 
main caffeine metabolizing enzyme . The second association with coffee consumption was detected with a SNP directly 
upstream of the Aryl Hydrocarbon receptor (AHR) locus, a gene that induces CYP1A1 CYP1A2 through their dioxin 
response element . For both SNPs, the observed effect size was around 0.2 additional cups of coffee per day per allele. 
We postulate that the effect on coffee consumption operates through an effect on caffeine metabolism, such that 
individuals with a higher caffeine clearance are able to drink more coffee than those with lower caffeine clearance. Given 
that caffeine is used as a probe to assess the pharmacokinetics of several therapeutic drugs these variants are 
candidates for having an effect on drug metabolism. 
 
Poster No: P029-T 
The RetChip v1.0 resequencing array - application of high-throughput analysis in diagnostic testing of hereditary 
retinal degenerations 
1*Heidi L. Schulz , 1*Lars Fritsche, 1Kerstin Meier, 1Britta S. Fiebig, 1Bernhard H.F. Weber 
1 Institute of Human Genetics, University of Regensburg, Germany 
*Authors contributed equally to the work 
Retinal degeneration (RD), the term generally used to describe a common phenotype found in more than two dozen 
different disease phenotypes, affects approximately one in 2.000 individuals worldwide. These inherited dystrophies, 
characterized by malfunction or loss of cone and/or rod photoreceptors, have unparalleled high genetic and phenotypic 
heterogeneity. Due to the significant clinical overlap between the disorders, the fact that more than 150 genetic loci harbor 
causative mutations, the large gene sizes and lack of mutational hotspots, it has been difficult to comprehensively survey 
the disease-causing mutations in clinical practice. Current diagnostic approaches, such as conventional Sanger 
sequencing or use of approaches that test for known mutations, regularly fail to detect the complete mutational spectrum. 
To address this limitation, while simultaneously reducing cost, time and personnel required for routine DNA testing, we 
have designed and implemented a fast and reliable genotyping platform, known as RetChip v.1.0. This array contains 
more than two million probes matching the coding and flanking intronic sequences of 72 RD genes as well as additional 
702 common variants and 587 known indel mutations. To streamline the set-up process, a multiplex PCR approach was 
implemented to amplify the 1.147 amplicons. 
Chip performance, accuracy, and reproducibility were assessed by analysing 14 controls and three RD subjects. The 
combined use of two analysis softwares (GSeq and SeqC) led to consistent call rates higher than 99.97%. All 
substitutions identified by the chip analysis were confirmed by dideoxy sequencing. To further validate the method, seven 
patients with known mutations in the ABCA4 gene were genotyped and all 44 known variations they carried were 
successfully identified. Currently, the RetChip is being used in routine molecular diagnosis of Stargardt disease and cone-
rod dystrophy patients. The advantage of this platform over current technologies is illustrated by the fact that in 50 
Stargardt disease patients at least one disease-associated allele was detected in 68% of cases, an increase of 14% over 
results obtained with a mutation-specific microarray. Even though 547 mutations have been published in the three genes 
investigated (ABCA4, CNGB3, ELOVL4), we found 18 novel variants of probable pathogenicity in the 50 patients. The 
significance of the RetChip platform will be even higher for less well-characterized RD phenotypes. 
The RetChip is a powerful tool that will significantly contribute to clinical practice. It will not only facilitate differential 
diagnosis but also enable predictive testing, identification of modifier variants and determination of genotype-phenotype 
correlations. Additionally, it will provide clinicians with information essential for prognosis and selection of therapeutic 
strategies. 
 
Poster No: P059-T 
tri e tocotrienol supplementation affects gene expression of peripheral blood mononuclear cells from different 
aged individuals 
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Wan Zurinah Wan Ngah1, Eng Chee Heng1, Noor Aini Abdul Hamid1, Noriah Ramli1and Zalina Hamid2 
UKM Medical Molecular Biology Institute/Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan 
Malaysia1, Sime Darby Bioganic, Kuala Langat, Malaysia2 
The different isomers of vitamin E have been reported to be protective against ageing, cardiovascular disease and cancer. 
However, human studies involving supplement of vitamin E are limited. In this study, the effect of Tri E tocotrienol 
supplementation was determined. Fourteen healthy female volunteers were recruited and divided into two age groups: 6 
young subjects aged 32+2 (3 received placebo & 3 Tri E ) and 8 older subjects aged 52+2 (4 received placebo & 4 Tri E) 
at a dose of 150mg tocotrienol rich fraction. Fasting blood (15mL) was taken before and after 3 and 6 months 
supplementation. Total RNA was extracted from PBMC using Qiagen RNeasy Mini Kit. Analysis using GeneSpring 10 GX 
suggested 134 genes and 257 genes differentially expressed in younger group after 3 and 6 month Tri E supplementation. 
About 94 genes were down-regulated and 40 genes up-regulated at 3 month supplementation. The number of genes 
affected increased to 182 genes up-regulated and 73 down-regulated at 6 month supplementation. The most highly down-
expressed genes in the younger group were involved in the cell cycle arrest (GADD45A, GADD45B, DDIT4, PCNA), 
apoptosis (PLEKHF1, BAK1), inflammation (ICAM1, ICAM2), angiogenesis (S100A4, NR4A2, NR4A3) and cholesterol 
synthesis (DHCR7, SC5DL). In the older group, Tri E supplementation caused changes in 21 genes and 591 genes 
between 3 and 6 months. At 3 month supplementation, 8 genes were up-regulated and 13 genes down-regulated in 
contrast to 507 genes down-regulated and 84 genes up-regulated at 6 month supplementation. Cytokines (IL-1A, IL-6, 
SOCS1, SOCS3), cell cycle arrest (DDIT4), apoptosis (PLEKHF1, CTSD, IER3, BAK1), inflammation (ICAM1, ICAM3), 
angiogenesis (S100A4), and cholesterol biosynthesis (DHC7) were down-regulated while histone binding protein (H2AB), 
antioxidant enzyme (GSTM1L), and G protein regulator (RGS18) were up-regulated in the older group. Genes such as 
ICAM1, DDIT4, PLEKHF1, BAK1, S100A4, and DHCR7 were down-regulated in both groups after Tri E supplementation. 
Up-regulated and down-regulated were analyzed using Adriadne Pathway Studio 7 shown enrichment of pathway related 
to NF-kB pathway. In conclusion, differences in gene expression were more profound in the older group compared to 
younger group after 6 month supplementation. 
 
Poster No: P074-T 
Personalized Nutrition: Will Livestock Lead the Way? 
Harris A. Lewin,  
Department of Animal Sciences and Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 West 
Gregory Drive, Urbana, Illinois 61801, USA 
The sequencing, annotation and functional characterization of the genomes of cattle and pigs have been rapidly 
translated into new products and services for the livestock industry. The animal breeding industry adopted marker-
assisted breeding in the late 1990s and is now implementing genomic selection for complex traits, such as milk production 
and carcass composition. In addition, the mapping and positional cloning of genes responsible for a large number of 
monogenic and polygenic traits has resulted in the creation of new models for human diseases and has informed our 
understanding of the genetics of complex traits. One of the most important areas of interface between human and 
livestock genomics is in the area of nutrition. In human and animal health, there is a dynamic interplay between host 
genotype and diet. However, for many diseases, the specific genes, pathways and networks that are influenced by diet 
are not well understood. In cattle and other livestock species it has been common practice for the past 50 years to 
develop special diet formulations based on breed and/or environmental conditions. Recently, we have discovered what 
may be the first example of a diet-regulated QTL (DGAT1) in dairy cattle that influences the development of metabolic 
disorders associated with the onset of lactation. Our data suggest that controlling energy intake during the prepartal 
period in DGAT1 genotyped animals can be used to optimize milk production performance while minimizing the incidence 
of postpartal metabolic disorders, such as fatty liver disease and ketosis. For human diseases, understanding of diet-
genotype interactions may be critical to promoting wellness in individuals genetically predisposed to diabetes, obesity, 
heart disease, gastrointestinal and immunological disorders and cancer. By implementing dietary restrictions in 
genetically-defined individuals, it may be possible to reduce the incidence and severity of such diseases. Thus, 
“personalized nutrition” could take on a significant role as a first line of defense against the “diseases of affluence” 
currently plaguing Western and developing nations. Research using non-inbred cattle and pigs as models may contribute 
critical knowledge that will pave the way toward the implementation of genetics-driven nutritional management of human 
diseases. 
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Poster No: P088-T 
The mechanisms of action of Sirtuin 1  
1Sascha Sauer, 1Chung-Ting Han, 1Susanne Holzhauser, 2Thomas Manke, 2Stefan Haas and 2Martin Vingron 
Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, D-14195 Berlin, Germany, 1Department Otto-Warburg-
Laboratory, 1Department of Computational Molecular Biology 
Sirtuin 1 (SIRT1), a NAD+-dependant deacetylase, has been implicated in the prevention of aging processes and 
metabolic diseases such as type 2 diabetes. SIRT1 modulates cellular gene expression by deacetylating a number of 
regulatory proteins such as nuclear receptors, transcriptional cofactors and histones. Resveratrol, a natural product that 
was found in red wine, was shown to activate SIRT1 directly. Synthetic SIRT1 activators have been described as 
promising new antidiabetic therapeutics. However, it was shown that the previously reported enzymatic activation of 
SIRT1 by small molecules were simply assay artefacts generated by fluorescently labelled substrate peptides. 
We discovered novel mechanisms of SIRT1 “activation” by resveratrol. Our results indicate specific effects of resveratrol 
on several histone modifications (namely H1K26, H3K9, H4K16) and on global gene expression.  
We used chromatin immunoprecipitation followed by second generation sequencing (ChIP-Seq) to compare patterns of 
histone modification between untreated and resveratrol-treated murine skeletal muscle cells. In general, resveratrol 
treatment results in global deacetylation of histones. But surprisingly, resveratrol induces dense acetylation of H1K26 on 
the exons of important metabolic sensors, in particular SIRT1, PPARgamma, and LXRalpha. Moreover, we found specific 
acetylation of H3K9 at transcriptional start sites (TSS) of a number of genes, which has a striking correlation with SIRT1 
binding. After integrating the chromatin modification data with gene expression data, we observed significant changes in 
gene expression of various genes involved in glycolysis, gluconeogenesis and fat oxidation. Amongst others, the H1K26 
acetylation pattern was associated with upregulated SIRT1, PPARgamma, and LXRalpha gene expression. Moreover, we 
found up regulations of uncoupling proteins UCP1 and UCP3 that are involved in thermogenesis. Finally we observed up 
regulation of the regulatory kinase PDK4 that inhibits the formation of the pyruvat dehydrogenase complex and prevents 
the entry of pyruvate into the tricarboxylic acid (TCA) cycle. These data to date lead to the hypothesis that resveratrol 
treatment results in energy dissipation in muscle cells.  
For future SIRT1 small molecule screening projects we developed a novel, unambiguous mass spectrometry-based assay 
including unlabelled peptide substrates.  
Using a structurally diverse library of ~10,000 natural products and their analogues we identified a number of new 
molecules that inhibit SIRT1 activity with low IC50 values. We have furthermore characterised the physiological function of 
these molecules in different cell culture models.  
In general, our data demonstrate how dietary compounds and potent synthetic molecules are likely to influence the 
expression of metabolically active genes through histone modifications. Novel SIRT1 inhibitors may be used as reference 
compounds to study SIRT1 biology. Our results shed light on the mechanism of SIRT 1 activation and provide new 
concepts for the development of small molecules in preventing and treating type 2 diabetes or in slowing aging processes. 
 
Poster No: P101-T 
OPA8 is mutated in dominant families with mild optic atrophy and severe deafness 
1Laëtitia Buret, 1Guy Rebillard, 1Benjamin Delprat, 1Marie Péquignot, 1Karim Chekroud, 2Karen Cornille, 3Ghislaine 
Hamard, 4Odile Boespflug-Tanguy ,1Christian Hamel, 1Guy Lenaers, 1Cécile Delettre. 
1Institute of Neurosciences of Montpellier, St Eloi hospital, Montpellier, France. 2 UMR866 Cellular Differentiation and 
Growth, SupAgro-INRA, Montpellier, France. 3 Technical service "homologous recombination", Cochin Institute, Paris, 
France. 4 CHRU Clermont-Ferrand, France. 
Dominant optic atrophy (DOA) is the most common form of inherited optic neuropathy. DOA affects retinal ganglion cells 
(RGCs) and the axons forming the optic nerve, leading to progressive visual loss. Today, there is no treatment able to 
stop the degenerative process. Unless several loci are implied only two genes have been identified: OPA1 the major gene 
of DOA and OPA3 associating a DOA with a cataract. 
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Using a candidate gene strategy on a cohort of OPA1-OPA3 negative patients, we found that a new gene OPA8 is 
mutated in 3 dominant families with mild optic neuropathy and severe deafness. OPA8 protein is preponderant in sensory 
neurons: it is expressed in the RGCs and the bipolar cells of retina and in the spiral ganglion neuron in the cochlea. OPA8 
plays a role in the control of apoptosis. Consistent with this function we have shown that OPA8 mutated cells are more 
sensitive to apoptotic stimuli. Moreover, overexpression of the protein is protecting against apoptosis, while that of the 
mutated protein is not. 
In order to understand the physiopathology of optic and auditory neuropathy linked to OPA8 mutations, we have 
generated a mutant mouse reproducing a pathogenic mutation. We have tested the visual acuity by electroretinogram 
(ERG) and visual evoked potential (VEP) and the auditory acuity by auditory evoked potential (AEP) and endocochlear 
potential (EP). The mouse presents at 2 months age an auditory loss between 10 and 15 dB according to the frequencies, 
in comparison with wild type mice. This auditory loss does not increase during the life of the animal. We observed on ERG 
a decreasing of b wave in mutant mice from 8 months. We will perform electronic microscopy to identify damaged cells in 
retina and cochlea and we will check for cells degeneration by immunofluorescence. Visual and auditory function will be 
studied on mice until 24 months.  
Identification of the new gene OPA8 allowed us to build a unique mouse model presenting similar phenotypes to those 
observed on patients mutated in OPA8. Insights provide by the study of this mouse will help us to understand the 
physiopathological mechanism of OPA8 mutations. 
 
9. Genomic Medicine and Pharmacogenomics 
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Poster No: P032-T 
From «Bedside to Bench and Back » : Innovative Diagnostic and Therapeutic Technologies for this New Decade. 
1B. Reversade, 2B. Merriman, 3A. Masri, 4H. Kayserili,  2H. Lee, 1M. Shboul, 1J. Tian, 1C.  Bonnard, 1N. Escande, 1S. Chng, 
2S. Nelson, 5H. Hamamy. 
1Institute of Medical Biology, A*STAR, Singapore, Singapore. 2 Dpt. of Human Genetics, University of California, Los 
Angeles, Los Angeles, USA. 3 Dpt. of Paediatrics, Jordan University Hospital, Amman, Jordan. 4 Medical Genetics 
Department, Istanbul Medical School and University, Istanbul, Turkey. 5Dpt. of Genetic Medicine & Development, Geneva 
University Hospital, Geneva, Switzerland. 
A novel high-throughput strategy comprising SNP-chip based mapping, array-based genomic pull-down and massively 
parallel re-sequencing was used to efficiently screen for causative mutations in ten rare syndromes. In each case, the 
responsible gene was identified. Disease pathogenesis was then examined by functional studies involving patient's 
induced-Pluripotent Stem (iPS) cells and animal modeling. Genetic therapy via homologous recombination in iPS cells by 
means of Zinc Finger Nuclease (ZFN)-mediated gene repair, is underway to validate the much anticipated "bedside to 
bench and back" paradigm. 
 
Poster No: P047-T 
Translating functional genomics into the clinics: Characterization and isolation of differentiating mesenchymal 
stem cells in live cell chips 
Christian Maercker1,2, Karen Bieback3, Dirk Breitkreutz1,2, Michael Angstmann1,2 
1Mannheim University of Applied Sciences, Mannheim, Germany; 2German Cancer Research Center, Heidelberg, 
Germany; 3University of Heidelberg, University Hospital Mannheim. 




Mesenchymal stem cells (MSCs) are a promising tool for regenerative medicine and tissue engineering due to the ease of 
their isolation and differentiation potential. They also can be easily transfected with viral vectors making them an 
interesting vehicle in gene-therapy approaches. However, MSC isolates are mixed populations containing diverse cellular 
precursors in different differentiation stages with diverse differentiation end points. Moreover, no specific biomarkers have 
been identified so far. To improve this situation, we have developed a method to monitor MSC differentiation by 
measuring cell adhesion to a substratum. In live cell chips in a multiwell format (ibidi and xCELLigence/Roche), cell 
adhesion is monitored by measuring the alternating-current resistance (impedance) on gold electrodes. Our experiments 
showed that the impedance profiles are not only specific for MSCs vs. other cell types, but also for developmental stages 
of stem cells in vitro differentiating into adipogenic or osteogenic precursors. We took advantage of these results by 
testing the influence of different components of the extracellular matrix (ECM) on cellular behavior. As expected, the 
adhesion profiles changed on different coatings. However, more interestingly, certain cell differentiation pathways 
obviously are promoted by certain matrix molecules. A five day measurement of cell adhesion in cell differentiation media 
showed that on type I and type IV collagens, the impedance values of MSCs in osteogenic induction medium are very 
high compared to cells in adipogenic medium. On fibronectin, we detected a high shoulder in the profile with adipogenic 
cells between 8 and 45 h after start of the experiment, with values even higher than in osteogenic medium. This result 
also could be confirmed by oil-red staining for microscopy after 5 days, showing a high rate of adipogenic cells. Therefore, 
this high-content screening approach, beside other possible applications in pharma research, is a promising tool to 
differentiate and enrich MSCs for molecular medicine. 
 
Poster No: P062-T 
Genome-wide expression profiling at maternal-fetal interface in case of recurrent miscarriage (RM) 
1Kärt Tomberg, 1,2Kristiina Rull, 3Sulev Kõks, 1Jaana Männik, 1Liis Uusküla, 4Meeli Sirotkina, 5Märt Möls, 6Signe Värv, 
7Robert K. Campbell, 1Maris Laan.  
1Human Molecular Genetics group, Institute of Molecular and Cell Biology, University of Tartu, Estonia, 2Department of 
Obstetrics and Gynecology, University of Tartu, Estonia, 3Department of Physiology, University of Tartu, Estonia, 
4Department of Pathology, Tartu University Hospital, Estonia, 5Institute of Mathematical Statistics, University of Tartu, 
Estonia, 6Department of Cell Biology, Institute of olecular and Cell Biology, University of Tartu, Estonia, 7Department of 
Molecular Biology, EMD Serono Research Institute, MA, USA 
Maternal-fetal interface plays a crucial role to ensure a successful pregnancy. RM (3 consecutive pregnancy losses) 
occurring in 1-3% of fertile couples has a heterogeneous background with contribution from both genetic and 
environmental factors. As several physiological processes are affected in the pathogenesis of RM, it serves as a good 
model to study the processes at the maternal-fetal interface. 
We aimed to map differentially expressed genes and pathways affected in case of RM. Affymetrix® GeneChip® HG-U133 
Plus 2.0 Array was applied to placental tissue from 4 RM cases (mean gestational age 63 days) and 6 elective abortions 
as controls (mean gestational age 62.8 days). Between the two groups 30 transcripts representing 27 genes showed 
differential expression. 10 genes with the highest fold-change were chosen for validation with Taqman® RT-qPCR (13 RM 
cases, 23 controls) and significant differential expression was replicated in 4 of the genes. RM patients exhibited an 
upregulation of tumor necrosis factor family member TRAIL (p=0.005) and downregulation of transcriptional repressor 
SNAI2 (p=0.043), both involved in apoptotic pathways. S100A8, encoding for inflammatory marker calprotectin, showed a 
significantly (p=0.005) higher expression in case of RM while ASMTL (p=0.055), gene of unknown function, was 
downregulated. Combinatory effect of TRAIL, S100A8 and ASMTL provided a highly sensitive test distinguishing RM 
cases from controls (ROC analysis, area under curve=0.967). Immunohistochemical staining detected TRAIL, SNAI2 and 
ASMTL mainly in trophoblastic cells and S100A8 in myeloid cells of maternal blood at maternal-fetal interface of first 
trimester placenta. 
In conclusion, genome wide expression profiling distinguished four differentially expressed genes in RM placentas: TRAIL, 
S100A8, SNAI2 and ASMTL. Although the detected gene expression alterations related to various pathways could be 
primary (causing) or secondary (consequence) events associated with the process of RM, the joint contribution of 
identified markers may provide a highly predictive test for detection of early pregnancy complications. 
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Genetic polymorphisms of SLC22A3-LPAL2-LPA gene cluster has direct and indirect effects on coronary 
atherosclerosis and coronary heart disease 
1Motoji Sawabe, 2Noriko Tanaka, 1Tomio Arai, 3Makiko Naka Mieno, 4Shinobu Ikeda, 4Masaaki Muramatsu 
1Department of Pathology, Tokyo Metropolitan Geriatric Hospital, 35-2 Itabashi, Tokyo 173-0015, Japan, 2Department of 
Biostatistics, Harvard School of Public Health, Boston, USA, 3Department of Medical Informatics, Center for Information, 
Jichi Medical University, Shimotsuke, Japan, 4Department of Molecular Epidemiology, Medical Research Institute, Tokyo 
Medical and Dental University, Tokyo, Japan 
[Objective] High serum lipoprotein(a) [Lp(a)] level is a genetic risk factor for cardiovascular events and LPA gene encodes 
apolipoprotein(a), a characteristic component of Lp(a). Not surprisingly, a recent genome-wide haplotype analysis 
identified a SLC22A3-LPAL2-LPA gene cluster as a susceptibility region of coronary heart disease (CHD) in European 
population [Nat Genet, 2009]. Since the physiological role and pathological role in atherogenesis of Lp(a) is unknown, we 
tried to analyze a complex relationship among serum Lp(a) level, coronary atherosclerosis, and myocardial infarction 
using a large number of autopsy cases [Heart, 2009]. We here analyze the effect of genetic polymorphisms of SLC22A3-
LPAL2-LPA gene cluster on CHD to clarify the contribution of these two intermediate phenotypes [serum Lp(a) level and 
coronary atherosclerosis] of CHD using the same cohort. [Methods] The subjects comprised 1,150 consecutive autopsy 
cases with an average age of 80 years. The coronary stenotic index (CSI) was studied using autopsy hearts. Unfrozen 
serum Lp(a) level was measured in 865 cases. Two genetic polymorphisms were analyzed; rs2048327 in SLC22A3 (C/T) 
and rs10755578 (C/G) in LPA. We performed a path analysis with adjustment of gender, age, hypertension, dyslipidemia, 
and smoking and drinking habits. [Results] Frequencies of rs2048327-T and rs10755578-C were 0.469 and 0.534, 
respectively and their linkage disequilibrium was low (D' = 0.331). The frequencies of four haplotypes were as follows: 
0.320 in T-C haplotype, 0.153 in T-G, 0.201 in C-C, and 0.326 in C-G. The path analysis confirmed significant effects of 
Lp(a) to CSI, Lp(a) to CHD, and CSI to CHD in each haplotype. Serum Lp(a) level was significantly higher in T-C 
haplotype (path coefficient = 0.073, t = 2.13, p = 0.033) and lower in C-G haplotype (-0.091, t = 2.69, p = 0.0073). T-G 
haplotype had a direct effect on CSI (0.087, t = 2.59, p = 0.0098) and CHD (0.079, t = 2.52, p = 0.012). [Conclusions] T-C 
haplotype works as a risk factor for coronary sclerosis and CHD through high serum Lp(a) level, and T-G haplotype had a 
direct positive effect on coronary sclerosis and CHD. Thus the genetic interaction between these two polymorphisms on 
CHD was observed. 
 
Poster No: P091-T 
 
Pharmacogenetics of CYP3A4 in Bangladeshi population including TB patients 
1Abdullah Al Maruf, 3Masum Ahmed, 2M.A.K. Azad, 1Md. Ashik Ullah, 1Abul Hasnat 
1Department of Clinical Pharmacy & Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh. 
2Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh. 
3National Institute of Diseases of Chest and Hospital, TB unit, Mohakhali, Dhaka-1212, Bangladesh 
The purpose of this study is to investigate the genotypes and phenotypes of CYP3A4 genes in Bangladeshi population 
and to compare these in healthy individuals with TB patients. Cytochrome P450 3A4 (CYP3A4) is the major cytochrome 
involved in metabolizing of >60% of all drugs used in humans. CYP3A4 exhibits a remarkable interindividual activity 
variation as high as 20-fold. Detection of CYP3A4 variant alleles and knowledge about their allelic frequencies in 
Bangladeshi healthy subjects and TB patients are important to lead to individualized drug dosing and improved 
therapeutics. Genotyping was done using the extracted genomic DNA from 200 unrelated healthy Bangladeshi subjects 
as well as from 90 TB patients followed by amplification of target alleles by PCR. Amplified alleles was digested by 
restriction enzymes (MboII, XcmI, BsmAI, ClaI, HinfI, HpyCH4III & HpaII) followed by gel electrophoresis & sequencing to, 
identify the targeted alleles namely CYP3A4*1B, CYP3A4*2, CYP3A4*4, CY3A4*5, CYP3A4*6, CYP3A4*10 & 
CYP3A4*18. In both groups (healthy individuals and TB patients), no mutations were detected for CYP3A4*2, CYP3A4*4, 
CYP3A4*5, CYP3A4*6, CYP3A4*10 & CYP3A4*18 alleles. Two samples with CYP3A4*1B allele were found to be 
heterozygous (1%) (n=200) in healthy subjects, where as only one sample with CYP3A4*1B allele was found to be 
heterozygous (1.11%) (n=90) in TB patients. This is the first investigation establishing CYP3A4 genotypes and 
demonstrating the absence of common CYP3A4 genotypes in Bangladeshi population. For phenotyping, morning spot 
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urine samples were collected from 93 healthy subjects. Cortisol and 6ȕ-hydroxy-cortisol was extracted and quantified by 
HPLC. For cortisol, the maximum and minimum concentration found was 819.26 ng/ml and 19.64 ng/ml respectively with 
an average of 123.75 ± 118.37 (SD). On the other hand, the maximum and minimum concentration of 6ȕ-hydroxy-cortisol 
was 466.65 ng/ml and 8.12 ng/ml respectively with an average of 101.57 ± 91.23 (SD). The ratios of 6ȕ-hydroxy-cortisol 
and cortisol ranged from 0.24 to 7.49 with an average of 1.84 ± 1.66 (SD). The within-day coefficient of variation (C.V.) 
was 4.5 % (n=93), while the between-day C.V. was found to be 8.7% (n=93). Correlation between phenotyping and 
genotyping results and statistical analysis will be done after phenotyping rest of the healthy subjects and TB patients. 
Clinical relevance of these genetic variants is under investigation. This is the first investigation establishing CYP3A4 
phenotypes and demonstrating the absence of common CYP3A4 genotypes in Bangladeshi population. 
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Poster: P009-T 
MtDNA and Y-chromosomal variation in populations of Sakha (Yakutia) 
1Sardana A Fedorova, 2Elza K.Khusnutdinova 
1Laboratory of molecular genetics, Yakut Research Center of Complex Medical Problems, Yakutsk, Russia, 677010 
2Department of Genomics, Institute of Biochemistry and Genetics, Ufa, Russia, 450054 
We have characterized, at high phylogenetic resolution, mtDNA variation (n=694) and Y chromosome haplotypes diversity 
(n=318) in populations of Sakha (Yakutia) - the Autonomous Republic situated in northeastern part of the Russian 
Federation that comprises 1/5 part of Russia’s total land area. The results were analyzed in a broader context of the 
Eurasian mtDNA and Y-chromosomal variability. Extended analysis confirms that Yakutia was colonized from the regions 
west and eastward of Lake Baikal with minor gene flow from Lower Amur/Southern Okhotsk region and/or Kamchatka. 
The genetic portraits of studied ethnic groups (Sakha or Yakuts, Evenks, Evens, Yukaghirs, Dolgans) were obtained and 
scenarios of ethnogenesis suggested by historians and archaeologists were compared with genetic reconstructions. We 
considered our results in connection with some epidemiologic and molecular genetic researches of hereditary diseases 
characterized by a high prevalence in the region such as spinocerebellar ataxia type 1, myotonic dystrophy, 3-M 
syndrome. 
 
Poster No: P026-T 
Genetic diseases and founder mutations in the Tunisian Population: Implications for diagnosis in North Africa 
and Middle East 
 
1Sonia Abdelhak, 1Lilia Romdhane , 1Rym Kefi-Ben Atig and 1Safa Romdhane 
1 Research Unit on Molecular Investigation of Genetic Orphan Diseases. Institut Pasteur de Tunis.13, Place Pasteur, 1002, 
Tunis. Tunisia 
Tunisia is a North African country of 10 million inhabitants at the cross road between Europe and Africa. Throughout its 
history, it has been the seat of the invasion and immigration of different ethnic groups. As its neighbouring and Middle 
Eastern countries, its population shows a high prevalence of consanguinity and endogamy, thus leading to emergence of 
genetic disorders at higher rates. We report, here on the spectrum of genetic diseases in Tunisia and on founder 
mutations. The review of the literature, including other available information (gray literature) showed that 346 genetic 
disorders for which cases have been identified in the Tunisian population. Among these, 62,9 % are autosomal recessive, 
23 % autosomal dominant, 5,4 % X-linked and the remaining are of Y-linked, mitochondrial and unknown mode of 
transmission. Fifty percent of the reported conditions in this study are caused by at least one mutation. For autosomal 
recessive diseases, most of the mutations were identified at homozygous state among the affected individuals. Part of the 
mutations was the result of a founder effect. Two classes of founder mutations have been identified in the Tunisian 
HUGO J (2010) 4:1–190 109
123

population. The first includes founder mutations that are reported so far only among Tunisian patients, they are mainly the 
result of the high rate of consanguinity and endogamy. The second founder mutations are shared with other populations 
originating mainly from other North African or Middle Eastern countries and in certain cases from both shores of 
Mediterranean. These mutations have captured historical events in the region and are particularly useful for the 
development of easy and cost effective tools for molecular diagnosis. 
 
Poster No: P041-T 
High-altitude adaptation of highland natives, human or yak: NOS3 gene as an example 
Qadar Pasha MA1 and Ghulam Mohammad2 
1Functional Genomics Unit, Institute of Genomics and Integrative Biology, Delhi, India 2Department of Medicine, Sonam 
Norboo Memorial Hospital, Leh, Ladakh, J&K, India. 
High-altitude (HA), time immemorial, has attracted humans for its beauty, adventure and, of course, natural laboratory 
setup owing to its hypobaric hypoxia environment. The attenuated hypoxic pulmonary vasoconstriction (HPV) and high 
nitric oxide (NO) level of highland-natives suggest the evolutionary (genetic) adaptation as they are continuously 
subjected to a stressful environment. NO is the most implicated molecule as it is the endogenous vasodilator required for 
maintaining vascular homeostasis and counteracting the effect of HPV. Hence, higher NO level in highland-natives 
certainly provides endurance for living and also indicates the selection pressure of those genes involved in vascular 
homeostasis. The native Himalayan Yak (Bos grunniens) and Tibeto-Burman Ladakhi population both being successfully 
adapted to the chronic hypoxia of HA (>3000m) served as cogent models to study the molecular basis of adaptation and 
endurance.  
 
Out of the >4000 SNPs analyzed in a genome-wide screen of native humans, we preferred to restrict to Endothelial nitric 
oxide synthase gene (NOS3), which codes for the enzyme eNOS that produces NO. Screening of NOS3 in yak, 
surprisingly, showed the complete homozygous selection of –922A and –786T promoter alleles when compared with 
highland-natives. The same alleles were over-represented significantly in highland-natives compared to sealand-natives 
(p=0.000). Genotype and allelic distribution of G894T and 4b/4a polymorphisms was significantly different in the two 
groups (p=0.00). Strong selection pressure was also demonstrated by highest r2 value (r2=1.00) when compared with rest 
of the world’s major populations. The circulating NO levels were significantly higher at HA compared to sealand 
(p<0.0001).  
 
The NOS3 variants, its haplotypes and higher NO levels in highland natives like human and yak strongly favor the 
involvement of this gene in evolutionary adaptation. 
 
Poster No: P056-T 
Genomic scale labeling of persistent genes 
 Jian-Dong Huang1, Yuanying Miao1, Rory M. Watt2, Antoine Danchin3, David K. Smith1, Hongzhe Sun4, Zhongjun 
Zhou1,Junwen Wang1 
1Department of Biochemistry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pok Fu Lam, Hong Kong SAR, 
People's Republic of China 2Oral Biosciences, Faculty of Dentistry, University of Hong Kong, Pok Fu Lam, Hong Kong 
SAR, People's Republic of China 3Amabiotics, Genoscope/CEA, 2, rue Gaston Cremieux, Evry Cedex, 91057, France 
4Department of Chemistry, University of Hong Kong, Pok Fu Lam, Hong Kong SAR, People's Republic of China 
Systematic characterization of the locations of proteins is important for understanding genome and proteome functions. 
This may be achieved by visualizing fluorescent protein (e.g. EGFP)-tagged proteins within live cells using fluorescence 
microscopy. Recombinnering technology allows the efficient integration of transformed linear dsDNA, containing short 
homologous regions (35-55 bp), into bacterial chromosome. To produce EGFP fusion proteins under the control of the 
target gene’s endogenous promoter, the PCR product containing the EGFP coding region, a selectable marker and 50 bp 
of sequence homologous to the chromosome regions immediately upstream and downstream of the target gene was 
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electroporated into an E. coli that contained recombineering functionality. Correctly EGFP-tagged strains were identified 
using selective medium and were confirmed by PCR. The localization patterns of the target gene products within 
immobilized viable cells were determined by fluorescence microscopy. We have tried to label all 611 persistent genes of E. 
coli. 253 of them have been tagged successfully among which 179 have been located successfully. Successfully located 
proteins have different cellular localization: the majority localized diffusely throughout the cell; some localized at either or 
both poles or at the center of the cell, some were membrane localized. Several proteins exhibited localization patterns that 
were different from previously results. The fluorescent intensities of the EGFP-tagged proteins varied. This might be 
caused by differing expression levels of the target proteins. Some gene products showed dynamic localization patterns at 
the different stages of the growth phase. The process of tagging genes with EGFP directly on the E. coli chromosome has 
revealed known localization patterns and new information. As the fluorescence intensity of EGFP-tagged genes varied 
from gene to gene, recombineering technology might allow the study gene expression levels. Our findings also show that 
the growth phase of strain should be considered when determining the localization patterns of proteins. 
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Genomic and functional analysis of the tumor cell of origin in HCC. 
Maia Chanrion1, Eric Sawey1, Scott Powers1 
1Cold Spring Harbor Laboratory 
There is substantial heterogeneity of the gene expression profiles and clinical outcome of human hepatocellular 
carcinomas (HCCs). While some of this is likely caused by the diversity of acquired genetic alterations, it is also possible 
that there could be diverse cells of origin for HCCs. Previously, we determined that hepatoblasts from day 14 embryos 
could be malignantly transformed by a combination of overexpression of MYC and loss of p53, but that more differentiated 
hepatoblasts from day 18 embryos were resistant to such malignant transformation (1). We used genomic analysis to 
investigate underlying mechanisms. By comparing expression profiles of D14 and D18 mouse liver hepatoblasts, we 
found that the most significantly altered signaling pathways involve the nuclear receptor RXRĮ, upregulated in D18. By 
silencing the expression of the nuclear hormone receptor RXRĮ in D18 hepatoblasts using shRNA, we found that we can 
induce D18 hepatoblasts to become malignantly transformed by MYC and loss of p53 after subcutaneous and in situ 
injections. Thus, day 14 hepatoblasts require only two oncogenetic “hits” while day 18 hepatoblasts require three hits. We 
validated the relevance of RXRĮ in human HCC as it relatively underexpressed in poor prognosis associated HCC 
patients (2). We also showed that the 9-cis-retinoic acid, an RXRĮ agonist, slowed exclusively the growth of differentiated 
HCC cell lines expressing RXRĮ. Our results pinpoint RXRĮ as an oncogenic determinant of the cell of origin and 
highlight its potential as a predictive marker of the response to the 9-cis-retinoic acid. 
(1) Zender et al., CSH symposia on Quantitative Biology, 2005 
(2) Lee JS et al., Nature genetics, 2006 
 
Poster No: P021-F 
Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.  
1,4 Arun Seth, 1Tania Benatar, 1Yutaka Amemiya, 1Wenyi Yang, 2Claire Holloway, 3Sharon Nofech-Mozes 
1Division of Molecular and Cellular Biology, Sunnybrook Research Institute, Sunnybrook Hospital, Canada 2Odette Cancer 
Center, Sunnybrook Hospital, Canada  3Department of Anatomic Pathology, Sunnybrook Hospital, Canada 4Department 
of Laboratory  Medicine and Pathobiology, University of Toronto, Canada 
To identify genes correlated with breast tumorigenesis and eventual metastasis, gene expression profiles were generated 
comparing primary patient tumors with subsequent metastatic breast tumors developed in the NOD/SCID mouse model. 
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Using 28K whole genome microarrays we compared the gene expression profile of tumors that grew and metastasized in 
the NOD/SCID model with other primary breast tumors with different growth and metastatic potentials. Five hundred and 
eighty two genes were significantly differentially expressed by our statistical comparison criteria using the GeneSpring GX 
7.3.1 software suite. In the metastatic set eight genes were selectively overexpressed (YB1, MMP7, MMP9, RAB5A, 
RABGDIB, EPHRB3, WNT2B, CSF1R) and 12 were selectively underexpressed (IGFBP7, GATA3, CST5, CDK6, 
SERBP1, MGP, TGF1L4, ESE3, ELF3, EDNRB, HECTD1, TINP1). Validation by qRT-PCR analysis of IGFBP7, GATA3 
and CSF1R expression has been confirmed in the primary tumors metastatic to bone and host tissues. IGFBP-7 
expression has been shown to be inversely correlated with disease progression in breast cancer. In order to investigate 
the role of IGFBP-7 in breast tumor suppression, it was overexpressed in the triple negative MDA-MB-468 human breast 
cancer line. Ectopic overexpression of IGFBP-7 clearly reduced the growth of the MDA-MB-468/IGFBP-7 cells compared 
to the parental MDA-MB-468 cells. Investigation of downstream signalling pathways affected by IGFBP-7 revealed that 
ectopic overexpression of IGFBP-7 strongly suppressed the phosphorylation of the ERK-1/2, while simultaneously 
increasing the phosphorylation of the ATK/PKB, a downstream effector of the PI3K pathway, suggesting that IGFBP-7 
mediates its anti-proliferative effects through modification of multiple downstream signalling. When injected 
subcutaneously into NOD/SCID mice, the increased expression of IGFBP-7 in the MDA-MB-468/ IGFBP-7 cells reduced 
the rate of tumor growth in comparison to the parental MDA-MB-468 cells. These results suggest that the growth of breast 
cancer could be prevented by the forced expression of IGFBP-7 protein. Work in progress will test how systemic or local 
IGFBP-7 treatment affects human primary breast tumors and breast cancer cell-line growth and metastasis in our 
NOD/SCID models. Our studies are expected to characterize critical mediators of the IGFBP-7 senescence response, its 
potential co-regulatory function in breast tumor suppression, and its value as a novel drug. 
 
Poster No: P036-F 
Digital Gene Expression Profiling of Acute Lymphoblastic Leukemia Cells 
1Jessica Nordlund, 1Anna Kiialainen, 1Olof Karlberg, 1Anders Lundmark, 2Mads Sønderkær, 2Kåre Lehmann Nielsen, 
3Gudmar Lönnerholm & 1Ann-Christine Syvänen 
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biotechnology, Chemistry and 
Environmental Engineering, Aalborg University, Aalborg, Denmark, 3For the Nordic Society of Pediatric Hematology and 
Oncology (NOPHO), and the Department of Children’s and Women’s Health, Uppsala University, Uppsala, Sweden  
Acute lymphoblastic leukemia (ALL) is one of the most common malignancies and a leading cause of illness-related death 
of children in developed countries. ALL is a heterogeneous disease with distinct molecular subtypes, which differ in their 
response to chemotherapy and subsequent risk for relapse. Genome-wide transcription profiling studies of ALL with 
microarray technology are successful in identifying expression signatures for subtype classification and risk of relapse. 
However, microarray studies are hampered by a priori knowledge of the gene sequences, high background, and a limited 
dynamic range. Recent advances in next generation sequencing (NGS) technologies have enabled highly quantitative 
sequencing-based approaches for transcriptome analysis. This advancement has allowed us to overcome the limited 
accuracy of hybridization based methods, thus facilitating a new scale of transcriptome measurement.  
To detect differences in gene expression profiles of ALL cells from different cytogenetic subtypes and chemotherapeutic 
treatment response of patients, we generated genome-wide transcriptome profiles from 24 well characterized ALL 
patients. These patients consist of four with T-cell lineage ALL and 20 from different subclasses of B-cell lineage ALL: 
High Hyperploidy (HeH), BCR-ABL1, TEL-AML, and dic(9;20). For transcriptome analysis, high quality RNA was isolated 
from bone marrow or peripheral blood samples taken from the patients at diagnosis. We used Digital Gene Expression 
(DGE) tag profiling on the Illumina Genome Analyzer (GA) to profile poly-a selected mRNA. DGE is analogous to serial 
analysis of gene expression (SAGE), which measures the frequency of a tag in the sequence library population, providing 
a digital count read out of overall gene expression. 
Each DGE library was sequenced on one lane of the Illumina GA. DGE analysis generated on average 9.5 million reads 
per sample, of which >80% mapped to the human transcriptome. Using bioinformatics approaches, we have annotated 
and quantified the expression of ~19,000 genes in ALL cells, and observed anti-sense transcription for approximately 50% 
of the genes. By pairwise comparison, we have detected differential gene expression between the distinct ALL subtypes 
and between patients in continuous remission compared to patients who have subsequently relapsed. 
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Detection of significant DNA copy number alterations in breast tumors from Mexican patients with high-
resolution SNP arrays and GISTIC analysis 
Hidalgo-Miranda A1, Rodriguez-Cuevas S2, Rebollar-Vega R1, Romero-Cordoba S1, Quintanar-Jurado V1, Bautista-Pina 
V2, Ciceron-Arellano I1, Carrillo-Sanchez K1, March-Mifsut S1, Jimenez-Sanchez G1, Uribe-Figueroa L1.  
1Laboratorio de Oncogenomica, Instituto Nacional de Medicina Genomica, Mexico, 2FundacionMexicana de Fomento 
Educativo para la Prevencion y Deteccion Oportuna del Cancer de Mama, Mexico. 
Breast cancer represents the second cause of cancer related death in Mexican women, and also represents an important 
health problem worldwide. Specific patterns of DNA copy number changes in breast tumors have been associated with 
particular tumor types and clinical behaviors. Analysis of these DNA copy number alterations have been carried out using 
different methods, like comparative genomic hybridization (either on metaphase chromosomes or different microarray 
platforms), and more recently, with high density oligonucleotide and SNP arrays. Increased array resolution, as well as the 
introduction of statistical methods to evaluate the significance of the copy number aberrations, has allowed the detection 
of particular gene targets in several human tumors. In order to define the pattern of statistically significant DNA copy 
number changes in breast tumors from Mexican patients, we used a high resolution SNP array to analyze the DNA copy 
number profiles of 89 breast normal/tumor pairs from Mexican patients. Tumor tissue and peripheral blood lymphocyte 
DNA from each patient was analyzed with the Affymetrix SNP 6.0 array. All tumor samples contained more than 80% 
tumor cells. Array normalization and paired copy number analysis using the SNP probes in the array was done using 
DChip, followed by segmentation using the GLAD algorithm and significant regions were identified using the Genomic 
Identification of Significant Targets in Cancer (GISTIC) method, both implemented in the GenePattern platform. GISTIC 
analysis identified 49 significant regions with copy number changes in the tumor compared to the paired normal tissue, 
including 22 amplifications and 27 deletions. In the amplifications events, seven were considered as “broad” (average: 72 
Mb), 11 were “focal” (average: 91 kb) and four were considered as “both”. In the case of the deletions, 15 were broad, 
nine were focal and three were both. Significant amplified regions were located at, 1q23.2, 1q42.2, 3q26.33, 5q23.1, 6q21, 
7q34, 8p12, 8q24.11, 9p21.3, 10p14, 11q13.3, 12p12.1, 13q32.3, 14q21.1, 16p13.13, 17p11.2, 17q11.2, 17q12, 17q21.32, 
17q23.3, 17q25.1 and 20q13.2. These regions contained 421 genes. Significant regions with deletion were found at 
1p36.12, 2q24.3, 3p21.1, 4p13, 5q15, 6q22.1, 6q26, 8p23.2, 9p24.3, 10q26.11, 11p15.5, 11q23.3, 13q14.2, 13q31.1, 
13q33.2, 14q32.12, 15q12, 16q21, 16q23.3, 17p12, 17p11.2, 17q21.2, 18p11.31, 19p13.3, 21q21.1, 22q13.2, Xq21.31. 
Some of these regions have not been previously reported as common areas of copy number change in breast cancer 
making the analysis of the genes inside these significant regions an interesting research task. To our knowledge, this is 
one of the first reports regarding high-resolution DNA copy number aberrations in breast cancer from a Latin American 
population, as well as one of the first analysis using the SNP 6.0 array in combination with a statistical method for the 
detection of significant regions with DNA copy number changes in breast cancer. 
 
Poster No: P066-F 
Transcriptional profiling by massively parallel ligation DNA sequencing reveals much about alterations that 
occur during the development of oral cancer 
1David I Smith, 1Rebecca Laborde, 2Brian Tuch, 2Melissa Barker, and 2Francisco De La Vegas 
1Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA 2Life Technologies, Foster City, CA, USA 
We utilized massively parallel ligation DNA sequencing on the SOLid Platform to comprehensively analyze transcriptomic 
alterations that occur during the development of cancer of the oral tongue. We utilized a protocol which preserves the 
standedness of each transcrip present in three oral tongue tumors as well as in matched normal oral mucosa from the 
same patients. Over 200 million 50 base pair reads were obained fromeach sample and then the transcriptional profilie of 
oral tongue tumor was directly compared to the matched normal oral mucosa sample. This enabled us to ascertain 
transcripts that had altered expression during tumor formation. In addition, we could characterize allele-specific changes 
in expression for the more abundantly expressed genes. The genes that had alterations in allele-specific expression were 
members of the same molecular pathways as genes that had change in expression. We could also examine the more 
abundantly expressed genes to directly identify mutaitons presaent in numerous gene transcripts. These genes were also 
members of the same molecular pathways as genes that either had changes in overall expression or in allele-specific 
expression. Finally, using a novel program to identify and prioritize potential transcripts which were fusions between 
different genes we have identified a series of potential nvel gene fusions, several of which wre preent in at least two of the 
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three oral tumors characterized. This work demonstrates the power of sequence-directed transcriptional profiling to more 
completely characterize the genomic alterations that underlie the development of cancers of the oral tongue. 
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Poster No: P030-F 
Identification of recent admixture in an Indian population of African ancestry: prospects for complex disease 
mapping 
Mitali Mukerji1, Ankita2, Pankaj Jha1, Vimal Rawat2, Debasis Dash2, Arijit Mukhopadhyay1, Indian Genome Variation 
Consortium1,2 and Analabha Basu3 
1Genomics and Molecular Medicine, 2G.N. Ramachandran Knowledge Centre for Genome Informatics, Institute of 
Genomics and Integrative Biology (CSIR), Delhi, India; National Institute of BioMedical Genomics, Kalyani, Kolkata, India 
Study of genetic variation in recently admixed populations not only reveals historical population events but is also a 
powerful approach for mapping disease genes. This has been successfully demonstrated in a number of admixed 
populations like Africo-American, Hispanic and Uyghur. India occupies a center stage in human evolution. The genetic 
structure of Indian populations that represents a substantial fraction of global diversity, has been shaped by multiples 
waves of migration and local admixture events. We studied an out-group population (OG-W-IP) of African-Indian origin 
that are reported to be the descendants of slaves from the Bantu speaking parts of East Africa and have been residing in 
the western part of India for nearly 500 years. We have carried out this study using a common data of 18534 autosomal 
markers that have been genotyped on 26 Indian populations using 50 K Affymetrix array and are also available in the 
HGDP panel and HapMap populations. Principal component analysis revealed clear separation of African population from 
Indian populations. STRUCTURE and ADMIXTURE analysis revealed that overall the OG-W-IPs derive 53% of their 
genomic ancestry from their African past with very little inter-individual ancestry variation (sd = 0.09). The block sizes also 
reveal that the admixture event has been recent. These results corroborate with the history of the population. Therefore 
OG-W-IP is a potential candidate population for admixture mapping. Since OG-W-IP reside in a high salt area of Gujarat 
they provide opportunity to design and test the “African salt-retention gene theory” and studies related to hypertension in 
recently admixed population. 
 
Poster No: P045-F 
Dried reagents for multiplex genotyping by tag-array minisequencing in microfluidic devices 
1Annika Ahlford, 2Bastian Kjeldsen, 2Jakob Reimers, 1Anders Lundmark, 3Massimo Romani, 2Anders Wolff, 1Ann-
Christine Syvänen and 2Monica Brivio 
1Department of Medical Sciences, Molecular Medicine, Uppsala University,Uppsala, Sweden. 2 Department of Micro- and 
Nanotechnology, Technical University of Denmark, DTU Nanotech, Kongens Lyngby, Denmark .3 Department of 
Advanced Diagnostic Technologies, Division of Tumor Genetics, National Cancer Research Institute (IST-Genova), 
Genova, Italy.  
 
By integrating miniaturized components and automating assay functionalities, lab-on-a-chip technologies offer promising 
tools for fast, cost-effective and efficient point-of-care DNA analysis. External reagent supply to the microfluidic system is 
one difficulty for integration of complex DNA-based assays and storing reagents on the microfluidic device could reduce 
the complexity. In this study we have addressed reagent storage by freeze-drying all reagents required for multiplex 
genotyping using PCR amplification and tag-array minisequencing with fluorescence detection, to be implemented in 
microfluidic chambers for cancer diagnostics using the tumor protein 53 (TP53) gene as a model. 
  
We performed tests to evaluate enzyme activity after freeze-drying in the presence of lyoprotectants and enzyme stability 




after storage and established optimal reaction protocols. The activity of the thermostable DNA polymerase remained high 
when stored at -21ºC for 6 month after freeze-drying. By accelerated stability tests, the half-life of activities for 
exonuclease I and shrimp alkaline phosphatase, used for PCR ”clean-up”, were estimated to 50 and 80 days, respectively. 
We carried out a systematic genotyping experiment comparing freeze-dried and standard liquid reagents in each step of 
the protocol, genotyping the five most common cancer mutation sites (codons 175, 248 and 273) and 13 SNPs in TP53. 
An accuracy of 99.1% was achived for successful genotypes generated by freeze-dried reagents when compared to liquid 
reagent. As a proof of principle the complete genotyping protocol was successfully performed in cyclic olefin copolymer 
test chambers using freeze-dried reagents.  
 
Our results indicate the feasibility to apply freeze-drying for reagent storage in the establishment of simple devices for 
multiplex DNA-analysis. Currently we are implementing the reagent deposition strategy in the development of a fully 
integrated and automated microfluidic chip for a complete genetic analysis comprising DNA extraction and amplification, 
genotyping and result readout. The system consists of a disposable biochip for all biochemical reactions and re-usable 
control components and functionalities. 
 
Poster No: P060-F 
Dissection of genes in the type I interferon pathway reveals two novel risk loci for SLE 
1Johanna K. Sandling, 1,§Sophie Garnier, 1,#Snaevar Sigurdsson, 1Chuan Wang, 2Gunnel Nordmark, 3Iva Gunnarsson, 
3Elisabet Svenungsson, 3Leonid Padyukov, 4Gunnar Sturfelt, 4Andreas Jönsen, 4Anders A. Bengtsson, 5Lennart 
Truedsson, 6Catharina Eriksson, 7Solbritt Rantapää-Dahlqvist, 8Anders Mälarstig, 8Rona Strawbridge, 8Anders Hamsten, 
9Robert R. Graham, 9Timothy W. Behrens, 2Maija-Leena Eloranta, 10Gunnar Alm, 2Lars Rönnblom and 1Ann-Christine 
Syvänen 
1Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Section of Rheumatology, 
Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 3Rheumatology Unit, Department of Medicine, 
Karolinska Institutet/Karolinska University Hospital, Stockholm, Sweden, 4Section of Rheumatology, Department Clinical 
Sciences, Lund University, Lund, Sweden, 5Department of Laboratory Medicine, Section of MIG, Lund University, Lund, 
Sweden, 6Department of Clinical Immunology, Umeå University Hospital, Umeå, Sweden, 7Department of Rheumatology, 
Umeå University Hospital, Umeå, Sweden, 8Atherosclerosis Research Unit, Department of Medicine, Solna Karolinska 
Institutet Stockholm, Sweden, 9Genentech Inc., South San Francisco, CA, USA, 10Department of Biomedical Sciences 
and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, §Current address INSERM 
UMR S937, Génétique Epidémiologique et Moléculaire des, Pathologies Cardiovasculaires, Université Paris VI, Paris, 
France, #Current address Broad Institute of Harvard and MIT, Boston, MA, USA 
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease in which the type I interferon (IFN) pathway 
plays a crucial role. We have previously shown that five genes in this pathway, IRF5, TYK2, STAT4, IFIH1 and IRF8 are 
associated with risk for SLE, as well as successfully replicated the previous reports on association for IRAK1, TNFAIP3, 
TNFSF4 and the IRF7 region (KIAA1542). Here we investigate 78 genes involved in the type I IFN pathway to identify 
additional SLE susceptibility loci. First, we genotyped SNPs in these 78 genes and 14 other candidate genes in Swedish 
SLE patients and controls. Genes with P < 0.01 in the initial screen were then followed up in an additional Swedish cohort. 
SNPs in five genes were nominally associated with SLE in this extended cohort. To replicate these findings we extracted 
data from a genome-wide association study on SLE performed in a US cohort. Combined analysis of the Swedish and US 
data confirmed two of these genes as SLE susceptibility loci. Our study highlights additional genes from the type I IFN 
system for further functional analysis, and more specifically points to the importance of genes in the IFIH1/DDX58 
pathway which is activated in cells other than the plasmacytoid dendritic cells, for example monocyte derived dendritic 
cells, in response to viral infections. 
 
Poster No: P089-F 
SNPome: Human Polygenic Disease SNP Network 
Yasha Hasija and Samir K. Brahmachari  
Council of Scientific and Industrial Research, Anusandhan Bhawan, 2 Rafi Marg, New Delhi-110001, INDIA  
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Common complex disorders follow an intricate pattern of inheritance, characterized by incomplete penetrance, genetic 
heterogeneity, as well as polygenic predisposition. In addition, environmental factors also play an important role in 
contributing to disease phenotypes. A gain in understanding of the association between genetic variations and their 
phenotypic effects is a step towards comprehending the etiology of these disorders. While genome-wide association 
studies are, to some extent, seeming to explain genetic predisposition to common diseases, the significance of allelic 
overlap in complex disorders cannot be undermined. With this preview, in the present study, the complex disorders were 
analyzed for the shared nature of their associated SNPs, and a network of complex disorders having common associated 
SNPs was constructed. These complex disorders were then classified into discrete groups based on the pathology and 
organ system involved. The biological systems sharing maximum overlap of associated SNPs were identified. We tried to 
address two basic questions through our analysis: (a) Are there any common SNPs that are essential to disorders of a 
particular biological system? and (b) Are there any generalized SNPs that may affect multiple human biological systems? 
 
Through this study, we identified SNPs associated with more than one disorder of the same human system (designated 
as ‘Intra-Systemic Overlapping SNPs’, indicative of genetic differences that make an individual prone to the disorders of a 
particular human biological system) as well as SNPs associated with disorders of multiple biological systems (designated 
as ‘Inter-Systemic Overlapping SNPs’). The genes harboring these inter- systemic overlapping SNPs may be central to 
the core intrinsic pathways, or may have an effect by interacting with other genes, that would involve multiple biological 
systems. A comprehensive network of these SNPs associated with more than one polygenic disorder, including both inter- 
and intra- systemic overlapping SNPs, was thereby constructed, hence building human polygenic disease SNP network, 
the SNPome. 
The study emphasizes the shared nature of common alleles in related complex disorders, such as Type 2 diabetes 
mellitus and obesity, schizophrenia and bipolar disorder, etc., as well as in non-related polygenic disorders, such as the 
ones associated with cardiovascular and musculoskeletal system disorders. 
 
13. Epigenetics and microRNA-mediated gene regulation 
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Poster No: P007-F 
A mutation in the 3'UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-
433 is linked to a new form of dominant X-linked chondrodysplasia.  
1,2Benoit Arveiler, 1Delphine Simon, 1Malika Barillot, 3Benoit Laloo, 1Thomas Barnetche, 1,2Caroline Rooryck, 1Camille 
Blanchard, 1Ingrid Burgelin, 1Michèle Marche, 1Isabelle Coupry, 4,5Nicolas Chassaing, 6Brigitte Gilbert-Dussardier, 
3Christophe Grosset, 1,2Didier Lacombe; 
1Université Victor Segalen Bordeaux 2, Bordeaux, France 2CHU de Bordeaux, Bordeaux, France, 3INSERM U889, 
Bordeaux, France, 4INSERM U563, Toulouse, France, 5CHU de Toulouse, Toulouse, France, 6CHU de Poitiers, Poitiers, 
France. 
A family with dominant X-linked chondrodysplasia was previously described. The disease locus was ascribed to a 24 Mb 
interval in Xp11.3-q13.1. We have identified a variant (c.*281A>T) in the 3’UTR of the HDAC6 gene that totally segregates 
with the disease. The variant is located in the seed sequence of hsa-miR-433. Our data showed that, in MG63 
osteosarcoma cells, hsa-miR-433 (miR433) down-regulated both the expression of endogenous HDAC6 and that of an 
eGFP-reporter mRNA bearing the wild-type 3’UTR of HDAC6. This effect was totally abrogated when the reporter mRNA 
bore the mutated HDAC6 3’UTR. The HDAC6 protein was found to be over-expressed in thymus from an affected male 
foetus. Concomitantly, the level of total alpha-tubulin, a target of HDAC6, was found to be increased in the affected foetal 
thymus, whereas the level of acetylated alpha-tubulin was found to be profoundly decreased. Skin biopsies were obtained 
from a female patient who presented a striking body asymmetry with hypotrophy of the left limbs. The mutated HDAC6 
allele was expressed in 31% of left arm-derived fibroblasts, whereas it was not expressed in the right arm. 
Overexpression of HDAC6 was observed in left arm-derived fibroblasts. Altogether these results strongly suggest that this 
HDAC6 3’UTR variant suppressed hsa-miR-433-mediated post-transcriptional regulation causing the overexpression of 
HDAC6. This variant is likely to constitute the molecular cause of this new form of X-linked chondrodysplasia. This 
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represents to our knowledge the first example of a skeletal disease caused by the loss of a miRNA-mediated post-
transcriptional regulation on its target mRNA. 
 
Poster No: P024-F 
Dynamic Changes in the Human Methylome During Differentiation 
Eleanor Wong3, 7 *, Louise Laurent1, 2 * and Chia-Lin Wei3, 7 #  
1UCSD Medical Center, Department of Reproductive Medicine. 200 West Arbor Drive, Mail Code 8433. San Diego, CA 
92103 2  Center for Regenerative Medicine, Dept of Chemical Physiology, The Scripps Research Institute, 10550 North 
Torrey Pines Road, La Jolla, CA 92037  3 Genome Technology & Biology Group, Genome Institute of Singapore, 
Singapore 138672.  7 Department of Biological Sciences, National University of Singapore 
DNA methylation is a critical epigenetic regulator in mammalian development. In our study, we present a whole genome 
comparative view of DNA methylation using bisulfite sequencing of three cultured cell types representing progressive 
stages of differentiation: human embryonic stem cells (hESCs), a fibroblastic differentiated derivative of the hESCs, and 
neonatal fibroblasts. We observed many notable common and cell type-specific features among all cell types. Promoter 
hypomethylation (both CG and CA) and higher levels of gene body methylation were positively correlated with 
transcription in all cell types. Exons were more highly methylated than introns and sharp transitions of methylation 
occurred at exon-intron boundaries, suggesting a role for differential methylation in transcript splicing. Developmental 
stage was reflected in both the level of global methylation and extent of non-CpG methylation, with hESC highest, 
fibroblasts intermediate, and monocytes lowest. Differentiation-associated differential methylation profiles were observed 
for developmentally regulated genes, including the HOX clusters, other homeobox transcription factors, and pluripotence-
associated genes such as POU5F1, TCF3, and KLF4. Our study highlight the value of high-resolution methylation maps, 
in conjunction with other systems-level analyses, for investigation of previously undetectable developmental regulatory 
mechanisms. 
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Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoieis: role of hsa-mir-
299-5p in CD34+ progenitor cells commitment 
Elena Tenedini1,4, Enrica Roncaglia1,4, Francesco Ferrari2, Claudia Orlandi1, Elisa Bianchi1, Silvio Bicciato1,3, Enrico 
Tagliafico1,3,4 and Sergio Ferrari1,3,4 
1Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2Department of Biology, 
University of Padova, Padova, Italy; 3Center for Genome Research, University of Modena and Reggio Emilia, Modena, 
Italy; 4BioPharmaNet, Emilia-Romagna High-Tech Network, Ferarra, BioPharmaNet, Emilia-Romagna High-Tech Network, 
Ferarra, Italy  
Hematopoiesis entails a series of hierarchically organized events that proceed throughout cell specification and 
terminates with cell differentiation. Commitment needs the transcription factors effort that, in concert with microRNAs, 
drives cell fate and responds to promiscuous patterns of gene expression by turning-on lineage-specific genes and 
repressing alternate lineage transcripts. We obtained microRNAs profiles from human CD34+ hematopoietic progenitor 
cells and in-vitro differentiated erythroblasts, megakaryoblasts, monoblasts and myeloblasts precursors, that we analyzed 
together with their gene expression profiles. The integrated analysis of microRNA-mRNA expression levels highlighted an 
inverse correlation between microRNAs specifically up-regulated in one single cell progeny and their putative target genes, 
which resulted down-regulated. Among the up-regulated lineage-enriched microRNAs, hsa-miR-299-5p emerged as 
having a role in controlling CD34+ progenitors fate, grown in multilineage culture conditions. Gain- and loss-of-function 
experiments revealed that hsa-miR-299-5p participates the regulation of hematopoietic progenitors fate, modulating 
megakaryocytic-granulocytic versus erythroid-monocytic differentiation. 
 
Poster No: P054-F 
Prediction of novel microRNAs on human Y-Chromosome 
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Arijit Mukhopadhyay1,2, Saurabh V Laddha1 and Subhashree Nayak2 
1G.N. Ramachandran Knowledge Centre for Genome Informatics, 2Genomics & Molecular Medicine, Institute of Genomics 
& Integrative Biology (CSIR), Delhi, India 
MicroRNAs are endogenous non-coding RNAs of ~22 nucleotides and shown to regulate gene expression at the 
posttranscriptional level by directly cleaving targeted mRNAs or repressing translation. There are almost 1000 mature 
miRNAs (miRBase, release-14) discovered in the human genome which are distributed non-randomly. So far not even a 
single miRNA has been reported from the human Y-chromosome. In this study we wanted to explore the possibility of Y-
chromosome specific miRNA in human. 
We have taken a sliding window of 125 nucleotides to scan the entire sequence of Y-chromosome available in the public 
domain (GRCh37 build, NCBI). We then predicted the possible secondary structure for each window using recently 
reported tool CID-miRNA (http://mirna.jnu.ac.in/cidmirna/). This was further filtered using a more stringent prediction tool, 
Vir-Mir (http://140.109.42.4/cgi-bin/miRNA/miRNA.cgi) to reduce false positives. To achieve higher specificity we have 
used the sequences specific to Y-chromosome followed by presence of Dicer substrate site using PHDcleav 
(http://imtech.res.in/raghava/phdcleav/submission.html).  
The initial prediction using CID-miRNA gave 1685 sequences with ‘grammar’ cutoff -0.609 for human specific prediction. 
Vir-Mir predicted a subset of 1135 sequences to be positive. When searched for specificity to Y-chromosome this was 
further reduced to 798 sequences. Dicer substrate site prediction gave 176 out of 798 sequences after using a cutoff 
score of 2.0. These were then matched against EST records and for 59 sequences there were at least an EST showing 
evidence for expression. 
Our informatics analysis shows that there are many sequences on the human Y-chromosome that are potential precursor 
microRNA. The experimental validation is in process and will be presented in the meeting. The identification of Y-
chromsome specific miRNA might lead to yet unknown ways of regulating male specific expression of genes and/or 
gender specific epigenetic regulation. 
 
Poster No: P069-F 
When 11p15.5 genomic imprinting meets pluripotency factors 
1Julie Demars, 1Mansur Ennuri Shmela, 2Sylvie Rossignol, 2Irène Netchine, 1Jun Okabe, 2Salah Azzi, 2Sylvie Cabrol, 
3,4Cédric Le Caignec, 3Albert David, 2Yves Le Bouc, 1Assam El-Osta, 1Christine Gicquel 
1Epigenetics in Human Health and Disease, Baker IDI Heart and Diabetes Institute, Melbourne, 3004, Victoria, Australia. 
2APHP, Hopital Armand Trousseau, Laboratoire d’Explorations Fonctionnelles Endocriniennes, Unité mixte de recherche 
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The paternally expressed IGF2 and maternally expressed H19 genes are located on the human 11p15.5 chromosomal 
region. A 4.2kb, paternally methylated, germline imprinting control region 1 (ICR1) between IGF2 and H19 is responsible 
for monoallelic expression of both IGF2 and H19. The ICR1 domain works as a methylation-sensitive chromatin insulator 
by binding the CCCTC-binding factor (CTCF) in a parent-specific manner. Many studies point to a crucial role of CTCF in 
maintaining rather than establishing imprinting of the ICR1 region. However, the germline-specific processes that 
establish the differential ICR1 methylation in the female and male germlines remain unknown. 
DNA methylation defects involving the IGF2/H19 domain result in two fetal growth disorders with opposite phenotypes: the 
Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder (maternal ICR1 gain of methylation in 10% of BWS cases) 
and the Silver-Russell syndrome (SRS), a growth retardation disorder (paternal ICR1 loss of methylation in 60% of SRS 
cases). Maternally-inherited deletions involving CTCF binding sites located within the ICR1 domain have been reported in 
a few BWS familial cases; however, attempts to identify such deletions or mutations in ICR1 CTCF binding sites in SRS 
patients, including a few familial cases, were negative. 
We therefore hypothesized that other sequences than CTCF binding sites located within the IGF2/H19 domain could be 
implicated in patients with ICR1 DNA methylation defects. We investigated extensively the ICR1 domain in a group of 
patients (21 BWS and 16 SRS) with an ICR1 gain/loss of methylation and no genetic abnormalities involving CTCF 
binding sites. 
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We identified three novel ICR1 imprinting anomalies in BWS patients. Those defects consisting of small deletions and a 
single mutation do not affect one of the seven CTCF binding sites. Interestingly, all of them involved pluripotency factor 
binding sequences, more particularly OCT4 and SOX2 binding sites. We also demonstrated by gel shift assay analysis 
that i) OCT4 and SOX2 proteins bind the identified sequences at the IGF2/H19 domain; ii) genetic anomalies identified in 
the three BWS patients with an ICR1 gain of methylation alter the binding of OCT4 and SOX2 pluripotency factors. 
Altogether, those results highlight the importance of other transcription factors (OCT4 and SOX2) than CTCF in the 
regulation of genomic imprinting at the 11p15.5 region. Further studies will investigate whether pluripotency factors play a 
role in the ICR1 differential acquisition of DNA methylation in germlines. 
 
Poster No: P083-W 
MicroRNA function in regulating pluripotency and differentiation of Human Embryonic Stem cells 
Lay Teng Ang1,2, Ludovic Vallier1 and Bing Lim2,3    
1Laboratory for Regenerative Medicine, University of Cambridge, Department of Surgery. Cambridge UK 2Stem Cell and 
Developmental Biology Group, Genome Institute of Singapore, Agency for Science, Technology and Research, 138672 
3Beth Israel Deaconess Medical Center, Harvard Medical School  
  
MicroRNAs (miRNAs) are key regulators of gene expression and are essential for early development in mouse embryos. 
The requirement of miRNAs is supported by genetic studies in the mouse showing that loss of Dicer or Dgcr8, key 
components of miRNA processing machinery, resulted in developmental arrest and embryonic lethality. In addition, 
mouse ESCs mutant for either enzyme, are defective in downregulating pluripotency markers upon differentiation, 
indicating that miRNAs are necessary to inhibit pluripotency during differentiation. Furthermore, knockouts of individual 
miRNA families such as miR-1 and miR-17-92b resulted in severe developmental defects in the mouse. Despite the 
importance of miRNAs in early development and the rapid identification of miRNAs, the possible function of many of these 
miRNAs remains to be precisely defined. This project aims to investigate the function of miRNA in regulating mechanisms 
governing pluripotency and early cell fate specification of mammals, using human ESCs as an in vitro model of 
development. 
 
MiRNAs that could potentially regulate pluripotency and differentiation were identified by performing miRNA expression 
profiling of the specification of hESCs into definitive endoderm. Importantly, high level of homogeneity was obtained using 
a fully chemically defined system and an efficient differentiation protocol. Using this approach, more than 20 miRNAs were 
found to be up or down regulated upon differentiation of hESCs. The expression data was validated with Taqman 
microRNA assay and miRNAs showing significant change in expression were functionally characterized by over-
expression and inhibition studies. 
Together these results will provide a comprehensive model explaining the function of miRNA in the transition between 
pluripotency and the endodermal pathway and expand the key gene regulatory network regulating these processes. The 
understanding of these mechanisms is essential for the generation of stable and fully functional endodermal cell states for 
future regenerative medicine applications. 
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Increased Sensitivity of Copy Number Variation Detection Using a High-Density Array CGH Platform  
HUGO J (2010) 4:1–190 119
123

Christine J. Shaw, Kathleen O'Moore, Joel Geoghegan, Nan Jiang, Todd A. Richmond, Vanessa L. Ott, Rohaizah James, 
Rebecca R. Selzer 
Roche NimbleGen, 504 S. Rosa Road, Madison, WI 53719, USA 
Array CGH methods have been widely used to investigate genome-wide DNA copy number variation associated with 
complex disorders. Disease association studies have become increasingly focused on CNVs, and several recent reports 
show links between CNVs and schizophrenia (Stefansson 2008; Stone 2008), autism (Sebat 2007; Marshall 2008; 
Glessner 2009), and cancer, among others. More recently, the focus of CNV research has migrated to detection of rare 
variants, with an allelic frequency < 5% (Conrad 2009, Manolio 2009). In an effort to increase detection of rare variants as 
well as more common CNVs, we sought to develop the highest density oligo array available for CNV detection, as well as 
a more sensitive algorithm for CNV detection on NimbleGen arrays. 
The 2.1M and 3x720K CNV-focused arrays contain empirically optimized probes, with the most comprehensive collection 
of targeted regions available, including Asian population-specific CNV regions. Utilization of the CNV-focused arrays 
enabled detection of hundreds of CNVs per individual. When compared to whole genome tiling arrays, 2- to 3- fold more 
CNVs were detected with the CNV-focused arrays. When the Roche-NimbleGen CNV-focused arrays were compared to 
competitive array platforms, we found an average of 300% and 245% more CNVs were detected with the 2.1M and the 
3x720 platforms, respectively. Additionally, the higher probe density of Roche-NimbleGen arrays allowed 2-fold higher 
detection of CNVs < 1,000 bp in size when compared to competitive array platforms. The increased sensitivity of CNV 
detection was aided by an improved segmentation algorithm (segMNT), included in NimbleScan v2.6 software. A 
comparison between the segMNT v1.1 and segMNT v1.2 algorithms shows increased sensitivity in detection of CNVs 
resulting in about 2-fold more CNVs detected per sample with segMNT v1.2. 
We demonstrate here the variability in sensitivity of CNV detection based on the platform and algorithm utilized. We show 
the increased detection of total CNVs, as well as CNVs of smaller size with the Roche NimbleGen CNV-focused arrays 
and NimbleScan v2.6 software. 
 
Poster No: P018-F 
Stoichiometry of base excision repair proteins contributes to the tissue selectivity of somatic CAG expansion in 
Huntington’s disease mice. 
Merienne K1 Goula A-V 1, Berquist, BR 2, Wheeler VC 3, Wilson DM 3rd2 and Trottier Y 1 
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CNRS/INSERM/ULP, BP10142, 67404 Illkirch Cédex, CU de Strasbourg, France 2Laboratory of Gerontology, National 
Institute on Aging, NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA 3Molecular Neurogenetics Unit, Center for 
Human Genetic Research, Massachusetts General Hospital, Boston MA 02114, USA 
 
Huntington’s disease (HD) is an inherited progressive neurodegenerative disorder caused by an unstable CAG repeat in 
the Huntingtin gene. Instability of the mutation affects both germline and somatic cells. Somatic instability is tissue-specific 
and increases with age. In particular, the CAG repeat sequence in the striatum, the brain region that preferentially 
degenerates in HD, is highly unstable, whereas it is rather stable in the disease-spared cerebellum. The mechanisms 
underlying the age-dependence and tissue-specificity of somatic CAG instability remain elusive. Recent studies have 
suggested that DNA oxidation and OGG1, a glycosylase involved in the repair of 8-oxoG lesions, contribute to this 
process. We show that in HD mice oxidative DNA damage alone is not sufficient to trigger somatic instability. Protein 
levels and activities of major base excision repair (BER) enzymes were compared between striatum and cerebellum of HD 
mice. Strikingly, 5’-flap endonuclease activity was much lower in the striatum than in the cerebellum of HD mice. 
Accordingly, Flap Endonuclease-1 (FEN1), the main enzyme responsible for 5’-flap endonuclease activity was also 
significantly lower in the striatum compared to the cerebellum. Finally, chromatin immunoprecipitation experiments 
revealed that POLb was specifically enriched at CAG expansions in the striatum, but not in the cerebellum of HD mice. 
These in vivo data fit a model in which POLb strand displacement activity during LP-BER promotes the formation of stable 
5’-flap structures at CAG repeats representing pre-expanded intermediates structures, which are not efficiently removed 
when FEN1 activity is constitutively low. We propose that the stoichiometry of BER enzymes is one critical factor 
underlying the tissue selectivity of somatic CAG expansions. 
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TaqMan® real time PCR based assays for detecting mouse copy number variations 
1Xiaoqing You, 1Annie Titus,1Fawn Wang, 1Kelly Li, 1Yu Wang 
1Life Technologies, 850 Lincoln Centre Drive, Foster City, CA 94404, USA 
Copy number variations (CNV) are found in many species including human and mouse. CNVs have been directly linked to 
biological functions and have been associated with genetic disorders and diseases. Mouse is the most commonly used 
mammalian model organism for genetics and disease research. The study of mouse copy number variations plays an 
important role in understanding functions and biological impact of genomic variations. 
We developed quantitative TaqMan® real time PCR assays that can be used to detect copy number variations in mice 
and to screen transgenic and knockout mice. Each assay reaction consists of a duplex assay: a FAM™ dye-based target 
assay designed to detect a target-of-interest on genome and VIC® dye-based reference assay that detects a sequence 
known to be present in two copies in a diploid genome. The copy number of the target of interest is determined based on 
the relative quantification of the target assay versus the reference assay. 
We designed mouse TaqMan® copy number reference assays and 28 TaqMan® copy number assays that target 18 
mouse genes using proprietary computational algorithms. We also designed assays for reporter genes (including 
neomycin resistance (Neo) gene, beta-D-galactosidase LacZ and green fluorescent protein (GFP)) that are frequently 
used as markers in targeted mouse mutagenesis and gene manipulation. The assays were tested on 48 DNA samples 
(including aneuploidy samples with known chromosome abnormality) from 17 mouse strains and 40 transgenic and 
knockout samples. The copy number results were subsequently compared with the expected genotypes of mouse 
samples. Our studies demonstrate that the assays detect copy number variations of different mouse strains/sub-strains 
with high accuracy and specificity. 
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Copy number variation in severe early onset childhood obesity 
1Bochukova E.G.*, 2Huang N., 1Keogh J.,1Henning E.,1 O’Rahilly R.,2 Hurles M.E.,1 Farooqi I.S. 
1 University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, 
Cambridge, CB2 0QQ, UK 2 Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK 
 
Severe obesity is highly heritable and genetically heterogeneous disorder. We set out to investigate the contribution of 
copy number variation to obesity in the Genetics of Obesity Study cohort (GOOS), using Affymetrix SNP 6.0 microarrays. 
Our discovery set consisted of 300 Caucasian patients with severe early-onset obesity, approximately half of whom also 
had developmental delay. Large (>500 kb), rare (<1%) deletions were significantly enriched in patients compared to 7,366 
controls (P<0.001). Multiple rare copy number variants (CNVs) were found recurrent in patients but absent or at much 
lower prevalence in controls. 
The most common recurrent CNV was identified in five patients with overlapping deletions on chromosome 16p11.2, only 
found in 2 out of 7,366 controls (P<5x10-5). The 16p11.2 deletion co-segregated with severe obesity in three of the 
patient’s families. Two of the patients harboured a larger de novo 16p11.2 deletion, extending through a neighbouring 
CNV region where deletions have previously been associated with autism and mental retardation phenotypes; both of 
these patients had mild developmental delay in addition to severe obesity. The 220 kb region of minimal overlap of the 
16p11.2 deletions contains several genes including SH2B1, known to be involved in leptin and insulin signalling. Deletion 
carriers exhibited hyperphagia and severe insulin resistance disproportionate for the degree of obesity. The phenotype of 
the patients was consistent with SH2B1 haploinsufficiency as an underlying molecular mechanism. 
We have then broadened our investigation into the extent of CNV contribution to early-onset obesity phenotype in the 
SCOOP cohort: 1,000 UK Caucasian patients with severe early-onset obesity from GOOS. This dataset was analysed for 
the presence of recurrent CNVs, previously reported by us. We found many of the recurrent CNVs present in this 
replication cohort, including the SH2B1-containing deletion. 




In conclusion, we show that copy number variation contributes significantly to the genetics of human obesity, warranting a 
further investigation into the influence of CNV-contained genes on the obesity phenotype. 
 
Poster No: P063-F 
Use of DNA –PET technology in human congenital disorders: a new whole genome approach 
Valere Cacheux1,  Kagistia.Hana Utami1, Elaine Chew1, Kim Ng1, Zhang Zhenshui1 Seong Soo Lim1, Pascal de Santa 
Barbara2, Sylvain Briault3, Robyn Jamieson4, Edison Liu1, Yijun Ruan1, Axel Hillmer1,  
1Genome Institute of Singapore, 2InsermERI25 Montpellier, France,3 CHROrleans France,4The Children’s Hospital at 
Westmead, Sydney, Australia. 
Identification and characterization of chromosomal anomalies and DNA alterations in human congenital disorders are still 
one of the biggest challenges in human genetics. Considering the limitations of current technologies (resolution for 
karyotype, coverage and inability to detect balanced rearrangements for array-CGH, time-consumption and low resolution 
for breakpoint mapping techniques), most of the cases are not detected or not widely explored. Recently, the development 
of whole genome paired-end sequencing approaches (DNA-PET) has demonstrated that such technologies can identify 
copy number variations, balanced and unbalanced DNA rearrangements, and then map the breakpoints at the gene level 
in normal and cancer genomes. 
In order to evaluate the ability of this technology to detect rearrangements and pinpoint the putative causative gene in 
congenital disorders, we applied the DNA-PET technology to 5 independent patients presenting a birth defect with or 
without known chromosomal anomalies (selected by karyotype).  
The DNA of these 5 patients was subjected to DNA-PET and high throughput sequencing processes. After random 
shearing, the DNA fragments were processed for extraction of PET construct and paired end sequencing. The PET 
sequences were then mapped to the human reference genome (Hg18) and structural variations detected as discordant 
PETs. Then, a Copy Number Variations (CNVs) filtration and a cross comparison using normal DNAs libraries were done 
and revealed specific and unique structural variations for each sample (between 50-100). Results obtained from the 5 
DNAs allowed the detection of specific breakpoints of chromosomal rearrangements and the causative disease gene in 2 
of the patients, the identification of candidate genes for 2 patients and a technical issue of interpretation for one patient. 
We present here the results, and discuss the advantages and current improvements of DNA-PET technology as a 
complete tool for identification, mapping and sequencing of chromosome rearrangements to identify new genetic 
syndromes. 
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Deletion of SULF1 and SLCO5A1 genes at 8q13 causes mesomelia-synostoses syndrome 
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Mesomelia-synostoses syndrome (MSS) or mesomelic dysplasia with acral dysostoses Verloes-David-Pfeiffer type is a 
rare autosomal dominant disorder characterized by mesomelic limb shortening, acral synostoses and multiple congenital 
malformations. So far, five patients in four unrelated families have been reported worldwide with MMS. Using whole 
genome oligonucleotide array CGH, we have identified an interstitial deletion at 8q13 in all patients. The deletions vary 
from 582 kb to 738 kb in size, but invariably encompass only two genes: SULF1, encoding the heparan sulfate 6-O-
endosulfatase 1 and SLCO5A1, encoding the solute carrier organic anion transporter family member 5A1. SULF1 acts as 
a regulator of numerous growth factors in skeletal embryonic development while the function of SLCO5A1 is yet unknown. 
Breakpoint sequence analyses performed in two families showed non-recurrent deletions. Our results strongly suggest 
that haploinsufficiency of SULF1 contributes to this mesomelic chondrodysplasia, highlighting the critical role of 
endosulfatase in human skeletal development. As co-deletion of SULF1 and SLCO5A1 - which does not result from a low-
copy repeats (LCRs)-mediated recombination event - was found in all patients, we suggest that haploinsufficiency of 
SULF1 combined with haploinsufficiency of SLCO5A1 (or the altered expression of a neighbouring gene through a 
position effect) could be necessary in the pathogenesis of MSS. 
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A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel 
sequencing 
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Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain. We have 
applied the Illumina massive parallel sequencing to deeply analyze the small RNA populations of two different forebrain 
areas, the frontal cortex (FC) and the striatum (ST) of healthy individuals and individuals with HD. More than 80% of the 
small-RNAs were annotated as miRNAs in all samples. Deep sequencing revealed length and sequence heterogeneity 
(IsomiRs) for the vast majority of miRNAs. Around 80-90% of the miRNAs presented modifications in the 3’-terminus 
mainly in the form of trimming and/or as nucleotide addition variants, while the 5’-terminus of the miRNAs was specially 
protected from changes. Expression profiling showed strong miRNA and isomiR expression deregulation in HD, most 
being common to both FC and ST. The putative targets of the seed-region of deregulated miRNAs/isomiRs strongly 
suggest that their altered expression contribute to the aberrant gene expression of HD. Many REST (RE1-Silencing 
Transcription Factor) modulated miRNAs were downregulated in HD, suggesting that repressed REST target miRNAs 
play a role in aberrant gene expression in HD. Our results show that miRNA variability is a ubiquitous phenomenon in the 
adult human brain, which may influence the mechanism of gene expression modulation. 
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Common genetic determinants of vitamin D insufficiency: a meta-analysis of genome-wide association studies  
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Background: Vitamin D is crucial for maintaining musculoskeletal health. Recently, vitamin D insufficiency has been linked 
to a number of extraskeletal disorders, including diabetes, cancer, and cardiovascular disease. Determinants of circulating 
25-hydroxyvitamin D (25-OH D) include sun exposure and dietary intake, but its high heritability suggests that genetic 
determinants may also play a role. 
Methods: We performed a genome-wide association study of 25-OH D among ~30,000 individuals of European descent 
from 15 cohorts. Five cohorts were designated as discovery cohorts (n=16,125), five as in silico replication cohorts 
(n=9,366), and five as de novo replication cohorts (n=8,378). Association results were combined using z-score-weighted 
meta-analysis. Vitamin D insufficiency was defined as 25-OH D <75 nmol/L. 
Findings: Variants at three loci reached genome-wide significance in the discovery cohorts, and were confirmed in the 
replication cohorts: 4p12 (overall P=1.9 x 10-109); 11q12 (P=2.1 x 10-27); 11p15 (P=3.3 x 10-20). Variants at an 
additional locus (20q13) were genome-wide significant in the pooled sample (P=6.0 x 10-10). All confirmed variants were 
biologically relevant, showing direct associations with 25(OH)D synthesis, clearance, or binding. Participants in the top 
quartile of genotype scores had 2.5-fold elevated odds of vitamin D insufficiency (P=2.3 x 10-48). 
Interpretation: Variants near genes involved in synthesis, hydroxylation, and vitamin D transport influence vitamin D status. 
Genetic variation at these loci identifies individuals of European descent who have substantially elevated risk of vitamin D 
insufficiency. 
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Chromosomal conformation patterns govern the formation of conjoined genes in eukaryotic genomes. 
 
Tulika Prakash Srivastava, Ritsuko Ozawa, Todd D. Taylor.  
MetaSystems Research Team, Computational Systems Biology Research Group, RIKEN Advanced Science Institute 
(ASI), Yokohama 230-0045, Japan. 
Conjoined genes (CGs) are the transcripts formed by joining at least one complete or partial exon from two distinct (child) 
genes which lie on the same chromosome, are in the same orientation, and sometimes independently encode for different 
proteins. Previously, we identified several hundred CGs in the human and other eukaryotic genomes, including mouse 
and fruit fly, and proposed their functional roles including formation of novel proteins and regulation of the expression of 
the child genes. We also found that the number of CGs conserved from human to other vertebrate genomes including 
chimpanzee, mouse, and dog is correlated with the order of complexity of the genomes. Three obvious questions that 
arise from these observations are the following: 1) are all the human child gene pairs resulting in the formation of CGs 
also conserved in other genomes, 2) is their arrangement in human syntenic in other genomes, and 3) do all those human 
child gene pairs which are syntenic in other genomes give rise to a CG in that genome? In the present analysis we found 
that 64% of the child genes are conserved from human to mouse. We also found that although the fraction of those 
human child gene pairs which are syntenic in mouse (60%) is similar to that of all the gene pairs in the human genome 
(68%), only a very small fraction (12.6%) of all known CGs in mouse were found in these human syntenic regions. Similar 
observations were made for the chimpanzee, dog and fruit fly genomes. Therefore, a pair of child genes giving rise to a 
CG in human may not necessarily result into a CG in other genomes in spite of their syntenic arrangement. Together, 
these observations indicate a selective conservation of human child genes along with increasing genomic complexity. 
Also, it is evident that the formation of CGs in each genome is a context dependent process governed by its own genomic 
requirements like genetic regulation and its overall complexity. Chromosomal folding patterns have been postulated to 
affect the formation of CGs. Our observations provide strong support for this hypothesis because, although the human 




child gene pairs remain syntenic in lower organisms, they may not give rise to a CG in that genome due to a different 
conformation of its chromosomes. 
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Genome-wide association studies of hematological, biochemical and physiological traits in a Japanese 
population identified 49 novel loci. 
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Recent development of genome-wide association studies (GWASs) led to the identification of numerous quantitative trait 
loci (QTL). Here, we report GWASs for hematological, biochemical and physiological traits in the Japanese populations. 
We enrolled around ~20,000 Japanese individuals under the support of BioBank Japan Project (http://biobankjp.org). 
Genotyping was performed using Illumina Human610-Quad BeadChip or HumanHap550v3 BeadChip. The stringent 
quality control filters were applied, including principal component analysis (PCA) and the estimation of identity-by-descent 
(IBD). Quantitative traits were adjusted with covariates (age, sex, smoking, drinking, etc.) and normalized as Z scores. 
Associations of the SNPs with the adjusted quantitative traits were evaluated using linear regression analysis. 
We identified 62 associations for 9 hematological traits (white blood cell count: WBC, neutrophil count, red blood cell 
count: RBC, hemoglobin concentration: Hb, hematocrit: Ht, mean corpuscular volume: MCV, mean corpuscular 
hemoglobin: MCH, mean corpuscular hemoglobin concentra¬tion: MCHC, and platelet count: PLT), 29 associations for 12 
biochemical traits (urate: UA, high-density lipoprotein: HDL, triglyceride: TG, gamma glutamyl transferase: GGT, alkaline 
phosphatase: ALP, aspartate aminotransferase: AST, alanine aminotransferase: ALT, creatine kinase: CK, total protein: 
TP, albumin: ALB, blood urea nitrogen: BUN, and serum creatinine: sCr), and 8 associations for adult height at genome-
wide significance levels (P < 5×10^–8). Of these, 49 associations were novel and 50 were the replications for the previous 
reports. 
In addition to the identifications of the newly associated loci, our study provides the following topics. (i): Different genetic 
backgrounds of QTL among different populations. Although IGF1 is a well-known gene that plays an important role in 
skeletal development, the association of the variation in IGF1 with adult height had not been established in Europeans. 
Our study identified that the multiple SNPs were independently associated with adult height in IGF1 locus, and that their 
minor allele frequencies were high in Asian populations but quite low or monomorphic in Europeans. (ii): Most of the 
identified QTL included the genes that were functionally related with the traits, such as CSF3 gene as QTL for WBC and 
neutrophil count, ABO gene as QTL for RBC, Hb and Ht, and GGT1 gene as QTL for GGT. (iii): Even though a number of 
QTL were identified, most of the QTL would be still unidentified. We evaluated the combined effects of the height-
associated loci incorporating a total of 51 loci that were previously or newly identified. However, the explained proportion 
of the variance of adult height was as low as 4.8%. 
Our study would enhance our knowledge for QTL and motivate the accumulations of the further studies. 
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Digital gene expression data, cross-species conservation and noncoding RNA 
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Recently developed sequencing technologies offer massively parallel production of short reads and become the 
technology of choice for a variety of sequencing-based assays, including gene expression. Among them, digital gene 
expression analysis (DGE), which combines generation of short tag signatures for cellular transcripts with massively 
parallel sequencing, offers a large dynamic range to detect transcripts and is limited only by sequencing depth. As 
recently described (Philippe et al, 2009), tag signatures can easily be mapped to a reference genome and used to perform 
gene discovery. This procedure distinguishes between transcripts originating from both DNA strands and categorizes tags 
corresponding to protein coding gene (CDS and 3'UTR), antisense, intronic or intergenic transcribed regions. Here, we 
have applied an integrated bioinformatics approach to investigate tags’properties, including cross-species conservation, 
and the ability to reveal novel transcripts located outside the boundaries of known protein or RNA coding genes. We 
mapped the tags from a human DGE library obtained with Solexa sequencing, against the human, chimpanzee, and 
mouse genomic sequences. We considered the subset of uniquely mapped tags in the human genome, and given their 
genomic location, determined according to Ensembl if they fall within a region annotated by a gene (CDS, UTR and intron) 
or an intergenic region. We found that 76.4 % of the tags located in human also matched to the chimpanzee genome. The 
level of conservation between human and chimpanzee varied among annotation categories: 85 % of conserved tags in 
the CDS, 81 % in the UTR, 76% and 73% respectively in intron and intergenic regions. With the same procedure applied 
to human and mouse, we obtained 11% of conserved tags in the CDS, 7% in UTR, 1% and 3% respectively in intronic 
and intergenic regions. We analysed in depth the common CDS and UTR tags in human and mouse for their functional 
relevance: 90% of them correspond to orthologous genes with a common HUGO. We used DAVID database to extract 
biological features, the gene clustering revealed specific molecular functions belonging to transcription cofactor and 
regulator activity, nucleotide binding, ligase and proteine kinase, hormone receptor, histone methyltransferase or GTPase 
activity, and also important signaling pathways like WNT pathway. Indeed, intergenic transcription includes mainly new, 
non protein-coding RNAs (npcRNAs), which could represent an important class of regulatory molecules. By integrating 
also SAGE genie and RNA-seq expression data, we selected intergenic tags conserved across species and assayed 
experimentally the npcRNA transcriptome with Q-PCR. We validated 80% of the 32 tested biological cases. These results 
demonstrate that considering tag conservation helps to identify conserved genes and functions, which is of great 
relevance when investigating expressed tags located in intergenic regions. 
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On the utility of biobanks linked to electronic medical records in genome-wide association studies 
Logan Dumitrescu1,2, Marylyn D. Ritchie1,2, Joshua C. Denny3,4, Jill M. Pulley5, Melissa A. Basford5, Andrea H. Ramirez4, 
Daniel R. Masys3,4, Jonathan L. Haines1,2, Dan M. Roden4,5,6, and Dana C. Crawford1,2  
Departments of 1Molecular Physiology and Biophysics, 2Center for Human Genetics Research, 3Biomedical Informatics, 
4Medicine, 5Office of Personalized Medicine, 6Pharmacology, Vanderbilt University, Nashville, TN 37232 
 
Low levels of high-density lipoprotein cholesterol (HDL-C) are predictive of cardiovascular disease and myocardial 
infarction. Both genetics and the environment contribute to the variability of HDL-C trait distribution in the general 
population. To identify the genetic variants associated with HDL-C, candidate gene and genome-wide association studies 
(GWAS) have been performed in epidemiologic studies drawn from general population settings. Collectively, these studies 
identified more than ten genes or genomic regions associated with HDL-C levels in populations of European-descent, 
many of which are highly replicable in subsequent studies. An alternative strategy to the well-characterized epidemiologic 
study is the use of large DNA repositories or biobanks linked to electronic medical records (EMRs) as a source of data 
suitable for genome-wide association studies for gene discovery and replication. The advantages of biobanks are several-
fold, including rapid accrual of samples, multiple phenotypes and traits linked to each DNA sample, and dense 
pharmacologic data for drug exposure assessment. To explore this alternative strategy, the National Human Genome 
Research Institute’s electronic Medical Records and Genomics (eMERGE) Network aims to assess the utility of EMRs 
coupled to DNA repositories as a tool for GWAS and other genome studies. BioVU, the Vanderbilt DNA Databank, is one 
such repository of DNA samples extracted from discarded blood samples collected for routine clinical testing. These DNA 
samples are linked to a de-identified image of the EMR called the Synthetic Derivative. To date, BioVU contains >78,000 
DNA samples in the repository. As a member of eMERGE, a subset of BioVU DNA samples was genotyped on the 
Illumina Human660W-Quadv1_A by the Center for Genotyping and Analysis at the Broad Institute. Natural language 
processing algorithms were developed to select DNA samples for genotyping from patients with normal 
electrocardiograms without evidence of cardiac disease, as the QRS duration (a trait of the electrocardiogram) was the 
primary trait for analysis. Data were cleaned using the quality control pipeline developed by the eMERGE Genomics 
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Working Group, and a total of 514,841 SNPs in 2,337 samples were available for the primary trait analysis. A subset of 
the genotyped samples also contained trait information on HDL-C. As a secondary analysis, single SNP tests of 
association for median HDL-C were performed on these 1,079 genotyped samples. In unadjusted linear regressions 
assuming an additive genetic model, transformed HDL-C was associated with CETP SNPs rs1532624 and rs1800775 at 
p-values (betas) 1.79x10-8 (0.083) and 2.62x10-8 (0.082), respectively. Two other CETP SNPs were also associated with 
HDL-C levels at a significance threshold of 10-7. Thus, our “top hits” in this EMR-based GWAS replicate the findings of 
several GWAS and candidate gene studies performed in epidemiologic cohorts for HDL-C, suggesting EMR-based DNA 
repositories will be useful for discovery and replication for a variety of algorithm defined phenotypes and traits linked to 
DNA samples. 
 
Poster No: P012-W 
Association of CD226 gene with systemic lupus erythematosus through impaired mRNA processing in T cells 
Angelica M. Delgado-Vega*1, Marta E. Alarcón-Riquelme1, and Serge V. Kozyrev1, Sara E. Löfgren*1, Caroline J. 
Gallant1, Elena Sánchez2, Johan Frostegård3, Lennart Truedsson4, Bernardo A. Pons-Estel5, Sandra D’Alfonso6, Torsten 
Witte7, Bernard Lauwerys8, Emöke Endreffy9, Laszlo Kovacs9, Carlos Vasconcelos10, Berta Martins11, Javier Martin2,  
1Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden. 2Instituto de Biomedicina y Parasitología 
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Sweden 4Clinical Microbiology and Immunology, Lund University, Lund, Sweden 5Department of Rheumatology, Sanatorio 
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Salazar, Porto, Portugal 
Objective. 
The variant Gly307Ser/rs763361 of CD226 gene has recently been associated with a number of autoimmune diseases. 
We here report a fine mapping of the gene locus and the genetic association of several SNPs with systemic lupus 
erythematosus in Europeans, together with functional analyses to give a better understanding on the mechanisms behind 
the gene association and potential contribution of these variants. 
Methods. 
Genetic association of 12 SNPs in the CD226 gene was conducted using 1163 SLE patients and 1481 healthy controls 
from a European multicenter collection. Genotyping was performed using a GoldenGate Custom Genotyping Assay and a 
BeadXpress Reader from Illumina or Taqman assays and the statistical association analyzed with PLINK v1.07. Gene 
expression was analyzed by quantitative real-time PCR and SYBR Green for signal detection, using total RNA purified 
from PBMCs from healthy donors. Surface detection of the protein was performed by a three-color flow cytometry using 
leukocytes isolated from healthy donors, where total lymphocytes, CD3+CD4+, CD3+CD8+, CD3-CD56+, CD3-CD19+ 
and CD3+CD56+ cells were analyzed. Expression analysis of reporter plasmids including different alleles of the risk 
haplotypes of the CD226 3’-UTR region was assessed by transfection of HEK293 cells and dual luciferase assay. 
 
Results. 
A risk haplotype (P = 1.7 x10-7) was detected in the 3’-UTR region of the gene, and revealed rs727088 as the strongest 
associated variant (PCMH-adjusted = 0.0115). Expression analysis showed that the risk haplotype correlated with 
decreased levels of CD226 transcripts and protein levels in the surface of T helper cells (CD4+), Cytotoxic T cells (CD8+) 
and NK T cells (CD3+CD56+), but not NK cells (CD3-CD56+) or B cells (CD19+). Luciferase assays suggest that 
rs727088 is the main polymorphism responsible for altered gene expression. 
Conclusion. 
Our data does not support Gly307Ser as main functional variant within CD226 gene and indicates rs727088 located in the 
3’UTR region as the potential causative SNP, by a mechanism that alters protein expression in T cells, potentially 
involving mRNA processing and/or stability. 
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Molecular genetic analysis of hereditary diseases in Bashkortostan Republic of Russia 
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E.K. Khusnutdinova, I.M. Khidiyatova, R.I. Khusainova, A.S. Karunas, V.L. Akhmetova, L.U. Dzhemileva, R.R. Valiev. 
Institute of Biochemistry and Genetics, Ufa Science Center, RAS 
 
Hereditary diseases are characterized by clinic polymorphism and genetic heterogeneity, that’s why the decision of the 
most important problem of medical genetics is determination of population singularity and structural features of genes, 
determining development of these diseases. Here we report the main results of molecular-genetic analysis of Wilson 
disease (WD), Duchenne muscular dystrophy (DMD), congenital adrenal hyperplasia (ɋȺɇ), Marfan syndrome (MFS) and 
non-syndromic hereditary deafness (NSHD) in Bashkortostan Republic. 
  
WD is an autosomal recessive disorder characterized by toxic accumulation of copper in liver, brain and other organs. 
Using SSCP analysis followed by direct sequencing, among 38 unrelated patients we have characterized the molecular 
defect in 81.8% of WD chromosomes and identified 9 different mutations and 3 polymorphic variants. The common 
His1069Gln mutation was represented in 43.9% of WD chromosomes. Three novel mutations (ɪ.Ala718Pro, 
p.Leu1057Pro and ɪ.Lys1315_Arg1316delinsGlu) were revealed. Mutation ɪ.Lys1315_Arg1316delinsGlu was detected in 
18.2% of Tatar chromosomes and 22.2% of Bashkir chromosomes. 
  
DMD is caused by mutations in the dystrophin gene consisting of 79 exons. We studied mutations spectrum of twenty 
exons (3, 4, 6, 8, 13, 17, 19, 42-53, 60) and promoter region of DMD gene in patients from 60 unrelated families. Exon 
deletions of the gene were revealed in 31.75% of families. We revealed also 2 new point mutations not described before 
and 1 polymorphism: p.Thr134ThrfsX7 (3.17%); p.Lys2210ArgfsX11 (1.6%); c.7728T>C (Asn2575Asn) (1.6%). 
ɋȺɇ is a group of autosomal recessive disorders of adrenal steroid genesis in which 21-hydroxylase deficiency accounts 
for over 95% of cases. We studied 83 patients with CAH. Mutations of the CYP21A2 gene were revealed in 69.19% of the 
studied CAH-chromosomes. The mutations were distributed as follows: delA2/LGC (26.74%), p.Arg356Trp (16.28%), 
I2splice (11.05%), p.Ile172Asn (7.56%), p.Gln318X (5.23%), p.Pro30Leu (1.16%) and p.Val.281Leu (1.16%). We found 7 
patients who carried 3 mutations, two from which formed a cluster: p.Gln318X+p.Arg356Thr (N=5), 
p.Ile172Asn+p.Gln318X (N=1), p.Ile172Asn+Arg356Thr (N=1). This complex of alleles probably resulted from large 
conversions or multiple mutations events. 
  
MFS is an inherited autosomal dominant connective tissue disorder. We analyzed 30 exons of FBN1 gene and 4 exons of 
TGFBR2 gene in 80 unrelated patients with MFS. We identified two missense mutations (p.Gly1176Tyr and p.Cys2489Tyr) 
which affect cbEGF-like motifs of fibrillin-1 protein in two patients with classical MFS. We also found 9 polymorphisms 
both in coding and non coding regions of FBN1 gene, five of them are not previously described. One novel mutation 
(p.T223M) has been found in TGFBR2 gene in two unrelated patients. 
  
NSHD is one of the most common disorders of sensorineural function. We analyzed the GJB2 gene in 100 unrelated 
patients. Four different frequent mutations 35delG (44% of GJB2 alleles), 312del14 (4%), del167T (3%) and 235delC 
(1.5%) were observed. The 35delG mutation of the GJB2 gene is responsible for deafness in 53% of the independent 
Russian families tested. 
These findings became a base for optimal scheme of DNA-diagnostics development of these hereditary diseases in the 
Volga-Ural region and ascertainment of the mutations origin, leading to these diseases. 
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Effect of Tumour Necrosis Factor Gene Polymorphism on Risk of Metabolic Syndrome in Young Obese Males 
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Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore 
 
Obesity is on the rise worldwide and is associated with the development of significant medical illnesses and 
consequences. One example is the metabolic syndrome or insulin resistance, a condition that consists of multiple, 
interrelated risk factors of metabolic origin strongly associated with risk of heart disease and type 2 diabetes. Adipose cell 
enlargement in obesity induces a proinflammatory state in the tissue with the infiltration of macrophages, which increases 
the level of cytokines such as tumour necrosis factor (TNF). The increased level of cytokines promotes ectopic lipid 
storage and induces insulin resistance locally and in other peripheral tissues. 
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In our study of the health profile of 713 local Chinese males aged 18 to 21 years old, metabolic syndrome was found to be 
prevalent (25.2%) in the obese individuals (n=377, body mass index, BMI>28kg/m2), while absent in the normal weight 
individuals (n=336, BMI<23kg/m2). Hence, we sought to find out whether associations exist between genetic variation in 
cytokine genes and metabolic syndrome or any of its five components in young obese males. DNA extracted from venous 
blood of the 377 obese were genotyped for five SNPs located near 5’ of TNF (rs1799964, rs1800630, rs1799724, 
rs1800629, rs361525) on the Sequenom MassARRAY platform and analysed for association with metabolic syndrome 
and its five components by logistic regression, assuming an additive model. rs1800629 allele G was associated with risk 
of metabolic syndrome in the obese (P=2.23 x 10-3, OR=3.263, 95%CI=1.529 to 6.964). This association remained 
significant after adjusting for BMI (P=2.12 x 10-3, OR=3.314, 95%CI=1.543 to 7.116). rs1800629 allele G was also 
associated with larger waist circumference (one of the components of metabolic syndrome) after adjusting for BMI 
(increase by 1.3cm per allele, P=3.19 x 10-2, 95%CI=0.112 to 2.479). Both BMI and TNF rs1800629 allele G accounted for 
about 5.8% of the variation of the outcome of having metabolic syndrome in the obese. The results showed that genetic 
variation in TNF plays a part in explaining the susceptibility to having metabolic syndrome in young obese males. 
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From Research to Clinic : the clinician-patient relationship as a key of the high throughput technology transfer 
into clinic 
1Sophie Julia, 1Alexandra Soulier, 2Anne Cambon-Thomsen 
1INSERM, France; 2CNRS, FRANCE 
Genetic testing is becoming a growing part of healthcare services. Seeing that genetic diseases are often molecularly and 
clinically highly heterogeneous, their clinical investigation requires sophisticated diagnostic tools. Rapid developments of 
high throughput technology (HTT) provide such opportunities but sequencing genes generates complex and 
heterogeneous information with different levels of clinical relevance. Some ethical issues specifically challenge the 
transfer of these improved technologies from the research laboratory to their clinical applications. Dealing with unexpected 
health related information as well as communicating data that lack widely accepted interpretation among clinicians are 
especially of relevance. 
Our concern is about the evaluation that estimates the clinical relevance of genetic information generated by new 
technologies. The process that allows validation of technologies and the interpretation of the results they provide is 
usually formalized in the ACCE framework – which considers successively Analytic validity; Clinical validity; Clinical utility; 
and Ethical, legal, and social implications of innovative technologies. The place allocated to the patient/clinician relation is 
not clear in this assessment. But, as emerging technologies provide complex data that deliver different levels of (un-
)certainty and thus may affect the clinician’s ability to communicate with patients, it seems that the patient/clinician relation 
should be thoroughly studied and become a relevant parameter in the evaluation process. 
ACCE framework does not specify this dimension. This paper therefore aims to illustrate by some case studies how such 
a level of complexity affects the relation between patient and clinician and to provide some insights about the way this 
dimension could be integrated into the technology validation process. Using qualitative focus groups and questioning 
them about these emerging technologies, we will analyze results concerning how various publics perceive the increasing 
complexity of data and its impact over the communication between clinicians and patients. 
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Introduction: Cystic fibrosis (CF) is one of the most common inherited disorders among Caucasians. The common 
mutations of CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene has been well established among 
Caucasian populations. However, little has been reported on the spectrum of mutations in Koreans. In this study, we 
summarized the results of CFTR mutational spectrum from Korean CF patients. 
Material and method: We have analyzed the complete coding regions and flanking intronic sequences of the CFTR gene 
among seven unrelated CF patients (2 males, 6 females). To rule-out large deletions or gene rearrangements, the 
multiplex ligation-dependent probe amplification (MLPA) analysis was performed in one patient detected with only one 
known mutation. 
Results: Twelve CFTR mutations were identified from seven patients including Q98R, Q220X, D979A, Q1291X, Q1352H, 
579+5G>A, IVS8-T5, 1766+2T>C, 2052delA, 2623-?_2751+?del, 3272-26A>G, and 3908insA. Q98R mutation was the 
only recurrently observed mutation with a frequency of 21.4% (3/14 alleles). No delta F508 mutation, which is known to be 
the most common mutation among Caucasians, was detected in Korean patients in this study. 
Conclusion: This study is the first to collectively summarize the CFTR mutational spectrum of Korean CF patients. 
Detection of no delta F508 mutation and a heterogeneous spectrum of CFTR mutations differed from the common CFTR 
mutational spectrum in Caucasians. Therefore, the genetic analysis of CFTR gene among Korean CF patients 
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The HUGO Gene Nomenclature Committee (HGNC) aims to approve a gene symbol and name for every human gene. 
Standardisation of gene symbols is important as it allows researchers to refer to the same gene without ambiguity and 
facilitates electronic data retrieval. The primary tenet of the HGNC is that every approved gene symbol must be unique. 
Gene symbols should also be acceptable to researchers to ensure their widespread use, and should be based on 
structure, function or homology wherever possible. The HGNC encourages the development of a common root symbol for 
members of a gene family, with a hierarchical numbering system to distinguish the individual members, as this is an 
efficient way to name large numbers of related genes and makes each family member instantly recognisable. We provide 
individual web pages on our site for many established gene families and have over one hundred specialist advisors that 
help us to accurately maintain these families. 
 
Here we present the story of one particular gene symbol, ABCA13, to demonstrate the steps taken when naming a gene. 
We explain how and why this gene received its current symbol and name (ATP-binding cassette, sub-family A (ABC1), 
member 13) and how the symbol has subsequently been used. The story begins with the development of the ABC (ATP-
binding cassette) gene superfamily and sub-family nomenclature scheme, following in depth discussions between the 
HGNC and the ABC research community. It then follows the identification and naming of ABCA13 as part of this family, its 
appearance in the biomedical literature and databases, its adoption for the mouse and rat orthologs as Abca13, and its 
subsequent breakthrough into the international media. 
 
For further information on human gene nomenclature, please email us at hgnc@genenames.org, or visit 
http://www.genenames.org/. The work of the HGNC is supported by the NHGRI and the Wellcome Trust. 
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Prediction of potential miRNA function modulators through the analysis of miRNA target variability in large 
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miRNAs are small non-coding RNAs involved in the fine tuning of gene expression through base pairing with the 3’UTRs 
of their target genes. It has been shown that genes that contain target sites for miRNAs have higher brain expression 
variability among individuals than those that are not targeted by miRNAs (Zhang and Su 2008); and that high miRNA 
activity is correlated with lower expression of their targets (Sood et al 2006). We can therefore hypothesize that the 
expression of those genes involved in miRNA activity will also correlate with the expression of miRNA target genes. For 
example, mice with Dgcr8 haploinsuficiency, a key gene involved in miRNA biogenesis, have shown to have a higher than 
expected proportion of upregulated genes among all miRNA targets in brain (Stark et al 2008). 
 
In order to identify novel candidate genes involved in the function of miRNA (such as DICER, DGCR8 and FMR1) we 
have examined the expression variability of miRNA target genes in three different large transcriptome datasets from 427 
liver human samples (Schadt et al 2008), 210 human lymphoblastoid HapMap samples , and 199 cortex human samples 
(Myers et al 2007). Briefly, for each individual, we assessed the expression ratio between genes predicted to be miRNA 
target and those that are not. We next analyzed the correlation between this ratio, taken as a molecular phenotypic trait, 
and the expression levels for each of the genes tested within each transcriptome. 
We found that: (i) the expression variability of targets compared to non-target genes observed among individuals also 
occurs among tissues. Particularly, in both HapMap and cortex samples, miRNA targets show higher expression than the 
non miRNA targets, whereas in liver, miRNA targets were downregulated when compared to the non targets. This 
suggests that miRNA repression might be higher in the liver, compared to the other tissues. (ii) We identified genes whose 
expression correlates with miRNA target/non target ratio in the three datasets used. which might be novel genes 
potentially involved in the silencing function of miRNA. In agreement with this, we have found among our best candidates, 
the FMR1 gene, which has been proved to be associated with miRNA activity (combined pvalue = 8.2 x 10-72). In addition, 
within the same set we also found STAU1 (Staufen), which has been shown to be involved in miRNA related p-body 
assembly (combined p value across three datasets = 5,2 x 10-66).  
Our results strongly suggest that this approach might be useful to identify novel candidate genes involved in the silencing 




Poster No: P080-F 
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In recent times, Alu repeats, the most abundant repetitive elements in the human genome (~11%) and miRNAs (~1000 
discovered miRNAs), small RNAs that alter gene expression at the post-transcriptional level have been the focus of 
research, owing to their multi-dimensional regulatory role at the genome wide level. miRNA mostly target 3' UTR regions 
which are also most preferred sites for Alu exonization, present in >5% of all human 3' UTRs. Role of Alu RNA in 
repressing transcriptional initiation has been demonstrated in response to heat shock. However, post transcriptional 
regulation mediated by miRNA targeting Alus has not been studied. We attempted to explore the role of miRNA targeting 
exonised Alus at genome wide scale in response to heat shock in HeLa cell line. Total RNA was isolated from HeLa cells 
following recovery for 2 hours, after heat shock treatment for 30 mins at 45°C. mRNA expression profiling was carried out 
using Illumina WG-6 v3.0 48K Beadchip and miRNA using Exiqon dual-channel arrays. The mRNA expression analysis 
was carried out using Illumina Beadstudio. For miRNA expression analysis we have used Gene-specific dye bias 
normalization, using GASSCO method from Bioconductor package. Validation of differentially expressed miRNAs and 
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mRNAs was carried out by Q-PCR using SYBR. The 3' UTR targets for miRNA was predicted using a consensus of 2 
softwares – miRanda and TargetScan, and only those miRNAs were taken for validation which had free energy less than -
20. Alu repeats were identified using repeat masker. Amongst the 3480 differentially expressed genes, 1341 were 
upregulated and 2439 were downregulated. 7 out of 12 differentially expressed genes were validated by Q-PCR. 15 
miRNAs were observed to be differentially expressed, out of which 3 were validated by Q-PCR, using SNORD non-coding 
RNAs as internal control. We found 9 genes to be negatively correlated with the expression of the validated miRNAs. 
Interestingly, 6 out of 9 genes have miRNA targets only in the Alu repeat present in 3'UTR of Alu exonised transcripts. 
These results suggest that miRNA mediated regulation of Alu exonized transcripts may add to the repertoire of 
transcriptomic diversity being contributed by Alu repeats. This regulation may be cell line and condition specific. Further 
experimental validations of these results are in progress in different cell lines. 
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Genome-wide association study detects a novel profile of genetic variations associated with individual response 
to opioid therapy for cancer pain  
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collaboration with the European Pharmacogenetic Opioid Study and the European Palliative Care Research Collaborative 




Patients treated for cancer pain experience different responses to opioid drugs and different side effects for reasons that 
are mostly unknown. We tested the hypothesis that genetic variations may be predictive of individual response to opioids 
by genome-wide association study (GWAS) using single nucleotide polymorphism (SNP)-arrays in patients who 
underwent opioid therapy for cancer pain. From the total study sample of 2294 patients we tested one million SNPs in 
patients selected for extremely poor (pain relief <40%; n=145) or good (pain relief >90%; n=293) responses to opioid 
therapy for cancer pain, using a DNA pooling approach. A first selection of SNPs based on allelic hybridization intensity 
detected 21,538 SNPs at a nominal p<1e-07. Among these SNPs, differences in chromosome counts between poor and 
good responders highlighted 72 SNPs (p<1e-05), which were further processed for genotyping in individual samples, 
resulting in 59 successfully genotyped SNPs. Almost all these SNPs (i.e., 56 of 59) showed statistically significant allelic 
association with opioid responder status (p<0.05), thus confirming the reliability of the DNA pooling approach in GWAS. 
Many of the associated SNPs mapped near or within genes that might be involved in the neural control of pain. Among 
putative candidate genes, gamma-aminobutyric acid (GABA) A receptor, beta 2 (GABRB2) gene encodes for the receptor 
of GABA, which mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor; ankyrin 3, node of Ranvier 
(ankyrin G) (ANK3) gene is a membrane-cytoskeleton linker that may participate in the maintenance/targeting of ion 
channels and cell adhesion molecules at the nodes of Ranvier and axonal initial segments; spondin 1, extracellular matrix 
protein (SPON1) gene encodes for a cell adhesion protein that promotes the attachment of spinal cord and sensory 
neuron cells; solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 (VGLUT2) 
(SLC17A6) gene mediates the uptake of glutamate into synaptic vesicles at presynaptic nerve terminals of excitatory 
neural cells. Overall, our results that deserve validation in independent groups of patients represent new findings that can 
direct further research to genetic variations hitherto not known to be predictive of individual response to opioids. 
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Purpose: i) To identify the causative gene in two large Tunisian families affected with autosomal recessive retinitis 
pigmentosa (RP) and linked to the RP25 locus. ii) To characterize the canine ortholog of EYS, mapping within RP25. 
 
Methods: Families were genotyped with microsatellite markers and SNP microarrays, and mapped using the Superlink 
and Merlin softwares. The 44 EYS exons were screened by PCR sequencing using primers designed in the intronic 
flanking sequences. Exonic rearrangements were searched by QM-PSF with fluorescent exon-specific primers. Total dog 
retinal RNA was extracted and subjected to RT-PCR to amplify the canine EYS cDNA. 
 
Results: Both families were linked to the RP25 locus (Z= +6.60 at ș=0 for D6S257 for family A, Z > +3.75 for multiples 
SNPs for family B), which contains the recently identified EYS gene. In family A, 15/18 patients were homozygous for a 
frameshift mutation (c.5928-2A>G) leading to p.Arg1976ArgfsX13. In family B, 8/9 patients carried a homozygous exon 12 
deletion leading to p.Cys590TyrfsX4. Both mutations cause a severe loss of the C-terminal part of the protein. Yet, 3/18 
and 1/9 patients in families A and B, respectively, were heterozygous for the causative mutations. QM-PSF revealed an 
exon 34 duplication segregating in trans in the 4 heterozygous patients. However, the duplication was also present in 14% 
of the Tunisian population as well as in an unaffected carrier of family B, thus excluding it as a causative mutation. In 
parallel, as a murine Eys ortholog does not exist, we sequenced the cDNA of the canine EYS ortholog as a first step 
towards the identification of an animal model for EYS-linked RP. By sequence alignments we determined that canine EYS 
comprises 43 coding exons and encodes a 3208 aa protein. Furthermore, canine EYS contains 3 additional exons that 
are not present in the human ortholog. Overall, the human and canine proteins show 75% homology for the regions 
common to both species. 
 
Conclusion: Heterozygous patients in the two families studied may carry an intronic EYS mutation causing exon skipping. 
We are currently RT-PCR-amplifying RNA from the lymphocytes of patients to identify aberrant transcripts. The 
identification of an EYS mutation in a dog affected with retinal progressive atrophy would provide a useful model for 
establishing future therapies for retinitis pigmentosa. 
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Although excellent progress has recently been made in defining the signaling pathways involved in the mouse mammary 
gland development, current knowledge about human mammary gland development is very restricted and still has to be 
elucidated. We identified an 18-year-old Thai woman who presented with absence of breasts (amastia), ectodermal 
dysplasia, and absence of the left kidney. The etiology of the disease is unknown. She was found to have a balanced 
chromosomal translocation of t(1;20)(p34.1;q13.13) inherited from her unaffected mother. We hypothesized that a gene 
was interrupted by one of the breakpoints which caused the phenotype. Using a combination of molecular genetics and 
cytogenetics experiments, we have demonstrated that a gene is disrupted on chromosome 1 of our patient. 
Measurements of its RNA and protein levels in her lymphoblastoid cell lines are severely deficient. Investigation of her 
DNA copy number using high-density SNP genotyping array showed no apparent deletions or duplications. In addition, 
sequencing of entire coding regions did not identify definite pathogenic mutation. However, microsatellite analysis showed 
that the proband inherited a paternal chromosome different from that of her unaffected siblings. In conclusion, we present 
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a new candidate involved in the development of breasts and nipples in humans. Its aberration may be responsible for 
amastia inherited in an autosomal recessive manner. This finding could provide new insights into developmental biology 
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The Alamut software is a decision-support system for mutation interpretation in medical molecular genetics. Alamut brings 
together molecular data and prediction methods for variant interpretation inside a graphical environment. A multiple 
protein alignment (MPA) of orthologues is included for each protein-coding human gene available in Alamut's database, 
bringing useful conservation information for missense variant interpretation. 
Currently, the sets of orthologous sequences used to build the alignments are drawn from the Ensembl Compara 
database. However, since orthologue collection and alignment by Ensembl Compara are the result of a purely automatic 
process, a number of MPAs don't reach the quality needed for variant interpretation. On the other hand, manually building 
accurate alignments is very time-consuming. This is why we have sought to define a semi-automatic procedure for 
orthologue MPA construction, described here. 
We have first sought how to quantify alignment quality. Based on work published by Tavtigian et al. (2008, 2009) and on 
recommendations published on the SIFT web site (Sorting Intolerant From Tolerant, a mutation classification system), we 
have chosen two criteria to assess alignment quality: average number of substitutions per position, and median of 
information content in alignments, a measure derived from Shannon's information theory. Correct alignments should 
contain on average three substitutions per position, and the median information content should be less than or equal to 
3.25. We use the Protpars (Protein Sequence Parsimony Method) program from the PHYLIP package to compute the 
number of substitutions per position, and the Alpro program of the DELILA package to calculate information content. 
New alignments are built as follows. Orthologous sequences are searched with the BlastP program, first against the 
Uniprot/Swissprot database. If sequences of distant species have not been found, BlastP is then run against the Refseq 
database, and finally against the NCBI non-redundant protein sequence database, if needed. The set of orthologues is 
then filtered manually, based on sequence length, identity with the human sequence, and available annotations. Selected 
sequences are then aligned with the M-Coffee program. M-coffee is a meta-aligner, combining the results of a number of 
multiple sequence alignment programs to construct a consensus alignment. If the alignment does not satisfy the above 
quality criteria, sequences creating large gaps are removed, and new sequences are added if needed to raise information 
content. As a final step, alignments are manually optimized with an alignment editor like JalView. 
While still needing manual phases, this procedure allows us to create correct alignments for variant interpretation in a 
manageable time frame. We anticipate to quickly build new alignments for approximately 50 of the genes most frequently 
analyzed with Alamut. These alignments are expected to provide better interpretation quality, either through human 
analysis or through variant scoring systems like SIFT, PolyPhen, or AlignGVGD. 
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The PON1 gene, located on the long arm of chromosome 7q21.3-22.1, is polymorphic and the expression levels vary 
widely in human populations. Its ability to detoxify carcinogenic oxidative stress products has led investigators to 
hypothesize that PON1 polymorphisms might contribute to the increased risk of cancer. The purpose of the present study 
was to evaluate the association between the PON1 T(-107)C promoter or exon G) polymorphisms and breast cancer risk 
in a hospital-based Malaysiano4 I102V (A population. The distribution of genotype and allele frequencies of these 
polymorphic variants will be determined in breast cancer patients and normal healthy individuals. Genotyping of these 
polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
method. Peripheral blood samples were collected from 387 breast cancer patients and 252 normal and healthy women 
who had no history of any malignancy. The CC, CT and TT genotypes, and T allele of T(-107)C polymorphism were 
detected in 21.4%, 49.4%, 29.2% and 53.9% of breast cancer cases, respectively. The genotype (P<0.0001) and allele 
(P<0.0001) frequencies were significantly different between the breast cancer cases and normal individuals. The AA and 
AG genotypes of I102V polymorphism were detected in 96.1% and 3.9% of the breast cancer patients but GG genotype 
was not found in the population. AG and GG genotypes were not noted among the control subjects. The G allele was 
found in 2% of the patients and none in the normal women. The adjusted odds ratio was calculated using the multivariate 
logistic regression method with an adjustment for age and ethnicity to determine the correlation between the genotypes or 
alleles of T(-107)C or I102V polymorphisms and breast cancer risk. Women who were TT homozygotes (OR=2.39; 95% 
CI, 1.50-3.80), CT heterozygotes (OR=2.02; 95% CI, 1.36-3.00) or carriers of T allele (OR=1.61; 95%, 1.27-2.03) were 
associated with significant breast cancer risk. The risk of breast cancer associated with I102V was not determined due to 
the absence of the polymorphic variant in the population. In conclusion, our findings suggest that the polymorphic variant 
of T(-107)C polymorphism might be a useful genetic marker to identify women who are at greater risk of developing breast 
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The PON2 gene is located adjacent to PON1 on the long arm of chromosome 7q21.3–22.1. Like PON1, PON2 is also 
polymorphic and it was hypothesized that the structurally-related PON2 has a similar function. The enzyme might be 
involved in the prevention of oxidative damage by detoxification of carcinogenic oxidative stress products. Two common 
polymorphisms have been identified at codon 311 (Cys311Ser) and 148 (Ala148Gly) of PON2 gene and these 
polymorphisms might contribute to increased risk of cancer. The present study was aimed to investigate whether 
Cys311Ser and Ala148Gly polymorphic variants of the PON2 gene are associated with breast cancer risk in a hospital-
based Malaysian population. The genotype and allele frequencies of these polymorphims will be determined in breast 
cancer patients and normal healthy individuals. These polymorphisms were genotyped using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method. Peripheral blood samples were collected from 387 breast 
cancer patients and 252 normal and healthy women who had no history of any malignancy. The CC, CS and SS 
genotypes, and S allele of Cys311Ser polymorphism were detected in 11.1%, 33.3%, 55.6% and 72.2% of breast cancer 
cases, respectively. The genotype (P=0.023) and allele (P=0.01) frequencies of Cys311Ser polymorphism were 
significantly different between the breast cancer cases and normal individuals. However, the distribution of genotype 
(P=0.253) and allele (P=0.0930) frequencies of Ala148Gly polymorphism showed lack of statistical significance. The CC, 
CG and GG genotypes, and G allele of Ala148Gly polymorphism were detected in 53.5%, 36.2%, 10.3% and 28.4% of 
breast cancer cases, respectively. The adjusted odds ratio was calculated using the multivariate logistic regression 
method with an adjustment for age and ethnicity to determine the correlation between the genotypes or alleles of 
Cys311Ser or Ala148Gly polymorphisms and breast cancer risk. Women who were SS homozygotes (OR=1.56; 95% CI, 
0.92-2.66) and CS heterozygotes (OR=1.00; 95% CI, 0.58-1.73) were not associated but carriers of S allele (OR=1.38; 
95%, 1.08-1.77) were associated with increased risk of breast cancer. Women who were heterozygous (OR=1.22; 95% CI, 
0.85-1.75) or homozygous (ORj=1.53; 95% CI, 0.82-2.86) for G allele, and carriers of G allele (OR=1.26; 95% CI, 0.96-
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1.64) were not associated with breast cancer risk. In conclusion, our findings suggest that women who are carriers of S 
allele might be at higher risk of developing breast cancer but the polymorphic variant of Ala148Gly polymorphism might 
not be a suitable marker for breast cancer susceptibility. 
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Cigarette smoking has negative environmental impact on genome integrity and may lead to DNA damage, 
chromosome/genome rearrangements and aneuploidy. To test the influence of tobacco smoking on genome stability 
during human intrauterine development we have analyzed the rate of aneuploidy (chromosomal biomarker of genomic 
instability) in spontaneous abortions (SA). Chorionic villi of consecutive cases 600 SA of 5-15 weeks gestation from 
women aged from 16 to 47 years (mean 30 years) were processed for molecular cytogenetic analysis. Interphase 
multiprobe FISH with DNA probes for chromosomes 1, 9, 13/21, 14/22, 15, 16, 18, X and Y was applied. Chromosome 
abnormalities (autosomal and gonosomal aneuploidy, polyploidy, multiple aneuploidy and polyploidy and chimerism) were 
found in 303 cases from 600 analyzed (50.0%). Chromosomal mosaicism due mitotic errors was detected in 157 cases 
from 600 analyzed (26.2%). Among 463 non-smoking females chromosomal pathology was detected in 237 cases (51.2%) 
including 122 mosaic cases (26.3%). Among 137 smoking females (22.8% of analyzed cases) chromosomal pathology 
was detected in 65 cases (47.4%) including 35 cases with mosaicism (25.5%). Therefore, the incidence of regular and 
mosaic forms of chromosomal abnormalities was similar in SA affected and non-affected by tobacco smoke. However, the 
level of stochastic (or spontaneous) aneuploidy per individual chromosome pair not involved in aneuploidy was 
significantly increased in SA affected by tobacco smoking (1.4-2.1%) in comparison to non-affected (0.3-1.2%). We 
conclude that developmental mitotic instability frequently associates with mosaic chromosome/genome instability and 
abnormal intrauterine embryo development. Cigarette smoke has negative environmental impact on spontaneous level of 
mitotic chromosome instability. Supported by Philip Morris USA Inc. 
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Immune-related diseases consist of a range of diseases, which include autoimmune and inflammatory disorders. 
Autoimmune disorders are initiated by damage to tissues and organs that arises from the response to self-antigens. By 
contrast, inflammatory disorders result from an excessive inflammatory response that is more harmful to host tissue than 
to exogenous antigens. Genetic predisposition is a major factor in susceptibility of immune-related diseases, and genome-
wide association studies (GWAS) of cohort samples offer an opportunity to dissect the susceptibility genes (loci) of such 
diseases. 
  
We have performed series of GWAS of immune-related diseases, including psoriasis, systemic lupus Erythematosus 
(SLE) and leprosy in Chinese populations, and obtained important results. We carried out the genome-wide association 
analysis using Illumina Human 610-Quad BeadChips in 1,139 psoriasis cases vs. 1,132 controls, 1,047 SLE cases vs. 
1,205 controls and 706 leprosy patients vs. 1,225 controls. 
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 In the replication stage of psoriasis, we took 64 top SNPS from GWAS for replication in two independent sample of 5,182 
cases and 6,516 controls of Chinese Han ancestry, and 539 cases and 824 controls of Chinese Uygur ancestry. In 
addition to the strong replication for two known susceptibility loci MHC and IL12B, we indentified a new susceptibility locus 
within the LCE cluster on 1q21. Our result was published in Nature Genetics in February 2009. 
 
In the replication stage of SLE, 78 SNPs were replicated in two additional Chinese Han cohorts (total 3,152 cases and 
7,050 controls). In this study, eight genes were validated as SLE susceptibility genes in Chinese Han population (MHC, 
BLK, IRF5, STAT4, TNFAIP3, TNFSF4, 6q21 and 22q11.21), nine new ones were identified as susceptibility genes or loci 
for SLE for the first time (ETS1, IKZF1, RASGRP3, SLC15A4, TNIP1, 7q11.23, 10q11.22, 11q23.3 and 16p11.2). The 
result was reported in Nature Genetics in November 2009. 
 
In the replication stage of leprosy, the top 93 SNPs were replicated in three independent samples consisting of 3,254 
cases and 5,955 controls. We identified significant association (P<10-10) within six genes CCDC122 (13q14), C13orf31 
(13q14), NOD2 (16q12), TNFSF15 (9q32), HLA-DR (6p21) and RIPK2 (8p21) and a suggestive association (P<10-7) 
within LRRK2 (12q12). Of interest, most of the identified genetic factors are in the NOD2-mediated signaling pathway 
(which regulates the innate immune response). This work was published in the journal The New England Journal of 
Medicine in December 2009. 
 
The GWAS of immune-related diseases in Chinese Han population enhanced our understanding of the genetic basis of 
these disorders and were expected to reveal new pathways that contribute to immune-related diseases. In addition, our 
studies highlighted the genetic heterogeneity of disease susceptibility between different ethnic populations, and called for 
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Introduction Docetaxel belongs to a class of taxane and have been recognized as the most chemotherapeutic agent in the 
treatment of advanced breast cancer. Docetaxel has a wide spectrum of antitumor activity and highly effective as 
monotherapy and combination therapy across a variety of tumour types including breast cancer. However, some of the 
breast cancer patient are either intrinsically resistance or develop resistance during the docetaxel regimen. One of the 
possible caused of drug resistance among this patient is DNA methylation which resulted in gene silencing and failed to 
chemotherapy treatment. Thus this study was used 5-azacytidine (azacytidine) as one of the DNA methylation inhibitor 
agent to investigate the role of epigenetic silencing in human breast cancer resistance to docetaxel cell line. 
 
Methods MCF-7 human breast cancer cell line (docetaxel- resistance and docetaxel sensitive) were treated in single 
docetaxel treatment and in combination with docetaxel and 8μM 5-azacytidine (azacytidine) at 24 and 48 hours. Cytotoxic 
assay (MTT assay) was used to measure the cell viability after appropriate time of treatment. Result in single treatment 
was compared to in combination treatment at 24 and 48 hours incubations by comparing the docetaxel inhibition 
concentrations (IC50) which has killed 50% of the cell lines. 
 
Results Statistical analysis does not show significant differences in IC50 values between both of the treatment at 24 and 
48 hours. 
  
Conclusions This study demonstrates that by adding 8μM azacytidine as DNA methylation inhibitors was not reversed 
docetaxel resistance in MCF-7 breast cancer resistance to docetaxel cell line. However result from this study could not 
totally conclude that DNA methylation does not occur in docetaxel resistance among breast cancer patient. Therefore 
future research needs to be done using another approach to investigate the involvement of DNA methylation on docetaxel 
resistance in breast cancer. 
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BlsI- and GlaI-PCR assays have been developed to study DNA methylation. A new method includes DNA hydrolysis by 
unique methyl-directed site-specific DNA endonucleases GlaI or BlsI with subsequent PCR. Study of DNA methylation in 
regulation region of human tumor suppressor genes has been performed for a new method evaluation. BlsI- and GlaI-
PCR assays have revealed different methylation patterns in promoter region of DAPK1, in promoter and first exon region 
of RARB and in first exon region of RASSF1A and SEPT9 tumor suppressor genes in malignant cell lines HeLa, Raji, U-
937, Jurkat and control L-68 cells. GlaI-PCR assay has shown a methylation of RARB promoter and first exon region in 
DNA from all malignant cell lines, but not in control L-68 cells. GlaI- and BlsI-PCR assays have displayed DNA 
methylation of RASSF1A first exon region in Raji and Jurkat cells and SEPT9 first exon region in U-937, Raji and HeLa 
cells. BlsI-PCR assay of DAPK1 promoter region has demonstrated an additional DNA methylation in Raji cells only. 
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Background: SOD1 gene mutations are the most commonly identified causes of Amyotrophic lateral sclerosis (ALS), 
accounting for approximately 20% of familial ALS (FALS) cases and around 4% of sporadic ALS (SALS) cases. However, 
the frequency of SOD1 gene mutations in ALS varies in different ethnic groups and no previous studies have been carried 
out in Korea. The aim of this study was to determine the frequency of SOD1 gene mutations in a Korean ALS population. 
  
Methods: A total of 154 ALS patients (146 SALS and 8 FALS) were screened for SOD1 gene mutation. We applied 
polymerase chain reaction (PCR) and direct sequencing of all coding exons and flanking intronic sequences of the SOD1 
gene. The sequences of the patients were compared with reference sequences to detect any sequence variations. 
Results: The overall frequency (FALS and SALS) of SOD1 gene mutations in our series was 5.2%. Two novel mutations 
(A5F and P69S) and three known mutations (F21C, G38R and G142A) were identified in seven FALS patients (87.5%, 
7/8). The F21C mutation was recurrently observed in three unrelated FALS patients. One novel mutation (P69S) was 
identified in a SALS patient (0.7%, 1/146). 
Conclusion: The frequency of SOD1 gene mutations in Korean FALS (87.5%) is much higher than those reported in the 
other ethnic groups but only one SALS case had SOD1 gene mutation. Therefore, screening of SOD1 gene is highly 
recommended in Korean FALS but other genes should be further studied in order to reveal the genetic background of 
Korean SALS. 
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Background Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous disorder that can be an 
autosomal-dominant, autosomal-recessive, or X-linked disease. The most common autosomal-dominant form of the 
disease derives from mutations in the SPAST gene. 
Methods The aim of this study was to analyze 49 patients diagnosed with HSP from the Estonian population for sequence 
variants of the SPAST gene and to describe the associated phenotypes. Healthy control individuals (n = 100) with no 
family history of HSP were also analyzed. All patient samples were screened using denaturing high performance liquid 
chromatography (DHPLC) and multiplex ligation-dependent probe amplification (MLPA) assay. Samples with abnormal 
DHPLC and MLPA profiles were sequenced, with the same regions sequenced in control samples. 
Results Sequence variants of SPAST were identified in 19/49 HSP patients (38.8%), twelve among them had pathogenic 
mutations. Within the latter group there was one sporadic case. Eight patients had pure, and four – complex HSP. The 
twelve variants were identified: seven pathogenic (c.1174-1G>C, c.1185delA, c.1276C>T, c.1352_1356delGAGAA, 
c.1378C>A, c.1518_1519insTC, c.1841_1842insA) and five non-pathogenic (c.131C>T, c.484G>A, c.685A>G, 
c.1245+202delG, c.1245+215G>C). Only 2 of these mutations had previously been described (c.131C>T, 
c.1245+202delG). Three mutations, c.1174-1G>C, c.1276 C>T, c.1378C>A, showed intrafamilial segregation. 
Conclusion This study identified new variants of the SPAST gene which included benign missense variants and short 
insertions/deletions. No large rearrangements were found. Based on these data, 7 new pathogenic variants of HSP are 
associated with clinical phenotypes. 
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(HRM) analysis for genetic treatment through translational readthroughs 
1Lai PS, 1Yim OS, 1Xiong G, 1Tay SKH, 1Low PS and 2, 3 Yap EPH  
1Dept of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital, 
Singapore 119074, 2Defence Research & Technology Office, Ministry of Defence, Singapore 669645, 3DSO National 
Laboratories, Defence Medical & Environmental Research Institute, Singapore 117510 
Duchenne’s Muscular Dystrophy (DMD) is a fatal X-linked disorder. There is no known cure and current management 
includes molecular diagnosis and carrier screening. Determination of the precise type of mutations present in patients will 
contribute towards identification of cohorts amenable for different types of future genetic treatment approaches such as 
antisense splicing or nonsense codon suppression. However, current control of disease transmission depends on genetic 
counseling and identification of female carriers. The most common and easily detectable mutations in DMD are deletions 
but point mutations account for the remaining 40% of patients. Conventional screening for non-deletion mutations and 
carrier analysis utilizes DNA sequencing as the method of choice, but faster, cheaper, and equally accurate alternatives 
may be possible. We report here a rapid and cheap mutation screening approach using High Resolution Melting (HRM) 
for identifying DMD mutations and carriers. This technique can be applied to amplify and melt products from all the coding 
exons in DMD gene. The different melt profiles generated are then analyzed to determine the mutant and wild-type 
homozygotes from the heterozygotes. A clinical case was evaluated from a family carrying an exon 60 nonsense mutation 




(UGA stop codon) using this approach. A 187-bases long fragment of the mutation-containing exon 60 of the DMD gene 
was amplified by PCR and subjected to HRM. The patient exhibited different melt profiles from normals, and two female 
relatives were found to be carriers of the mutation. The HRM results were confirmed to be accurate by re-sequencing. 
Subsequent genetic correction assays were carried out using aminoglycoside-induced translational readthrough approach. 
A construct carrying this exon 60 nonsense mutation in a luciferase reporter gene vector was assayed for luciferase 
activity after treatment with different concentrations of gentamycin, paromomycin and tobramycin at 24, 48 and 72 hours. 
Highest readthroughs of about 18% was observed using 2.0 mg/ml gentamycin at 48 hours treatment indicating gene 
correction during translation. Our results show that HRM screening can identify point mutations, in particular nonsense 
mutations which are amenable for genetic correction by drug-induced translation readthough approach. It can thus be 
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Four novel cis-acting elements of CYP1A1 and CYP1A2 identified by allelic expression imbalance in Chinese 
human livers 
Dazhi Wang1, Jinxiu Shi1, Zhongyang Shen2, Hui Wang2᧨Beilan Wang1, Hong Zheng2, Zhengwen Jiang1, 3,* and Wei 
Huang1,* 
CYP1A1 and CYP1A2 are the major two P450 genes responsible for the metabolic activation of various polycyclic 
aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines (HAAs) to electrophilic reactive intermediates, leading to 
toxicity and cancer. Cis-acting variants were observed to make up to 20% of inter-individual variability in mRNA level of 
CYP1A2. In this study, we used the relative expression levels of two SNP alleles in the same sample as an effective 
approach for identifying cis-acting elements of CYP1A1 and CYP1A2. We selected 16 tagSNPs representative of all 
common SNPs (>8%) within a ~37kb region including 6kb CYP1A1 gene, 7.76kb CYP1A2 gene and 23.3kb spacer region, 
and genotyped them in 96 Chinese liver samples. Four tagSNPs were used as marker SNPs for determining allelic 
expression ratio of CYP1A1 or CYP1A2. Association analysis was carried out on allelic expression ratio as quantitative 
phenotype and the heterozygosity of tagSNPs. Four cis-acting regulatory SNPs (rSNP) CYP1A1-940C>T (rs4646418), 
CYP1A1+2573C>T (rs4646422), CYP1A2-2217G>A (rs2069521) and CYP1A2+734A>C (rs762551) were identified. 
CYP1A1-940C>T (rs4646418), located in a G-rich domain upstream of CYP1A1, was affecting expression of both 
CYP1A1 and CYP1A2, while the other three were affecting expression level of either CYP1A1 (by +2573C>T) or CYP1A2 
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Interactors of the cardiac ion channel, KCNE1, encoded by a Long-QT Syndrome-causative gene, identified 
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Long-QT Syndrome (LQTS), a hereditary cardiac disease characterised by syncope and tragic sudden death, is caused 
by functional disturbances in ion channels that orchestrate cardiac repolarisation. Disease-causing mutations in several 
ion channel-encoding genes are not sufficient to explain the clinical variability associated with LQTS. KCNE1 (encoded by 
a known LQTS-causative gene) regulates a number of ion channel subunits. We aimed to identify proteins that, by their 
interaction with KCNE1, alter disease severity. 
Yeast 2 hybrid (Y2H) technology isolated C-terminal KCNE1-interacting proteins from a human cardiac c-DNA library. 
Standard selection protocols revealed the strength and specificity of interactions, while database mining provided 
supportive evidence for plausibility of proposed interactions and allowed prioritisation of putative interactors for verification 




studies (co-immunoprecipitation and 3D fluorescent microscopy). 8.98 x105 cDNA library clones were screened. 
Following selection steps, 100 clones were sequenced and assessed further. 
Interesting interactors identified include actin isoforms, Yotiao, Xin, heat shock protein beta-7 (HSPB7) and the cardiac 
isoform of myosin-binding protein C (MYBPC3). A plausible role for the first four in the potassium channel interactome is 
corroborated by existing data; although more tenuous, binding of KCNE1 with sarcomeric telethonin makes an interaction 
with other myofibrillar components, such as MYBPC3, plausible. The potential for involvement of sequence variants in the 
genes encoding the identified interactors, as either direct cause or modifiers of LQTS, will be assessed in unrelated LQTS 
subjects and an extended South African LQTS-affected family (Brink et al., Circulation [2005]), respectively. 
These candidate interactors are excellent, novel KCNE1-binding partners which, with further investigation of their roles in 
ion channel regulation, will increase understanding of ion channel function. Furthermore, defining their role in the 
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Chromosome-Wide Haplotype Sharing: Integrating Recombination Information into Studies on Human Population 
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The vast recombination information in human genome is generally ignored or deliberately avoided in studies on human 
population genetic relationship, because estimation of recombination parameter from genotyping data is practically 
computationally challenging. Here we propose chromosome-wide haplotype sharing as a measure of genetic similarity 
between human populations, which is an indirect approach to integrate recombination information into human genetic 
relationship studies without involving estimation of recombination parameter. By analyzing 20,177 SNPs on chromosome 
21 with density of 1.6 kb per SNP in 11 human populations representing African, European and East Asian, we found 
chromosome-wide recombination among populations is strongly correlated and this correlation further correlates the 
genetic difference between human populations, indicating recombination of human populations are evolutionarily related. 
We further demonstrated haplotype sharing can be used to reconstruct reliable phylogeny of human populations, where 
about 40% of variation in haplotype sharing matrix can be attributed to recombination, while only about 10% of the 
variation can be attributed to drift. With simulation studies, we found that haplotype sharing in single genome region of 
100 kb is sufficient to study populations diverged 40~500 generations, while larger window size is necessary for 
populations separated recently (< 40 generations). However, for distantly related populations (> 500 generations), the 
utility of single region to reconstruct correct phylogeny is limited, suggesting that the linear correlation of haplotype sharing 
and population divergence could have been disturbed by recurrent recombination events at large time scale. 
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Expression and Somatic CNVs of GPx3 gene in breast cancer 
Wang Zhimin1, Fei Fei2, Wang Haifeng1, Fu Deyuan2, Wang Beilan1, Chen li2, Xu Shijie1, Shao Zhimin2, Huang Wei1* 
Chinese National Human Genome Center at Shanghai 
Breast cancer is one of the most common malignant diseases in the world. However, the genetic events leading to the 
development of breast cancer are not clear yet. In this study, whole genome expression assay and copy number 
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variations (CNVs) analysis were performed in 20 primary breast carcinomas and paired normal adjacent tissue by using 
Illumina HumanCNV370-Duo BeadChip and Sentrix® Human-8 Expression BeadChip. We found that the expression of 
GPx3 was widely inactivated in breast cancers (p=0.0001), but the methylation status was no difference. Moreover 
somatic CNVs of GPx3 gene were detected in these breast cancer samples. It was found that higher DNA copy numbers 
caused increased expression levels (p=0.027). Direct sequencing and real time quantitative PCR (RT-qPCR) confirmed 
the somatic CNVs. And RT-qPCR results of more 48 paired samples showed CNVs of GPx3 related with estrogen 
receptor (ER) status (p=0.041). Thus, our results indicated that the CNVs of GPx3 may be a valuable biomarker for the 
carcinogenesis and progression of the breast cancer. 
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Comparative proteomic analysis of Neuro 2a cells in response to siRNA-mediated silencing of Dot1  
Chunmei Wang,  Sauna Tsai,  Saiming Ngai   
Department of Biology, The Chinese University of Hong Kong, Shatin, Hong Kong SAR. China 
Dot1(disruptor of telomeric silencing) specifically catalyzes the methylation of H3K79. In budding yeast, Dot1 was involved 
in telomeric silencing, meiotic checkpoint control and DNA-damage responses. However, its biological function in 
mammals remains unknown. In this study, Dot1 silencing Neuro-2a (N2a) cell line was established via transfection with 
Dot1-siRNA. The roles of Dot1 in N2a cells was investigated using proteomic approach.The results indicated that Dot1 
silencing resulted in the loss of cell normal neuronal shape. Whereas, Dot1 silencing showed no apparent effects on cell 
growth, cell cycle or induced cell death. Three proteins (stress-induced-phosphoprotein1, RAD23b homolog and 
peroxiredoxin 1) were up-regulated and five proteins (far upstream element-binding protein 1 (FBP-1), nucleosome 
assembly protein 1-like 1 (NAP1L1) isoform 2, eukaryotic translation initiation factor (eIFs) 3, nascent polypeptide-
associated complex (NAC) alpha subunit and prohibitin) were down-regulated after Dot1 silencing. Moreover, decreased 
expression of p53 was also observed. This research provided us the evidences for the multi-functions of Dot1 at onaxon 
and dendrite outgrowth, transcriptional regulation, protein translation and folding, apoptosis and DNA breaks repair, which 
indicated the roles of Dot1 in brain dysfunction of neurodegenerative disease or aging. 
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Comparing genome-wide chromatin profiles using ChIP-chip or ChIP-seq 
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Netherlands. 2Institute for Theoretical Physics, Leibniz Universität Hannover, Appelstr. 2, D-30167, Hannover, Germany. 
3Department of Physiological Chemistry, University Medical Center Utrecht, Universiteitsweg 100, 3508 AB Utrecht, The 
Netherlands. 4Hubrecht Institute, KNAW and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The 
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ChIP-chip and ChIP-seq technologies provide genomewide measurements of various types of chromatin marks at an 
unprecedented resolution. With ChIP samples collected from different tissue types and/or individuals, we can now begin 
to characterize stochastic or systematic changes in epigenetic patterns during development (intra-individual) or at the 
population level (inter-individual). This requires statistical methods that permit a simultaneous comparison of multiple ChIP 
samples on a global as well as locus-specific scale. Current analytical approaches are mainly geared towards single 
sample investigations, and therefore have limited applicability in this comparative setting. This shortcoming presents a 
bottleneck in biological interpretations of multiple sample data. 
To address this limitation, we introduce a parametric classification approach for the simultaneous analysis of two (or more) 
ChIP samples. We consider several competing models that reflect alternative biological assumptions about the global 
distribution of the data. Inferences about locus-specific and genomewide chromatin differences are reached through the 
estimation of multivariate mixtures. Parameter estimates are obtained using a version of the Incremental Expectation 
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Maximization algorithm (IEM). We demonstrate efficient scalability and application to three very diverse ChIP-chip and 
ChIP-seq experiments. The proposed approach is evaluated against several published ChIP-chip and ChIPseq software 
packages. We recommend its use as a first-pass algorithm to identify candidate regions in the epigenome, possibly 
followed by some type of second-pass algorithm to fine-tune detected peaks in accordance with biological or technological 
criteria. 
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Identification of Mutations in the ATP2A2 gene in Chinese patients with Darier's disease  
 
ZM Niu1 , ZH Zhang2, B Chai3, W Huang1 
Chinese National Human Genome Center at Shanghai 
Darier’s disease (DD), also known as Darier-White disease or keratosis follicularis, is an autosomal dominant skin 
disorder characterized loss of adhesion between epidermal cells and abnormal keratinization. The relationship of ATP2A2 
mutations and DD has been widely reported since 1999. In our study, we examined the ATP2A2 gene mutations of eight 
sporadic and two familial Chinese DD patients. The entire coding regions, about 500bp promoter and at least 50bp of the 
exon-intronic boundary sequence of ATP2A2 were directly sequenced from the genomic DNA extracted from the blood 
samples. A total of five mutations had been identified. In a familiar patient, we found a S920Y missense change which 
was previously described by Sakuntabhai et al. in 1999. The other four mutations we found in sporadic patients haven’t 
been reported before. They are two frame shift changes, 2236insC and 3356-3357delTG, which cause codon changes; 
and two exon-intronic boundary region changes,1851-6A to G in intron10 and 3084+5G to C in intron16, which may cause 
the alternative splicing changes. Our results provide the new mutations of ATP2A2 gene for Chinese patients with DD. 
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Diagnostic Center, King Chulalongkorn Memorial Hospital, Thai Red Cross 4Department of Internal Medicine, Faculty of 
Medicine, Chulalongkorn University 5Division of Neurology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn 
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Benign Adult Familial Myoclonic Epilepsy (BAFME) is an autosomal dominant disorder typically characterized by adult-
onset cortical tremor and generalized seizures. BAFME diagnosis is based on clinical and electrophysiological criteria 
including irregular postural myoclonic tremor of the distal limbs, familial history of epilepsy, autosomal dominant 
inheritance and a rather benign outcome. The diagnosis is confirmed by electrophysiological features favoring cortical 
reflex myoclonus (enhanced C reflex at rest, giant somatosensory evoked potentials (SEPs), premyoclonus cortical spikes 
detected by jerk-locked back-averaging method) and good response to antiepileptic drugs. Although BAFME were 
previously mapped on chromosome 8q24 and 8q23.3–q24.1 in Japanese pedigrees and chromosome 2p11.1–2q12.2 in 
European pedigrees, the causative genes have not been identified. Here we studied a large BAFME family in Thailand 
consisting of approximately 13 affected members. We performed linkage analyses using six microsatellite markers 
covering chromosome 8q23.3-q24.1, and three covering chromosome 2p11.1-q12.2. Amplified fragments were resolved 
on an ABI PRISM 3100 Genetic Analyzer and analyzed with GeneScan Analysis and Genotyper software. Two-point 
linkage analysis was carried out by MLINK program. Our data demonstrate that two reported loci were excluded and the 
causative gene responsible for BAFME in the Thai pedigree may be located on a new region other than 8q23.3–q24.1 and 
2p11.1–q12.2. In summary, we have excluded two previously linked loci for BAFME in Thai family. Currently, we are 
performing whole genome linkage analysis using 400 tandem repeat markers with average spacing of 10 cM, attempting 
to identify a new locus for this disease. Knowing the etiology of this disease will provide accurate genetic counseling for 
the affected families and better understanding the disease. 
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SibEnzyme Ltd., Novosibirsk, Russian Federation 
Earlier we have developed a simple method to carry out mammalian DNA digestion with restriction enzymes in silico 
based on the known DNA sequence of corresponding genomes [1]. This method allows to calculate lengths of all DNA 
fragments, which are formed after a whole genome digestion at recognition sites of restriction enzyme, and to construct 
the distribution diagrams of the calculated DNA fragments. These distribution diagrams display distinct peaks of DNA 
fragments of the definite lengths due to a presence of DNA repeats in eukaryotic genomes. Comparison of the obtained 
peaks in distribution diagrams and results of human chromosomal DNA hydrolysis by several restriction endonucleases 
has shown a good correspondence of theoretical and experimental data for 17 restriction enzymes [2]. Theoretical 
patterns of DNA cleavage with endonucleases are formed mostly as a mix of Alu and LINE1 repeats digestion products. 
As a rule DNA fragments of 300 bp and less are produced from Alu repeats [3]. The Alu repeats, which belongs to SINE 
group, is one of the most abundant and well characterized repetitive elements in human genome and include more than 
1150 thousand copies (about 10% of human genome). 
In this work we have suggested a method to carry out Alu repeats digestion with restriction endonucleases in silico. We 
have presented an advanced Alu repeats data base [4], which allows to construct the digestion diagrams in a simple way, 
and developed a software for a work on standard personal computer with providing the calculations results in several 
minutes. Human Alu repeats cleavage at definite nucleotide sequences (4-, 5-, 6- and 7-bp), which are the recognition 
sites of known restriction endonucleases, has been performed and corresponding diagrams of DNA fragments distribution 
have been constructed. The theoretical data have been compared to experimental patterns of human DNA hydrolysis with 
restriction endonucleases (AluI, AsuHPI, BpmI, Bpu10I, Bst2UI, BstSCI, BstDEI, BssECI, BstMAI, BstSFI, BstXI and HinfI) 
and a good correspondence for the most of DNA digestion diagrams has been observed. 
The suggested method allows to simplify a study of human DNA cleavage with restriction endonucleases considering set 
of Alu repeats sequences instead of the whole human genome (about 440 million bps vs more than 3 billion bps). 
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Detection of cell-free methylated DNA in plasma is a promising tool for tumour diagnosis and monitoring. Due to the very 
low amount of cell-free DNA in plasma, sensitivity of the detection methods are of utmost importance. The vast majority of 
currently available methods for analysing DNA methylation are based on bisulphite-mediated deamination of cytosine. 
Cytosine is rapidly converted to uracil during bisulphite-treatment, whereas 5-methylcytosine is only slowly converted. 
Hence, bisulphite-treatment converts an epigenetic modification into a difference in sequence, amenable to analysis either 
by sequencing or PCR based methods. However, the recovery of bisulphite-converted DNA is very poor. Here we 
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introduce an alternative method for the crucial steps of bisulphite removal and desulphonation, vastly improving recovery, 
especially for specimens with low levels of methylated DNA. 
The method is based on an accelerated deamination step and magnetic silica purification of DNA in combination with a 
first round of PCR amplifying 18 methylated markers concurrently, followed by individual detection of the 18 methylated 
markers by real-time PCR. Detection frequencies of methylated copies (calculated as the percentage of positive results of 
18 markers analysed 6 times each)range from 31% when analysing 1.25 methylated copies to 86% when analysing 10 
methylated copies. 
The present method allows low levels of DNA to be easily and reliably analysed, a prerequisite for the clinical usefulness 
of cell-free methylated DNA detection in plasma. 
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The demand for genetic services has increased due to the rapid development and increased public awareness of genetics. 
Therefore assessing the knowledge of medical students is very important to collect baseline information which may help in 
designing future genetic educational programs. To fulfill this requirement we carried out a survey of general knowledge of 
genetics among medical students of Faculty of Medicine, University of Colombo using a self administered questioner 
developed and validated for this purpose. The questioner was administered to all students of the faculty during April 2009. 
634 (51.8%) responded. 288 (45.4%) were males. Analysis of the total marks showed that 56 (8.8%), 103 (16.2%), 107 
(16.9%), 299 (47.2%) and 69 (10.9%) students had obtained 0-20%, 21-40%, 41-60%, 61-80% and 81-100% marks 
respectively. Comparison between students in different years showed that knowledge was highest among first and second 
year students. Regarding different aspects of genetics, it was found that the average marks for the nature of genetic 
martial, transmission, gene expression, gene regulation and genetics and society was 58.8%, 69.53%, 63.3%, 69.8% and 
50.4% respectively. However, overall knowledge on evolution was very much less (27.8%) than the other aspects. 
Comparison of the groups of students regarding the different aspects showed that the knowledge on nature of genetic 
material, transmission, gene expression and gene regulation was more than 70% in first, second and fourth year students. 
However the knowledge on other aspects was low among all students. This information would be very useful in designing 
future genetic education programmes. 
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Focal segmental glomerulosclerosis (FSGS) is a histological glomerular phenotype that can be familial, primary 
(idiopathic), or secondary to a multitude of pathological processes affecting the kidney, including such tubulointerstitial 
diseases as nephronophthisis. Mutations in a number of distinct nephronophthisis genes (NPHPs) have been described to 
date. We describe consanguineous unrelated Saudi Arabian families with sequence variants in one of the NPHP genes, 
namely NPHP1. Affected individuals in the two families presented with end-stage renal disease and clinical and 
histological features consistent with focal segmental glomerulosclerosis. Since FSGS patients may present atypical 
radiological findings, making the clinical diagnosis of the genetic syndrome difficult, we applied whole-genome single-
nucleotide polymorphism analysis followed by state of the art sequence capture and exome sequencing on genomic DNA 
samples from these families. This analysis facilitated accurate diagnosis after isolation of homozygosity run of ~ 2 Mb. 
This homozygous run falls between rs6754115 (genomic position 109,328,776) and rs17464100 (genomic position 
111,284,252), and is identical in affected subjects from the unrelated families. This provides evidence that this deletion is 
widely spread in the families’ geographical regions, and implies its significant involvement in the development of chronic 
kidney failure in Saudi Arabia. This work emphasizes the importance performing genetic screening for this NPHP allele in 
CRF patients an outline an essay for this purpose. 
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About 50% of the human genome consists of repetitive elements comprised of tandem and interspersed repeats. Among 
the various types of tandem repeat sequences, the dinucleotide (TG/CA)n repeats are one of the most abundant. These 
repeats also exhibit length polymorphism and in many cases have been shown to modulate gene expression and have 
the propensity to undergo conformational transitions under in vivo conditions. The genome sequence of chimpanzee (Pan 
troglodytes) offers the most relevant nonhuman dataset for comparison of these repeats in human. We carried out a 
whole genome analysis of these repeats in the human and chimpanzee genomes including the genic, intergenic, and 
promoter regions. We classified these repeats into three length categories (Type I (6  n < 12), Type II (12  n < 23), and 
Type III (n  23)) based on their biological functions like length polymorphism, role in modulation of gene expression, 
propensity to undergo conformational transitions, recombination, etc. and examined their distribution in the two genomes. 
We then examined the conservation and polymorphism of the orthologous repeats in the selected regions. All three 
processes of expansion, contraction, and conservation of the repeats were observed. We also observed that a 
significantly higher proportion of (TG/CA)n repeats were expanded either in chimpanzee or human, while almost similar 
proportions of these repeats remained conserved or have contracted. However, no bias was evident with respect to the 
genomic location of these repeats. 
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Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that chiefly affects the sacroiliac joints and the spine. 
Genetic factors, in addition to the HLA-B27, play a major role in the pathogenesis of AS. In this study, we investigated the 
association of polymorphisms in transporter genes TAP1 and TAP2 with AS in Chinese Han population. TAP genes were 
genotyped in 194 AS patients and 475 randomly chosen unrelated controls by resequencing the entire gene regions 
directly, including 2000bp promoter, as well as all exons and at least 200bp of the exon-intronic boundary sequence. The 
genetic association with TAP1 and TAP2 was confirmed. There are 232 polymorphisms were identified and 105 of them 
were novel. Differences in genotypes and allele frequencies of 82 SNPs with MAF>5% were assessed by the use of 
contingency tables and the calculation of chi-square test. We found several associated polymorphisms and the most 
significant of which was rs41316548 located in intron_11 of TAP2 gene. The frequencies of the A allele is significantly 
increased in case compared with the control group (10.4% vs. 3.29%, P = 1.71E-07) with an odds ratio being 3.417 (95% 
confidence interval, 2.104-5.551), and the A allele showed significant susceptibility to AS (P = 1.80E-07, in dominant 
disease model) with an odds ratio being 3.618 (95% confidence interval, 2.181-6.002). TAP1 and TAP2 are involved in 




antigen processing and presentation, and polymorphisms in these genes may be associated with altered antigen-peptide 
selection and the level of restoration of surface expression of MHC class I molecules. Our study suggested that TAP 
genes may act as a potential factor in the mechanism of AS pathogenesis. 
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X-linked mental retardation (XLMR) affects 1-2/1,000 males and accounts for approximately 10% of all mental retardation 
(MR). To date, almost 90 different XLMR genes have been identified. Mutations in these genes are seen in approximately 
50% of the families. Thus, many more XLMR genes remain to be identified, especially for the non-syndromic forms of 
XLMR. We have set out to find the causative gene defect in a total of 200 families with this condition. To this end, we 
systematically enrich X-chromosomal exons employing several gene partitioning techniques followed by next generation 
sequencing, and depending on the outcome, by sequencing flow-sorted X-chromosomes. In contrast to previous studies 
(Tarpey et al., Nat. Genet. 2009) this strategy should enable us to detect mutations in the entire non-repetitive portion of 
the X-chromosome. 
 
Poster No: P121-T 
Gene Expression Profiling of Ovarian Granulosa Cell Tumour from Formalin-fixed Paraffin-embedded (FFPE) 
samples. 
 
1,5Norfilza Mohd Mokhtar, 1 Koon Vui-Kee, 2 Ahmad Zailani Hatta, 3 Isa Mohammed Rose, 4 Razmin Ghazali, A Rahman 
A Jamal 5 
1Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, 2Department of Obstetrics and 
Gynecology of UKM Medical Centre,3Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, 
4Unit Histopathology, Department of Pathology, Hospital Kuala Lumpur, 5UKM Medical Molecular Biology Institute, Kuala 
Lumpur, Malaysia 
Introduction: Ovarian granulosa cell tumours (GCTs) are uncommon gynaecological cancer that comprises around 2 to 
5% of all ovarian neoplasm. The rarity of this tumour makes the early diagnosis is more crucial as it can easily 
misdiagnose with other malignant tumours. The purpose of this study was to identify the differences of expressed genes 
in ovarian GCTs and normal ovary tissues using the high-throughput microarray analysis.  
Material and Methods: Total RNA was extracted from eight archived formalin-fixed paraffin embedded (FFPE) samples of 
ovarian GCTs and normal ovarian tissues. The extracted RNA were then analysed using Illumina Whole-Genome DASL 
assay (cDNA-mediated annealing, selection, extension, and ligation). We used GeneSpring GX10.0 and FlexArray 
software to determine the differentially expressed genes. 
Results: Unsupervised clustering of gene expression correctly clusters the samples into two major groups. Of 24,526 
known genes, 215 genes were differentially expressed with cut-off p-values < 0.05 and 2-fold changes in ovarian GCTs 
compared to normal ovaries. Among these, 47 genes were up-regulated and 168 genes were down-regulated in ovarian 
GCTs compared to normal ovaries. Biological processes for the genes were associated with cell cycle and growth, cell 
adhesion, anti-apoptosis and apoptosis. 
Conclusion: Using the array data, we identified genes with their functional groups in ovarian GCTs. Further 
characterisation of the genes and their signalling pathways are essential to understand the pathogenesis of the tumour. 
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Background: DNA methylation may play a role in the etiology of neuropsychiatric disorders, possibly through abnormal 
genomic methylation patterns that regulate genes involved in brain development or physiology. Our aim is to investigate 
DNA methylation profiles of schizophrenia. 
 
Methods: In order to better understand both the wild type genomic DNA methylation patterns and aberrant methylation 
events that occur in disease states, we have developed a cost-effective, unbiased, whole-genome methylation profiling 
technique, methylation mapping analysis by paired-end sequencing (MethylMAPS), that can assay the methylation state 
of more than 80% of the CpG sites in the human genome. The Methyl-MAPS method couples advances in next 
generation sequencing with enzymatic fractionation of DNA by methylation state, allowing for mapping of methylation at 
high genomic coverage in non-psychiatric controls and schizophrenia cases. Our Methyl-MAPS data have been validated 
by bisulfite sequencing using the Sequenom MassARRAY platform, with >75% correlation across 46 genomic regions that 
included gene promoters, internal exons and introns, and repeat sequences. 
 
Results: We focused on the prefrontal cortex due to converging evidence from neuroimaging and functional studies 
implicating this region in schizophrenia. Secondarily, we also examined the auditory cortex within the schizophrenia 
samples, because schizophrenia disorder includes defects in sensory perception and processing. These data provide the 
first genome-wide DNA methylation profiling study of schizophrenia, allowing for identification of aberrant methylated 
regions including genes as well as repetitive elements that are typically ignored in existing DNA methylation profiling 
methods. These data are overlaid with whole genome gene expression data from the same sample subjects to determine 
the influence of DNA methylation on gene transcript activity. Differentially methylated regions with marked differences in 
transcriptional activity among our cases and controls will then be subject to further validation on the Pyrosequencing 
platform. 
 
Discussion: This large-scale whole genome DNA methylation study has identified numerous methylation changes, that will 
serve as candidates for further investigations into the role of DNA methylation in schizophrenia disorder. DNA methylation 
abnormalities thus identified may have clinical utility as biomarkers, and evaluation of the frequency of these alterations 
may help identify etiologic factors involved in schizophrenia. 
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Although short indels (<100bp) are referred as the second most abundant genetic variation in the human genome, little 
attention is paid to their effect on gene regulation and disease susceptibility. We identified a 14bp indel (rs11274804) 
within the second intron of human cardiovascular disease (CVD) candidate gene, Na(+)-Ca(2+) exchanger (NCX1) and 
screened the locus in two Eastern-European sample sets: essential hypertension (Estonia; cases n=470/controls=652) 
and coronary artery disease, CAD (Czech; cases n=257/controls=413). The analyzed genomic segment (348bp) was 
hypervariable, represented by seven different indel alleles (minor allele frequencies <8.4%). An association was detected 
between the carrier status of 14bp indel allele and the diagnosis of CAD (P=0.0016, OR=2.02), but not with hypertension. 
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A suggestive evidence was also detected for the association with heart rate, serum triglyceride and LDL levels (P=0.04). 
The alignments of human-chimpanzee-macaque sequences revealed that the major human variant (allele frequency 
90.45%) was actually a human-specific deletion compared to other primates. This derived variant was surrounded by an 
abundance of other short (5-43bp) deletions and duplication (40bp) polymorphisms. High variation occurrence indicates a 
potential indel hotspot area triggered by the initial deletion in human lineage. In order to characterize the human 
population diversity of hypervariable region in NCX1 intron 2, 12 populations from three continents Europe (n=150), Asia 
(n=71), and Africa (n=364) were analyzed. Among African populations (both North- and Sub-Saharan Africa) the carrier-
frequency of the ancestral allele lacking the 14bp deletion was significantly higher compared to other populations (allele 
frequencies up to 35%). 
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Secretory factors and extracellular receptors that drive cancer progression make attractive immunotherapeutic targets. To 
discover such novel targetable oncogenes, we used a whole-genome data-mining approach that takes advantage of large 
independent microarray studies of breast tumors annotated for clinical outcomes. Genes without previous implication in 
breast cancer were identified based on their significant association with cancer recurrence in multiple cohorts, and further 
filtered for secretory factors and extracellular receptors based on gene ontology. A high-content screening strategy was 
then applied to the candidates to assess the phenotypic consequences of altering candidate gene expression. This screen 
suggested that serine protease inhibitor Kazal-type 1 (SPINK1), a secreted extracellular factor, was associated with 
breast cancer aggressiveness. We demonstrate that enforced SPINK1 expression and exposure to exogenous 
recombinant SPINK1 induce both invasiveness and survival of breast cancer cells and down-regulation of SPINK1 is 
associated with cancer cell death. Moreover, increased expression of SPINK1 resulted in an increased resistance to drug-
induced apoptosis. Immunohistochemical analysis of breast cancer tissue microarrays suggested that high SPINK1 
expression was not seen in normal breast but is apparent in advanced disease. Moreover, SPINK1 shows nuclear 
localization primarily in higher grade breast cancers. This nuclear localization was recapitulated when tagged exogenous 
SPINK1 was applied to cells in vitro. SPINK1 is therefore a marker for cellular robustness in breast cancer and maybe a 
potential therapeutic target in this disease. 
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HGVbaseG2P: an advanced database for the integration and interrogation of genetic association datasets 
Hastings R, Thorisson GA, Gollapudi VLS, Beck T, Lancaster O, Free R, Brookes AJ* 
Department of Genetics, University of Leicester, UK 
University of Leicester, UK  
Genetic association study data are rarely published in any comprehensive fashion, neither in journals nor in databases, 
and in the case of negative findings such data are often not reported at all. Consequently, it is difficult to compare and 
contrast the results of different studies, and it is completely impossible to examine a full and unbiased picture of all the 
data that exist. 
To address this deficit, the Human Genome Variation Genotype to Phenotype database (HGVbaseG2P: 
http://www.hgvbaseg2p.org) has been constructed. This free and open access resource provides a new publication 
medium for summary-level genetic association data, combining the best features of a database and a scientific journal. In 
doing so, it employs powerful graphical and text based data presentation methods which enable the simultaneous 
visualisation and co-examination of many studies, without any risk of re-identification of study subjects. 
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The latest release of HGVbaseG2P (v3) improves upon the foundations of previous versions by providing a simpler 
interface, and enhanced search capabilities. These allow researchers to identify studies of interest based on 
chromosomal regions/genes and markers. Studies of interest can be selected for comparison at both genome-wide and 
region-specific levels. 
We constantly and actively search for new data available in publications and multiple online public resources, not least the 
NHGRI GWAS catalog (http://www.genome.gov/gwastudies). Consequently, the database now hosts >18,000,000 p-
values and 352 studies (vs 2,000 p-values and 373 studies in the NHGRI GWAS catalog), representing ~5% of all such 
data yet produced. 
We will soon release new software that will allow researchers to directly submit studies and association data into 
HGVbaseG2P. This will be accompanied by a data access control system enabling data submitters to decide what studies 
and which data elements are to be shared and with whom (e.g. collaborators, own research group). 
By summer 2010 the complete HGVbaseG2P code base will be available for labs, consortia, institutes, etc, to install on 
their own servers so they can run their own genetic association database. Such installations will be interoperable and can 
be searched as a federated network, whilst leaving data curation and data sharing issues fully under the auspices of each 
database team whose efforts will thereby be more easily and more fully recognized. 
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Previous efforts to identify functional disease-causing DNA variants were focussed on the coding regions of candidate 
genes, as coding variants (cSNPs) might have a direct impact on the structure and function of the affected proteins. 
However, abnormal expression of finely regulated genes can also influence different biological processes. Thus, analysis 
of the evolutionary conservation in the regulatory regions of candidate genes as well as investigation of the functional 
impact of polymorphisms in these regions (rSNPs) should improve our knowledge of complex disease etiology. 
In an effort to study regulatory polymorphisms in the genome level, we have previously studied several layers of 
information in the context of regulatory regions including gene structure, SNP content, genomic patterns (i.e. CpG islands, 
conserved regions) and in silico analysis together with experimental results from electrophoretic mobility shift assays 
(EMSA) and promoter activity assays. These data has been integrated into a web-based environment, which is freely 
available and can be used to combine and analyze regulatory genomics data (see www.regulatorygenomics.org). 
 
We have now combined the different layers of regulatory genomics data that has been stored in this database and we 
present a detailed genome wide computational analysis of regulatory regions content This analysis allowed us to establish 
criteria and parameters for better predictions of active regulatory regions as well as improved prediction of rSNPs with 
impact on gene expression. A better annotation should provide a more effective selection of regulatory targets that might 
have an impact on human disease and thereby facilitates our efforts of understanding the genetic determinants of 
complex human diseases. 
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Next-generation sequencing (NGS) technologies have revolutionized genome sequencing by coupling extremely high 
throughput with low cost, thereby providing researchers with unprecedented opportunities to address many important 
biomedical problems efficiently. Large-scale resequencing projects, e.g. 1000 Genomes, TCGA, and TSP, have been 
initiated to extend our knowledge of single nucleotide polymorphisms (SNPs), short insertions/deletions (INDELs) and 
structural variations (SVs) and relate these variants to human diseases. The amount of NGS data submitted to public 
repositories such as the Short Read Archives (SRA) at the NIH National Center of Biotechnology Information (NCBI) is 
growing exponentially and submissions represent a wide array of technology platforms and sequence collection strategies. 
To process and analyze these data for variation detection in a uniform manner is a challenge requiring a standard 
modular pipeline. In collaboration with investigators at Boston College and the University of Michigan, NCBI is developing 
a framework Variation Discovery and Annotation Pipeline (Gpipe). The pipeline generates quality input sequence data 
from the Short Read Archives, checks sample identities, aligns the read data with the human reference genome 
sequences, refines the mapping of placed reads (duplicate removal and base quality recalibration etc), and calls SNPs, 
INDELs, and SVs according to data availability and project-specific policies. A centrally implemented pipeline streamlines 
the data processing workflow for the data generated by next-generation sequencing technologies. 
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Mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene are responsible for cystic fibrosis, 
an autosomic recessive lethal disease that is characterized by frequent pulmonary infections, a permanent inflammation, 
pancreatic insufficiency and male sterility. The CFTR gene is weakly expressed in epithelial tissues derived from the 
affected organs (lung, colon, pancreas, epidydime, sweat glands,…) and almost absent in other tissues. CFTR is not only 
regulated in a tissue-specific manner but also during development. Epigenetic changes have been suggested to be 
important for this tightly regulated expression (Blackledge et al., 2007 ; Paul et al., 2007) but no clear mechanism has 
been identified. Our aim is to investigate epigenetic factors responsible for the spatio-temporal regulation of CFTR 
expression. 
 
Previously, we identified YY1 (Yin Yang 1) as a strong transcriptional repressor, which binds to the CFTR minimal 
promoter. YY1 could act by recruiting chromatin modifiers and DNA methyltransferases (Ko et al., 2008 ; Yao et al., 2001). 
By co-immunoprecipitation assays and chromatin immunoprecipitation experiments, we demonstrated that YY1 is able to 
recruit chromatin modifiers, such as CBP and HDAC, in the CFTR minimal promoter. This mechanism is accompanied by 
histone acetylation changes at the CFTR promoter region. 
Moreover, to determine whether DNA methylation in the promoter region correlates with gene expression, we analyzed 
DNA methylation at high resolution using bisulphite and genomic sequencing. We found that DNA methylation in the 
minimal promoter of the CFTR gene ranges from 12% to 98% in various human cell lines. Currently, we are analyzing 
DNA methylation by pyrosequencing in 20 normal tissues including those that are affected in cystic fibrosis.  
To decipher the molecular mechanism governing this epigenetic change, it will be interesting to evaluate the YY1 role in 
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the methylation of the CFTR promoter. All together, these results provide further inside into the mechanisms responsible 
for the regulation of CFTR expression. 
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The frequency and spectrum of germline mutations in BRCA1 and BRCA2 genes vary according to ethnic groups and 
founder mutations were identified in some ethnic groups such as Ashkenazi Jews, Icelander, Norwegians, and European 
groups. In Korean population, although a few reports on the BRCA1/BRCA2 germline mutation frequencies are available, 
most of them used screening methods such as F-CSGE or DHPLC so that it is difficult to know real frequency of BRCA 
mutations. Here we performed a comprehensive mutation analysis for 265 Korean breast cancer patients by using whole 
gene sequencing covering all exons and their flaking intronic regions of BRCA1 and BRCA2 genes. Overall, 50 patients 
(18.9%) carried 37 deleterious mutations including 15 novel mutations. Among them, four BRCA1 mutations (c.3627dupA, 
c.5445G>A, c.1511dupG, c.5496_5506del11insA) and 3 BRCA2 mutations (c.97G>T, c.7480C>T, c.6952C>T) accounted 
for 20/50 (40%) of all mutations detected in this group of patients. It is notable that the estimated mutation detection rate 
in our study is significantly higher than those of previous studies using screening methods (2.5~11%) and similar to that of 
recent study using whole gene sequencing (18.4%). Therefore, whole gene sequencing seems the method of choice for 
detecting BRCA1/BRCA2 gene mutations in Korean population considering that significant number of mutations would be 
missed by using screening method. And, a two-tiered approach could be suggested for cost-effectiveness by screening of 
above recurrent mutations followed by whole gene sequencing in cases without these mutations. 
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Myopia is the most common form of vision disorder worldwide. High-grade myopia (HM), defined as an axial eye length 
of >26 mm or a refractive error of <-5.00 diopters, is also designated as ‘pathologic’ myopia. Previous pedigree analysis 
had identified several susceptible loci for high grade myopia. However, with its high heterogeneity, the genetic mechanism 
underlying HM still remains largely uncertain. 
To identify the susceptible genes at a population level, we conducted a cost efficient association analysis and named our 
strategy as PLaS-GWAS (Pooling Large Samples and Genome Wide Association Study). Briefly, DNA samples from 407 
cases with <-8.00 diopter in both eyes and 294 controls with >-0.50 diopter were accurately measured with a NanoDrop 
3300 fluorospectrometer. Equal amount of DNA from each sample of case and control groups was pooled together 
respectively. Genotyping was then performed using Illumina 1M duo chip with 3 replicate arrays for each pool. The allele 
frequency of each locus was obtained by computing the averaged ratio of signal intensity of each allele. After association 
analysis using Z-test, promising SNPs (p values ~10-5) were genotyped individually by MassArray in most samples to 
verify PLaS-GWAS discovery. These two steps resulted in several loci that appear to be associated with HM, including 
MYP3 locus, PDE4B, PHF10, 11q14.1, and PODN. Among these, PDE4B is a novel candidate involved in HM 
pathogenesis (PLaS-GWAS, p=1.3*10-6; individually genotyping, p=0.02). Interestingly, PDE4B is a member of type IV 
cyclic nucleotide phosphodiesterase family. The gene product of PDE4B specifically hydrolyzes cAMP which is actively 
involved in eye development. Next, animal model was utilized to further explore the possible role of PDE4B in HM 
formation. When one eye of Guinea Pigs was induced to myopia by form deprivation, PDE4B expression was reduced in 
sclera in comparison with the fellow eye. Furthermore, after the subconjunctival injection of pde4 inhibitor for 4 weeks, the 
normal guinea pigs developed a significant amount of myopia. 
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Our results strongly suggest that the PDE4B gene plays an important role in HM pathogenesis. In addition, PLaS-GWAS 
showed as an effective and cost efficient way to perform large scale genome wide association study. 
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X-linked adrenoleukodystrophy (X-ALD) is the most frequent inherited monogenic demyelinating disease (minimal 
incidence 1:17,000, OMIM 300100). X-ALD leads to neuroinflammation and demyelination leading to death in boys or to 
axonal degeneration in spinal cords in adults (adrenomyeloneuropathy or AMN). The disease is caused by loss of function 
of the ABCD1 gene, a peroxisomal ATP-binding cassette transporter that imports very long-chain fatty acids (VLCFA) into 
peroxisomes for degradation. The mouse model for X-ALD (Ald knock-out) exhibits a late-onset phenotype closely related 
to adrenomyeloneuropathy, with neurodegenerative features beginning at 15 months of age (1,2). Recently, we have 
found that oxidative damage might be a major contributor to disease pathogenesis in the mouse. Indeed, Abcd1 deficient 
mice present accumulation of MDAL (malonaldehyde-lysine), a consequence of lipoxidative damage to proteins, in spinal 
cords as early as 3.5 months of age. At 12 months, Abcd1- mice accumulate additional oxidative damage products arising 
from metal-catalyzed oxidation and glycoxidation/lipoxidation to proteins. Importantly, we observed that VLCFA excess is 
able to generate ROS and decrease reduced glutathione levels. Using gas chromatography/mass spectrometry -
tocopherol analog Trolox is able to reverse oxidative?we have found that the  lesions in vitro, thus providing therapeutic 
hope (3). In addition, we have treated human fibroblasts with a cocktail of 3 different antioxidants, which have been 
proven to prevent C26:0 dependent-ROS production in vitro. A preclinical test to treat an ALD mouse model for 5 months 
with a cocktail of these 3 antioxidants has normalized oxidative lesions in spinal cords, and has reversed 
immunohistochemical signs of axonal degeneration, such as synaptophysin, and APP accumulation in axonal swellings, 
together with microgliosis and astrocytosis. Further, the cocktail prevents and reverts the impairment of locomotor and 
neurobehavioural abilities that characterize the disease, thus providing the conceptual proof for oxidative stress as the 
major causative factor leading to neurodegeneration in X-adrenoleukodystrophy. Results will be translated in a clinical trial 
for X-adrenoleukodystrophy patients. 
(1) Pujol et al, Hum Mol Genet. 2002 Mar 1;11(5):499-505; (2) Pujol et al, Hum Mol Genet. 2004 Dec1;13(23):2997-3006 ; (3) 
Fourcade et al, Hum Mol Genet 2008. Jun 15;17(12):1762-73 
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[Background:] Genome-wide single-nucleotide-polymorphism (SNP) arrays providing hundred of thousands of SNPs on 
human genome have been broadly applied to study important human genetic/genomic topics. Data quality of SNP arrays 
plays an important role on the accuracy and precision of down-stream data analyses. However, good quality indices still 
await development.  
[Results:] We propose new quality indices to measure data quality of SNP arrays, and statistical properties of the quality 
indices are investigated. The indices quantify a departure of the estimated individual-level allele frequencies from the 
expected ones via Mahalanobis distances. The proposed quality indices are shown, through empirical studies of several 
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large genomic projects, to follow log-normal distributions with different parameters characterized by ethnic populations. 
Databases of allele frequency references and quality index references for different SNP array platforms based on samples 
in various reference populations are established. Furthermore, a confidence interval method, based on the underlying 
empirical distributions, is developed to identify SNP arrays or DNA samples with poor quality. Interestingly, the method 
can also be applied to identify chromosome aneuploidies. Analyses of authentic biological data and simulated data show 
that our method has high sensitivity and specificity for detections of poor SNP arrays and aberrant chromosomes.  
[Conclusions:] This paper develops computationally efficient and practically useful measures of data quality and detectors 
of poor SNP arrays. SNP Array Quality Control (SAQC) written in R and R-GUI is developed as a user-friendly tool for 
evaluation and visualization of data quality of genome-wide SNP genotyping studies. 
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In interphasic cells, the mammalian genome, packed into the chromatin fiber, is spatially restrained to specific 
chromosomal territories. However, beyond the simple nucleosomal array, very little is known about the organization and 
the dynamics of the chromatin fiber within chromosomal territories. Although it is largely admitted that one essential 
determinant is chromatin-looping in relation with gene expression and other chromosomal activities, the basic structural 
landscape of the chromatin remains largely unknown at the supranucleosomal level. Indeed, at that scale (~10-350 kb), 
the organization of the chromatin fiber and its dynamics in living cells are difficult to access by cell imaging techniques due 
to intrinsic limitations of light microscopes. The Chromosome Conformation Capture (3C) assay, and derived technologies, 
represents a real technological advance. Indeed, such techniques allow direct quantification of the average interaction 
frequency between two distant genomic regions, at the supranucleosomal scale, in their native genomic context. 
Our laboratory contributed to the recent development of the 3C technologies by improving the quantification of the 
interaction frequencies (3C-qPCR method) (Hagège et al., 2007 Nat. Protocols 2, 1722). 
- In a first approach, we applied this method to analyze long-range chromatin interactions at the Dlk1/Gtl2 (Braem et al., 
2008 J. Biol. Chem. 283, 18612) and Igf2/H19 imprinted loci. We identified several locus-specific looping interactions, thus 
bringing original insights into the complex mechanisms of gene regulation at both loci. 
- In a second approach, we have determined random collision frequencies occurring between genomic sites separated by 
increasing genomic distances and sought to establish whether some fundamental intrinsic constraints apply to the 
supranucleosomal chromatin fiber. We demonstrate that, in the absence of long-range locus-specific interactions, gene-
rich domains of the mammalian chromatin fiber fold into a basic statistical helix. Using bioinformatics analyses, we show 
that conserved sequences at co-regulated gene loci are highly overrepresented at genomic distances corresponding to 
one and two helix turns relative to transcription start sites. Therefore, the basic statistical helix organization of the 
chromatin affects the dynamics of long-range genomic interactions and may contribute to mammalian genome evolution. 
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Introduction: Cystic fibrosis (CF) is the most common fatal inherited disorder among Caucasians. CF has been recently 
recognized more commonly within many nonwhite populations. However, little has been reported on its occurrence in 
Southeast Asians including Koreans. In this study, we have identified 8 known and 5 novel cystic fibrosis transmembrane 
conductance regulator (CFTR) mutations from 8 Korean CF patients. 
Material and method: We have analyzed the complete coding regions and flanking intronic sequences of the CFTR gene 
among 8 unrelated CF patients (2 males, 6 females). To rule-out large deletions or gene rearrangements, the multiplex 
ligation-dependent probe amplification (MLPA) analysis was performed in one patient detected with only one known 
mutation. 
Results: We have identified 8 previously known mutations, namely Q98R, Q220X, Q1291X, Q1352H, 579+5G>A, IVS8-T5, 
2623-?_2751+?del, and 3272-26A>G. Q98R was the most commonly identified known mutations with frequency of 37.5% 
(3/8 alleles). No delta F508 mutation, which is known to be the most common mutation among Caucasians, was detected 
in Korean patients of this study. The newly identifed mutations, some of which has already been published as case 
reports, include L441P, D979A, 1766+2T>C, 2052delA, and 3908insA. 
Conclusion: This study is the first to collectively summarize the CFTR mutational spectrum of Korean CF patients. 
Detection of no delta F508 mutation, and five novel and seven rare mutations reflects a heterogeneous spectrum of CFTR 
mutations in Korean CF patients, which might be different from that of Caucasian populations. Therefore, more 
specialized practice guidelines and management of data-base for molecular diagnosis of CF are necessary for Southeast 
Asians including Korean population. 
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Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder characterized by a clonal expansion of mature CD5+ 
B-lymphocytes and represents the most frequent leukemia in the Western world. Its clinical course is very variable 
depending on several prognostic markers, including genomic complexity, mutational status of immunoglobulin heavy 
chain variable region (IgVH) and p53 functionality. Chromosomal abnormalities are present in majority of CLL cases 
(>80%) and are routinely analyzed using CLL-specific FISH panel (probes for 13q14, 17p13, 11q22 deletions and 
chromosome 12 gains). Deletion of 13q14 region, coding DLEU genes, miR-15a, miR-16-1 and RB1, is the most frequent 
(in approx. 60% of cases) and its prognostic impact depends on the range of deletion and number of involved alleles. 
Recently, a novel deletion of 22q11 was detected in CLL patients, this locus encodes Lambda immunoglobulin light chain 
subgenes (IgL-Lambda). Interestingly, several protein-coding genes (PRAME, ZNF280A, ZNF280B, GGTLC2) and 
microRNA are localized within V subgenes of variable IgL-Lambda region, in contrast to IgL-Kappa and IgH locus. These 
protein-coding genes and microRNA are alternatively deleted in process of immunoglobulin gene splicing during B-
lymphocyte development and could play a role in CLL pathogenesis.  
We analyzed genomes of 40 CLL patients using array-CGH (Human Genome CGH Microarray 4x44K, Agilent); FISH data 
were available for all these patients. Additional aberrations not detected by FISH were found in the majority of samples 
(87,5 %). Deletion of 13q14 was observed in 60% of patients (24/40) and in all those cases included miR-15a and miR-
16-1. Monoalelic 13q14 deletion as a sole aberration suggesting a good prognosis occurred in 9 cases. Detail 
characterization of 22q11 locus with deletions of approx. 0.77 Mb in 7 cases, demonstrated IgL-Lambda gene 
recombination, which was confirmed by PCR analysis (BIOMED-2 protocol). Additional IgL-Lambda rearrangements, not 
detected by array-CGH, were assessed in 9 patients using the PCR method (in total, 16 patients with IgL-Lambda 
deletions were detected).  
Interestingly, one of IgL-Lambda variable segment (V2-8) includes an annotated microRNA gene miR-650. Also other 
subgenes of V2 family include homologues for miR-650, which overlay the leader exon of V2 subgenes. IgL-Lambda 
rearrangement led to miR-650 deletion in 87,5 % of cases (14/16). We detected high expression of this miRNA (RT-qPCR, 
TaqMan Assay, ABI) in two cases, where IgL rearrangement uses a subgen from V2 family. It implies that miR-650 




expression depends on the presence and the type of IgL-Lambda rearrangement and miR-650 could be involved in B-
lymphocyte development. 
To conclude, whole genome array-CGH has proved wide application in clinical diagnostics and brought more precise 
characterization of CLL cells than routinely used FISH. These methods are useful for assessment of complex genomic 
changes during course of disease and bring new insight into CLL pathogenesis and biology.  
This work was supported by research grants MSMT MSM0021622430 and IGA MZ CR NS10439-3/2009. 
 
 
Poster No: P136-F 
Gene-based approach for genome-wide association studies 
1Nam Yunsun 
1KNIH, Korea, Republic 
In most genome-wide association studies (GWAS), single-locus case-control comparisons are used to identify single 
nucleotide polymorphisms associated with a disease. However, there are several limitations in these methods. For 
example, these methods are underpowered to detect small risk effects and it has difficulty in understanding and 
interpreting significant SNPs with a biological meaning. To overcome the limitations, many new methods have been 
suggested [1,2,3]. Biological functions of genes are much better investigated than SNPs, so it will be easier to understand 
significant genes with a biological theme. 
Here we suggest two method for measuring the significance value of a gene. One is called minP method and the other is 
called Fisher’s combination method. We have applied our methods to the data set consisting of 1,042 T2DM (Type 2 
diabetes mellitus) patients and 2,943 healthy controls from KoGES study, and present the results of two methods. 
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a severe cardiac disorder caused mainly by dominant 
mutations of the desmosomal cell adhesion proteins plakophilin-2 (PKP2), desmoplakin (DSP), desmoglein-2 (DSG2), 
and desmocollin-2 (DSC2). Upon search of 29 Finnish ARVC probands, we have previously identified PKP2 missense 
mutations in 10% of the patients. In order to further characterize the genetic basis of ARVC in Finland, we screened the 
probands for three other desmosomal genes and conducted a search for ARVC-associated mutations in a large Finnish 
population sample (Health 2000 Study, N = 6300). A novel frameshift mutation (E1020fsX1037) of DSG2 appeared in one 
ARVC proband, and another patient carried a DSP variant, T1373A, whereas DSC2 was not mutated in any of the 29 
patients. Multiplex ligation-dependent probe amplification (MLPA) did not reveal any deletions or duplications in the 
desmosomal genes. Immunohistochemical analyses showed a reduced amount of both desmoglein-2 and plakophilin-2 in 
the endomyocardial samples of the DSG2 mutation carrier, indicating disturbance of the desmosomal protein interactions. 
In the population sample, a total of 31 subjects (0.5% [95% CI 0.33-0.71%]) carried a desmosomal gene mutation, PKP2 
Q59L being the most prevalent form (n = 19). The penetrance of ARVC was substantially reduced as only a subset of 
these mutation carriers showed ARVC-related arrhythmic and electrocardiographic features. In conclusion, up to 1 in 200 
Finns carry a mutation with a proposed risk of ARVC. However, our findings suggest that penetrance of a typical ARVC 
phenotype may require additional (genetic or nongenetic) factors in addition to the mutant desmosomal gene itself. 
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Glioblastoma multiforme (GBM) is the most common form of malignant brain tumor in adults. Patients with GBM have a 
uniformly poor prognosis, with a median survival of one year thus, advances on all scientific and clinical fronts are needed. 
We have developed a human glioblastoma xenograft model in immunodeficient rodents that is characterised by a highly 
infiltrative non-angiogenic phenotype. Upon serial transplantation this phenotype will develop into a highly angiogenic 
tumor. Thus, we have developed an animal model where we are able to establish two characteristic tumor phenotypes 
that define human glioblastoma (i.e. diffuse infiltration and high neovascularization). It is well established that the cancer 
genome is moulded by the dual processes of somatic mutation and selection. In order to assess whether the observed 
phenotypic shift is due to clonal selection in vivo, we have performed high-resolution aCGH on primary tumors and 
xenografts derived thereof. We show that although the overall genomic pattern is highly conserved, additional genomic 
events may be involved in the angiogenic switch observed in vivo. We are currently further analysing our findings by 
applying whole exome resequencing to the analysed samples in order to delineate the mutational evolution of xenografted 
gliomas at single nucleotide resolution and identify new mutational events linked to the phenotypic switch. `This molecular 
dissection of the two hallmarks of GBM could lead to the identification of potential biomarkers and will facilitate the 
elucidation of the molecular pathways involved in the switch from invasive to angiogenic growth, thereby potentially 
opening new  diagnostic and treatment avenues in the clinic.  
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Genome-wide association (GWA) studies are a powerful and efficient approach to identify genetic variants associated with 
complex human traits. GWA studies became feasible as a result of several key advances in genetic knowledge, 
genotyping technologies, statistical analysis algorithms, and the availability of large collections of samples. Although GWA 
studies have successfully identified important genetic variants associated with many human traits, including diseases, the 
identification of functional connections between variants and phenotypes remains the major barrier to interpretation of 
GWA study results. Here we developed a novel gene mapping approach that integrates GWA and genome-wide 
expression-QTL (eQTL) data to simultaneously interpret both datasets under a single statistical framework. We applied 
our approach to several human diseases and their hematological, biochemical, and physical traits using publicly available 
expression data from lymphoblastoid cell lines. Our approach identified genetically and functionally associated variants in 
these datasets. The applicability of our approach is supported by the enrichment of previously identified genes involved in 
these phenotypes in our analysis. Additionally, we identified several new candidate genes with notable functional 
association to the phenotypes examined. Our method not only dramatically shortens the time required to discover 
functional SNPs but also has the potential to aid our understanding of the normal variation in gene expression, resulting 
from yet to be identified combinations of genetic polymorphisms involved in complex diseases and traits. 
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[Background] 
The nuclear receptor constitutive androstane receptor (CAR; NR1I3) is involved in detoxification and regulation of 
xenobiotics and endogenous molecules. CAR has also been shown to be involved in the metabolism of hepatic bile acids 
and cholesterol. Such function of CAR gene has been established in mice, however the role of human CAR gene is not 
well known yet. 
In this study, we performed search for genotype-phenotype associations in consecutive autopsies of elderly Japanese 
population, focusing on human CAR polymorphisms and metabolic phenotypes. 
[Methods] 
Six polymorphisms in human NR1I3 gene were genotyped using melting curve analysis or TagMan Assay. The study 
subjects (n=1536) were consecutive autopsies of elderly Japanese population registered in the Japanese SNPs for 
geriatric research (JG-SNP) database. Multiple logistic regression analyses were performed to examine the genetic 
effects and interaction effects on the metabolic disease. The estimates were adjusted for gender and age at death of the 
subjects; the presence of hypertension, hyperlipidemia, and diabetes mellitus; and the smoking and drinking status. The 
P-value under 0.05 was considered statistically significant. The SAS system for Windows ver.9.1.3 was used for all 
statistical analyses. 
[Results] 
We found that NR1I3 rs2307424 C-carrier (CC+CT) was associated with reduced risk of hyperlipidemia (p=0.0115). The 
odds ratio (OR) was 0.38 (95% confidence interval [CI], 0.182-0.806) after adjustment for significant risk factors such as 
age, gender, prevalence of hypertension and diabetes mellitus. Moreover, rs55802895 A-carrier (AA+AG) had increased 
risk of hyperlipidemia (OR=2.25, 95%CI 1.009-4.995, p=0.0474), after adjustment. 
[Conclusion] 
We provide data that CAR polymorphism is association with lipid profile in human. This is in agreement with the fact that 
mice CAR regulates cholesterol metabolism. 
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Chromosomal abnormalities such as rearrangements, copy number gains and losses are characteristic attributes of 
cancer often resulting in activation of oncogenes and inactivation of tumour suppressor genes. Epithelial ovarian cancer 
(EOC) is the leading cause of death from gynecological malignancy in women and is characterized by a high degree of 
chromosomal instability. In this study, we performed genomic and transcriptomic profiling of 125 benign, borderline and 
malignant ovarian tumours using Affymetrix SNP 6.0 and Affymetrix GeneChip U133 Plus 2 arrays to investigate the 
molecular changes associated with such instability. CGHmix was used to detect copy number alterations (CNA) and 
determine the frequencies of amplifications and deletions in all the samples. We then jointly evaluated the propensities of 
amplifications and deletions for each genomic locus to distinguish the exclusively amplified or deleted regions that are 




most likely to be non-random chromosomal events and hypothesized that such events harbored driver genes. Correlation 
of copy number and gene expression changes in these regions enabled us to prioritize functionally relevant aberrations. 
We found that 43% of 52,000 probesets analyzed had a significant correlation between CNA and gene expression 
changes, suggesting that a large number of expression differences in tumours resulted from local copy number changes. 
Moreover, 27% of the genome was significantly predisposed to amplifications while 20% of the genome was significantly 
predisposed to deletions. In addition we mapped the occurrence of loss of heterozygosity (LOH) in the tumours and 
correlated LOH with gene expression changes to identify potential tumour suppressor genes that may be silenced by LOH. 
We found 37% of the genome bearing LOH in more than 10% of tumours. Subsequent overlap with clinicopathological 
parameters such as tumour grade and disease-free survival has identified our best candidate novel oncogenes and/or 
tumour suppressor genes. Gene-by-gene screening of these candidates using cell-based assays is ongoing which will 
reveal new insights into the role of genetic aberrations in ovarian cancer. 
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Elevated C-reactive protein (CRP) level, an inflammatory marker, is considered to be a predictor of a variety of aging-
related diseases such as cardiovascular disease. Serum CRP level is known to be influenced by a complex interaction of 
genetic and environmental factors. We conducted a genome-wide association study among 8,837 unrelated Koreans and 
tested for influence of gene-environment interaction on serum CRP level. We initially analyzed the association of serum 
CRP with various environmental and clinical variables to identify possible confounding variables. We analyzed natural log 
transformed CRP for investigating interactions between 352,228 single nucleotide polymorphism (SNP) markers and 
nongenetic factors including education, physical activity, cigarette smoking, alcohol drinking, history of disease, and 
history of medication. We included a term for the additive effect of genotype, a term for covariate, and a term for the 
interaction between the nongenetic risk factor in multiple linear regression models. Subsequently, all analyses were 
stratified by sex with adjustments for age, residence, body mass index, nine biochemical variables, and five lifestyle 
variables. We found significant evidence for interaction between multiple loci and nongenetic factors (e.g. rs7553007 of 
CRP gene and positive history of hepatitis (p=0.026), cigarette smoking, or insulin medication). While we consider these 
interaction analyses exploratory and the results must be confirmed in future studies, accounting for genotype by 
environment interaction might explain, in part, the problem of missing heritability that have been identified in previous 
genome wide association studies. 
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Elevated production of IgE (atopy) is often associated with development of allergic diseases and is known to be a complex 
trait influenced by both genetic and environmental factors. 
160 HUGO J (2010) 4:1–190
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Aim of the project was to define genetic loci responsible for atopy in human. We combined the genome-wide study in 
mouse with the candidate locus approach in human. 
In the genome-wide search for IgE-controlling loci in mouse recombinant congenic strains, several regions on 
chromosomes 1, 2, 3, 4, 5, 8, 10, 16 and 18 contributed to IgE regulation. From the conserved synteny between mouse 
and human genomes, we identified corresponding orthologous regions on human chromosomes. Majority of the 
orthologous regions have been already reported as atopy loci in humans, thus supporting the precision and the predictive 
power of our approach. However, the human region 8q12 orthologous for the shortest IgE locus Lmr9 (chromosome 4) in 
mouse has not been described in human studies of atopy. Therefore, in the 8q12 region, we selected three microsatellite 
markers D8S1828, D8S285, and D8S1816, and tested them for non-parametric linkage and association (QTDT) with 
levels of total IgE and specific IgEs to twenty inhalant and five food allergens in Czech atopic nuclear families. In the 
position marked by D8S285 (57.22 Mb, 71cM) we demonstrated the novel human IgE-controlling locus exhibiting 
suggestive linkage to composite inhalant allergic sensitization and to nine specific IgEs. 
We also tested the effects of several the most promising candidate chromosomal regions reported by other scientific 
groups on atopy and associated traits in Czech and Russian atopic families. Linkage and association (QTDT) to plant-
specific IgEs were identified at loci 5q33, 7p14, 12q13 and 13q14 in the Czech population. In Russian family group, cat-
specific IgE (which is the most abundant in Russian patients with asthma from Siberia) showed suggestive linkage with 
the 12q24.3 region. 
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Fanconi anemia (FA) is a rare recessively inherited disorder characterized by genome instability, DNA crosslink 
hypersensitivity, congenital malformations, bone marrow failure, and predisposition to malignancy. At least 13 FA genes 
have been identified. The International Fanconi Anemia Registry (IFAR) was established at The Rockefeller University in 
1982 in order to collect data regarding patients with FA and their families. In addition, the Fanconi Anemia Mutation 
Database, http://www.rockefeller.edu/fanconi/mutate/, was established in 1998 to accelerate the availability of information 
on mutations in these 13 important cancer-predisposing genes. 
The new IFAR project proposes to develop a comprehensive, ontology-driven Phenotype Recording Instrument (PRI) and 
database for FA. The PRI will integrate the existing IFAR data held in multiple disparate data sources for a unique look at 
the FA patient population, which includes the patient data available in the current IFAR database, the polymorphic (SNP) 
and mutation data available for patients representing the known FA genes, as well as pedigree information showing the 
inheritance patterns from multiple generations. Furthermore, the NIH’s Genomics Center (NHGRI) is currently sequencing 
certain patient tissue samples using Next Generation technology, which will further enhance the current IFAR patient data. 
The new development effort will also include “deep phenotyping” from new patient history questionnaires. We are 
hypothesizing the addition of these two data stores, full gene sequencing and deep phenotyping, will add significantly to 
the understanding of FA while providing a deeper basic scientific understanding of DNA repair mechanisms, and more 
prognostic ability for the current patient population.  
The enhanced data model resulting from the aforementioned data sources will all be modeled using an OWL ontology 
defined with Protégé. We are committed to a more elaborate semantic query mechanism for data mining of this 
comprehensive and “state of the art” data warehouse for FA patients. We will build data mining and visualization tools that 
will be required to maximize the research view of this integrated patient data. As the name of the existing IFAR system 
implies, this registry is an International collaboration. The new system will enable worldwide international collaboration 
between FA researchers. To accomplish this, we will build a web-based system utilizing the Java JSP front-end coupled 
with an Oracle 10g database backend for performance and data integrity. This is truly a unique medical informatics 
opportunity made possible because of the 28 year collection of FA data combined with next generation sequencing and 
deep phenotyping data. 
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The original sequencing and annotation of the Caenorhabditis elegans genome along with recent advances in sequencing 
technology provide an exceptional opportunity for the genomic analysis of wild-type and mutant strains. Using the Illumina 
Genome Analyzer, we have sequenced the entire genome of Rec-1, a strain that alters the distribution of meiotic 
crossovers without changing the overall frequency. Rec-1 was derived from ethylmethane sulfonate (EMS)-treated strains, 
one of which had a high level of transposable element mobility. Sequencing of this strain provides an opportunity to 
examine the consequences on the genome of altering the distribution of meiotic recombination events. 
Our analysis of high-throughput sequencing was able to detect regions of direct repeat sequences, deletions, insertions of 
transposable elements, and base pair differences. A subset of sequence alterations affecting coding regions were 
confirmed by an independent approach using oligo array comparative genome hybridization. The major phenotype of the 
Rec-1 strain is an alteration in the preferred position of the meiotic recombination event with no other significant 
phenotypic consequences. In this study, we observed no evidence of a mutator effect at the nucleotide level attributable to 
the Rec-1 mutation. 
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The unique properties of mitochondrial DNA lie in the fact that their inheritance is uniparental. Thus, its analyses provide 
critical information regarding on the origin of species, population genetics and forensic studies. Malaysia with its distinct 
multiracial population is one of the most important regions for studying genetic diversity of human populations, in terms of 
evolution and diseases. However, a significant number of Malaysia’s distinct ethnicities especially the indigenous groups 
have been underrepresented in many scientific reports. The efforts to collect samples and generate data especially for 
mtDNA markers in these groups are lacking. This study represents a pioneering effort to investigate mtDNA variants for 
four Malaysia indigenous groups and has resulted in new knowledge. Mitochondrial DNA HVS-1 and -2 sequences and 
RFLP polymorphisms were genotyped and analyzed in 188 individuals from four indigenous groups, Jehai, Kensiu, 
Temuan and Bidayuh. Mitochondrial haplotypes, and haplogroup frequency distributions were determined in order to 
characterize the mtDNA structure and diversity in Malaysia indigenous group senario. A total of 64 mtDNA haplotypes 
were observed. The indigenous groups exhibited low diversity reflecting enhanced genetic drift, bottle neck or founder 
effects in these small, isolated populations. The majority of mtDNA haplogroups were found to be exclusive and distinct to 
them. Most mtDNA variants belonged to three major haplogroups M, N and R. The most frequent were haplogroups 
included M21a and R21, which both reflect very old lineages, deeply rooted in South East Asian population’s lineages 
(~60,000 years ago). This was evident in about 80% of the Negritos (subgroups of Jehai and Kensiu) that were genotyped. 
The mtDNA data indicated very old variants suggesting that the Negritos in Malaysia are descendants of the earliest 
inhabitants in South East Asia. This invetigation also indicated some admixture of our indigenous groups with other 
Southeast Asian ethnic groups. The low level of gene flow among these groups supports the Out of Africa hypothesis. In 
addition, 7 new mutations were discovered and have been reported to the international Mitomap database. 
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